Compounds and methods for treatment and diagnosis of chlamydial infection

ABSTRACT

Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. patent applicationSer. No. 07/556,877, filed Jun. 20, 2000, now U.S. Pat. No. 6,432,916issued Aug. 13, 2002, which is a continuation-in-part of U.S. patentapplication Ser. No. 09/454,684 filed Dec. 3, 1999, which is acontinuation of U.S. patent application Ser. No. 09/426,571, filed Oct.22, 1999, which is a continuation-in-part of U.S. patent applicationSer. No. 09/410,568, filed Oct. 1, 1999, which is a continuation-in-partof U.S. patent application Ser. No. 09/288,594 filed Apr. 8, 1999, nowU.S. Pat. No. 6,447,779 issued Sep. 10, 2002, which is acontinuation-in-part of U.S. patent application Ser. No. 09/208,277,filed Dec. 8, 1998, now U.S. Pat. No. 6,166,177 issued Dec. 26, 2000.

TECHNICAL FIELD

The present invention relates generally to the detection and treatmentof Chlamydial infection. In particular, the invention is related topolypeptides comprising a Chlamydia antigen and the use of suchpolypeptides for the serodiagnosis and treatment of Chlamydialinfection.

BACKGROUND OF THE INVENTION

Chlamydiae are intracellular bacterial pathogens that are responsiblefor a wide variety of important human and animal infections. Chlamydiatrachomatis is one of the most common causes of sexually transmitteddiseases and can lead to pelvic inflammatory disease (PID), resulting intubal obstruction and infertility. Chlamydia trachomatis may also play arole in male infertility. In 1990, the cost of treating PID in the USwas estimated to be $4 billion. Trachoma, due to ocular infection withChlamydia trachomatis, is the leading cause of preventable blindnessworldwide. Chlamydia pneumonia is a major cause of acute respiratorytract infections in humans and is also believed to play a role in thepathogenesis of atherosclerosis and, in particular, coronary heartdisease. Individuals with a high titer of antibodies to Chlamydiapneumonia have been shown to be at least twice as likely to suffer fromcoronary heart disease as seronegative individuals. Chlamydialinfections thus constitute a significant health problem both in the USand worldwide.

Chlamydial infection is often asymptomatic. For example, by the time awoman seeks medical attention for PID, irreversible damage may havealready occurred resulting in infertility. There thus remains a need inthe art for improved vaccines and pharmaceutical compositions for theprevention and treatment of Chlamydia infections. The present inventionfulfills this need and further provides other related advantages.

SUMMARY OF THE INVENTION

The present invention provides compositions and methods for thediagnosis and therapy of Chlamydia infection. In one aspect, the presentinvention provides polypeptides comprising an immunogenic portion of aChlamydia antigen, or a variant of such an antigen. Certain portions andother variants are immunogenic, such that the ability of the variant toreact with antigen-specific antisera is not substantially diminished.Within certain embodiments, the polypeptide comprises an amino acidsequence encoded by a polynucleotide sequence selected from the groupconsisting of (a) a sequence of

SEQ ID NO: 1, 15, 21-25, 44-64, 66-76, 79-88, 110-119, 120, 122, 124,126, 128, 130, 132, 134, 136, 169-174, 181-188, 263, 265 and 267-290;(b) the complements of said sequences; and (c) sequences that hybridizeto a sequence of (a) or (b) under moderately stringent conditions. Inspecific embodiments, the polypeptides of the present invention compriseat least a portion of a Chlamydial protein that includes an amino acidsequence selected from the group consisting of sequences recited in

SEQ ID NO: 5-14, 17-20, 26, 28, 30-32, 34, 39-43, 65, 89-109, 138-158,167, 168, 224-262, 246, 247, 254-256, 292, 294-305 and variants thereof.

The present invention further provides polynucleotides that encode apolypeptide as described above, or a portion thereof (such as a portionencoding at least 15 amino acid residues of a Chlamydial protein),expression vectors comprising such polynucleotides and host cellstransformed or transfected with such expression vectors.

In a related aspect, polynucleotide sequences encoding the abovepolypeptides, recombinant expression vectors comprising one or more ofthese polynucleotide sequences and host cells transformed or transfectedwith such expression vectors are also provided.

In another aspect, the present invention provides fusion proteinscomprising an inventive polypeptide, or, alternatively, an inventivepolypeptide and a known Chlamydia antigen, as well as polynucleotidesencoding such fusion proteins, in combination with a physiologicallyacceptable carrier or immunostimulant for use as pharmaceuticalcompositions and vaccines thereof.

The present invention further provides pharmaceutical compositions thatcomprise: (a) an antibody, both polyclonal and monoclonal, orantigen-binding fragment thereof that specifically binds to a Chlamydialprotein; and (b) a physiologically acceptable carrier. Within otheraspects, the present invention provides pharmaceutical compositions thatcomprise one or more Chlamydia polypeptides disclosed herein, or apolynucleotide molecule encoding such a polypeptide, and aphysiologically acceptable carrier. The invention also provides vaccinesfor prophylactic and therapeutic purposes comprising one or more of thedisclosed polypeptides and an immunostimulant, as defined herein,together with vaccines comprising one or more polynucleotide sequencesencoding such polypeptides and an immunostimulant.

In yet another aspect, methods are provided for inducing protectiveimmunity in a patient, comprising administering to a patient aneffective amount of one or more of the above pharmaceutical compositionsor vaccines.

In yet a further aspect, methods for the treatment of Chlamydiainfection in a patient are provided, the methods comprising obtainingperipheral blood mononuclear cells (PBMC) from the patient, incubatingthe PBMC with a polypeptide of the present invention (or apolynucleotide that encodes such a polypeptide) to provide incubated Tcells and administering the incubated T cells to the patient. Thepresent invention additionally provides methods for the treatment ofChlamydia infection that comprise incubating antigen presenting cellswith a polypeptide of the present invention (or a polynucleotide thatencodes such a polypeptide) to provide incubated antigen presentingcells and administering the incubated antigen presenting cells to thepatient. Proliferated cells may, but need not, be cloned prior toadministration to the patient. In certain embodiments, the antigenpresenting cells are selected from the group consisting of dendriticcells, macrophages, monocytes, B-cells, and fibroblasts. Compositionsfor the treatment of Chlamydia infection comprising T cells or antigenpresenting cells that have been incubated with a polypeptide orpolynucleotide of the present invention are also provided. Withinrelated aspects, vaccines are provided that comprise: (a) an antigenpresenting cell that expresses a polypeptide as described above and (b)an immunostimulant.

The present invention further provides, within other aspects, methodsfor removing Chlamydial-infected cells from a biological sample,comprising contacting a biological sample with T cells that specificallyreact with a Chlamydial protein, wherein the step of contacting isperformed under conditions and for a time sufficient to permit theremoval of cells expressing the protein from the sample.

Within related aspects, methods are provided for inhibiting thedevelopment of Chlamydial infection in a patient, comprisingadministering to a patient a biological sample treated as describedabove. In further aspects of the subject invention, methods anddiagnostic kits are provided for detecting Chlamydia infection in apatient. In one embodiment, the method comprises: (a) contacting abiological sample with at least one of the polypeptides or fusionproteins disclosed herein; and (b) detecting in the sample the presenceof binding agents that bind to the polypeptide or fusion protein,thereby detecting Chlamydia infection in the biological sample. Suitablebiological samples include whole blood, sputum, serum, plasma, saliva,cerebrospinal fluid and urine. In one embodiment, the diagnostic kitscomprise one or more of the polypeptides or fusion proteins disclosedherein in combination with a detection reagent. In yet anotherembodiment, the diagnostic kits comprise either a monoclonal antibody ora polyclonal antibody that binds with a polypeptide of the presentinvention.

The present invention also provides methods for detecting Chlamydiainfection comprising: (a) obtaining a biological sample from a patient;(b) contacting the sample with at least two oligonucleotide primers in apolymerase chain reaction, at least one of the oligonucleotide primersbeing specific for a polynucleotide sequence disclosed herein; and (c)detecting in the sample a polynucleotide sequence that amplifies in thepresence of the oligonucleotide primers. In one embodiment, theoligonucleotide primer comprises at least about 10 contiguousnucleotides of a polynucleotide sequence peptide disclosed herein, or ofa sequence that hybridizes thereto.

In a further aspect, the present invention provides a method fordetecting Chlamydia infection in a patient comprising: (a) obtaining abiological sample from the patient; (b) contacting the sample with anoligonucleotide probe specific for a polynucleotide sequence disclosedherein; and (c) detecting in the sample a polynucleotide sequence thathybridizes to the oligonucleotide probe. In one embodiment, theoligonucleotide probe comprises at least about 15 contiguous nucleotidesof a polynucleotide sequence disclosed herein, or a sequence thathybridizes thereto.

These and other aspects of the present invention will become apparentupon reference to the following detailed description. All referencesdisclosed herein are hereby incorporated by reference in their entiretyas if each was incorporated individually.

SEQUENCE IDENTIFIERS

SEQ ID NO: 1 is the determined DNA sequence for the C. trachomatis clone1-B1-66.

SEQ ID NO: 2 is the determined DNA sequence for the C. trachomatis clone4-D7-28.

SEQ ID NO: 3 is the determined DNA sequence for the C. trachomatis clone3-G3-10.

SEQ ID NO: 4 is the determined DNA sequence for the C. trachomatis clone10-C10-31.

SEQ ID NO: 5 is the predicted amino acid sequence for 1-B1-66.

SEQ ID NO: 6 is the predicted amino acid sequence for 4-D7-28.

SEQ ID NO: 7 is a first predicted amino acid sequence for 3-G3-10.

SEQ ID NO: 8 is a second predicted amino acid sequence for 3-G3-10.

SEQ ID NO: 9 is a third predicted amino acid sequence for 3-G3-10.

SEQ ID NO: 10 is a fourth predicted amino acid sequence for 3-G3-10.

SEQ ID NO: 10 is a fifth predicted amino acid sequence for 3-G3-10.

SEQ ID NO: 12 is the predicted amino acid sequence for 10-C10-31.

SEQ ID NO: 13 is the amino acid sequence of the synthetic peptide1-B1-66/48-67.

SEQ ID NO: 14 is the amino acid sequence of the synthetic peptide1-B1-66/58-77.

SEQ ID NO: 15 is the determined DNA sequence for the C. trachomatisserovar LGV II clone 2C7-8

SEQ ID NO: 16 is a DNA sequence of a putative open reading frame from aregion of the C. trachomatis serovar D genome to which 2C7-8 maps

SEQ ID NO: 17 is the predicted amino acid sequence encoded by the DNAsequence of

SEQ ID NO: 16

SEQ ID NO: 18 is the amino acid sequence of the synthetic peptideCtC7.8-12

SEQ ID NO: 19 is the amino acid sequence of the synthetic peptideCtC7.8-13

SEQ ID NO: 20 is the predicted amino acid sequence encoded by a secondputative open reading from C. trachomatis serovar D

SEQ ID NO: 21 is the determined DNA sequence for clone 4C9-18 from C.trachomatis LGV II

SEQ ID NO: 22 is the determined DNA sequence homologous to LipoamideDehydrogenase from C. trachomatis LGV II

SEQ ID NO: 23 is the determined DNA sequence homologous to Hypotheticalprotein from C. trachomatis LGV II

SEQ ID NO: 24 is the determined DNA sequence homologous to UbiquinoneMehtyltransferase from C. trachomatis LGV II

SEQ ID NO: 25 is the determined DNA sequence for clone 4C9-18#2 BL21pLysS from C. trachomatis LGV II

SEQ ID NO: 26 is the predicted amino.acid sequence for 4C9-18#2 from C.trachomatis LGV II

SEQ ID NO: 27 is the determined DNA sequence for Cp-SWIB from C.pneumonia strain TWAR

SEQ ID NO: 28 is the predicted amino acid sequence for Cp-SWIB from C.pneumonia strain TWAR

SEQ ID NO: 29 is the determined DNA sequence for Cp-S13 from C.pneumonia strain TWAR

SEQ ID NO: 30 is the predicted amino acid sequence for Cp-S13 from C.pneumonia strain TWAR

SEQ ID NO: 31 is the amino acid sequence for a 10 mer consensus peptidefrom CtC7.8-12 and CtC7.8-13

SEQ ID NO: 32 is the predicted amino acid sequence for clone 2C7-8 fromC. trachomatis LGV II

SEQ ID NO: 33 is the DNA sequence corresponding to nucleotides597304-597145 of the C. trachomatis serovar D genome (NCBI, BLASTNsearch), which shows homology to clone 2C7-8

SEQ ID NO: 34 is the predicted amino acid sequence encoded by thesequence of SEQ ID NO: 33

SEQ ID NO: 35 is the DNA sequence for C.p. SWIB Nde (5′ primer) from C.pneumonia

SEQ ID NO: 36 is the DNA sequence for C.p. SWIB EcoRI (3′ primer) fromC. pneumonia

SEQ ID NO: 37 is the DNA sequence for C.p. S13 Nde (5′ primer) from C.pneumonia

SEQ ID NO: 38 is the DNA sequence for C.p. S13 EcoRI (3′ primer) from C.pneumonia

SEQ ID NO: 39 is the amino acid sequence for CtSwib 52-67 peptide fromC. trachomatis LGV II

SEQ ID NO: 40 is the amino acid sequence for CpSwib 53-68 peptide fromC. pneumonia

SEQ ID NO: 41 is the amino acid sequence for HuSwib 288-302 peptide fromHuman SWI domain

SEQ ID NO: 42 is the amino acid sequence for CtSWI-T 822-837 peptidefrom the topoisomerase-SWIB fusion of C. trachomatis

SEQ ID NO: 43 is the amino acid sequence for CpSWI-T 828-842 peptidefrom the topoisomerase-SWIB fusion of C. pneumonia

SEQ ID NO: 44 is a first determined DNA sequence for the C. trachomatisLGV II clone 19783.3,jen.seq(1>509)CTL2#11-3′, representing the 3′ end.

SEQ ID NO: 45 is a second determined DNA sequence for the C. trachomatisLGV II clone 19783.4,jen.seq(1>481)CTL2#11-5′, representing the 5′ end.

SEQ ID NO: 46 is the determined DNA sequence for the C. trachomatis LGVII clone 19784CTL2_(—)12consensus.seq(1>427)CTL2#12.

SEQ ID NO: 47 is the determined DNA sequence for the C. trachomatis LGVII clone 19785.4,jen.seq(1>600)CTL2#16-5′, representing the 5′ end.

SEQ ID NO: 48 is a first determined DNA sequence for the C. trachomatisLGV II clone 19786.3,jen.seq(1>600)CTL2#18-3′, representing the 3′ end.

SEQ ID NO: 49 is a second determined DNA sequence for the C. trachomatisLGV II clone 19786.4,jen.seq(1>600)CTL2#18-5′, representing the 5′ end.

SEQ ID NO: 50 is the determined DNA sequence for the C. trachomatis LGVII clone 19788CTL2_(—)21consensus.seq(1>406)CTL2#21.

SEQ ID NO: 51 is the determined DNA sequence for the C. trachomatis LGVII clone 19790CTL2_(—)23consensus.seq(1>602)CTL2#23.

SEQ ID NO: 52 is the determined DNA sequence for the C. trachomatis LGVII clone 19791CTL2_(—)24consensus.seq(1>145)CTL2#24.

SEQ ID NO: 53 is the determined DNA sequence for the C. trachomatis LGVII clone CTL2#4.

SEQ ID NO: 54 is the determined DNA sequence for the C. trachomatis LGVII clone CTL2#8b.

SEQ ID NO: 55 is the determined DNA sequence for the C. trachomatis LGVII clone 15-G1-89, sharing homology to the lipoamide dehydrogenase geneCT557.

SEQ ID NO: 56 is the determined DNA sequence for the C. trachomatis LGVII clone 14-H1-4, sharing homology to the thiol specific antioxidantgene CT603.

SEQ ID NO: 57 is the determined DNA sequence for the C. trachomatis LGVII clone 12-G3-83, sharing homology to the hypothetical protein CT622.

SEQ ID NO: 58 is the determined DNA sequence for the C. trachomatis LGVII clone 12-B3-95, sharing homology to the lipoamide dehydrogenase geneCT557.

SEQ ID NO: 59 is the determined DNA sequence for the C. trachomatis LGVII clone 11-H4-28, sharing homology to the dnaK gene CT396.

SEQ ID NO: 60 is the determined DNA sequence for the C. trachomatis LGVII clone 11-H3-68, sharing partial homology to the PGP6-D virulenceprotein and L1 ribosomal gene CT318.

SEQ ID NO: 61 is the determined DNA sequence for the C. trachomatis LGVII clone 11-G1-34, sharing partial homology to the malate dehydrogenasegene CT376 and to the glycogen hydrolase gene CT042.

SEQ ID NO: 62 is the determined DNA sequence for the C. trachomatis LGVII clone 11-G10-46, sharing homology to the hypothetical protein CT610.

SEQ ID NO: 63 is the determined DNA sequence for the C. trachomatis LGVII clone 11-C12-91, sharing homology to the OMP2 gene CT443.

SEQ ID NO: 64 is the determined DNA sequence for the C. trachomatis LGVII clone 11-A3-93, sharing homology to the HAD superfamily gene CT103.

SEQ ID NO: 65 is the determined amino acid sequence for the C.trachomatis LGV II clone 14-H1-4, sharing homology to the thiol specificantioxidant gene CT603.

SEQ ID NO: 66 is the determined DNA sequence for the C. trachomatis LGVII clone CtL2#9.

SEQ ID NO: 67 is the determined DNA sequence for the C. trachomatis LGVII clone CtL2#7.

SEQ ID NO: 68 is the determined DNA sequence for the C. trachomatis LGVII clone CtL2#6.

SEQ ID NO: 69 is the determined DNA sequence for the C. trachomatis LGVII clone CtL2#5.

SEQ ID NO: 70 is the determined DNA sequence for the C. trachomatis LGVII clone CtL2#2.

SEQ ID NO: 71 is the determined DNA sequence for the C. trachomatis LGVII clone CtL2#1.

SEQ ID NO: 72 is a first determined DNA sequence for the C. trachomatisLGV II clone 23509.2CtL2#3-5′, representing the 5′ end.

SEQ ID NO: 73 is a second determined DNA sequence for the C. trachomatisLGV II clone 23509.1CtL2#3-3′, representing the 3′ end.

SEQ ID NO: 74 is a first determined DNA sequence for the C. trachomatisLGV II clone 22121.2CtL2#10-5′, representing the 5′ end.

SEQ ID NO: 75 is a second determined DNA sequence for the C. trachomatisLGV II clone 22121.1CtL2#10-3′, representing the 3′ end.

SEQ ID NO: 76 is the detennined DNA sequence for the C. trachomatis LGVII clone 19787.6CtL2#19-5′, representing the 5′ end.

SEQ ID NO: 77 is the determined DNA sequence for the C. pneumoniae LGVII clone CpS13-His.

SEQ ID NO: 78 is the determined DNA sequence for the C. pneumoniae LGVII clone Cp_SWIB-His.

SEQ ID NO: 79 is the determined DNA sequence for the C. trachomatis LGVII clone 23-G7-68, sharing partial homology to the L11, L10 and L1ribosomal protein.

SEQ ID NO: 80 is the determined DNA sequence for the C. trachomatis LGVII clone 22-F8-91, sharing homology to the pmpC gene.

SEQ ID NO: 81 is the determined DNA sequence for the C. trachomatis LGVII clone 21-E8-95, sharing homology to the CT610-CT613 genes.

SEQ ID NO: 82 is the determined DNA sequence for the C. trachomatis LGVII clone 19-F12-57, sharing homology to the CT858 and recA genes.

SEQ ID NO: 83 is the determined DNA sequence for the C. trachomatis LGVII clone 19-F12-53, sharing homology to the CT445 gene encoding glutamyltRNA synthetase.

SEQ ID NO: 84 is the determined DNA sequence for the C. trachomatis LGVII clone 19-A5-54, sharing homology to the cryptic plasmid gene.

SEQ ID NO: 85 is the determined DNA sequence for the C. trachomatis LGVII clone 17-E11-72, sharing partial homology to the OppC_(—)2 and pmpDgenes.

SEQ ID NO: 86 is the determined DNA sequence for the C. trachomatis LGVII clone 17-C1-77, sharing partial homology to the CT857 and CT858 openreading frames.

SEQ ID NO: 87 is the determined DNA sequence for the C. trachomatis LGVII clone 15-H2-76, sharing partial homology to the pmpD and SycE genes,and to the CT089 ORF.

SEQ ID NO: 88 is the determined DNA sequence for the C. trachomatis LGVII clone 15-A3-26, sharing homology to the CT858 ORF.

SEQ ID NO: 89 is the determined amino acid sequence for the C.pnuemoniae clone Cp_SWIB-His.

SEQ ID NO: 90 is the determined amino acid sequence for the C.trachomatis LGV II clone CtL2_LPDA_FL.

SEQ ID NO: 91 is the determined amino acid sequence for the C.pnuemoniae clone CpS13-His.

SEQ ID NO: 92 is the determined amino acid sequence for the C.trachomatis LGV II clone CtL2_TSA_FL.

SEQ ID NO: 93 is the amino acid sequence for Ct-Swib 43-61 peptide fromC. trachomatis LGV II.

SEQ ID NO: 94 is the amino acid sequence for Ct-Swib 48-67 peptide fromC. trachomatis LGV II.

SEQ ID NO: 95 is the amino acid sequence for Ct-Swib 52-71 peptide fromC. trachomatis LGV II.

SEQ ID NO: 96 is the amino acid sequence for Ct-Swib 58-77 peptide fromC. trachomatis LGV II.

SEQ ID NO: 97 is the amino acid sequence for Ct-Swib 63-82 peptide fromC. trachomatis LGV II.

SEQ ID NO: 98 is the amino acid sequence for Ct-Swib 51-66 peptide fromC. trachomatis LGV II.

SEQ ID NO: 99 is the amino acid sequence for Cp-Swib 52-67 peptide fromC. pneumonia.

SEQ ID NO: 100 is the amino acid sequence for Cp-Swib 37-51 peptide fromC. pneumonia.

SEQ ID NO: 101 is the amino acid sequence for Cp-Swib 32-51 peptide fromC. pneumonia.

SEQ ID NO: 102 is the amino acid sequence for Cp-Swib 37-56 peptide fromC. pneumonia.

SEQ ID NO: 103 is the amino acid sequence for Ct-Swib 36-50 peptide fromC. trachomatis.

SEQ ID NO: 104 is the amino acid sequcnce for Ct-S13 46-65 peptide fromC. trachomatis.

SEQ ID NO: 105 is the amino acid sequence for Ct-S13 60-80 peptide fromC. trachomatis.

SEQ ID NO: 106 is the amino acid sequence for Ct-S13 1-20 peptide fromC. trachomatis.

SEQ ID NO: 107 is the amino acid sequence for Ct-S13 46-65 peptide fromC. trachomatis.

SEQ ID NO: 108 is the amino acid sequence for Ct-S13 56-75 peptide fromC. trachomatis.

SEQ ID NO: 109 is the amino acid sequence for Cp-S13 56-75 peptide fromC. pneumoniae.

SEQ ID NO: 110 is the determined DNA sequence for the C. trachomatis LGVII clone 21-G12-60, containing partial open reading frames forhypothetical proteins CT875, CT229 and CT228.

SEQ ID NO: 111 is the determined DNA sequence for the C. trachomatis LGVII clone 22-B3-53, sharing homology to the CT110 ORF of GroEL.

SEQ ID NO: 112 is the determined DNA sequence for the C. trachomatis LGVII clone 22-A1-49, sharing partial homology to the CT660 and CT659 ORFs.

SEQ ID NO: 113 is the determined DNA sequence for the C. trachomatis LGVII clone 17-E2-9, sharing partial homology to the CT611 and CT610 ORFs.

SEQ ID NO: 114 is the determined DNA sequence for the C. trachomatis LGVII clone 17-C10-31, sharing partial homology to the CT858 ORF.

SEQ ID NO: 115 is the determined DNA sequence for the C. trachomatis LGVII clone 21-C7-66, sharing homology to the dnaK-like gene.

SEQ ID NO: 116 is the determined DNA sequence for the C. trachomatis LGVII clone 20-G3-45, containing part of the pmpB gene CT413.

SEQ ID NO: 117 is the determined DNA sequence for the C. trachomatis LGVII clone 18-C5-2, sharing homology to the S1 ribosomal protein ORF.

SEQ ID NO: 118 is the determined DNA sequence for the C. trachomatis LGVII clone 17-C5-19, containing part of the ORFs for CT431 and CT430.

SEQ ID NO: 119 is the determined DNA sequence for the C. trachomatis LGVII clone 16-D4-22, contains partial sequences of ORF3 and ORF4 of theplasmid for growth within mammalian cells.

SEQ ID NO: 120 is the determined full-length DNA sequence for the C.trachomatis serovar LGV II Cap1 gene CT529.

SEQ ID NO: 121 is the predicted full-length amino acid sequence for theC. trachomatis serovar LGV II Cap1 gene CT529.

SEQ ID NO: 122 is the determined full-length DNA sequence for the C.trachomatis serovar E Cap1 gene CT529.

SEQ ID NO: 123 is the predicted full-length amino acid sequence for theC. trachomatis serovar E Cap1 gene CT529.

SEQ ID NO: 124 is the determined full-length DNA sequence for the C.trachomatis serovar 1A Cap1 gene CT529.

SEQ ID NO: 125 is the predicted full-length amino acid sequence for theC. trachomatis serovar 1A Cap1 gene CT529.

SEQ ID NO: 126 is the determined full-length DNA sequence for the C.trachomatis serovar G Cap1 gene CT529.

SEQ ID NO: 127 is the predicted full-length amino acid sequence for theC. trachomatis serovar G Cap1 gene CT529.

SEQ ID NO: 128 is the determined full-length DNA sequence for the C.trachomatis serovar F1 NII Cap1 gene CT529.

SEQ ID NO: 129 is the predicted full-length amino acid sequence for theC. trachomatis serovar F1 NII Cap1 gene CT529.

SEQ ID NO: 130 is the determined full-length DNA sequence for the C.trachomatis serovar L1 Cap1 gene CT529.

SEQ ID NO: 131 is the predicted full-length amino acid sequence for theC. trachomatis serovar L1 Cap1 gene CT529.

SEQ ID NO: 132 is the determined full-length DNA sequence for the C.trachomatis serovar L3 Cap1 gene CT529.

SEQ ID NO: 133 is the predicted full-length amino acid sequence for theC. trachomatis serovar L3 Cap1 gene CT529.

SEQ ID NO: 134 is the determined full-length DNA sequence for the C.trachomatis serovar Ba Cap1 gene CT529.

SEQ ID NO: 135 is the predicted full-length amino acid sequence for theC. trachomatis serovar Ba Cap1 gene CT529.

SEQ ID NO: 136 is the determined full-length DNA sequence for the C.trachomatis serovar MOPN Cap1 gene CT529.

SEQ ID NO: 137 is the predicted full-length amino acid sequence for theC. trachomatis serovar MOPN Cap1 gene CT529.

SEQ ID NO: 138 is the determined amino acid sequence for the Cap1 CT529ORF peptide #124-139 of C. trachomatis serovar L2.

SEQ ID NO: 139 is the determined amino acid sequence for the Cap1 CT529ORF peptide #132-147 of C. trachomatis serovar L2.

SEQ ID NO: 140 is the determined amino acid sequence for the Cap1 CT529ORF peptide #138-155 of C. trachomatis serovar L2.

SEQ ID NO: 141 is the determined amino acid sequence for the Cap1 CT529ORF peptide #146-163 of C. trachomatis serovar L2.

SEQ ID NO: 142 is the determined amino acid sequence for the Cap1 CT529ORF peptide #154-171 of C. trachomatis serovar L2.

SEQ ID NO: 143 is the determined amino acid sequence for the Cap1 CT529ORF peptide #162-178 of C. trachomatis serovar L2.

SEQ ID NO: 144 is the determined amino acid sequence for the Cap1 CT529ORF peptide #138-147 of C. trachomatis serovar L2.

SEQ ID NO: 145 is the determined amino acid sequence for the Cap1 CT529ORF peptide #139-147 of C. trachomatis serovar L2.

SEQ ID NO: 146 is the determined amino acid sequence for the Cap1 CT529ORF peptide #140-147 of C. trachomatis serovar L2.

SEQ ID NO: 147 is the determined amino acid sequence for the Cap1 CT529ORF peptide #138-146 of C. trachomatis serovar L2.

SEQ ID NO: 148 is the determined amino acid sequence for the Cap1 CT529ORF peptide #138-145 of C. trachomatis serovar L2.

SEQ ID NO: 149 is the determined amino acid sequence for the Cap1 CT529ORF peptide #F140->I of C. trachomatis serovar L2.

SEQ ID NO: 150 is the determined amino acid sequence for the Cap1 CT529ORF peptide ##S139>Ga of C. trachomatis serovar L2.

SEQ ID NO: 151 is the determined amino acid sequence for the Cap1 CT529ORF peptide ##S139>Gb of C. trachomatis serovar L2.

SEQ ID NO: 152 is the determined amino acid sequence for the peptide #2C7.8-6 of the 216aa ORF of C. trachomatis serovar L2.

SEQ ID NO: 153 is the determined amino acid sequence for the peptide #2C7.8-7 of the 216aa ORF of C. trachomatis serovar L2.

SEQ ID NO: 154 is the determined amino acid sequence for the peptide #2C7.8-8 of the 216aa ORF of C. trachomatis serovar L2.

SEQ ID NO: 155 is the determined amino acid sequence for the peptide #2C7.8-9 of the 216aa ORF of C. trachomatis serovar L2.

SEQ ID NO: 156 is the determined amino acid sequence for the peptide #2C7.8-10 of the 216aa ORF of C. trachomatis serovar L2.

SEQ ID NO: 157 is the determined amino acid sequence for the 53 aminoacid residue peptide of the 216aa ORF within clone 2C7.8 of C.trachomatis serovar L2.

SEQ ID NO: 158 is the determined amino acid sequence for the 52 aminoacid residue peptide of the CT529 ORF within clone 2C7.8 of C.trachomatis serovar L2.

SEQ ID NO: 159 is the determined DNA sequence for the 5′ (forward)primer for cloning full-length CT529 serovar L2.

SEQ ID NO: 160 is the determined DNA sequence for the 5′ (reverse)primer for cloning full-length CT529 serovar L2.

SEQ ID NO: 161 is the determined DNA sequence for the 5′ (forward)primer for cloning full-length CT529 for serovars other than L2 andMOPN.

SEQ ID NO: 162 is the determined DNA sequence for the 5′ (reverse)primer for cloning full-length CT529 serovars other than L2 and MOPN.

SEQ ID NO: 163 is the determined DNA sequence for the, 5′ (forward)primer for cloning full-length CT529 serovar MOPN.

SEQ ID NO: 164 is the determined DNA sequence for the 5′ (reverse)primer for cloning full-length CT529 serovar MOPN.

SEQ ID NO: 165 is the determined DNA sequence for the 5′ (forward)primer for pBIB-KS.

SEQ ID NO: 166 is the determined DNA sequence for the 5′ (reverse)primer for pBIB-KS.

SEQ ID NO: 167 is the determined amino acid sequence for the 9-merepitope peptide Cap1#139-147 from serovar L2.

SEQ ID NO: 168 is the determined amino acid sequence for the 9-merepitope peptide Cap1#139-147 from serovar D.

SEQ ID NO: 169 is the determined full-length DNA sequence for the C.trachomatis pmpI gene.

SEQ ID NO: 170 is the determined full-length DNA sequence for the C.trachomatis pmpG gene.

SEQ ID NO: 171 is the determined full-length DNA sequence for the C.trachomatis pmpE gene.

SEQ ID NO: 172 is the determined full-length DNA sequence for the C.trachomatis pmpD gene.

SEQ ID NO: 173 is the determined full-length DNA sequence for the C.trachomatis pmpC gene.

SEQ ID NO: 174 is the determined full-length DNA sequence for the C.trachomatis pmpB gene.

SEQ ID NO: 175 is the predicted full-length amino acid sequence for theC. trachomatis pmpI gene.

SEQ ID NO: 176 is the predicted full-length amino acid sequence for theC. trachomatis pmpG gene.

SEQ ID NO: 177 is the predicted full-length amino acid sequence for theC. trachomatis pmpE gene.

SEQ ID NO: 178 is the predicted full-length amino acid sequence for theC. trachomatis pmpD gene.

SEQ ID NO: 179 is the predicted full-length amino acid sequence for theC. trachomatis pmpC gene.

SEQ ID NO: 180 is the predicted full-length amino acid sequence for theC. trachomatis pmpB gene.

SEQ ID NO: 181 is the determined DNA sequence minus the signal sequencefor the C. trachomatis pmpI gene.

SEQ ID NO: 182 is a subsequently determined full-length DNA sequence forthe C. trachomatis pmpG gene.

SEQ ID NO: 183 is the determined DNA sequence minus the signal sequencefor the C. trachomatis pmpE gene.

SEQ ID NO: 184 is a first determined DNA sequence representing thecarboxy terminus for the C. trachomatis pmpD gene.

SEQ ID NO: 185 is a second determined DNA sequence representing theamino terminus minus the signal sequnce for the C. trachomatis pmpDgene.

SEQ ID NO: 186 is a first determined DNA sequence representing thecarboxy terminus for the C. trachomatis pmpC gene.

SEQ ID NO: 187 is a second determined DNA sequence representing theamino terminus minus the signal sequence for the C. trachomatis pmpCgene.

SEQ ID NO: 188 is the determined DNA sequence representing the C.pneumoniae serovar MOMPS pmp gene in a fusion molecule with Ra12.

SEQ ID NO: 189 is the predicted amino acid sequence minus the signalsequence for the C. trachomatis pmpI gene.

SEQ ID NO: 190 is subsequently predicted amino acid sequence for the C.trachomatis pmpG gene.

SEQ ID NO: 191 is the predicted amino acid sequence minus the signalsequence for the C. trachomatis pmpE gene.

SEQ ID NO: 192 is a first predicted amino acid sequence representing thecarboxy terminus for the C. trachomatis pmpD gene.

SEQ ID NO: 193 is a second predicted amino acid sequence representingthe Amino terminus minus the signal sequence for the C. trachomatis pmpDgene.

SEQ ID NO: 194 is a first predicted amino acid sequence representing theCarboxy terminus for the C. trachomatis pmpC gene.

SEQ ID NO: 195 is a second predicted amino acid sequence representingthe Amino terminus for the C. trachomatis pmpC gene.

SEQ ID NO: 196 is the predicted amino acid sequence representing the C.pneumoniae serovar MOMPS pmp gene in a fusion molecule with Ra12.

SEQ ID NO: 197 is the determined DNA sequence for the 5′ oligo primerfor cloning the C. trachomatis pmpC gene in the SKB vaccine vector.

SEQ ID NO: 198 is the determined DNA sequence for the 3′ oligo primerfor cloning the C. trachomatis pmpC gene in the SKB vaccine vector.

SEQ ID NO: 199 is the determined DNA sequence for the insertion sequencefor cloning the C. trachomatis pmpC gene in the SKB vaccine vector.

SEQ ID NO: 200 is the determined DNA sequence for the 5′ oligo primerfor cloning the C. trachomatis pmpD gene in the SKB vaccine vector.

SEQ ID NO: 201 is the determined DNA sequence for the 3′ oligo primerfor cloning the C. trachomatis pmpD gene in the SKB vaccine vector.

SEQ ID NO: 202 is the determined DNA sequence for the insertion sequencefor cloning the C. trachomatis pmpD gene in the SKB vaccine vector.

SEQ ID NO: 203 is the determined DNA sequence for the 5′ oligo primerfor cloning the C. trachomatis pmpE gene in the SKB vaccine vector.

SEQ ID NO: 204 is the determined DNA sequence for the 3′ oligo primerfor cloning the C. trachomatis pmpE gene in the SKB vaccine vector.

SEQ ID NO: 205 is the determined DNA sequence for the 5′ oligo primerfor cloning the C. trachomatis pmpG gene in the SKB vaccine vector.

SEQ ID NO: 206 is the determined DNA sequence for the 3′ oligo primerfor cloning the C. trachomatis pmpG gene in the SKB vaccine vector.

SEQ ID NO: 207 is the determined DNA sequence for the 5′ oligo primerfor cloning the amino terminus portion of the C. trachomatis pmpC genein the pET17b vector.

SEQ ID NO: 208 is the determined DNA sequence for the 3′ oligo primerfor cloning the amino terminus portion of the C. trachomatis pmpC genein the pET17b vector.

SEQ ID NO: 209 is the determined DNA sequence for the 5′ oligo primerfor cloning′the carboxy terminus portion of the C. trachomatis pmpC genein the pET17b vector.

SEQ ID NO: 210 is the determined DNA sequence for the 3′ oligo primerfor cloning the carboxy terminus portion of the C. trachomatis pmpC genein the pET17b vector.

SEQ ID NO: 211 is the determined DNA sequence for the 5′ oligo primerfor cloning the amino termninus portion of the C. trachomatis pmpD genein the pET17b vector.

SEQ ID NO: 212 is the determined DNA sequence for the 3′ oligo primerfor cloning the amino terminus portion of the C. trachomatis pmpD genein the pET17b vector.

SEQ ID NO: 213 is the determined DNA sequence for the 5′ oligo primerfor cloning the carboxy terminus portion of the C. trachomatis pmpD genein the pET17b vector.

SEQ ID NO: 214 is the determined DNA sequence for the 3′ oligo primerfor cloning the carboxy terminus portion of the C. trachomatis pmpD genein the pET17b vector.

SEQ ID NO: 215 is the determined DNA sequence for the 5′ oligo primerfor cloning the C. trachomatis pmpE gene in the pET17b vector.

SEQ ID NO: 216 is the determined DNA sequence for the 3′ oligo primerfor cloning the C. trachomatis pmpE gene in the pET17b vector.

SEQ ID NO: 217 is the determined DNA sequence for the insertion sequencefor cloning the C. trachomatis pmpE gene in the pET17b vector.

SEQ ID NO: 218 is the amino acid sequence for the insertion sequence forcloning the C. trachomatis pmpE gene in the pET17b vector.

SEQ ID NO: 219 is the determined DNA sequence for the 5′ oligo primerfor cloning the C. trachomatis pmpG gene in the pET17b vector.

SEQ ID NO: 220 is the determined DNA sequence for the 3′ oligo primer.for cloning the C. trachomatis pmpG gene in the pET17b vector.

SEQ ID NO: 221 is the amino acid sequence for the insertion sequence forcloning the C. trachomatis pmpG gene in the pET17b vector.

SEQ ID NO: 222 is the determined DNA sequence for the 5′ oligo primerfor cloning the C. trachomatis pmpI gene in the pET17b vector.

SEQ ID NO: 223 is the determined DNA sequence for the 3′ oligo primerfor cloning the C. trachomatis pmpI gene in the pET17b vector.

SEQ ID NO: 224 is the determined amino acid sequence for the C.pneumoniae Swib peptide 1-20.

SEQ ID NO: 225 is the determined amino acid sequence for the C.pneumoniae Swib peptide 6-25.

SEQ ID NO: 226 is the determined amino acid sequence for the C.pneumoniae Swib peptide 12-31.

SEQ ID NO: 227 is the determined amino acid sequence for the C.pneumoniae Swib peptide 17-36.

SEQ ID NO: 228 is the determined amino acid sequence for the C.pneumoniae Swib peptide 22-41.

SEQ ID NO: 229 is the determined amino acid sequence for the C.pneumoniae Swib peptide 27-46.

SEQ ID NO: 230 is the determined amino acid sequence for the C.pneumoniae Swib peptide 42-61.

SEQ ID NO: 231 is the determined amino acid sequence for the C.pneumoniae Swib peptide 46-65.

SEQ ID NO: 232 is the determined amino acid sequence for the C.pneumoniae Swib peptide 51-70.

SEQ ID NO: 233 is the determined amino acid sequence for the C.pneumoniae Swib peptide 56-75.

SEQ ID NO: 234 is the determined amino acid sequence for the C.pneumoniae Swib peptide 61-80.

SEQ ID NO: 235 is the determined amino acid sequence for the C.pneumoniae Swib peptide 66-87.

SEQ ID NO: 236 is the determined amino acid sequence for the C.trachomatis OMCB peptide 103-122.

SEQ ID NO: 237 is the determined amino acid sequence for the C.trachomatis OMCB peptide 108-127.

SEQ ID NO: 238 is the determined amino acid sequence for the C.trachomatis OMCB peptide 113-132.

SEQ ID NO: 239 is the determined amino acid sequence for the C.trachomatis OMCB peptide 118-137.

SEQ ID NO: 240 is the determined amino acid sequence for the C.trachomatis OMCB peptide 123-143.

SEQ ID NO: 241 is the determined amino acid sequence for the C.trachomatis OMCB peptide 128-147.

SEQ ID NO: 242 is the determined amino acid sequence for the C.trachomatis OMCB peptide 133-152.

SEQ ID NO: 243 is the determined amino acid sequence for the C.trachomatis OMCB peptide 137-156.

SEQ ID NO: 244 is the determined amino acid sequence for the C.trachomatis OMCB peptide 142-161.

SEQ ID NO: 245 is the determined amino acid sequence for the C.trachomatis OMCB peptide 147-166.

SEQ ID NO: 246 is the determined amino acid sequence for the C.trachomatis OMCB peptide 152-171.

SEQ ID NO: 247 is the determined amino acid sequence for the C.trachomatis OMCB peptide 157-176.

SEQ ID NO: 248 is the determined amino acid sequence for the C.trachomatis OMCB peptide 162-181.

SEQ ID NO: 249 is the determined amino acid sequence for the C.trachomatis OMCB peptide 167-186.

SEQ ID NO: 250 is the determined amino acid sequence for the C.trachomatis OMCB peptide 171-190.

SEQ ID NO: 251 is the determined amino acid sequence for the C.trachomatis OMCB peptide 171-186.

SEQ ID NO: 252 is the determined amino acid sequence for the C.trachomatis OMCB peptide 175-186.

SEQ ID NO: 252 is the determined amino acid sequence for the C.trachomatis OMCB peptide 175-186.

SEQ ID NO: 253 is the determined amino acid sequence for the C.pneumoniae OMCB peptide 185-198.

SEQ ID NO: 254 is the determined amino acid sequence for the C.trachomatis TSA peptide 96-115.

SEQ ID NO: 255 is the determined amino acid sequence for the C.trachomatis TSA peptide 101-120.

SEQ ID NO: 256 is the determined amino acid sequence for the C.trachomatis TSA peptide 106-125.

SEQ ID NO: 257 is the determined amino acid sequence for the C.trachomatis TSA peptide 111-130.

SEQ ID NO: 258 is the determined amino acid sequence for the C.trachomatis TSA peptide 116-135.

SEQ ID NO: 259 is the determined amino acid sequence for the C.trachomatis TSA peptide 121-140.

SEQ ID NO: 260 is the determined amino acid sequence for the C.trachomatis TSA peptide 126-145.

SEQ ID NO: 261 is the determined amino acid sequence for the C.trachomatis TSA peptide 131-150.

SEQ ID NO: 262 is the determined amino acid sequence for the C.trachomatis TSA peptide 136-155.

SEQ ID NO: 263 is the determined full-length DNA sequence for the C.trachomatis CT529/Cap1 gene serovar I.

SEQ ID NO: 264 is the predicted full-length amino sequence for the C.trachomatis CT529/Cap1 gene serovar I.

SEQ ID NO: 265 is the determined full-length DNA sequence for the C.trachomatis CT529/Cap1 gene serovar K.

SEQ ID NO: 266 is the predicted full-length amino sequence for the C.trachomatis CT529/Cap1 gene serovar K.

SEQ ID NO: 267 is the determined DNA sequence for the C. trachomatisclone 17-G4-36 sharing homology to part of the ORF of DNA-dirrected RNApolymerase beta subunit-CT315 in serD.

SEQ ID NO: 268 is the determined DNA sequence for the partial sequenceof the C. trachomatis CT016 gene in clone 2E10.

SEQ ID NO: 269 is the determined DNA sequence for the partial sequenceof the C. trachomatis tRNA syntase gene in clone 2E10.

SEQ ID NO: 270 is the determined DNA sequence for the partial sequencefor the C. trachomatis clpX gene in clone 2E10.

SEQ ID NO: 271 is a first determined DNA sequence for the C. trachomatisclone CtL2gam-30 representing the 5′ end.

SEQ ID NO: 272 is a second determined DNA sequence for the C.trachomatis clone CtL2gam-30 representing the 3′ end.

SEQ ID NO: 273 is the determined DNA sequence for the C. trachomatisclone CtL2gam-28.

SEQ ID NO: 274 is the determined DNA sequence for the C. trachomatisclone CtL2gam-27.

SEQ ID NO: 275 is the determined DNA sequence for the C. trachomatisclone CtL2gam-26.

SEQ ID NO: 276 is the determined DNA sequence for the C. trachomatisclone CtL2gam-24.

SEQ ID NO: 277 is the determined DNA sequence for the C. trachomatisclone CtL2gam-23.

SEQ ID NO: 278 is the determined DNA sequence for the C. trachomatisclone CtL2gam-21.

SEQ ID NO: 279 is the determined DNA sequence for the C. trachomatisclone CtL2gam-18.

SEQ ID NO: 280 is the determined DNA sequence for the C. trachomatisclone CtL2gam-17.

SEQ ID NO: 281 is a first determined DNA sequence for the C. trachomatisclone CtL2gam-15 representing the 5′ end.

SEQ ID NO: 282 is a second determined DNA sequence for the C.trachomatis clone CtL2gam-15 representing the 3′ end.

SEQ ID NO: 283 is the determined DNA sequence for the C. trachomatisclone CtL2gam-13.

SEQ ID NO: 284 is the determined DNA sequence for the C. trachomatisclone CtL2gam-10.

SEQ ID NO: 285 is the determined DNA sequence for the C. trachomatisclone CtL2gam-8.

SEQ ID NO: 286 is a first determined DNA sequence for the C. trachomatisclone CtL2gam-6 representing the 5′ end.

SEQ ID NO: 287 is a second determined DNA sequence for the C.trachomatis clone CtL2gam-6 representing the 3′ end.

SEQ ID NO: 288 is the determined DNA sequence for the C. trachomatisclone CtL2gam-5.

SEQ ID NO: 289 is the determined DNA sequence for the C. trachomatisclone CtL2gam-2.

SEQ ID NO: 290 is the determined DNA sequence for the C. trachomatisclone CtL2gam-1.

SEQ ID NO: 291 is the determined full-length DNA sequence for the C.pneumoniae homologue of the CT529 gene.

SEQ ID NO: 292 is the predicted full-length amino acid sequence for theC. pneumoniae homologue of the CT529 gene.

SEQ ID NO: 293 is the determined DNA sequence for the insertion sequencefor cloning the C. trachomatis pmpG gene in the SKB vaccine vector.

SEQ ID NO: 294 is the amino acid sequence of an open reading frame ofclone CT603.

SEQ ID NO: 295 is the amino acid sequence of a first open reading frameof clone CT875.

SEQ ID NO: 296 is the amino acid sequence of a second open reading frameof clone CT875.

SEQ ID NO: 297 is the amino acid sequence of a first open reading frameof clone CT858.

SEQ ID NO: 298 is the amino acid sequence of a second open reading frameof clone CT858.

SEQ ID NO: 299 is the amino acid sequence of an open reading frame ofclone CT622.

SEQ ID NO: 300 is the amino acid sequence of an open reading frame ofclone CT610.

SEQ ID NO: 301 is the amino acid sequence of an open reading frame ofclone CT396.

SEQ ID NO: 302 is the amino acid sequence of an open reading frame ofclone CT318.

SEQ ID NO: 304 is the amino acid sequence for C. trachomatis, serovar L2rCt529c1-125 having a modified N-terminal sequence (6-His tag).

SEQ ID NO: 305 is the amino acid sequence for C. trachomatis, serovar L2rCt529c1-125.

SEQ ID NO: 306 is the sense primer used in the synthesis of thePmpA(N-term) fusion protein.

SEQ ID NO: 307 is the antisense primer used in the synthesis of thePmpA(N-term) fusion protein.

SEQ ID NO: 308 is the DNA sequence encoding the PmpA(N-term) fusionprotein.

SEQ ID NO: 309 is the amino acid sequence of the PmpA(N-term) fusionprotein.

SEQ ID NO: 310 is the sense primer used in the synthesis of thePmpA(C-term) fusion protein.

SEQ ID NO: 311 is the antisense primer used in the synthesis of thePmpA(C-term) fusion protein.

SEQ ID NO: 312 is the DNA sequence encoding the PmpA(C-term) fusionprotein.

SEQ ID NO: 313 is the amino acid sequence of the PmpA(C-term) fusionprotein.

SEQ ID NO: 314 is the sense primer used in the synthesis of thePmpF(N-term) fusion protein.

SEQ ID NO: 315 is the antisense primer used in the synthesis of thePmpF(N-term) fusion protein.

SEQ ID NO: 316 is the DNA sequence encoding the PmpF(N-term) fusionprotein.

SEQ ID NO: 317 is the amino acid sequence of the PmpF(N-term) fusionprotein.

SEQ ID NO: 318 is the sense primer used in the synthesis of thePmpF(C-term) fusion protein.

SEQ ID NO: 319 is the antisense primer used in the synthesis of thePmpF(C-term) fusion protein.

SEQ ID NO: 320 is the DNA sequence encoding the PmpF(C-term) fusionprotein.

SEQ ID NO: 321 is the amino acid sequence of the PmpF(C-term) fusionprotein.

SEQ ID NO: 322 is the sense primer used in the synthesis of thePmpH(N-term) fusion protein.

SEQ ID NO: 323 is the antisense primer used in the synthesis of thePmpH(N-term) fusion protein.

SEQ ID NO: 324 is the DNA sequence encoding the PmpH(N-term) fusionprotein.

SEQ ID NO: 325 is the amino acid sequence of the PmpH(N-term) fusionprotein.

SEQ ID NO: 326 is the sense primer used in the synthesis of thePmpH(C-term) fusion protein.

SEQ ID NO: 327 is the antisense primer used in the synthesis of thePmpH(C-term) fusion protein.

SEQ ID NO: 328 is the DNA sequence encoding the PmpH(C-term) fusionprotein.

SEQ ID NO: 329 is the amino acid sequence of the PmpH(C-term) fusionprotein.

SEQ ID NO: 330 is the sense primer used in the synthesis of the PmpB(1)fusion protein.

SEQ ID NO: 331 is the antisense primer used in the synthesis of thePmpB(1) fusion protein.

SEQ ID NO: 332 is the DNA sequence encoding the PmpB(1) fusion protein.

SEQ ID NO: 333 is the amino acid sequence of the PmpB(1) fusion protein.

SEQ ID NO: 334 is the sense primer used in the synthesis of the PmpB(2)fusion protein.

SEQ ID NO: 335 is the antisense primer used in the synthesis of thePmpB(2) fusion protein.

SEQ ID NO: 336 is the DNA sequence encoding the PmpB(2) fusion protein.

SEQ ID NO: 337 is the amino acid sequence of the PmpB(2) fusion protein.

SEQ ID NO: 338 is the sense primer used in the synthesis of the PmpB(3)fusion protein.

SEQ ID NO: 339 is the antisense primer used in the synthesis of thePmpB(3) fusion protein.

SEQ ID NO: 340 is the DNA sequence encoding the PmpB(3) fusion protein.

SEQ ID NO: 341 is the amino acid sequence of the PmpB(3) fusion protein.

SEQ ID NO: 342 is the sense primer used in the synthesis of the PmpB(4)fusion protein.

SEQ ID NO: 343 is the antisense primer used in the synthesis of thePmpB(4) fusion protein.

SEQ ID NO: 344 is the DNA sequence encoding the PmpB(4) fusion protein.

SEQ ID NO: 345 is the amino acid sequence of the PmpB(4) fusion protein.

SEQ ID NO: 346 is the sense primer used in the synthesis of the PmpC(1)fusion protein.

SEQ ID NO: 347 is the antisense primer used in -the synthesis of thePmpC(1) fusion protein.

SEQ ID NO: 348 is the DNA sequence encoding the PmpC(1) fusion protein.

SEQ ID NO: 349 is the amino acid sequence of the PmpC(1) fusion protein.

SEQ ID NO: 350 is the sense primer used in the synthesis of the PmpC(2)fusion protein.

SEQ ID NO: 351 is the antisense primer used in the synthesis of thePmpC(2) fusion protein.

SEQ ID NO: 352 is the DNA sequence encoding the PmpC(2) fusion protein.

SEQ ID NO: 353 is the amino acid sequence of the PmpC(2) fusion protein.

SEQ ID NO: 354 is the sense primer used in the synthesis of the PmpC(3)fusion protein.

SEQ ID NO: 355 is the antisense primer used in the synthesis of thePmpC(3) fusion protein.

SEQ ID NO: 356 is the DNA sequence encoding the PmpC(3) fusion protein.

SEQ ID NO: 357 is the amino acid sequence of the PmpC(3) fusion protein.

DESCRIPTION OF THE FIGURES

FIG. 1 illustrates induction of INF-γ from a Chlamydia-specific T cellline activated by target cells expressing clone 4C9-18#2.

FIG. 2 illustrates retroviral vectors pBIB-KS1,2,3 modified to contain aKosak translation initiation site and stop codons.

FIG. 3 shows specific lysis in a chromium release assay of P815 cellspulsed with Chlamydia peptides CtC7.8-12 (SEQ ID NO: 18) and CtC7.8-13(SEQ ID NO: 19).

FIG. 4 shows antibody isotype titers in C57B1/6 mice immunized with C.trachomatis SWIB protein.

FIG. 5 shows Chlamydia-specific T-cell proliferative responses insplenocytes from C3H mice immunized with C. trachomatis SWIB protein.

FIG. 6 illustrates the 5′ and 3′ primer sequences designed from C.pneumoniae which were used to isolate the SWIB and S13 genes from C.pneumoniae.

FIGS. 7A and 7B show induction of IFN-γ from a human anti-chlamydiaT-cell line (TCL-8) capable of cross-reacting to C. trachomatis and C.pneumonia upon activation by monocyte-derived dendritic cells expressingchlamydial proteins.

FIG. 8 shows the identification of T cell epitopes in Chlamydialribosomal S13 protein with T-cell line TCL 8 EB/DC.

FIG. 9 illustrates the proliferative response of CP-21 T-cells generatedagainst C. pnuemoniae-infected dendritic cells to recombinant C.pneumonia-SWIB protein, but not C. trachomatis SWIB protein.

FIG. 10 shows the C. trachomatis-specific SWIB proliferative responsesof a primary T-cell line (TCT-10 EB) from an asymptomatic donor.

FIG. 11 illustrates the identification of T-cell epitope in C.trachomatis SWIB with an antigen specific T-cell line (TCL-10 EB).

DETAILED DESCRIPTION OF THE INVENTION

As noted above, the present invention is generally directed tocompositions and methods for the diagnosis and treatment of Chlamydialinfection. In one aspect, the compositions of the subject inventioninclude polypeptides that comprise at least one immunogenic portion of aChlamydia antigen, or a variant thereof.

In specific embodiments, the subject invention discloses polypeptidescomprising an immunogenic portion of a Chlamydia antigen, wherein theChlamydia antigen comprises an amino acid sequence encoded by apolynucleotide molecule including a sequence selected from the groupconsisting of (a) nucleotide sequences recited in SEQ ID NO: 1, 15,21-25, 44-64, 66-76, 79-88, 110-119, 120, 122, 124, 126, 128, 130, 132,134, 136, 169-174, 181-188, 263, 265 and 267-290 (b) the complements ofsaid nucleotide sequences, and (c) variants of such sequences.

As used herein, the termr “polypeptide” encompasses amino acid chains ofany length, including full length proteins (i.e., antigens), wherein theamino acid residues are linked by covalent peptide bonds. Thus, apolypeptide comprising an immunogenic portion of one of the inventiveantigens may consist entirely of the immunogenic portion, or may containadditional sequences. The additional sequences may be derived from thenative Chlamydia antigen or may be heterologous, and such sequences may(but need not) be immunogenic.

The term “polynucleotide(s),” as used herein, means a single ordouble-stranded polymer of deoxyribonucleotide or ribonucleotide basesand includes DNA and corresponding RNA molecules, including HnRNA andmRNA molecules, both sense and anti-sense strands, and comprehends cDNA,genomic DNA and recombinant DNA, as well as wholly or partiallysynthesized polynucleotides. An HnRNA molecule contains introns andcorresponds to a DNA molecule in a generally one-to-one manner. An mRNAmolecule corresponds to an HnRNA and DNA molecule from which the intronshave been excised. A polynucleotide may consist of an entire gene, orany portion thereof. Operable anti-sense polynucleotides may comprise afragment of the corresponding polynucleotide, and the definition of“polynucleotide” therefore includes all such operable anti-sensefragments.

An “immunogenic portion” of an antigen is a portion that is capable ofreacting with sera obtained from a Chlamydia-infected individual (i.e.,generates an absorbance reading with sera from infected individuals thatis at least three standard deviations above the absorbance obtained withsera from uninfected individuals, in a representative ELISA assaydescribed herein). Such immunogenic portions generally comprise at leastabout 5 amino acid residues, more preferably at least about 10, and mostpreferably at least about 20 amino acid residues. Methods for preparingand identifying immunogenic portions of antigens of known sequence arewell known in the art and include those summarized in Paul, FundamentalImmunology, 3rd ed., Raven Press, 1993, pp. 243-247 and references citedtherein. Such techniques include screening polypeptides for the abilityto react with antigen-specific antibodies, antisera and/or T-cell linesor clones. As used herein, antisera and antibodies are“antigen-specific” if they specifically bind to an antigen (i.e., theyreact with the protein in an ELISA or other immunoassay, and do notreact detectably with unrelated proteins). Such antisera and antibodiesmay be prepared as described herein, and using well known techniques. Animmunogenic portion of a native Chlamydia protein is a portion thatreacts with such antisera and/or T-cells at a level that is notsubstantially less than the reactivity of the full length polypeptide(e.g., in an ELISA and/or T-cell reactivity assay). Such immunogenicportions may react within such assays at a level that is similar to orgreater than the reactivity of the full length polypeptide. Such screensmay generally be performed using methods well known to those of ordinaryskill in the art, such as those described in Harlow and Lane,Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988.For example, a polypeptide may be immobilized on a solid support andcontacted with patient sera to allow binding of antibodies within thesera to the immobilized polypeptide. Unbound sera may then be removedand bound antibodies detected using, for example, ¹²⁵I-labeled ProteinA.

Examples of immunogenic portions of antigens contemplated by the presentinvention include, for example, the T cell stimulating epitopes providedin SEQ ID NO: 9, 10, 18, 19, 31, 39, 93-96, 98, 100-102, 106, 108,138-140, 158, 167, 168, 246, 247 and 254-256. Polypeptides comprising atleast an immunogenic portion of one or more Chlamydia antigens asdescribed herein may generally be used, alone or in combination, todetect Chlamydial infection in a patient.

The compositions and methods of the present invention also encompassvariants of the above polypeptides and polynucleotide molecules. Suchvariants include, but are not limited to, naturally occurring allelicvariants of the inventive sequences. In particular, variants includeother Chlamydiae serovars, such as serovars D, E and F, as well as theseveral LGV serovars which share homology to the inventive polypeptideand polynucleotide molecules described herein. Preferably, the serovarhomologues show 95-99% homology to the corresponding polypeptidesequence(s) described herein.

A polypeptide “variant,” as used herein, is a polypeptide that differsfrom the recited polypeptide only in conservative substitutions and/ormodifications, such that the antigenic properties of the polypeptide areretained. In a preferred embodiment, variant polypeptides differ from anidentified sequence by substitution, deletion or addition of five aminoacids or fewer. Such variants may generally be identified by modifyingone of the above polypeptide sequences, and evaluating the antigenicproperties of the modified polypeptide using, for example, therepresentative procedures described herein. In other words, the abilityof a variant to react with antigen-specific antisera may be enhanced orunchanged, relative to the native protein, or may be diminished by lessthan 50%, and preferably less than 20%, relative to the native protein.Such variants may generally be identified by modifying one of the abovepolypeptide sequences and evaluating the reactivity of the modifiedpolypeptide with antigen-specific antibodies or antisera as describedherein. Preferred variants include those in which one or more portions,such as an N-terminal leader sequence or transmembrane domain, have beenremoved. Other preferred variants include variants in which a smallportion (e.g., 1-30 amino acids, preferably 5-15 amino acids) has beenremoved from the N- and/or C-terminal of the mature protein.

As used herein, a “conservative substitution” is one in which an aminoacid is substituted for another amino acid that has similar properties,such that one skilled in the art of peptide chemistry would expect thesecondary structure and hydropathic nature of the polypeptide to besubstantially unchanged. Amino acid substitutions may generally be madeon the basis of similarity in polarity, charge, solubility,hydrophobicity, hydrophilicity and/or the amphipathic nature of theresidues. For example, negatively charged amino acids include asparticacid and glutamic acid; positively charged amino acids include lysineand arginine; and amino acids with uncharged polar head groups havingsimilar hydrophilicity values include leucine, isoleucine and valine;glycine and alanine; asparagine and glutamine; and serine, threonine,phenylalanine and tyrosine. Other groups of amino acids that mayrepresent conservative changes include: (1) ala, pro, gly, glu, asp,gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala,phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. A variant may also,or alternatively, contain nonconservative changes. In a preferredembodiment, variant polypeptides differ from a native sequence bysubstitution, deletion or addition of five amino acids or fewer.Variants may also (or alternatively) be modified by, for example, thedeletion or addition of amino acids that have minimal influence on theimmunogenicity, secondary structure and hydropathic nature of thepolypeptide. Variants may also, or alternatively, contain othermodifications, including the deletion or addition of amino acids thathave minimal influence on the antigenic properties, secondary structureand hydropathic nature of the polypeptide. For example, a polypeptidemay be conjugated to a signal (or leader) sequence at the N-terminal endof the protein which co-translationally or post-translationally directstransfer of the protein. The polypeptide may also be conjugated to alinker or other sequence for ease of synthesis, purification oridentification of the polypeptide (e.g., poly-His), or to enhancebinding of the polypeptide to a solid support. For example, apolypeptide may be conjugated to an immunoglobulin Fc region.

A polynucleotide “variant” is a sequence that differs from the recitednucleotide sequence in having one or more nucleotide deletions,substitutions or additions such that the immunogenicity of the encodedpolypeptide is not diminished, relative to the native protein. Theeffect on the immunogenicity of the encoded polypeptide may generally beassessed as described herein. Such modifications may be readilyintroduced using standard mutagenesis techniques, such asoligonucleotide-directed site-specific mutagenesis as taught, forexample, by Adelman et al. (DNA, 2:183, 1983). Nucleotide variants maybe naturally occurring allelic variants as discussed below, ornon-naturally occurring variants. The polypeptides provided by thepresent invention include variants that are encoded by polynucleotidesequences which are substantially homologous to one or more of thepolynucleotide sequences specifically recited herein. “Substantialhomology,” as used herein, refers to polynucleotide sequences that arecapable of hybridizing under moderately stringent conditions. Suitablemoderately stringent conditions include prewashing in a solution of5×SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50° C.-65° C.,5×SSC, overnight or, in the event of cross-species homology, at 45° C.with 0.5×SSC; followed by washing twice at 65° C. for 20 minutes witheach of 2×, 0.5× and 0.2×SSC containing 0.1% SDS. Such hybridizingpolynucleotide sequences are also within the scope of this invention, asare nucleotide sequences that, due to code degeneracy, encode apolypeptide that is the same as a polypeptide of the present invention.

Two nucleotide or polypeptide sequences are said to be “identical” ifthe sequence of nucleotides or amino acid residues in the two sequencesis the same when aligned for maximum correspondence as described below.Comparisons between two sequences are typically performed by comparingthe sequences over a comparison window to identify and compare localregions of sequence similarity. A “comparison window” as used herein,refers to a segment of at least about 20 contiguous positions, usually30 to about 75, 40 to about 50, in which a sequence may be compared to areference sequence of the same number of contiguous positions after thetwo sequences are optimally aligned.

Optimal alignment of sequences for comparison may be conducted using theMegalign program in the Lasergene suite of bioinformatics software(DNASTAR, Inc., Madison, Wis.), using default parameters. This programembodies several alignment schemes described in the followingreferences: Dayhoff, Mo. (1978) A model of evolutionary change inproteins—Matrices for detecting distant relationships. In Dayhoff, Mo.(ed.) Atlas of Protein Sequence and Structure, National BiomedicalResarch Foundaiton, Washington D.C. Vol. 5, Suppl. 3, pp. 345-358; HeinJ. (1990) Unified Approach to Alignment and Phylogenes pp. 626-645Methods in Enzymology vol. 183, Academic Press, Inc., San Diego, Calif.;Higgins, D. G. and Sharp, P. M. (1989) Fast and sensitive multiplesequence alignments on a microcomputer CABIOS 5:151-153; Myers, E. W.and Muller W. (1988) Optimal alignments in linear space CABIOS 4:11-17;Robinson, E. D. (1971) Comb. Theor 11:105; Santou, N. Nes, M. (1987) Theneighbor joining method. A new method for reconstructing phylogenetictrees Mol. Biol. Evol. 4:406-425; Sneath, P. H. A. and Sokal, R. R.(1973) Numerical Taxonomy—the Principles and Practice of NumericalTaxonomy, Freeman Press, San Francisco, Calif.; Wilbur, W. J. andLipman, D. J. (1983) Rapid similarity searches of nucleic acid andprotein data banks Proc. Natl. Acad., Sci. USA 80:726-730.

Alternatively, optimal alignment of sequences for comparison may beconducted by the local identity algorithm of Smith and Waterman (1981)Add. APL. Math 2:482, by the identity alignment algorithm of Needlemanand Wunsch (1970) J. Mol. Biol. 48:443, by the search for similaritymethods of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. (U.S.A.) 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT,BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package,Genetics Computer Group (GCG), 575 Science Dr., Madison, Wis.), or byinspection.

One illustrative example of algorithms that are suitable for determiningpercent sequence identity and sequence similarity are the BLAST andBLAST 2.0 algorithms, which are described in Altschul et al. (1977) Nuc.Acids Res. 25:3389-3402 and Altschul et al. (1990) J. Mol. Biol.215:403-410, respectively. BLAST and BLAST 2.0 can be used, for examplewith the parameters described herein to determine percent sequenceidentity for the polynucleotides and polypeptides of the invention.Software for performing BLAST analyses is publicly available through theNational Center for Biotechnology Information, National Library ofMedicine, Building 38A, Bethesda. Md. 20894. In one illustrativeexample, cumulative scores can be calculated using, for nucleotidesequences, the parameters M (reward score for a pair of matchingresidues; always >0) and N (penalty score for mismatching residues;always <0). For amino acid sequences, a scoring matrix can be used tocalculate the cumulative score. Extension of the word hits in eachdirection are halted when: the cumulative alignment score falls off bythe quantity X from its maximum achieved value; the cumulative scoregoes to zero or below. due to the accumulation of one or morenegative-scoring residue alignments; or the end of either sequence isreached. The BLAST algorithm parameters W, T and X determine thesensitivity and speed of the alignment. The BLASTN program (fornucleotide sequences) uses as defaults a wordlength (W) of 11, andexpectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff andHenikoff(11989) Proc. Natl. Acad. Sci. USA 89:10915) alignments, (B) of50, expectation (E) of 10, M=5 N=−4 and a comparison of both strands.

Preferably, the “percentage of sequence identity” is determined bycomparing two optimally aligned sequences over a window of comparison ofat least 20 positions, wherein the portion of the polynucleotide oramino acid sequence in the comparison window may comprise additions ordeletions (i.e. gaps) of 20 percent or less, usually 5 to 15 percent, or10 to 12 percent, as compared to the reference sequences (which does notcomprise additions or deletions) for optimal alignment of the twosequences. The percentage is calculated by determining the number ofpositions at which the identical nucleic acid bases or amino acidresidue occurs in both sequences to yield the number of matchedpositions, dividing the number of matched positions by the total numberof positions in the reference sequence (i.e. the window size) andmultiplying the results by 100 to yield the percentage of sequenceidentity.

Therefore, the present invention provides polynucleotide and polypeptidesequences having substantial identity to the sequences disclosed herein,for example those comprising at least 50% or more sequence identity,preferably at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%,97%, 98%, or 99% or higher, sequence identity compared to apolynucleotide or polypeptide sequence of this invention using themethods described herein, (e.g., BLAST analyisis using standardparameters, as described below). One skilled in this art will recognizethat these values can be appropriately adjusted to determinecorresponding identity of proteins encoded by two polynucleotidesequences by taking into account codon degeneracy, amino acidsimilarity, reading frame positioning and the like.

In additional embodiments, the present invention provides isolatedpolynucleotides or polypeptides comprising various lengths of contiguousstretches of sequence identical to or complementary to one or more ofthe sequences disclosed herein. For example, polynucleotides and-polypeptides encompassed by this invention may comprise at least about15, 20, 30, 40, 50, 75, 100, 150, 200, 300, 400, 500 or 1000 or morecontiguous nucleotides of one or more of the disclosed sequences, aswell as all intermediate lengths therebetween. It will be readilyunderstood that “intermediate lengths”, in this context, means anylength between the quoted values, such as 16, 17, 18, 19, etc.; 21, 22,23, etc.; 30, 31, 32, etc.; 50, 51, 52, 53, etc.; 100, 101, 102, 103,etc.; 150, 151, 152, 153, etc.; including all integers through the200-500; 500-1,000, and the like.

The polynucleotides of the present invention, or fragments thereof,regardless of the length of the coding sequence itself, may be combinedwith other DNA sequences, such as promoters, polyadenylation signals,additional restriction enzyme sites, multiple cloning sites, othercoding segments, and the like, such that their overall length may varyconsiderably. It is therefore contemplated that a nucleic acid fragmentof almost any length may be employed, with the total length preferablybeing limited by the ease of preparation and use in the intendedrecombinant DNA protocol. For example, illustrative DNA segments withtotal lengths of about 10,000, about 5000, about 3000, about 2,000,about 1,000, about 500, about 200, about 100, about 50 base pairs inlength, and the like, (including all intermediate lengths) arecontemplated to be useful in many implementations of this invention.

Also included in the scope of the present invention are alleles of thegenes encoding the nucleotide sequences recited in herein. As usedherein, an “allele” or “allellic sequence” is an alternative form of thegene which may result from at least one mutation in the nucleic acidsequence. Alleles may result in altered mRNAs or polypeptides whosestructure or function may or may not be altered. Any given gene may havenone, one, or many allelic forms. Common mutational changes which giverise to alleles are generally ascribed to natural deletions, additions,or substitutions of nucleotides. Each of these types of changes mayoccur alone or in combination with the others, one or more times in agiven sequence. In specific embodiments, the subject invention disclosespolypeptides comprising at least an immunogenic portion of a Chlamydiaantigen (or a variant of such an antigen), that comprises one or more ofthe amino acid sequences encoded by (a) a polynucleotide sequenceselected from the group consisting of SEQ ID NO: 1-4, 15 21-25, 44-64,66-76 and 79-88; (b) the complements of such DNA sequences or (c) DNAsequences substantially homologous to a sequence in (a) or (b). Asdiscussed in the Examples below, several of the Chlamydia antigensdisclosed herein recognize a T cell line that recognizes both Chlamydiatrachomatis and Chlamydia pneumoniae infected monocyte-derived dendriticcells, indicating that they may represent an immunoreactive epitopeshared by Chlamydia trachomatis and Chlamydia pneumoniae. The antigensmay thus be employed in a vaccine for both C. trachomatis genital tractinfections and for C. pneumonia infections. Further characterization ofthese Chlamydia antigens from Chlamydia trachomatis and Chlamydiapneumonia to determine the extent of cross-reactivity is provided inExample 6. Additionally, Example 4 describes cDNA fragments (SEQ ID NO:15, 16 and 33) isolated from C. trachomatis which encode proteins (SEQID NO: 17-19 and 32) capable of stimulating a Chlamydia-specific murineCD8+ T cell line.

In general, Chlamydia antigens, and polynucleotide sequences encodingsuch antigens, may be prepared using any of a variety of procedures. Forexample, polynucleotide molecules encoding Chlamydia antigens may beisolated from a Chlamydia genomic or cDNA expression library byscreening with a Chlamydia-specific T cell line as described below, andsequenced using techniques well known to those of skill in the art.Additionally, a polynucleotide may be identified, as described in moredetail below, by screening a microarray of cDNAs forChlamydia-associated expression (i.e., expression that is at least twofold greater in Chlamydia-infected cells than in controls, as determinedusing a representative assay provided herein). Such screens may beperformed using a Synteni microarray (Palo Alto, Calif.) according tothe manufacturer's instructions (and essentially as described by Schenaet al., Proc. Natl. Acad. Sci. USA 93:10614-10619, 1996 and Heller etal., Proc. Natl. Acad. Sci. USA 94:2150-2155, 1997). Alternatively,polypeptides may be amplified from cDNA prepared from cells expressingthe proteins described herein. Such polynucleotides may be amplified viapolymerase chain reaction (PCR). For this approach, sequence-specificprimers may be designed based on the sequences provided herein, and maybe purchased or synthesized.

Antigens may be produced recombinantly, as described below, by insertinga polynucleotide sequence that encodes the antigen into an expressionvector and expressing the antigen in an appropriate host. Antigens maybe evaluated for a desired property, such as the ability to react withsera obtained from a Chlamydia-infected individual as described herein,and may be sequenced using, for example, traditional Edman chemistry.See Edman and Berg, Eur. J. Biochem. 80:116-132, 1967.

Polynucleotide sequences encoding antigens may also be obtained byscreening an appropriate Chlamydia cDNA or genomic DNA library forpolynucleotide sequences that hybridize to degenerate oligonucleotidesderived from partial amino acid sequences of isolated antigens.Degenerate oligonucleotide sequences for use in such a screen may bedesigned and synthesized, and the screen may be performed, as described(for example) in Sambrook et al., Molecular Cloning: A LaboratoryManual, Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y. (andreferences cited therein). Polymerase chain reaction (PCR) may also beemployed, using the above oligonucleotides in methods well known in theart, to isolate a nucleic acid probe from a cDNA or genomic library. Thelibrary screen may then be performed using the isolated probe.

An amplified portion may be used to isolate a full length gene from asuitable library (e.g., a Chlamydia cDNA library) using well knowntechniques. Within such techniques, a library (cDNA or genomic) isscreened using one or more polynucleotide probes or primers suitable foramplification. Preferably, a library is size-selected to include largermolecules. Random primed libraries may also be preferred for identifying5′ and upstream regions of genes. Genomic libraries are preferred forobtaining introns and extending 5′ sequences.

For hybridization techniques, a partial sequence may be labeled (e.g.,by nick-translation or end-labeling with ³²P) using well knowntechniques. A bacterial or bacteriophage library is then screened byhybridizing filters containing denatured bacterial colonies (or lawnscontaining phage plaques) with the labeled probe (see Sambrook et al.,Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories,Cold Spring Harbor, N.Y., 1989). Hybridizing colonies or plaques aresclected and expanded, and the DNA is isolated for further analysis.cDNA clones may be analyzed to determine the amount of additionalsequence by, for example, PCR using a primer from the partial sequenceand a primer from the vector. Restriction maps and partial sequences maybe generated to identify one or more overlapping clones. The completesequence may then be determined using standard techniques, which mayinvolve generating a series of deletion clones. The resultingoverlapping sequences are then assembled into a single contiguoussequence. A full length cDNA molecule can be generated by ligatingsuitable fragments, using well known techniques.

Alternatively, there are numerous amplification techniques for obtaininga full length coding sequence from a partial cDNA sequence. Within suchtechniques, amplification is generally performed via PCR. Any of avariety of commercially available kits may be used to perform theamplification step. Primers may be designed using techniques well knownin the art (see, for example, Mullis et al., Cold Spring Harbor Symp.Quant. Biol. 51:263, 1987; Erlich ed., PCR Technology, Stockton Press,N.Y., 1989), and software well known in the art may also be employed.Primers are preferably 22-30 nucleotides in length, have a GC content ofat least 50% and anneal to the target sequence at temperatures of about68° C. to 72° C. The amplified region may be sequenced as describedabove, and overlapping sequences assembled into a contiguous sequence.

One such amplification technique is inverse PCR (see Triglia et al.,Nucl. Acids Res. 16:8186, 1988), which uses restriction enzymes togenerate a fragment in the known region of the gene. The fragment isthen circularized by intramolecular ligation and used as a template forPCR with divergent primers derived from the known region. Within analternative approach, sequences adjacent to a partial sequence may beretrieved by amplification with a primer to a linker sequence and aprimer specific to a known region. The amplified sequences are typicallysubjected to a second round of amplification with the same linker primerand a second primer specific to the known region. A variation on thisprocedure, which employs two primers that initiate extension in oppositedirections from the known sequence, is described in WO 96/38591.Additional techniques include capture PCR (Lagerstrom et al., PCRMethods Applic. 1:111-19, 1991) and walking PCR (Parker et al., Nucl.Acids. Res. 19:3055-60, 1991). Transcription-Mediated Amplification, orTMA is another method that may be utilized for the amplification of DNA,rRNA, or mRNA, as described in Patent No. PCT/US91/03184. Thisautocatalytic and isothermic non-PCR based method utilizes two primersand two enzymes: RNA polymerase and reverse transcriptase. One primercontains a promoter sequence for RNA polymerase. In the firstamplification, the promoter-primer hybridizes to the target rRNA at adefined site. Reverse transcriptase creates a DNA copy of the targetrRNA by extension from the 3′ end of the promoter-primer. The RNA in theresulting complex is degraded and a second primer binds to the DNA copy.A new strand of DNA is synthesized from the end of the primer by reversetranscriptase creating double stranded DNA. RNA polymerase recognizesthe promoter sequence in the DNA template and initiates transcription.Each of the newly synthesized RNA amplicons re-enters the TMA processand serves as a template for a new round of replication leading to theexpotential expansion of the RNA amplicon. Other methods employingamplification may also be employed to obtain a full length cDNAsequence.

In certain instances, it is possible to obtain a full length cDNAsequence by analysis of sequences provided in an expressed sequence tag(EST) database, such as that available from GenBank. Searches foroverlapping ESTs may generally be performed using well known programs(e.g., NCBI BLAST searches), and such ESTs may be used to generate acontiguous full length sequence. Full length cDNA sequences may also beobtained by analysis of genomic fragments.

Polynucleotide variants may generally be prepared by any method known inthe art, including chemical synthesis by, for example, solid phasephosphoramidite chemical synthesis. Modifications in a polynucleotidesequence may also be introduced using standard mutagenesis techniques,such as oligonucleotide-directed site-specific mutagenesis (see Adelmanet al., DNA 2:183, 1983). Alternatively, RNA molecules may be generatedby in vitro or in vivo transcription of DNA sequences encoding aChlamydial protein, or portion thereof, provided that the DNA isincorporated into a vector with a suitable RNA polymerase promoter (suchas T7 or SP6). Certain portions may be used to prepare an encodedpolypeptide, as described herein. In addition, or alternatively, aportion may be administered to a patient such that the encodedpolypeptide is generated in vivo (e.g., by transfectingantigen-presenting cells, such as dendritic cells, with a cDNA constructencoding a Chlamydial polypeptide, and administering the transfectedcells to the patient).

A portion of a sequence complementary to a coding sequence (i.e., anantisense polynucleotide) may also be used as a probe or to modulategene expression. cDNA constructs that can be transcribed into antisenseRNA may also be introduced into cells of tissues to facilitate theproduction of antisense RNA. An antisense polynucleotide may be used, asdescribed herein, to inhibit expression of a Chlamydial protein.Antisense technology can be used to control gene expression throughtriple-helix formation, which compromises the ability of the doublehelix to open sufficiently for the binding of polymerases, transcriptionfactors or regulatory molecules (see Gee et al., In Huber and Carr,Molecular and Immunologic Approaches, Futura Publishing Co. (Mt. Kisco,N.Y.; 1994)). Alternatively, an antisense molecule may be designed tohybridize with a control region of a gene (e.g., promoter, enhancer ortranscription initiation site), and block transcription of the gene; orto block translation by inhibiting binding of a transcript to ribosomes.

A portion of a coding sequence, or of a complementary sequence, may alsobe designed as a probe or primer to detect gene expression. Probes maybe labeled with a variety of reporter groups, such as radionuclides andenzymes, and are preferably at least 10 nucleotides in length, morepreferably at least 20 nucleotides in length and still more preferablyat least 30 nucleotides in length. Primers, as noted above, arepreferably 22-30 nucleotides in length.

Any polynucleotide may be further modified to increase stability invivo. Possible modifications include, but are not limited to, theaddition of flanking sequences at the 5′ and/or 3′ ends; the use ofphosphorothioate or 2′ O-methyl rather than phosphodiesterase linkagesin the backbone; and/or the inclusion of nontraditional bases such asinosine, queosine and wybutosine, as well as acetyl- methyl-, thio- andother modified forms of adenine, cytidine, guanine, thymine and uridine.

Nucleotide sequences as described herein may be joined to a variety ofother nucleotide sequences using established recombinant DNA techniques.For example, a polynucleotide may be cloned into any of a variety ofcloning vectors, including plasmids, phagemids, lambda phage derivativesand cosmids. Vectors of particular interest include expression vectors,replication vectors, probe generation vectors and sequencing vectors. Ingeneral, a vector will contain an origin of replication functional in atleast one organism, convenient restriction endonuclease sites and one ormore selectable markers. Other elements will depend upon the desireduse, and will be apparent to those of ordinary skill in the art.

Synthetic polypeptides having fewer than about 100 amino acids, andgenerally fewer than about 50 amino acids, may be generated usingtechniques well known in the art. For example, such polypeptides may besynthesized using any of the commercially available solid-phasetechniques, such as the Merrifield solid-phase synthesis method, whereamino acids are sequentially added to a growing amino acid chain. SeeMerrifield, J. Am. Chem. Soc. 85:2149-2146, 1963. Equipment forautomated synthesis of polypeptides is commercially available fromsuppliers such as Perkin Elmer/Applied BioSystems Division, Foster City,Calif., and may be operated according to the manufacturer'sinstructions.

As noted above, immunogenic portions of Chlamydia antigens may beprepared and identified using well known techniques, such as thosesummarized in Paul, Fundamental Immunology, 3d ed., Raven Press, 1993,pp. 243-247 and references cited therein. Such techniques includescreening polypeptide portions of the native antigen for immunogenicproperties. The representative ELISAs described herein may generally beemployed in these screens. An immunogenic portion of a polypeptide is aportion that, within such representative assays, generates a signal insuch assays that is substantially similar to that generated by the fulllength antigen. In other words, an immunogenic portion of a Chlamydiaantigen generates at least about 20%, and preferably about 100%, of thesignal induced by the full length antigen in a model ELISA as describedherein.

Portions and other variants of Chlamydia antigens may be generated bysynthetic or recombinant means. Variants of a native antigen maygenerally be prepared using standard mutagenesis techniques, such asoligonucleotide-directed site-specific mutagenesis. Sections of thepolynucleotide sequence may also be removed using standard techniques topermit preparation of truncated polypeptides.

Recombinant polypeptides containing portions and/or variants of a nativeantigen may be readily prepared from a polynucleotide sequence encodingthe polypeptide using a variety of techniques well known to those ofordinary skill in the art. For example, supernatants from suitablehost/vector systems which secrete recombinant protein into culture mediamay be first concentrated using a commercially available filter.Following concentration, the concentrate may be applied to a suitablepurification matrix such as an affinity matrix or an ion exchange resin.Finally, one or more reverse phase HPLC steps can be employed to furtherpurify a recombinant protein.

Any of a variety of expression vectors known to those of ordinary skillin the art may be employed to express recombinant polypeptides asdescribed herein. Expression may be achieved in any appropriate hostcell that has been transformed or transfected with an expression vectorcontaining a polynucleotide molecule that encodes a recombinantpolypeptide. Suitable host cells include prokaryotes, yeast and highereukaryotic cells. Preferably, the host cells employed are E. coli, yeastor a mammalian cell line, such as COS or CHO. The DNA sequencesexpressed in this manner may encode naturally occurring antigens,portions of naturally occurring antigens, or other variants thereof.

In general, regardless of the method of preparation, the polypeptidesdisclosed herein are prepared in an isolated, substantially pure, form.Preferably, the polypeptides are at least about 80% pure, morepreferably at least about 90% pure and most preferably at least about99% pure.

Within certain specific embodiments, a polypeptide may be a fusionprotein that comprises multiple polypeptides as described herein, orthat comprises at least one polypeptide as described herein and anunrelated sequence, such as a known Chlamydial protein. A fusion partnermay, for example, assist in providing T helper epitopes (animmunological fusion partner), preferably T helper epitopes recognizedby humans, or may assist in expressing the protein (an expressionenhancer) at higher yields than the native recombinant protein. Certainpreferred fusion partners are both immunological and expressionenhancing fusion partners. Other fusion partners may be selected so asto increase the solubility of the protein or to enable the protein to betargeted to desired intracellular compartments. Still further fusionpartners include affinity tags, which facilitate purification of theprotein. A DNA sequence encoding a fusion protein of the presentinvention may be constructed using known recombinant DNA techniques toassemble separate DNA sequences encoding, for example, the first andsecond polypeptides, into an appropriate expression vector. The 3′ endof a DNA sequence encoding the first polypeptide is ligated, with orwithout a peptide linker, to the 5′ end of a DNA sequence encoding thesecond polypeptide so that the reading frames of the sequences are inphase to permit mRNA translation of the two DNA sequences into a singlefusion protein that retains the biological activity of both the firstand the second polypeptides.

A peptide linker sequence may be employed to separate the first and thesecond polypeptides by a distance sufficient to ensure that eachpolypeptide folds into its secondary and tertiary structures. Such apeptide linker sequence is incorporated into the fusion protein usingstandard techniques well known in the art. Suitable peptide linkersequences may be chosen based on the following factors: (1) theirability to adopt a flexible extended conformation; (2) their inabilityto adopt a secondary structure that could interact with functionalepitopes on the first and second polypeptides; and (3) the lack ofhydrophobic or charged residues that might react with the polypeptidefunctional epitopes. Preferred peptide linker sequences contain Gly, Asnand Ser residues. Other near neutral amino acids, such as Thr and Alamay also be used in the linker sequence. Amino acid sequences which maybe usefully employed as linkers include those disclosed in Maratea etal., Gene 40:39-46, 1985; Murphy et al., Proc. Natl. Acad. Sci. USA83:8258-8562, 1986; U.S. Pat. No. 4,935,233 and U.S. Pat. No. 4,751,180.The linker sequence may be from 1 to about 50 amino acids in length. Asan alternative to the use of a peptide linker sequence (when desired),one can utilize non-essential N-terminal amino acid regions (whenpresent) on the first and second polypeptides to separate the functionaldomains and prevent steric hindrance.

The ligated DNA sequences are operably linked to suitabletranscriptional or translational regulatory elements. The regulatoryelements responsible for expression of DNA are located only 5′ to theDNA sequence encoding the first polypeptides. Similarly, stop codonsrequired to end translation and transcription termination signals areonly present 3′ to the DNA sequence encoding the second polypeptide.

Fusion proteins are also provided that comprise a polypeptide of thepresent invention together with an unrelated immunogenic protein.Preferably the immunogenic protein is capable of eliciting a recallresponse. Examples of such proteins include tetanus, tuberculosis andhepatitis proteins (see, for example, Stoute et al. New Engl. J. Med.,336:86-91, 1997).

Within preferred embodiments, an immunological fusion partner is derivedfrom protein D, a surface protein of the gram-negative bacteriumHaemophilus influenza B (WO 91/18926). Preferably, a protein Dderivative comprises approximately the first third of the protein (e.g.,the first N-terminal 100-110 amino acids), and a protein D derivativemay be lipidated. Within certain preferred embodiments, the first 109residues of a Lipoprotein D fusion partner is included on the N-terminusto provide the polypeptide with additional exogenous T-cell epitopes andto increase the expression level in E. coli (thus functioning as anexpression enhancer). The lipid tail ensures optimal presentation of theantigen to antigen presenting cells. Other fusion partners include thenon-structural protein from influenzae virus, NS1 (hemaglutinin).Typically, the N-terminal 81 amino acids are used, although differentfragments that include T-helper epitopes may be used.

In another embodiment, the immunological fusion partner is the proteinknown as LYTA, or a portion thereof (preferably a C-tcrminal portion).LYTA is derived from Streptococcus pneumoniae, which synthesizes anN-acetyl-L-alanine amidase known as amidase LYTA (encoded by the LytAgene; Gene 43:265-292, 1986). LYTA is an autolysin that specificallydegrades certain bonds in the peptidoglycan backbone. The C-terminaldomain of the LYTA protein is responsible for the affinity to thecholine or to some choline analogues such as DEAE. This property hasbeen exploited for the development of E. coli C-LYTA expressing plasmidsuseful for expression of fusion proteins. Purification of hybridproteins containing the C-LYTA fragment at the amino terminus has beendescribed (see Biotechnology 10:795-798, 1992). Within a preferredembodiment, a repeat portion of LYTA may be incorporated into a fusionprotein. A repeat portion is found in the C-terminal region starting atresidue 178. A particularly preferred repeat portion incorporatesresidues 188-305.

In another embodiment, a Mycobacterium tuberculosis-derived Ra12polynucleotide is linked to at least an immunogenic portion of apolynucleotide of this invention. Ra12 compositions and methods fortheir use inenhancing expression of heterologous polynucleotidesequences is described in U.S. patent application Ser. No. 60/158,585,the disclosure of which is incorporated herein by reference in itsentirety. Briefly, Ra12 refers to a polynucleotide region that is asubsequence of a Mycobacterium tuberculosis MTB32A nucleic acid. MTB32Ais a serine protease of 32 KD molecular weight encoded by a gene invirulent and avirulent strains of M. tuberculosis. The nucleotidesequence and amino acid sequence of MTB32A have been described (U.S.patent application Ser. No. 60/158,585; see also, Skeiky et al.,Infection and Immun. (1999) 67:3998-4007, incorporated herein byreference. In one embodiment, the Ra12 polypeptide used in theproduction of fusion polypeptides comprises a C-terminal fragment of theMTB32A coding sequence that is effective for enhancing the expressionand/or immunogenicity of heterologous Chlamydial antigenic polypeptideswith which it is fused. In another embodiment, the Ra12 polypeptidecorresponds to an approximately 14 kD C-terminal fragment of MTB32Acomprising some or all of amino acid residues 192 to 323 of MTB32A.

Recombinant nucleic acids, which encode a fusion polypeptide comprisinga Ra12 polypeptide and a heterologous Chlamydia polypeptide of interest,can be readily constructed by conventional genetic engineeringtechniques. Recombinant nucleic acids are constructed so that,preferably, a Ra12 polynucleotide sequence is located 5′ to a selectedheterologous Chlamydia polynucleotide sequence. It may-also beappropriate to place a Ra12 polynucleotide sequence 3′ to a selectedheterologous polynucleotide sequence or to insert a heterologouspolynucleotide sequence into a site within a Ra12 polynucleotidesequence.

In addition, any suitable polynucleotide that encodes a Ra12 or aportion or other variant thereof can be used in constructing recombinantfusion polynucleotides comprising Ra12 and one or more Chlamydiapolynucleotides disclosed herein. Preferred Ra12 polynucleotidesgenerally comprise at least about 15 consecutive nucleotides, at leastabout 30 nucleotides, at least about 60 nucleotides, at least about 100nucleotides, at least about 200 nucleotides, or at least about 300nucleotides that encode a portion of a Ra12 polypeptide.

Ra12 polynucleotides may comprise a native sequence (i.e., an endogenoussequence that encodes a Ra12 polypeptide or a portion thereof) or maycomprise a variant of such a sequence. Ra12 polynucleotide variants maycontain one or more substitutions, additions, deletions and/orinsertions such that the biological activity of the encoded fusionpolypeptide is not substantially diminished, relative to a fusionpolypeptide comprising a native Ra12 polypeptide. Variants preferablyexhibit at least about 70% identity, more preferably at least about 80%identity and most preferably at least about 90% identity to apolynucleotide sequence that encodes a native Ra12 polypeptide or aportion thereof.

In another aspect, the present invention provides methods for using oneor more of the above polypeptides or fusion proteins (or polynucleotidesencoding such polypeptides or fusion proteins) to induce protectiveimmunity against Chlamydial infection in a patient. As used herein, a“patient” refers to any warm-blooded animal, preferably a human. Apatient may be afflicted with a disease, or may be free of detectabledisease and/or infection. In other words, protective immunity may beinduced to prevent or treat Chlamydial infection.

In this aspect, the polypeptide, fusion protein or polynucleotidemolecule is generally present within a pharmaceutical composition or avaccine. Pharmaceutical compositions may comprise one or morepolypeptides, each of which may contain one or more of the abovesequences (or variants thereof), and a physiologically acceptablecarrier. Vaccines may comprise one or more of the above polypeptides andan immunostimulant, such as an adjuvant or a liposome (into which thepolypeptide is incorporated). Such pharmaceutical compositions andvaccines may also contain other Chlamydia antigens, either incorporatedinto a combination polypeptide or present within a separate polypeptide.

Alternatively, a vaccine may contain polynucleotides encoding one ormore polypeptides or fusion proteins as described above, such that thepolypeptide is generated in situ. In such vaccines, the polynucleotidesmay be present within any of a variety of delivery systems known tothose of ordinary skill in the art, including nucleic acid expressionsystems, bacterial and viral expression systems. Appropriate nucleicacid expression systems contain the necessary polynucleotide sequencesfor expression in the patient (such as a suitable promoter andterminating signal). Bacterial delivery systems involve theadministration of a bacterium (such as Bacillus-Calmette-Guerrin) thatexpresses an immunogenic portion of the polypeptide on its cell surface.In a preferred embodiment, the polynucleotides may be introduced using aviral expression system (e.g., vaccinia or other pox virus, retrovirus,or adenovirus), which may involve the use of a non-pathogenic(defective) virus. Techniques for incorporating polynucleotides intosuch expression systems are well known to those of ordinary skill in theart. The polynucleotides may also be administered as “naked” plasmidvectors as described, for example, in Ulmer et al., Science259:1745-1749, 1993 and reviewed by Cohen, Science 259:1691-1692, 1993.Techniques for incorporating DNA into such vectors are well known tothose of ordinary skill in the art. A retroviral vector may additionallytransfer or incorporate a gene for a selectable marker (to aid in theidentification or selection of transduced cells) and/or a targetingmoiety, such as a gene that encodes a ligand for a receptor on aspecific target cell, to render the vector target specific. Targetingmay also be accomplished using an antibody, by methods known to those ofordinary skill in the art.

Other formulations for therapeutic purposes include colloidal dispersionsystems, such as macromolecule complexes, nanocapsules, microspheres,beads, and lipid-based systems including oil-in-water emulsions,micelles, mixed micelles, and liposomes. A preferred colloidal systemfor use as a delivery vehicle in vitro and in vivo is a liposome (i.e.,an artificial membrane vesicle). The uptake of naked polynucleotides maybe increased by incorporating the polynucleotides into and/or ontobiodegradable beads, which are efficiently transported into the cells.The preparation and use of such systems is well known in the art.

In a related aspect, a polynucleotide vaccine as described above may beadministered simultaneously with or sequentially to either a polypeptideof the present invention or a known Chlamydia antigen. For example,administration of polynucleotides encoding a polypeptide of the presentinvention, either “naked” or in a delivery system as described above,may be followed by administration of an antigen in order to enhance theprotective immune effect of the vaccine.

Polypeptides and polynucleotides disclosed herein may also be employedin adoptive immunotherapy for the treatment of Chlamydial infection.Adoptive immunotherapy may be broadly classified into either active orpassive immunotherapy. In active immunotherapy, treatment relies on thein vivo stimulation of the endogenous host immune system with theadministration of immune response-modifying agents (for example,vaccines, bacterial adjuvants, and/or cytokines).

In passive immunotherapy, treatment involves the delivery of biologicreagents with established immune reactivity (such as effector cells orantibodies) that can directly or indirectly mediate anti-Chlamydiaeffects and does not necessarily depend on an intact host immune system.Examples of effector cells include T lymphocytes (for example, CD8+cytotoxic T-lymphocyte, CD4+ T-helper), killer cells (such as NaturalKiller cells, lymphokine-activated killer cells), B cells, or antigenpresenting cells (such as dendritic cells and macrophages) expressingthe disclosed antigens. The polypeptides disclosed herein may also beused to generate antibodies or anti-idiotypic antibodies (as in U.S.Pat. No. 4,918,164), for passive immunotherapy.

The predominant method of procuring adequate numbers of T-cells foradoptive immunotherapy is to grow immune T-cells in vitro. Cultureconditions for expanding single antigen-specific T-cells to severalbillion in number with retention of antigen recognition in vivo are wellknown in the art. These in vitro culture conditions typically utilizeintermittent stimulation with antigen, often in the presence ofcytokines, such as IL-2, and non-dividing feeder cells. As noted above,the immunoreactive polypeptides described herein may be used to rapidlyexpand antigen-specific T cell cultures in order to generate sufficientnumber of cells for immunotherapy. In particular, antigen-presentingcells, such as dendritic, macrophage, monocyte, fibroblast, or B-cells,may be pulsed with immunoreactive polypeptides, or polynucleotidesequence(s) may be introduced into antigen presenting cells, using avariety of standard techniques well known in the art. For example,antigen presenting cells may be transfected or transduced with apolynucleotide sequence, wherein said sequence contains a promoterregion appropriate for increasing expression, and can be expressed aspart of a recombinant virus or other expression system. Several viralvectors may be used to transduce an antigen presenting cell, includingpox virus, vaccinia virus, and adenovirus; also, antigen presentingcells may be transfected with polynucleotide sequences disclosed hereinby a variety of means, including gene-gun technology, lipid-mediateddelivery, electroporation, osmotic shock, and particlate deliverymechanisms, resulting in efficient and acceptable expression levels asdetermined by one of ordinary skill in the art. For cultured T-cells tobe effective in therapy, the cultured T-celis must be able to grow anddistribute widely and to survive long term in vivo. Studies havedemonstrated that cultured T-cells can be induced to grow in vivo and tosurvive long term in substantial numbers by repeated stimulation withantigen supplemented with IL-2 (see, for example, Cheever, M., et al,“Therapy With Cultured T Cells: Principles Revisited,” ImmunologicalReviews, 157:177, 1997).

The polypeptides disclosed herein may also be employed to generateand/or isolate chlamydial-reactive T-cells, which can then beadministered to the patient. In one technique, antigen-specific T-celllines may be generated by in vivo immunization with short peptidescorresponding to immunogenic portions of the disclosed polypeptides. Theresulting antigen specific CD8+ or CD4+ T-cell clones may be isolatedfrom the patient, expanded using standard tissue culture techniques, andreturned to the patient.

Alternatively, peptides corresponding to immunogenic portions of thepolypeptides may be employed to generate Chlamydia reactive T cellsubsets by selective in vitro stimulation and expansion of autologous Tcells to provide antigen-specific T cells which may be subsequentlytransferred to the patient as described, for example, by Chang et al,(Crit. Rev. Oncol. Hematol., 22(3), 213, 1996). Cells of the immunesystem, such as T cells, may be isolated from the peripheral blood of apatient, using a commercially available cell separation system, such asIsolex™ System, available from Nexell Therapeutics, Inc. Irvine, Calif.The separated cells are stimulated with one or more of theimmunoreactive polypeptides contained within a delivery vehicle, such asa microsphere, to provide antigen-specific T cells. The population ofantigen-specific T cells is then expanded using standard techniques andthe cells are administered back to the patient.

In other embodiments, T-cell and/or antibody receptors specific for thepolypeptides disclosed herein can be cloned, expanded, and transferredinto other vectors or effector cells for use in adoptive immunotherapy.In particular, T cells may be transfected with the appropriate genes toexpress the variable domains from chlamydia specific monoclonalantibodies as the extracellular recognition elements and joined to the Tcell receptor signaling chains, resulting in T cell activation, specificlysis, and cytokine release. This enables the T cell to redirect itsspecificity in an MHC-independent manner. See for example, Eshhar, Z.,Cancer Immunol Immunother, 45(3-4):131-6, 1997 and Hwu, P., et al,Cancer Res, 55(15):3369-73, 1995. Another embodiment may include thetransfection of chlamydia antigen specific alpha and beta T cellreceptor chains into alternate T cells, as in Cole, D J, et al, CancerRes, 55(4):748-52, 1995.

In a further embodiment, syngeneic or autologous dendritic cells may bepulsed with peptides corresponding to at least an immunogenic portion ofa polypeptide disclosed herein. The resulting antigen-specific dendriticcells may either be transferred into a patient, or employed to stimulateT cells to provide antigen-specific T cells which may, in turn, beadministered to a patient. The use of peptide-pulsed dendritic cells togenerate antigen-specific T cells and the subsequent use of suchantigen-specific T cells to eradicate disease in a murine model has beendemonstrated by Cheever et al, Immunological Reviews, 157:177, 1997).Additionally, vectors expressing the disclosed polynucleotides may beintroduced into stem cells taken from the patient and clonallypropagated in vitro for autologous transplant back into the samepatient.

Within certain aspects, polypeptides, polynucleotides, T cells and/orbinding agents disclosed herein may be incorporated into pharmaceuticalcompositions or immunogenic compositions (i.e., vaccines).Alternatively, a pharmaceutical composition may comprise anantigen-presenting cell (e.g. a dendritic cell) transfected with aChlamydial polynucleotide such that the antigen presenting cellexpresses a Chlamydial polypeptide. Pharmaceutical compositions compriseone or more such compounds and a physiologically acceptable carrier.Vaccines may comprise one or more such compounds and an immunostimulant.An immunostimulant may be any substance that enhances or potentiates animmune response to an exogenous antigen. Examples of immunostimulantsinclude adjuvants, biodegradable microspheres (e.g., polylacticgalactide) and liposomes (into which the compound is incorporated; seee.g., Fullerton, U.S. Pat. No. 4,235,877). Vaccine preparation isgenerally described in, for example, M. F. Powell and M. J. Newman,eds., “Vaccine Design (the subunit and adjuvant approach),” Plenum Press(N.Y., 1995). Pharmaceutical compositions and vaccines within the scopeof the present invention may also contain other compounds, which may bebiologically active or inactive. For example, one or more immunogenicportions of other Chlamydial antigens may be present, eitherincorporated into a fusion polypeptide or as a separate compound, withinthe composition or vaccine.

A pharmaceutical composition or vaccine may contain DNA encoding one ormore of the polypeptides as described above, such that the polypeptideis generated in situ. As noted above, the DNA may be present within anyof a variety of delivery systems known to those of ordinary skill in theart, including nucleic acid expression systems, bacteria and viralexpression systems. Numerous gene delivery techniques are well known inthe art, such as those described by Rolland, Crit. Rev. Therap. DrugCarrier Systems 15:143-198, 1998, and references cited therein.Appropriate nucleic acid expression systems contain the necessary DNAsequences for expression in the patient (such as a suitable promoter andterminating signal). Bacterial delivery systems involve theadministration of a bacterium (such as Bacillus-Calmette-Guerrin) thatexpresses an immunogenic portion of the polypeptide on its cell surfaceor secretes such an epitope.

In a preferred embodiment, the DNA may be introduced using a viralexpression system (e.g., vaccinia or other pox virus, retrovirus,adenovirus, baculovirus, togavirus, bacteriophage, and the like), whichoften involves the use of a non-pathogenic (defective), replicationcompetent virus.

For example, many viral expression vectors are derived from viruses ofthe retroviridae family. This family includes the murine leukemiaviruses, the mouse mammary tumor viruses, the human foamy viruses, Roussarcoma virus, and the immunodeficiency viruses, including human,simian, and feline. Considerations when designing retroviral expressionvectors are discussed in Comstock et al. (1997).

Excellent murine leukemia virus (MLV)-based viral expression vectorshave been developed by Kim et al. (1998). In creating the MLV vectors,Kim et al. found that the entire gag sequence, together with theimmediate upstream region, could be deleted without significantlyaffecting viral packaging or gene expression. Further, it was found thatnearly the entire U3 region could be replaced with the immediately-earlypromoter of human cytomegalovirus without deleterious effects.Additionally, MCR and internal ribosome entry sites (IRES) could beadded without adverse effects. Based on their observations, Kim et al.have designed a series of MLV-based expression vectors comprising one ormore of the features described above.

As more has been learned about human foamy virus (HFV), characteristicsof HFV that are favorable for its use as an expression vector have beendiscovered. These characteristics include the expression of pol bysplicing and start of translation at a defined initiation codon. Otheraspects of HFV viral expression vectors are reviewed in Bodem et al.(1997).

Murakami et al. (1997) describe a Rous sarcoma virus (RSV)-basedreplication-competent avian retrovirus vectors, IR1 and IR2 to express aheterologous gene at a high level. In these vectors, the IRES derivedfrom encephalomyocarditis virus (EMCV) was inserted between the env geneand the heterologous gene. The IR1 vector retains the splice-acceptorsite that is present downstream of the env gene while the IR2 vectorlacks it. Murakami et al. have shown high level expression of severaldifferent heterologous genes by these vectors.

Recently, a number of lentivirus-based retroviral expression vectorshave been developed. Kafri et al. (1997) have shown sustained expressionof genes delivered directly into liver and muscle by a humanimmunodeficiency virus (HIV)-based expression vector. One benefit of thesystem is the inherent ability of HIV to transduce non-dividing cells.Because the viruses of Kafri et al. are pseudotyped with vesicularstomatitis virus G glycoprotein (VSVG), they can transduce a broad rangeof tissues and cell types.

A large number of adenovirus-based expression vectors have beendeveloped, primarily due to the advantages offered by these vectors ingene therapy applications. Adenovirus expression vectors and methods ofusing such vectors are the subject of a number of United States patents,including U.S. Pat. No. 5,698,202, U.S. Pat. No. 5,616,326, U.S. Pat.No. 5,585,362, and U.S. Pat. No. 5,518,913, all incorporated herein byreference.

Additional adenoviral constructs are described in Khatri et al. (1997)and Tomanin et al. (1997). Khatri et al. described novel ovineadenovirus expression vectors and their ability to infect bovine nasalturbinate and rabbit kidney cells as well as a range of human cell type,including lung and foreskin fibroblasts as well as liver, prostate,breast, colon and retinal lines. Tomanin et al. describe adenoviralexpression vectors containing the T7 RNA polymerase gene. Whenintroduced into cells containing a heterologous gene operably linked toa T7 promoter, the vectors were able to drive gene expression from theT7 promoter. The authors suggest that this system may be useful for thecloning and expression of genes encoding cytotoxic proteins.

Poxviruses are widely used for the expression of heterologous genes inmammalian cells. Over the years, the vectors have been improved to allowhigh expression of the heterologous gene and simplify the integration ofmultiple heterologous genes into a single molecule. In an effort todiminish cytopathic effects and to increase safety, vaccinia virusmutant and other poxviruses that undergo abortive infection in mammaliancells are receiving special attention (Oertli et al., 1997). The use ofpoxviruses as expression vectors is reviewed in Carroll and Moss (1997).

Togaviral expression vectors, which includes alphaviral expressionvectors have been used to study the structure and function of proteinsand for protein production purposes. Attractive features of togaviralexpression vectors are rapid and efficient gene expression, wide hostrange, and RNA genomes (Huang, 1996). Also, recombinant vaccines basedon alphaviral expression vectors have been shown to induce a stronghumoral and cellular immune response with good immunological memory andprotective effects (Tubulekas et al., 1997). Alphaviral expressionvectors and their use are discussed, for example, in Lundstrom (1997).

In one study, Li and Garoff (1996) used Semliki Forest virus (SFV)expression vectors to express retroviral genes and to produce retroviralparticles in BHK-21 cells. The particles produced by this method hadprotease and reverse transcriptase activity and were infectious.Furthermnore, no helper virus could be detected in the virus stocks.Therefore, this system has features that are attractive for its use ingene therapy protocols.

Baculoviral expression vectors have traditionally been used to expressheterologous proteins in insect cells. Examples of proteins includemammalian chemokine receptors (Wang et al., 1997), reporter proteinssuch as green fluorescent protein (Wu et al., 1997), and FLAG fusionproteins (Wu et al., 1997; Koh et al., 1997). Recent advances inbaculoviral expression vector technology, including their use in viriondisplay vectors and expression in marnrmalian cells is reviewed byPossee (1997). Other reviews on baculoviral expression vectors includeJones and Morikawa (1996) and O'Reilly (1997).

Other suitable viral expression systems are disclosed, for example, inFisher-Hoch et al., Proc. Natl. Acad. Sci. USA 86:317-321, 1989; Flexneret al., Ann. N.Y. Acad. Sci. 569:86-103, 1989; Flexner et al., Vaccine8:17-21, 1990; U.S. Pat. Nos. 4,603,112, 4,769,330, and 5,017,487; WO89/01973; U.S. Pat. No. 4,777,127; GB 2,200,651; EP 0,345,242; WO91/02805; Berkner, Biotechniques 6:616-627, 1988; Rosenfeld et al.,Science 252:431-434, 1991; Kolls et al., Proc. Natl. Acad. Sci. USA91:215-219, 1994; Kass-Eisler et al., Proc. Natl. Acad. Sci. USA90:11498-11502, 1993; Guzman et al., Circulation 88:2838-2848, 1993; andGuzman et al., Cir. Res. 73:1202-1207, 1993. Techniques forincorporating DNA into such expression systems are well known to thoseof ordinary skill in the art. In other systems, the DNA may beintroduced as “naked” DNA, as described, for example, in Ulmer et al.,Science 259:1745-1749, 1993 and reviewed by Cohen, Science259:1691-1692, 1993. The uptake of naked DNA may be increased by coatingthe DNA onto biodegradable beads, which are efficiently transported intothe cells.

It will be apparent that a vaccine may comprise a polynucleotide and/ora polypeptide component, as desired. It will also be apparent that avaccine may contain pharmaceutically acceptable salts of thepolynucleotides and/or polypeptides provided herein. Such salts may beprepared from pharmaceutically acceptable non-toxic bases, includingorganic bases (e.g., salts of primary, secondary and tertiary amines andbasic amino acids) and inorganic bases (e.g., sodium, potassium,lithium, ammonium, calcium and magnesium salts). While any suitablecarrier known to those of ordinary skill in the art may be employed inthe pharmaceutical compositions of this invention, the type of carrierwill vary depending on the mode of administration. Compositions of thepresent invention may be formulated for any appropriate manner ofadministration, including for example, topical, oral, nasal,intravenous, intracranial, intraperitoneal, subcutaneous orintramuscular administration. For parenteral administration, such assubcutaneous injection, the carrier preferably comprises water, saline,alcohol, a fat, a wax or a buffer. For oral administration, any of theabove carriers or a solid carrier, such as mannitol, lactose, starch,magnesium stearate, sodium saccharine, talcum, cellulose, glucose,sucrose, and magnesium carbonate, may be employed. Biodegradablemicrospheres (e.g., polylactate polyglycolate) may also be employed ascarriers for the pharmaceutical compositions of this invention. Suitablebiodegradable microspheres are disclosed, for example, in U.S. Pat. Nos.4,897,268 and 5,075,109.

Such compositions may also comprise buffers (e.g., neutral bufferedsaline or phosphate buffered saline), carbohydrates (e.g., glucose,mannose, sucrose or dextrans), mannitol, proteins, polypeptides or aminoacids such as glycine, antioxidants, bacteriostats, chelating agentssuch as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide),solutes that render the formulation isotonic, hypotonic or weaklyhypertonic with the blood of a recipient, suspending agents, thickeningagents and/or preservatives. Alternatively, compositions of the presentinvention may be formulated as a lyophilizate. Compounds may also beencapsulated within liposomes using well known technology.

Any of a variety of immunostimulants may be employed in the vaccines ofthis invention. For example, an adjuvant may be included. Most adjuvantscontain a substance designed to protect the antigen from rapidcatabolism, such as aluminum hydroxide or mineral oil, and a stimulatorof immune responses, such as lipid A, Bortadella pertussis orMycobacterium tuberculosis derived proteins. Suitable adjuvants arecommercially available as, for example, Freund's Incomplete Adjuvant andComplete Adjuvant (Difco Laboratories, Detroit, Mich.); Merck Adjuvant65 (Merck and Company, Inc., Rahway, N.J.); AS-2 (SmithKline Beecham,Philadelphia, Pa.); aluminum salts such as aluminum hydroxide gel (alum)or aluminum phosphate; salts of calcium, iron or zinc; an insolublesuspension of acylated tyrosine; acylated sugars; cationically oranionically derivatized polysaccharides; polyphosphazenes; biodegradablemicrospheres; monophosphoryl lipid A and quil A. Cytokines, such asGM-CSF or interleukin-2, -7, or -12, may also be used as adjuvants.

Within the vaccines provided herein, under select circumstances, theadjuvant composition may be designed to induce an immune responsepredominantly of the Th1 type or Th2 type. High levels of Th1-typecytokines (e.g., IFN-γ, TNFα, IL-2 and IL-12) tend to favor theinduction of cell mediated immune responses to an administered antigen.In contrast, high levels of Th2-type cytokines (e.g., IL-4, IL-5, IL-6and IL-10) tend to favor the induction of humoral immune responses.Following application of a vaccine as provided herein, a patient willsupport an immune response that includes Th1- and Th2-type responses.Within a preferred embodiment, in which a response is predominantlyTh1-type, the level of Th1-type cytokines will increase to a greaterextent than the level of Th2-type cytokines. The levels of thesecytokines may be readily assessed using standard assays. For a review ofthe families of cytokines, see Mosmann and Coffman, Ann. Rev. Immunol.7:145-173, 1989.

Preferred adjuvants for use in eliciting a predominantly Th1-typeresponse include, for example, a combination of monophosphoryl lipid A,preferably 3-de-O-acylated monophosphoryl lipid. A (3D-MPL), togetherwith an aluminum salt. MPL adjuvants are available from CorixaCorporation (Seattle, Wash.; see U.S. Pat. Nos. 4,436,727; 4,877,611;4,866,034 and 4,912,094). CpG-containing oligonucleotides (in which theCpG dinucleotide is unmethylated) also induce a predominantly Th1response. Such oligonucleotides are well known and are described, forexample, in WO 96/02555 and WO 99/33488. Immunostimulatory DNA sequencesare also described, for example, by Sato et al., Science 273:352, 1996.Another preferred adjuvant is a saponin, preferably QS21 (AquilaBiopharmaceuticals Inc., Framingham, Mass.), which may be used alone orin combination with other adjuvants. For example, an enhanced systeminvolves the combination of a monophosphoryl lipid A and saponinderivative, such as the combination of QS21 and 3D-MPL as described inWO 94/00153, or a less reactogenic composition where the QS21 isquenched with cholesterol, as described in WO 96/33739. Other preferredformulations comprise an oil-in-water emulsion and tocopherol. Aparticularly potent adjuvant formulation involving QS21, 3D-MPL andtocopherol in an oil-in-water emulsion is described in WO 95/17210.

Other preferred adjuvants include Montanide ISA 720 (Seppic, France),SAF (Chiron, California, United States), ISCOMS (CSL), MF-59 (Chiron),the SBAS series of adjuvants (e.g., SBAS-2 or SBAS-4, available fromSmithKline Beecham, Rixensart, Belgium), Detox (Corixa Corporation;Seattle, Wash.), RC-529 (Corixa Corporation; Seattle, Wash.) and otheraminoalkyl glucosaminide 4-phosphates (AGPs), such as those described inpending U.S. patent application Ser. Nos. 08/853,826 and 09/074,720, thedisclosures of which are incorporated herein by reference in theirentireties.

Any vaccine provided herein may be prepared using well known methodsthat result in a combination of antigen, immunostimulant and a suitablecarrier or excipient. The compositions described herein may beadministered as part of a sustained release formulation (i.e., aformulation such as a capsule, sponge or gel (composed ofpolysaccharides, for example) that effects a slow release of compoundfollowing administration). Such formulations may generally be preparedusing well known technology (see, e.g., Coombes et al., Vaccine14:1429-1438, 1996) and administered by, for example, oral, rectal orsubcutaneous implantation, or by implantation at the desired targetsite. Sustained-release formulations may contain a polypeptide,polynucleotide or antibody dispersed in a carrier matrix and/orcontained within a reservoir surrounded by a rate controlling membrane.

Carriers for use within such formulations are biocompatible, and mayalso be biodegradable; preferably the formulation provides a relatively.constant level of active component release. Such carriers includemicroparticles of poly(lactide-co-glycolide), as well as polyaciylate,latex, starch, cellulose and dextran. Other delayed-release carriersinclude supramolecular biovectors, which comprise a non-liquidhydrophilic core (e.g., a cross-linked polysaccharide oroligosaccharide) and, optionally, an external layer comprising anamphiphilic compound, such as a phospholipid (see e.g., U.S. Pat. No.5,151,254 and PCT applications WO 94/20078, WO/94/23701 and WO96/06638). The amount of active compound contained within a sustainedrelease formulation depends upon the site of implantation, the rate andexpected duration of release and the nature of the condition to betreated or prevented.

Any of a variety of delivery vehicles may be employed withinpharmaceutical compositions and vaccines to facilitate production of anantigen-specific immune response that targets Chlamydia-infected cells.Delivery vehicles include antigen presenting cells (APCs), such asdendritic cells, macrophages, B cells, monocytes and other cells thatmay be engineered to be efficient APCs. Such cells may, but need not, begenetically modified to increase the capacity for presenting theantigen, to improve activation and/or maintenance of the T cellresponse, to have anti-Chlamydia effects per se and/or to beimmunologically compatible with the receiver (i.e., matched HLAhaplotype). APCs may generally be isolated from any of a variety ofbiological fluids and organs, and may be autologous, allogeneic,syngeneic or xenogeneic cells.

Certain preferred embodiments of the present invention use dendriticcells or progenitors thereof as antigen-presenting cells. Dendriticcells are highly potent APCs (Banchereau and Steinman, Nature392:245-251, 1998) and have been shown to be effective as aphysiological adjuvant for eliciting prophylactic or therapeuticimmunity (see Timmerman and Levy, Ann. Rev. Med. 50:507-529, 1999). Ingeneral, dendritic cells may be identified based on their typical shape(stellate in situ, with marked cytoplasmic processes (dendrites) visiblein vitro), their ability to take up, process and present antigens withhigh efficiency, and their ability to activate naive T cell responses.Dendritic cells may, of course, be engineered to express specificcell-surface receptors or ligands that are not commonly found ondendritic cells in vivo or ex vivo, and such modified dendritic cellsare contemplated by the present invention. As an alternative todendritic cells, secreted vesicles antigen-loaded dendritic cells(called exosomes) may be used within a vaccine (see Zitvogel et al.,Nature Med. 4:594-600, 1998).

Dendritic cells and progenitors may be obtained from peripheral blood,bone marrow, lymph nodes, spleen, skin, umbilical cord blood or anyother suitable tissue or fluid. For example, dendritic cells may bedifferentiated ex vivo by adding a combination of cytokines such asGM-CSF, IL-4, IL-13 and/or TNFα to cultures of monocytes harvested fromperipheral blood. Alternatively, CD34 positive cells harvested fromperipheral blood, umbilical cord blood or bone marrow may bedifferentiated into dendritic cells by adding to the culture mediumcombinations of GM-CSF, IL-3, TNFα, CD40 ligand, LPS, flt3 ligand and/orother compound(s) that induce differentiation, maturation andproliferation of dendritic cells.

Dendritic cells are conveniently categorized as “immature” and “mature”cells, which allows a simple way to discriminate between two wellcharacterized phenotypes. However, this nomenclature should not beconstrued to exclude all possible intermediate stages ofdifferentiation. Immature dendritic cells are characterized as APC witha high capacity for antigen uptake and processing, which correlates withthe high expression of Fcγ receptor and mannose receptor. The maturephenotype is typically characterized by a lower expression of thesemarkers, but a high expression of cell surface molecules responsible forT cell activation such as class I and class II MHC, adhesion molecules(e.g., CD54 and CD11) and costimulatory molecules (e.g., CD40, CD80,CD86 and 4-1BB).

APCs may generally be transfected with a polynucleotide encoding aChlamydial protein (or portion or other variant thereof) such that theChlamydial polypeptide, or an immunogenic portion thereof, is expressedon the cell surface. Such transfection may take place ex vivo, and acomposition or vaccine comprising such transfected cells may then beused for therapeutic purposes, as described herein. Alternatively, agene delivery vehicle that targets a dendritic or other antigenpresenting cell may be administered to a patient, resulting intransfection that occurs in vivo. In vivo and ex vivo transfection ofdendritic cells, for example, may generally be performed using anymethods known in the art, such as those described in WO 97/24447, or thegene gun approach described by Mahvi et al., Immunology and cell Biology75:456-460, 1997. Antigen loading of dendritic cells may be achieved byincubating dendritic cells or progenitor cells with the Chlamydialpolypeptide, DNA (naked or within a plasmid vector) or RNA; or withantigen-expressing recombinant bacterium or viruses (e.g., vaccinia,fowlpox, adenovirus or lentivirus vectors). Prior to loading, thepolypeptide may be covalently conjugated to an immunological partnerthat provides T cell help (e.g., a carrier molecule). Alternatively, adendritic cell may be pulsed with a non-conjugated immunologicalpartner, separately or in the presence of the polypeptide.

Routes and frequency of administration of pharmaceutical compositionsand vaccines, as well as dosage, will vary from individual toindividual. In general, the pharmaceutical compositions and vaccines maybe administered by injection (e.g., intracutaneous, intramuscular,intravenous or subcutaneous), intranasally (e.g., by aspiration) ororally. Between 1 and 3 doses may be administered for a 1-36 weekperiod. Preferably, 3 doses are administered, at intervals of 3-4months, and booster vaccinations may be given periodically thereafter.Alternate protocols may be appropriate for individual patients. Asuitable dose is an amount of polypeptide or DNA that, when administeredas described above, is capable of raising an immune response in animmunized patient sufficient to protect the patient from Chlamydialinfection for at least 1-2 years. In general, the amount of polypeptidepresent in a dose (or produced in situ by the DNA in a dose) ranges fromabout 1 pg to about 100 mg per kg of host, typically from about 10 pg toabout 1 mg, and preferably from about 100 μg to about 1 μg. Suitabledose sizes will vary with the size of the patient, but will typicallyrange from about 0.1 mL to about 5 mL.

While any suitable carrier known to those of ordinary skill in the artmay be employed in the pharmaceutical compositions of this invention,the type of carrier will vary depending on the mode of administration.For parenteral administration, such as subcutaneous injection, thecarrier preferably comprises water, saline, alcohol, a fat, a wax or abuffer. For oral administration, any of the above carriers or a solidcarrier, such as mannitol, lactose, starch, magnesium stearate, sodiumsaccharine, talcum, cellulose, glucose, sucrose, and magnesiumcarbonate, may be employed. Biodegradable microspheres (e.g., polylacticgalactide) may also be employed as carriers for the pharmaceuticalcompositions of this invention. Suitable biodegradable microspheres aredisclosed, for example, in U.S. Pat. Nos. 4,897,268 and 5,075,109.

In general, an appropriate dosage and treatment regimen provides theactive compound(s) in an amount sufficient to provide therapeutic and/orprophylactic benefit. Such a response can be-monitored by establishingan improved clinical outcome in treated patients as compared tonon-treated patients. Increases in preexisting immune responses to aChlamydial protein generally correlate with an improved clinicaloutcome. Such immune responses may generally be evaluated using standardproliferation, cytotoxicity or cytokine assays, which may be performedusing samples obtained from a patient before and after treatment.

In another aspect, the present invention provides methods for using thepolypeptides described above to diagnose Chlamydial infection. In thisaspect, methods are provided for detecting Chlamydial infection in abiological sample, using one or more of the above polypeptides, eitheralone or in combination. For clarity, the term “polypeptide” will beused when describing specific embodiments of the inventive diagnosticmethods. However, it will be clear to one of skill in the art that thefusion proteins of the present invention may also be employed in suchmethods.

As used herein, a “biological sample” is any antibody-containing sampleobtained from a patient. Preferably, the sample is whole blood, sputum,serum, plasma, saliva, cerebrospinal fluid or urine. More preferably,the sample is a blood, serum or plasma sample obtained from a patient.The polypeptides are used in an assay, as described below, to determinethe presence or absence of antibodies to the polypeptide(s) in thesample, relative to a predetermined cut-off value. The presence of suchantibodies indicates previous sensitization to Chlamydia antigens whichmay be indicative of Chlamydia-infection.

In embodiments in which more than one polypeptide is employed, thepolypeptides used are preferably complementary (i.e., one componentpolypeptide will tend to detect infection in samples where the infectionwould not be detected by another component polypeptide). Complementarypolypeptides may generally be identified by using each polypeptideindividually to evaluate serum samples obtained from a series ofpatients known to be infected with Chlamydia. After determining whichsamples test positive (as described below) with each polypeptide,combinations of two or more polypeptides may be formulated that arecapable of detecting infection in most, or all, of the samples tested.

A variety of assay formats are known to those of ordinary skill in theart for using one or more polypeptides to detect antibodies in a sample.See, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold SpringHarbor Laboratory, 1988, which is incorporated herein by reference. In apreferred embodiment, the assay involves the use of polypeptideimmobilized on a solid support to bind to and remove the antibody fromthe sample. The bound antibody may then be detected using a detectionreagent that contains a reporter group. Suitable detection reagentsinclude antibodies that bind to the antibody/polypeptide complex andfree polypeptide labeled with a reporter group (e.g., in asemi-competitive assay). Alternatively, a competitive assay may beutilized, in which an antibody that binds to the polypeptide is labeledwith a reporter group and allowed to bind to the immobilized antigenafter incubation of the antigen with the sample. The extent to whichcomponents of the sample inhibit the binding of the labeled antibody tothe polypeptide is indicative of the reactivity of the sample with theimmobilized polypeptide.

The solid support may be any solid material known to those of ordinaryskill in the art to which the antigen may be attached. For example, thesolid support may be a test well in a microtiter plate, or anitrocellulose or other suitable membrane. Alternatively, the supportmay be a bead or disc, such as glass, fiberglass, latex or a plasticmaterial such as polystyrene or polyvinylchloride. The support may alsobe a magnetic particle or a fiber optic sensor, such as those disclosed,for example, in U.S. Pat. No. 5,359,681.

The polypeptides may be bound to the solid support using a variety oftechniques known to those of ordinary skill in the art. In the contextof the present invention, the term “bound” refers to both noncovalentassociation, such as adsorption, and covalent attachment (which may be adirect linkage between the antigen and functional groups on the supportor may be a linkage by way of a cross-linking agent). Binding byadsorption to a well in a microtiter plate or to a membrane ispreferred. In such cases, adsorption may be achieved by contacting thepolypeptide, in a suitable buffer, with the solid support for a suitableamount of time. The contact time varies with temperature, but istypically between about 1 hour and 1 day. In general, contacting a wellof a plastic microtiter plate (such as polystyrene or polyvinylchloride)with an amount of polypeptide ranging from about 10 ng to about 1 μg,and preferably about 100 ng, is sufficient to bind an adequate amount ofantigen.

Covalent attachment of polypeptide to a solid support may generally beachieved by first reacting the support with a bifunctional reagent thatwill react with both the support and a functional group, such as ahydroxyl or amino group, on the polypeptide. For example, thepolypeptide may be bound to supports having an appropriate polymercoating using benzoquinone or by condensation of an aldehyde group onthe support with an amine and an active hydrogen on the polypeptide(see, e.g., Pierce Immunotechnology Catalog and Handbook, 1991, atA12-A13).

In certain embodiments, the assay is an enzyme linked immunosorbentassay (ELISA). This assay may be performed by first contacting apolypeptide antigen that has been immobilized on a solid support,commonly the well of a microtiter plate, with the sample, such thatantibodies to the polypeptide within the sample are allowed to bind tothe immobilized polypeptide. Unbound sample is then removed from theimmobilized polypeptide and a detection reagent capable of binding tothe immobilized antibody-polypeptide complex is added. The amount ofdetection reagent that remains bound to the solid support is thendetermined using a method appropriate for the specific detectionreagent.

More specifically, once the polypeptide is immobilized on the support asdescribed above, the remaining protein binding sites on the support aretypically blocked. Any suitable blocking agent known to those ofordinary skill in the art, such as bovine serum albumin (BSA) or Tween20™ (Sigma Chemical Co., St. Louis, Mo.) may be employed. Theimmobilized polypeptide is then incubated with the sample, and antibodyis allowed to bind to the antigen. The sample may be diluted with asuitable dilutent, such as phosphate-buffered saline (PBS) prior toincubation. In general, an appropriate contact time (i.e., incubationtime) is that period of time that is sufficient to detect the presenceof antibody within an HGE-infected sample. Preferably, the contact timeis sufficient to achieve a level of binding that is at least 95% of thatachieved at equilibrium between bound and unbound antibody. Those ofordinary skill in the art will recognize that the time necessary toachieve equilibrium may be readily determined by assaying the level ofbinding that occurs over a period of time. At room temperature, anincubation time of about 30 minutes is generally sufficient.

Unbound sample may then be removed by washing the solid support with anappropriate buffer, such as PBS containing 0.1% Tween 2™. Detectionreagent may then be added to the solid support. An appropriate detectionreagent is any compound that binds to the immobilizedantibody-polypeptide complex and that can be detected by any of avariety of means known to those in the art. Preferably, the detectionreagent contains a binding agent (such as, for example, Protein A,Protein G, immunoglobulin, lectin or free antigen) conjugated to areporter group. Preferred reporter groups include enzymes (such ashorseradish peroxidase), substrates, cofactors, inhibitors, dyes,radionuclides, luminescent groups, fluorescent groups and biotin. Theconjugation of binding agent to reporter group may be achieved usingstandard methods known to those of ordinary skill in the art. Commonbinding agents may also be purchased conjugated to a variety of reportergroups from many commercial sources (e.g., Zymed Laboratories, SanFrancisco, Calif., and Pierce, Rockford, Ill.).

The detection reagent is then incubated with the immobilizedantibody-polypeptide complex for an amount of time sufficient to detectthe bound antibody. An appropriate amount of time may generally bedetermined from the manufacturer's instructions or by assaying the levelof binding that occurs over a period of time. Unbound detection reagentis then removed and bound detection reagent is detected using thereporter group. The method employed for detecting the reporter groupdepends upon the nature of the reporter group. For radioactive groups,scintillation counting or autoradiographic methods are generallyappropriate. Spectroscopic methods may be used to detect dyes,luminescent groups and fluorescent groups. Biotin may be detected usingavidin, coupled to a different reporter group (commonly a radioactive orfluorescent group or an enzyme). Enzyme reporter groups may generally bedetected by the addition of substrate (generally for a specific periodof time), followed by spectroscopic or other analysis of the reactionproducts.

To determine the presence or absence of anti-Chlamydia antibodies in thesample, the signal detected from the reporter group that remains boundto the solid support is generally compared to a signal that correspondsto a predetermined cut-off value. In one preferred embodiment, thecut-off value is the average mean signal obtained when the immobilizedantigen is incubated with samples from an uninfected patient. Ingeneral, a sample generating a signal that is three standard deviationsabove the predetermined cut-off value is considered positive forChlamydia-infection. In an alternate preferred embodiment, the cut-offvalue is determined using a Receiver Operator Curve, according to themethod of Sackett et al., Clinical Epidemiology: A Basic Science forClinical Medicine, Little Brown and Co., 1985, pp. 106-107. Briefly, inthis embodiment, the cut-off value may be determined from a plot ofpairs of true positive rates (i.e., sensitivity) and false positiverates (100%-specificity) that correspond to each possible cut-off valuefor the diagnostic test result. The cut-off value on the plot that isthe closest to the upper left-hand corner (i.e., the value that enclosesthe largest area) is the most accurate cut-off value, and a samplegenerating a signal that is higher than the cut-off value determined bythis method may be considered positive. Alternatively, the cut-off valuemay be shifted to the left along the plot, to minimize the falsepositive rate, or to the right, to minimize the false negative rate. Ingeneral, a sample generating a signal that is higher than the cut-offvalue determined by this method is considered positive for Chlamydialinfection.

In a related embodiment, the assay is performed in a rapid flow-throughor strip test format, wherein the antigen is immobilized on a membrane,such as nitrocellulose. In the flow-through test, antibodies within thesample bind to the immobilized polypeptide as the sample passes throughthe membrane. A detection reagent (e.g., protein A-colloidal gold) thenbinds to the antibody-polypeptide complex as the solution containing thedetection reagent flows through the membrane. The detection of bounddetection reagent may then be performed as described above. In the striptest format, one end of the membrane to which polypeptide is bound isimmersed in a solution containing the sample. The sample migrates alongthe membrane through a region containing detection reagent and to thearea of immobilized polypeptide. Concentration of detection reagent atthe polypeptide indicates the presence of anti-Chlamydia antibodies inthe sample. Typically, the concentration of detection reagent at thatsite generates a pattern, such as a line, that can be read visually. Theabsence of such a pattern indicates a negative result. In general, theamount of polypeptide immobilized on the membrane is selected togenerate a visually discernible pattern when the biological samplecontains a level of antibodies that would be sufficient to generate apositive signal in an ELISA, as discussed above. Preferably, the amountof polypeptide immobilized on the membrane ranges from about 25 ng toabout 1 μg, and more preferably from about 50 ng to about 500 ng. Suchtests can typically be performed with a very small amount (e.g., onedrop) of patient serum or blood.

Of course, numerous other assay protocols exist that are suitable foruse with the polypeptides of the present invention. The abovedescriptions are intended to be exemplary only. One example of analternative assay protocol which may be usefully employed in suchmethods is a Western blot, wherein the proteins present in a biologicalsample are separated on a gel, prior to exposure to a binding agent.Such techniques are well known to those of skill in the art.

The present invention further provides agents, such as antibodies andantigen-binding fragments thereof, that specifically bind to aChliamydial protein. As used herein, an antibody, or antigen-bindingfragment thereof, is said to “specifically bind” to a Chlamydial proteinif it reacts at a detectable level (within, for example, an ELISA) witha Chlamydial protein, and does not react detectably with unrelatedproteins under similar conditions. As used herein, “binding” refers to anoncovalent association between two separate molecules such that acomplex is formed. The ability to bind may be evaluated by, for example,determining a binding constant for the formation of the complex. Thebinding constant is the value obtained when the concentration of thecomplex is divided by the product of the component concentrations. Ingeneral, two compounds are said to “bind,” in the context of the presentinvention, when the binding constant for complex formation exceeds about10³ L/mol. The binding constant may be determined using methods wellknown in the art.

Binding agents may be further capable of differentiating betweenpatients with and without a Chlamydial infection using therepresentative assays provided herein. In other words, antibodies orother binding agents that bind to a Chlamydial protein will generate asignal indicating the presence of a Chlamydial infection in at leastabout 20% of patients with the disease, and will generate a negativesignal indicating the absence of the disease in at least about 90% ofindividuals without infection. To determine whether a binding agentsatisfies this requirement, biological samples (e.g., blood, sera,sputum urine and/or tissue biopsies) from patients with and withoutChlamydial infection (as determined using standard clinical tests) maybe assayed as described herein for the presence of polypeptides thatbind to the binding agent. It will be apparent that a statisticallysignificant number of samples with and without the disease should beassayed. Each binding agent should satisfy the above criteria; however,those of ordinary skill in the art will recognize that binding agentsmay be used in combination to improve sensitivity.

Any agent that satisfies the above requirements may be a binding agent.For example, a binding agent may be a ribosome, with or without apeptide component, an RNA molecule or a polypeptide. In a preferredembodiment, a binding agent is an antibody or an antigen-bindingfragment thereof. Antibodies may be prepared by any of a variety oftechniques known to those of ordinary skill in the art. See, e.g.,Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring HarborLaboratory, 1988. In general, antibodies can be produced by cell culturetechniques, including the generation of monoclonal antibodies asdescribed herein, or via transfection of antibody genes into suitablebacterial or mammalian cell hosts, in order to allow for the productionof recombinant antibodies. In one technique, an immunogen comprising thepolypeptide is initially injected into any of a wide variety of mammals(e.g., mice, rats, rabbits, sheep or goats). In this step, thepolypeptides of this invention may serve as the immunogen withoutmodification. Alternatively, particularly for relatively shortpolypeptides, a superior immune response may be elicited if thepolypeptide is joined to a carrier protein, such as bovine serum albuminor keyhole limpet hemocyanin. The immunogen is injected into the animalhost, preferably according to a predetermined schedule incorporating oneor more booster immunizations, and the animals are bled periodically.Polyclonal antibodies specific for the polypeptide may then be purifiedfrom such antisera by, for example, affinity chromatography using thepolypeptide coupled to a suitable solid support.

Monoclonal antibodies specific for an antigenic polypeptide of interestmay be prepared, for example, using the technique of Kohler andMilstein, Eur. J. Immunol. 6:511-519, 1976, and improvements thereto.Briefly, these methods involve the preparation of immortal cell linescapable of producing antibodies having the desired specificity (i.e.,reactivity with the polypeptide of interest). Such cell lines may beproduced, for example, from spleen cells obtained from an animalimmunized as described above. The spleen cells are then immortalized by,for example, fusion with a myeloma cell fusion partner, preferably onethat is syngeneic with the immunized animal. A variety of fusiontechniques may be employed. For example, the spleen cells and myelomacells may be combined with a nonionic detergent for a few minutes andthen plated at low density on a selective medium that supports thegrowth of hybrid cells, but not myeloma cells. A preferred selectiontechnique uses HAT (hypoxanthine, aminopterin, thymidine) selection.After a sufficient time, usually about 1 to 2 weeks, colonies of hybridsare observed. Single colonies are selected and their culturesupernatants tested for binding activity against the polypeptide.Hybridomas having high reactivity and specificity are preferred.

Monoclonal antibodies may be isolated from the supernatants of growinghybridoma colonies. In addition, various techniques may be employed toenhance the yield, such as injection of the hybridoma cell line into theperitoneal cavity of a suitable vertebrate host, such as a mouse.Monoclonal antibodies may then be harvested from the ascites fluid orthe blood. Contaminants may be removed from the antibodies byconventional techniques, such as chromatography, gel filtration,precipitation, and extraction. The polypeptides of this invention may beused in the purification process in, for example, an affinitychromatography step.

Within certain embodiments, the use of antigen-binding fragments ofantibodies may be -preferred. Such fragments include Fab fragments,which may be prepared using standard techniques. Briefly,immunoglobulins may be purified from rabbit serum by affinitychromatography on Protein A bead columns (Harlow and Lane, Antibodies: ALaboratory Manual, Cold Spring Harbor Laboratory, 1988) and digested bypapain to yield Fab and Fc fragments. The Fab and Fc fragments may beseparated by affinity chromatography on protein A bead columns.

Monoclonal antibodies of the present invention may be coupled to one ormore therapeutic agents. Suitable agents in this regard includeradionuclides, differentiation inducers, drugs, toxins, and derivativesthereof. Preferred radionuclides include ⁹⁰Y, ¹²³I, ¹²⁵I, ¹³¹I, ¹⁸⁶Re,¹⁸⁸Re, ²¹¹At, and ²¹²Bi. Preferred drugs include methotrexate, andpyrimidine and purine analogs. Preferred differentiation inducersinclude phorbol esters and butyric acid. Preferred toxins include ricin,abrin, diptheria toxin, cholera toxin, gelonin, Pseudomonas exotoxin,Shigella toxin, and pokeweed antiviral protein.

A therapeutic agent may be coupled (e.g., covalently bonded) to asuitable monoclonal antibody either directly or indirectly (e.g., via alinker group). A direct reaction between an agent and an antibody ispossible when each possesses a substituent capable of reacting with theother. For example, a nucleophilic group, such as an amino or sulfhydrylgroup, on one may be capable of reacting with a carbonyl-containinggroup, such as an anhydride or an acid halide, or with an alkyl groupcontaining a good leaving group (e.g., a halide) on the other.

Alternatively, it may be desirable to couple a therapeutic agent and anantibody via a linker group. A linker group can function as a spacer todistance an antibody from an agent in order to avoid interference withbinding capabilities. A linker group can also serve to increase thechemical reactivity of a substituent on an agent or an antibody, andthus increase the coupling efficiency. An increase in chemicalreactivity may also facilitate the use of agents, or functional groupson agents, which otherwise would not be possible.

It will be evident to those skilled in the art that a variety ofbifunctional or polyfunctional reagents, both homo- andhetero-functional (such as those described in the catalog of the PierceChemical Co., Rockford, Ill.), may be employed as the linker group.Coupling may be effected, for example, through amino groups, carboxylgroups, sulfhydryl groups or oxidized carbohydrate residues. There arenumerous references describing such methodology, e.g., U.S. Pat. No.4,671,958, to Rodwell et al.

Where a therapeutic agent is more potent when free from the antibodyportion of the immunoconjugates of the present invention, it may bedesirable to use a linker group which is cleavable during or uponinternalization into a cell. A number of different cleavable linkergroups have been described. The mechanisms for the intracellular releaseof an agent from these linker groups include cleavage by reduction of adisulfide bond (e.g., U.S. Pat. No. 4,489,710, to Spitler), byirradiation of a photolabile bond (e.g., U.S. Pat. No. 4,625,014, toSenter et al.), by hydrolysis of derivatized amino acid side chains(e.g., U.S. Pat. No. 4,638,045, to Kohn et al.), by serumcomplement-mediated hydrolysis (e.g., U.S. Pat. No. 4,671,958, toRodwell et al.), and acid-catalyzed hydrolysis (e.g., U.S. Pat. No.4,569,789, to Blattler et al.).

It may be desirable to couple more than one agent to an antibody. In oneembodiment, multiple molecules of an agent are coupled to one antibodymolecule. In another embodiment, more than one type of agent may becoupled to one antibody. Regardless of the particular embodiment,immunoconjugates with more than one agent may be prepared in a varietyof ways. For example, more than one agent may be coupled directly to anantibody molecule, or linkers which provide multiple sites forattachment can be used. Alternatively, a carrier can be used.

A carrier may bear the agents in a variety of ways, including covalentbonding either directly or via a linker group. Suitable carriers includeproteins such as albumins (e.g., U.S. Pat. No. 4,507,234, to Kato etal.), peptides and polysaccharides such as aminodextran (e.g., U.S. Pat.No. 4,699,784, to Shih et al.). A carrier may also bear an agent bynoncovalent bonding or by encapsulation, such as within a liposomevesicle (e.g., U.S. Pat. Nos. 4,429,008 and 4,873,088). Carriersspecific for radionuclide agents include radiohalogenated smallmolecules and chelating compounds. For example, U.S. Pat. No. 4,735,792discloses representative radiohalogenated small molecules and theirsynthesis. A radionuclide chelate may be formed from chelating compoundsthat include those containing nitrogen and sulfur atoms as the donoratoms for binding the metal, or metal oxide, radionuclide. For example,U.S. Pat. No. 4,673,562, to Davison et al. discloses representativechelating compounds and their synthesis.

A variety of routes of administration for the antibodies andimmunoconjugates may be used. Typically, administration will beintravenous, intramuscular, subcutaneous or in site-specific regions byappropriate methods. It will be, evident that the precise dose of theantibody/immunoconjugate will vary depending upon the antibody used, theantigen density, and the rate of clearance of the antibody.

Antibodies may be used in diagnostic tests to detect the presence ofChlamydia antigens using assays similar to those detailed above andother techniques well known to those of skill in the art, therebyproviding a method for detecting Chlamydial infection in a patient.

Diagnostic reagents of the present invention may also comprise DNAsequences encoding one or more of the above polypeptides, or one or moreportions thereof. For example, at least two oligonucleotide primers maybe employed in a polymerase chain reaction (PCR) based assay to amplifyChlamydia-specific cDNA derived from a biological sample, wherein atleast one of the oligonucleotide primers is specific for a DNA moleculeencoding a polypeptide of the present invention. The presence of theamplified cDNA is then detected using techniques well known in the art,such as gel electrophoresis. Similarly, oligonucleotide probes specificfor a DNA molecule encoding a polypeptide of the present invention maybe used in a hybridization assay to detect the presence of an inventivepolypeptide in a biological sample.

As used herein, the term “oligonucleotide primer/probe specific for aDNA molecule” means an oligonucleotide sequence that has at least about80%, preferably at least about 90% and more preferably at least about95%, identity to the DNA molecule in question. Oligonucleotide primersand/or probes which may be usefully employed in the inventive diagnosticmethods preferably have at least about 10-40 nucleotides. In a preferredembodiment, the oligonucleotide primers comprise at least about 10contiguous nucleotides of a DNA molecule encoding one of thepolypeptides disclosed herein. Preferably, oligonucleotide probes foruse in the inventive diagnostic methods comprise at least about 15contiguous oligonucleotides of a DNA molecule encoding one of thepolypeptides disclosed herein. Techniques for both PCR based assays andhybridization assays are well known in the art (see, for example, Mulliset al. Ibid; Ehrlich, Ibid). Primers or probes may thus be used todetect Chlamydia-specific sequences in biological samples. DNA probes orprimers comprising oligonucleotide sequences described above may be usedalone or in combination with each other.

The following Examples are offered by way of illustration and not by wayof limitation.

EXAMPLE 1 ISOLATION OF DNA SEQUENCES ENCODING CHLAMYDIA ANTIGENS

Chlamydia antigens of the present invention were isolated by expressioncloning of a genomic DNA library of Chlamydia trachomatis LGV IIessentially as described by Sanderson et al. (J. Exp. Med., 1995,182:1751-1757) and were shown to induce PBMC proliferation and INF-γ inan immunoreactive T cell line.

A Chlamydia-specific T cell line was generated by stimulating PBMCs froma normnal donor with no history of chiamydial genital tract infectionwith elementary bodies of Chlamydia trachomatis LGV II. This T cellline, referred to as TCL-8, was found to recognize both Chlamydiatrachomatis and Chlamydia pneumonia infected monocyte-derived dendriticcells.

A randomly sheared genomic library of Chlamydia trachomatis LGV II wasconstructed in Lambda ZAP (Stratagene, La Jolla, Calif.) and theamplified library plated out in 96 well microtiter plates at a densityof 30 clones/well. Bacteria were induced to express recombinant proteinin the presence of 2 mM IPTG for 3 h, then pelleted and resuspended in200 μl of RPMI 10% FBS. 10 μl of the induced bacterial suspension wastransferred to 96 well plates containing autologous monocyte-deriveddendritic cells. After a 2 h incubation, dendritic cells were washed toremove free E. coli and Chlamydia-specific T cells were added. PositiveE. coli pools were identified by determining IFN-γ production andproliferation of the T cells in response to the pools.

Four positive pools were identified, which were broken down to yieldfour pure clones (referred to as 1-B1-66, 4-D7-28, 3-G3-10 and10-C10-31), with insert sizes 481 bp, 183 bp, 110 bp and 1400 bp,respectively. The determined DNA sequences for 1-B1-66, 4-D7-28, 3-G3-10and 10-C10-31 are provided in SEQ ID NO: 1-4, respectively. Clone1-B1-66 is approximately in region 536690 of the C. trachomatis genome(NCBI C. trachomatis database). Within clone 1-B1-66, an open readingframe (ORF) has been identified (nucleotides 115-375) that encodespreviously indentified 9 kDa protein (Stephens, et al. Genbank AccessionNo. AE001320), the suqence of which is provided in SEQ ID NO: 5) Clone4-D7-28 is a smaller region of the sequence amino acids 22-82 of1-B1-66). Clone 3-G-10 is approximaiely in region 74595 of the C.trachomatis genome. The insert is clone in the antiserse orientaitionwith respect to its orientaion in the genome. The close 10-C10-31contains an open reading frame that corresponds to a previouslypublished sequence for S13 ribosomal protein from Chamydia trachomatis(Gun L. et al. J. Bacteriblogy, 177 2594-2601, 1995). The predictedprotein sequeences for 4-D7-28 and 10-C10-31 are provided in SEQ ID NO:6 and 12, respectively. Predicted protein sequences for 3-G3-10 ableprovided in SEQ ID NO: 7-11.

In a redated series of screening studies, an additional T cell line wasused to screen the genomic DNA library of Chlamydia trachoinatis LGV IIdescribed above. A Chlamydia-specific T cell line (TCT-1) was derivedfrom a patient with a chlamydial genital tract infection by stimulatingpatient PBMC with autologous monocyte-derived dendritic cells infectedwith elementary bodies of Chlamydia trachornatis LGV II. One clone,4C9-18 (SEQ ID NO: 21), containing a 1256 bp insert, elicited a specificimmune response, as measured by standard proliferation assays, from theChilamydia-specific T cell line TCT-1. Subsequent analysis revealed thisclone to contain three known sequences: lipoamide dehydrogenase (GenbankAccession No. AE001326), disclosed in SEQ ID NO: 22; a hypotheticalprotein CT429 (Genbank Accession No. AE001316), disclosed in SEQ ID NO:23; and part of an open reading frame of ubiquinone methyltransferaseCT428 (Genbank Accession No. AE001316), disclosed in SEQ ID NO: 24.

In further studies involving clone 4C9-18 (SEQ ID NO: 21), thefull-length amino acid sequence for lipoamide dehydrognase (SEQ ID NO:22) from C. trachomatis (LGV II) was expressed in clone CtL2-LPDA-FL, asdisclosed in SEQ ID NO: 90.

To further characterize the open reading frame containing the T cellstimulating epitope(s), a cDNA fragitent containing nucleotides 1-695 ofclone 4C9-18 with a cDNA sequence encoding a 6×-Histidine tag on theamino terminus was subcloned into the NdeI/EcoRI site of the pET17bvector (Novagen, Madison, Wis.), referred to as clone 4C9-18#2 BL21pLysS (SEQ ID NO: 25, with the corresponding amino acid sequenceprovided in SEQ ID NO: 26) and transformed into E. coli. Selectiveinduction of the transformed E. coli with 2 mM IPTG for three hoursresulted in the expression of a 26 kDa protein from clone 4C9-18#2 BL21pLysS, as evidenced by standard Coomassie-stained SDS-PAGE. To determinethe immunogenicity of the protein encoded by clone 4C9-18#2 BL21 pLysS,E. coli expressing the 26 kDa protein were titered onto 1×10⁴monocyte-derived dendritic cells and incubated for two hours. Thedendritic cell cultures were washed and 2.5×10⁴ T cells (TCT-1) addedand allowed to incubate for an additional 72 hours, at which time thelevel of INF-γ in the culture supernatant was determined by ELISA. Asshown in FIG. 1, the T-cell line TCT-1 was found to respond to inducedcultures as measured by IFN-g, indicating a Chlamydia-specific T-cellresponse against the lipoamide dehydrogenase sequence. Similarly, theprotein encoded by clone 4C9-18#2 BL21 pLysS was shown to stimulate theTCT-1 T-cell line by standard proliferation assays.

Subsequent studies to identify additional Chlamydia trachomatis antigensusing the above-described CD4+ T-cell expression cloning techniqueyielded additional clones. The TCT-1 and TCL-8 Chlamydia-specific T-celllines, as well as the TCP-21 T-cell line were utilized to screen theChlamydia trachomatis LGVII genomic library. The TCP-21 T-cell line wasderived from a patient having a humoral immune response to Chlamydiapnuemoniae. The TCT-1 cell line identified 37 positive pools, the TCT-3cell line identified 41 positive pools and the TCP-21 cell lineidentified 2 positive pools. The following clones were derived from 10of these positive pools. Clone 11-A3-93 (SEQ ID NO: 64), identified bythe TCP-21 cell line, is a 1339 bp genomic fragment sharing homology tothe HAD superfamily (CT103). The second insert in the same clone shareshomology with the fab I gene (CT104) present on the complementarystrand. Clone 11-C12-91 (SEQ ID NO: 63), identified using the TCP-21cell line, has a 269 bp insert that is part of the OMP2 gene (CT443) andshares homology with the 60 kDa cysteine rich outer membrane protein ofC. pnuemoniae.

Clone 11-G10-46, (SEQ ID NO: 62), identified using the TCT-3 cell line,contains a 688 bp insert that shares homology to the hypotheticalprotein CT610. Clone 11-G1-34, (SEQ ID NO: 61), identified using theTCT-3 cell line, has two partial open reading frames (ORF) with aninsert size of 1215 bp. One ORF shares homology to the malatedehydrogenase gene (CT376), and the other ORF shares homology to theglycogen hydrolase gene (CT042). Clone 11-H3-68, (SEQ ID NO: 60),identified using the TCT-3 cell line, has two ORFs with a total insertsize of 1180 bp. One partial ORF encodes the plasmid-encoded PGP6-Dvirulence protein while the second ORF is a complete ORF for the L1ribosomal gene (CT318). Clone 11-H4-28, (SEQ ID NO: 59), identifiedusing the TCT-3 cell line, has an insert size of 552 bp and is part ofthe ORF for the dnaK gene (CT396). Clone 12-B3-95, (SEQ ID NO: 58),identified using the TCT-1 cell line, has an insert size of 463 bp andis a part of the ORF for for the lipoamide dehydrogenase gene (CT557).Clones 15-G1-89 and 12-B3-95 are identical, (SEQ ID NO: 55 and 58,respectively), identified using the TCT-1 cell line, has an insert sizeof 463 bp and is part of the ORF for the lipoamide dehydrogenase gene(CT557). Clone 12-G3-83, (SEQ ID NO: 57), identified using the TCT-1cell line, has an insert size of 1537 bp and has part of the ORF for thehypothetical protein CT622.

Clone 23-G7-68, (SEQ ID NO: 79), identified using the TCT-3 cell line,contains a 950 bp insert and contains a small part of the L11 ribosomalORF, the entire ORF for L1 ribosomal protein and a part of the ORF forL10 ribosomal protein. Clone 22-F8-91, (SEQ ID NO: 80), identified usingthe TCT-1 cell line, contains a 395 bp insert that contains a part ofthe pmpC ORF on the complementary strand of the clone. Clone 21-E8-95,(SEQ ID NO: 81), identified using the TCT-3 cell line, contains a 2,085bp insert which contains part of CT613 ORF, the complete ORF for CT612,the complete ORF for CT611 and part of the ORF for CT610. Clone19-F12-57, (SEQ ID NO: 82), identified using the TCT-3 cell line,contains a 405 bp insert which contains part of the CT 858 ORF and asmall part of the recA ORF. Clone 19-F12-53, (SEQ ID NO: 83), identifiedusing the TCT-3 cell line, contains a 379 bp insert that is part of theORF for CT455 encoding glutamyl tRNA synthetase. Clone 19-A5-54, (SEQ IDNO: 84), identified using the TCT-3 cell line, contains a 715 bp insertthat is part of the ORF3 (complementary strand of the clone) of thecryptic plasmid. Clone 17-E11-72, (SEQ ID NO: 85), identified using theTCT-1 cell line, contains a 476 bp insert that is part of the ORF forOpp_(—)2 and pmpD. The pmpD region of this clone is covered by the pmpDregion of clone 15-H2-76. Clone 17-C1-77, (SEQ ID NO: 86), identifiedusing the TCT-3 cell line, contains a 1551 bp insert that is part of theCT857 ORF, as well as part of the CT858 ORF. Clone 15-H2-76, (SEQ ID NO:87), identified using the TCT-1 cell line, contains a 3,031 bp insertthat contains a large part of the pmpD ORF, part of the CT089 ORF, aswell as part of the ORF for SycE. Clone 15-A3-26, (SEQ ID NO: 88),contains a 976 bp insert that contains part of the ORF for CT858. Clone17-G4-36, (SEQ ID NO: 267), identified using the TCT-10 cell line,contains a 680 bp insert that is in frame with beta-gal in the plasmidand shares homology to part of the ORF for DNA-directed RNA polymerasebeta subunit (CT315 in SerD).

Several of the clones described above share homology to variouspolymorphic membrane proteins. The genomic sequence of Chlamydiatrachomatis contains a family of nine polymorphic membrane proteingenes, referred to as pmp. These genes are designated pmpA, pmpB, pmpC,pmpD, pmpE, pmpF, pmpG, pmpH and pmpI. Proteins expressed from thesegenes are believed to be of biological relevance in generating aprotective immune response to a Chlamydial infection. In particular,pmpC, pmpD, pmpE and pmpI contain predictable signal peptides,suggesting they are outer membrane proteins, and therefore, potentialimmunological targets.

Based on the Chlamydia trachomatis LGVII serovar sequence, primer pairswere designed to PCR amplify the full-length fragments of pmpC, pmpD,pmpE, pmpG, pmpH and pmpI. The resulting fragments were subcloned intothe DNA vaccine vector JA4304 or JAL, which is JA4304 with a modifiedlinker (SmithKline Beecham, London, England). Specifically, PmpC wassubcloned into the JAL vector using the 5′ oligo GAT AGG CGC GCC GCA ATCATG AAA TTT ATG TCA GCT ACT GCT G and the 3′ oligo CAG AAC GCG TTT AGAATG TCA TAC GAG CAC CGC A, as provided in SEQ ID NO: 197 and 198,respectively. PCR amplification of the gene under conditions well knownin the art and ligation into the 5′ ASCI/3′ MluI sites of the JAL vectorwas completed after inserting the short nucleotide sequence GCAATC (SEQID NO: 199) upstream of the ATG to create a Kozak-like sequence. Theresulting expression vector contained the full-length pmpC genecomprising 5325 nucleotides (SEQ ID NO: 173) containing the hypotheticalsignal sequence, which encodes a 187 kD protein (SEQ ID NO: 179). ThepmpD gene was subcloned into the JA4304 vaccine vector following PCRamplification of the gene using the following oligos: 5′ oligo-TGC AATCAT GAG TTC GCA GAA AGA TAT AAA AAG C (SEQ ID NO: 200) and 3′ oligo-CAGAGC TAG CTT AAA AGA TCA ATC GCA ATC CAG TAT TC (SEQ ID NO: 201). Thegene was ligated into the a 5′ blunted HIII/3′ MluI site of the JA4304vaccine vector using standard techniques well known in the art. TheCAATC (SEQ ID NO: 202) was inserted upstream of the ATG to create aKozak-like sequence. This clone is unique in that the last threonine ofthe HindIII site is missing due to the blunting procedure, as is thelast glycine of the Kozak-like sequence. The insert, a 4593 nucleotidefragment (SEQ ID NO: 172) is the full-length gene for pmpD containingthe hypothetical signal sequence, which encodes a 161 kD protein (SEQ IDNO: 178). PmpE was subcloned into the JA4304 vector using the 5′oligo-TGC AAT CAT GAA AAA AGC GTT TTT CTT TTT C (SEQ ID NO: 203), andthe 3′ oligo-CAG AAC GCG TCT AGA ATC GCA GAG CAA TTT C (SEQ ID NO: 204).Following PCR amplification, the gene was ligated into the 5′ bluntedHIII/3′ MluI site of JA4304. To facilitate this, a short nucleotidesequence, TGCAATC (SEQ ID NO: 293), was added upstream of the initiationcodon for creating a Kozak-like sequence and reconstituting the HindIIIsite. The insert is the full-length pmpE gene (SEQ ID NO: 171)containing the hypothetical signal sequence. The pmpE gene encodes a 105kD protein (SEQ ID NO: 177). The pmpG gene was PCR amplified using the5′ oligo-GTG CAA TCA TGA TTC CTC AAG GAA TTT ACG (SEQ ID NO: 205), andthe 3′ oligo-CAG AAC GCG TTT AGA ACC GGA CTT TAC TTC C (SEQ ID NO: 206)and subcloned into the JA4304 vector. Similar cloning strategies werefollowed for the pmpI and pmpK genes. In addition, primer pairs weredesigned to PCR amplify the full-length or overlapping fragments of thepmp genes, which were then subcloned for protein expression in thepET17b vector (Novagen, Madison, Wis.) and transfected into E. coli BL21pLysS for expression and subsequent purification utilizing thehistidine-nickel chromatographic methodology provided by Novagen.Several of the genes encoding the recombinant proteins, as describedbelow, lack the native signal sequence to facilitate expression of theprotein. Full-length protein expression of pmpC was accomplished throughexpression of two overlapping fragments, representing the amino andcarboxy termini. Subcloning of the pmpC-amino terminal portion, whichlacks the signal sequence, (SEQ ID NO: 187, with the corresponding aminoacid sequence provided in SEQ ID NO: 195) used the 5′ oligo-CAG ACA TATGCA TCA CCA TCA CCA TCA CGA GGC GAG CTC GAT CCA AGA TC (SEQ ID NO: 207),and the 3′ oligo-CAG AGG TAC CTC AGA TAG CAC TCT CTC CTA TTA AAG TAG G(SEQ ID NO: 208) into the 5′ NdeI/3′ KPN cloning site of the vector. Thecarboxy terminus portion of the gene, pmpC-carboxy terminal fragment(SEQ ID NO: 186, with the corresponding amino acid sequence provided inSEQ ID NO: 194), was subcloned into the 5′ NheI/3′ KPN cloning site ofthe expression vector using the following primers: 5′ oligo-CAG AGC TAGCAT GCA TCA CCA TCA CCA TCA CGT TAA GAT TGA GAA CTT CTC TGG C (SEQ IDNO: 209), and 3′ oligo-CAG AGG TAC CTT AGA ATG TCA TAC GAG CAC CGC AG(SEQ ID NO: 210). PmpD was also expressed as two overlapping proteins.The pmpD-amino terminal portion, which lacks the signal sequence, (SEQID NO: 185, with the corresponding amino acid sequence provided in SEQID NO: 193) contains the initiating codon of the pET17b and is expressedas a 80 kD protein. For protein expression and purification purposes, asix-histidine tag follows the initiation codon and is fused at the28^(th) (b amino acid (nucleotide 84) of the gene. The following primerswere used, 5′ oligo, CAG ACA TAT GCA TCA CCA TCA CCA TCA CGG GTT AGC(SEQ ID NO: 211), and the 3′ oligo-CAG AGG TAC CTC AGC TCC TCC AGC ACACTC TCT TC (SEQ ID NO: 212), to splice into the 5′ NdeI/3′ KPN cloningsite of the vector. The pmpD-carboxy terminus portion (SEQ ID NO: 184)was expressed as a 92 kD protein (SEQ ID NO: 192). For expression andsubsequent purification, an additional methionine, alanine and serinewas included, which represent the initiation codon and the first twoamino acids from the pET17b vector. A six-histidine tag downstream ofthe methionine, alanine and serine is fused at the 691^(st) amino acid(nucleotide 2073) of the gene. The 5′ oligo-CAG AGC TAG CCA TCA CCA TCACCA TCA CGG TGC TAT TTC TTG CTT ACG TGG (SEQ ID NO: 213) and the 3′oligo-CAG AGG TAC TTn AAA AGA TCA ATC GCA ATC CAG TAT TCG (SEQ ID NO:214) were used to subclone the insert into the 5′ NheI/3′ KPN cloningsite of the expression vector. PmpE was expressed as a 106 kD protein(SEQ ID NO: 183 with the corresponding amino acid sequence provided inSEQ ID NO: 191). The pmpE insert also lacks the native signal sequence.PCR amplification of the gene under conditions well known in the art wasperformed using the following oligo primers: 5′ oligo-CAG AGG ATC CACATC ACC ATC ACC ATC ACG GAC TAG CTA GAG AGG TTC (SEQ ID NO: 215), andthe 3′ oligo-CAG AGA ATT CCT AGA ATC GCA GAG CAA TTT C (SEQ ID NO: 216),and the amplified insert was ligated into a 5′ BamHI/3′ EcoRI site ofJA4304. The short nucleotide sequence, as provided in SEQ ID NO: 217,was inserted upstream of the initiation codon for creating theKozak-like sequence and reconstituting the HindIII site. The expressedprotein contains the initiation codon and the downstream 21 amino acidsfrom the pET17b expression vector, i.e., MASMTGGQQMGRDSSLVPSSDP (SEQ IDNO: 218). In addition, a six-histidine tag is included upstream of thesequence described above and is fused at the 28^(th) amino acid(nucleotide 84) of the gene, which eliminates the hypothetical signalpeptide. The sequences provided in SEQ ID NO: 183 with the correspondingamino acid sequence provided in SEQ ID NO: 191 do not include theseadditional sequences. The pmpG gene (SEQ ID NO: 182, with thecorresponding amino acid sequence provided in SEQ ID No; 190) was PCRamplified under conditions well known in the art using the followingoligo primers: 5′ oligo-CAG AGG TAC CGC ATC ACC ATC ACC ATC ACA TGA TTCCTC AAG GAA TTT ACG (SEQ ID NO: 219), and the 3′ oligo-CAG AGC GGC CGCTTA GAA CCG GAC TTT ACT TCC (SEQ ID NO: 220), and ligated into the 5′KPN/3′ NotI cloning site of the expression vector. The expressed proteincontains an additional amino acid sequence at the amino end, namely,MASMTGGQQNGRDSSLVPHHHHHH (SEQ ID NO: 221), which comprises theinitiation codon and additional sequence from the pET17b expressionvector. The pmpI gene (SEQ ID NO: 181, with the corresponding amino acidsequence provided in SEQ ID No; 189) was PCR amplified under conditionswell known in the art using the following oligo primers: 5′ oligo-CAGAGC TAG CCA TCA CCA TCA CCA TCA CCT CTT TGG CCA GGA TCC C (SEQ ID NO:222), and the 3′ oligo-CAG AAC TAG TCT AGA ACC TGT AAG TGG TCC (SEQ IDNO: 223), and ligted into the expression vector at the 5′ NheI/3′ SpeIcloning site. The 95 kD expressed protein contains the initiation codonplus an additional alanine and serine from the pET17b vector at theamino end of the protein. In addition, a six-histidine tag is fused atthe 21^(st) amino acid of the gene, which eliminates the hypotheticalsignal peptide.

Clone 14H1-4, (SEQ ID NO: 56), identified using the TCT-3 cell line,contains a complete ORF for the TSA gene, thiol specificantioxidant—CT603 (the CT603 ORF is a homolog of CPn0778 from C.pnuemoniae). The TSA open reading frame in clone 14-H1-4 was amplifiedsuch that the expressed protein possess an additional methionine and a6×histidine tag (amino terminal end). This amplified insert wassub-cloned into the Nde/EcoRI sites of the pET17b vector. Upon inductionof this clone with IPTG, a 22.6 kDa protein was purified by Ni-NTAagarose affinity chromatography. The determined amino acid sequence forthe 195 amino acid ORF of clone 14-H1-4 encoding the TSA gene isprovided in SEQ ID NO: 65. Further analysis yielded a full-length clonefor the TSA gene, referred to as CTL2-TSA-FL, with the full-length aminoacid sequence provided in SEQ ID NO: 92.

Further studies yielded 10 additional clones identified by the TCT-1 andTCT-3 T-cell lines, as described above. The clones identified by theTCT-1 line are: 16-D4-22, 17-C5-19, 18-C5-2, 20-G3-45 and 21-C7-66;clones identified by the TCT line are: 17-C10-31, 17-E2-9, 22-A1-49 and22-B3-53. Clone 21-G12-60 was recognized by both the TCT-1 and TCT-3 Tcell lines. Clone 16-D4-22 (SEQ ID NO: 119), identified using the TCT-1cell line contains a 953 bp insert that contains two genes, parts ofopen reading frame 3 (ORF3) and ORF4 of the C. trachomatis plasmid forgrowth within mammalian cells. Clone 17-C5-19 (SEQ ID NO: 118), containsa 951 bp insert that contains part of the ORF for DT431, encoding forclpP_(—)1 protease and part of the ORF for CT430 (diaminopimelateepimerase). Clone 18-C5-2 (SEQ ID NO: 117) is part of the ORF for S1ribosomal protein with a 446 bp insert that was identified using theTCT-1 cell line. Clone 20-G3-45 (SEQ ID NO: 116), identified by theTCT-1 cell line, contains a 437 bp insert that is part of the pmpB gene(CT413). Clone 21-C7-66 (SEQ ID NO: 115), identified by the TCT-1 line,contains a 995 bp insert that encodes part of the dnaK like protein. Theinsert of this clone does not overlap with the insert of the TCT-3 clone11-H4-28 (SEQ ID NO: 59), which was shown to be part of the dnaK geneCT396 Clone 17-C10-31 (SEQ ID NO: 114), identified by the TCT-3 cellline, contains a 976 bp insert. This clone contains part of the ORF forCT858, a protease containing IRBP and DHR domains. Clone 17-E2-9 (SEQ IDNO: 113) contains part of ORFs for two genes, CT611 and CT610, that spana 1142 bp insert. Clone 22-A1-49 (SEQ ID NO: 112), identified using theTCT-3 line, also contains two genes in a 698 bp insert. Part of the ORFfor CT660 (DNA gyrase{gyrA_(—)2}) is present on the top strand where asthe complete ORF for a hypothetical protein CT659 is present on thecomplementary strand. Clone 22-B3-53 (SEQ ID NO: 111), identified by theTCT-1 line, has a 267 bp insert that encodes part of the ORF for GroEL(CT110). Clone 21-G12-60 (SEQ ID NO: 110), identified by both the TCT-1and TCT-3 cell lines contains a 1461 bp insert that contains partialORFs for hypothetical proteins CT875, CT229 and CT228.

Additional Chlamydia antigens were obtained by screening a genomicexpression library of Chlamydia trachomatis (LGV II serovar) in LambdaScreen-i vector (Novagen, Madison, Wis.) with sera pooled from severalChlamydia-infected individuals using techniques well known in the art.The following immuno-reactive clones were identified and the insertscontaining Chlamydia genes sequenced: CTL2#1 (SEQ ID NO: 71); CTL2#2(SEQ ID NO: 70); CTL2#3-5′ (SEQ ID NO: 72, a first determined genomicsequence representing the 5′ end); CTL2#3-3′ (SEQ ID NO: 73, a seconddetermined genomic sequence representing the 3′ end); CTL2#4 (SEQ ID NO:53); CTL2#5 (SEQ ID NO: 69); CTL2#6 (SEQ ID NO: 68); CTL2#7 (SEQ ID NO:67); CTL2#8b (SEQ ID NO: 54); CTL2#9 (SEQ ID NO: 66); CTL2#10-5′ (SEQ IDNO: 74, a first determined genomic sequence representing the 5′ end);CTL2#10-3′ (SEQ ID NO: 75, a second determined genomic sequencerepresenting the 3′ end); CTL2#11-5′ (SEQ ID NO: 45, a first determinedgenomic sequence representing the 5′ end); CTL2#11-3′ (SEQ ID NO: 44, asecond determined genomic sequence representing the 3′ end); CTL2#12(SEQ ID NO: 46); CTL2#16-5′ (SEQ ID NO: 47); CTL2#18-5′ (SEQ ID NO: 49,a first determined genomic sequence representing the 5′ end); CTL2#18-3′(SEQ ID NO: 48, a second determined genomic sequence representing the 3′end); CTL2#19-5′ (SEQ ID NO: 76, the determined genomic sequencerepresenting the 5′ end); CTL2#21 (SEQ ID NO: 50); CTL2#23 (SEQ ID NO:51; and CTL2#24 (SEQ ID NO: 52).

Additional Chlamydia trachomatis antigens were identified by serologicalexpression cloning. These studies used sera pooled from severalChlamydia-infected individuals, as described above, but, IgA, and IgMantibodies were used in addition to IgG as a secondary antibody. Clonesscreened by this method enhance detection of antigens recognized by anearly immune response to a Chlamydial infection, that is a mucosalhumoral immune response. The following immunoreactive clones werecharacterized and the inserts containing Chlamydia genes sequenced:CTL2gam-1 (SEQ ID NO: 290), CTL2gam-2 (SEQ ID NO: 289), CTL2gam-5 (SEQID NO: 288), CTL2gam-6-3′ (SEQ ID NO: 287, a second determined genomicsequence representing the 3′ end), CTL2gam-6-5′ (SEQ ID NO: 286, a firstdetermined genomic sequence representing the 5′ end), CTL2gam-8 (SEQ IDNO: 285), CTL2gam-10 (SEQ ID NO: 284), CTL2gam-13 (SEQ ID NO: 283),CTL2gam-15-3′ (SEQ ID NO: 282, a second determined genomic sequencerepresenting the 3′ end), CTL2gam-15-5′ (SEQ ID NO: 281, a firstdetermined genomic sequence representing the 5′ end), CTL2gam-17 (SEQ IDNO: 280), CTL2gam-18 (SEQ ID NO: 279), CTL2gam-21 (SEQ ID NO: 278),CTL2gam-23 (SEQ ID NO: 277), CTL2gam-24 (SEQ ID NO: 276), CTL2gam-26(SEQ ID NO: 275), CTL2gam-27 (SEQ ID NO: 274), CTL2gam-28 (SEQ ID NO:273), CTL2gam-30-3′ (SEQ ID NO: 272, a second determined genomicsequence representing the 3′ end) and CTL2gam-30-5′ (SEQ ID NO: 271, afirst determined genomic sequence representing the 5′ end).

EXAMPLE 2 INDUCTION OF T CELL PROLIFERATION AND INTERFERON-γ PRODUCTIONBY CHLAMYDIA TRACHOMATIS ANTIGENS

The ability of recombinant Chlamydia trachomatis antigens to induce Tcell proliferation and interferon-γ production is determined as follows.

Proteins are induced by IPTG and purified by Ni-NTA agarose affinitychromatograph (Webb et al., J. Immunology 157:5034-5041, 1996). Thepurified polypeptides are then screened for the ability to induce T-cellproliferation in PBMC preparations. PBMCs from C. trachomatis patientsas well as from normal donors whose T-cells are known to proliferate inresponse to Chlamydia antigens, are cultured in medium comprising RPMI1640 supplemented with 10% pooled human serum and 50 μg/ml gentamicin.Purified polypeptides are added in duplicate at concentrations of 0.5 to10 μg/mL. After six days of culture in 96-well round-bottom plates in avolume of 200 μl, 50 μl of medium is removed from each well fordetermination of INF-γ levels, as described below. The plates are thenpulsed with 1 μCi/well of tritiated thymidine for a further 18 hours,harvested and tritium uptake determined using a gas scintillationcounter. Fractions that result in proliferation in both replicates threefold greater than the proliferation observed in cells cultured in mediumalone are considered positive.

INF-γ is measured using an enzyme-linked immunosorbent assay (ELISA).ELISA plates are coated with a mouse monoclonal antibody directed tohuman INF-γ (PharMingen, San Diego, Calif.) in PBS for four hours atroom temperature. Wells are then blocked with PBS containing 5% (W/V)non-fat dried milk for I hour at room temperature. The plates are washedsix times in PBS/0.2% TWEEN-20 and samples diluted 1:2 in culture mediumin the ELISA plates are incubated overnight at room temperature. Theplates are again washed and a polyclonal rabbit anti-human IFN-γ serumdiluted 1:3000 in PBS/10% normal goat-serum is added to each well. Theplates are then incubated for two hours at room temperature, washed andhorseradish peroxidase-coupled anti-rabbit IgG (Sigma Chemical So., St.Louis, Mo.) is added at a 1:2000 dilution in PBS/5% non-fat dried milk.After a further two hour incubation at room temperature, the plates arewashed and TMB substrate added. The reaction is stopped after 20 minwith 1 N sulfuric acid. Optical density is determined at 450 nm using570 nm as a reference wavelength. Fractions that result in bothreplicates giving an OD two fold greater than the mean OD from cellscultured in medium alone, plus 3 standard deviations, are consideredpositive.

Using the above methodology, recombinant 1B1-66 protein (SEQ ID NO: 5)as well as two synthetic peptides corresponding to amino acid residues48-67 (SEQ ID NO: 13; referred to as 1-B1-66/48-67) and 58-77 (SEQ IDNO: 14, referred to as 1B1-66/58-77), respectively, of SEQ ID NO: 5,were found to induce a proliferative response and IFN-γ production in aChlamydia-specific T cell line used to screen a genomic library of C.trachomatis LGV II.

Further studies have identified a C. trachomatis-specific T-cell epitopein the ribosomal S13 protein. Employing standard epitope mappingtechniques well known in the art, two T-cell epitopes in the ribosomalS13 protein (rS13) were identified with a Chlamydia-specific T-cell linefrom donor CL-8 (T-cell line TCL-8 EB/DC). FIG. 8 illustrates that thefirst peptide, rS13 1-20 (SEQ ID NO: 106), is 100% identical with thecorresponding C. pneumoniae sequence, explaining the cross-reactivity ofthe T-cell line to recombinant C. trachomatis- and C. pneumoniae-rS13.The response to the second peptide rS13 56-75 (SEQ ID NO: 108) is C.trachomatis-specific, indicating that the rS13 response in this healthyasymptomatic donor was elicited by exposure to C. trachomatis and not toC. pneumoniae, or any other microbial infection.

As described in Example 1, Clone 11C12-91 (SEQ ID NO: 63), identifiedusing the TCP-21 cell line, has a 269 bp insert that is part of the OMP2gene (CT443) and shares homology with the 60 kDa cysteine rich outermembrane protein of C. pneumoniae, referred to as OMCB. To furtherdefine the reactive epitope(s), epitope mapping was performed using aseries of overlapping peptides and the immunoassay previously described.Briefly, proliferative responses were determined by stimulating 2.5×10⁴TCP-21 T-cells in the presence of 1×10⁴ monocyte-derived dendritic cellswith either non-infectious elementary bodies derived from C. trachomatisand C. pneumoniae, or peptides derived from the protein sequence of C.trachomatis or C. pneumoniae OMCB protein (0.1 μg/ml). The TCP-21T-cells responded to epitopes CT-OMCB #167-186, CT-OMCB #171-190,CT-OMCB #171-186, and to a lesser extent, CT-OMCB #175-186 (SEQ ID NO:249-252, respectively). Notably, the TCP-21 T-cell line also gave aproliferative response to the homologous C. pneumoniae peptide CP-OMCB#171-186 (SEQ ID NO: 253), which was equal to or greater than theresponse to the C. trachomatis peptides. The amino acid substitutions inposition two (i.e., Asp for Glu) and position four (i.e., Cys for Ser)did not alter the proliferative response of the T-cells and thereforedemonstrating this epitope to be a cross-reactive epitope between C.trachomatis and C. pneumoniae.

To further define the epitope described above, an additional T-cellline, TCT-3, was used in epitope mapping experiments. The immunoassayswere performed as described above, except that only peptides from C.trachomatis were tested. The T-cells gave a proliferative response totwo peptides, CT-OMCB #152-171 and CT-OMCB #157-176 (SEQ ID NO: 246 and247, respectively), thereby defining an additional immunogenic epitopein the cysteine rich outer membrane protein of C. trachomatis.

Clone 14H1-4, (SEQ ID NO: 56, with the corresponding full-length aminoacid sequence provided in SEQ ID NO: 92), was identified using the TCT-3cell line in the CD4 T-cell expression cloning system previouslydescribed, and was shown to contain a complete ORF for the, thiolspecific antioxidant gene (CT603), referred to as TSA. Epitope mappingimmunoassays were performed, as described above, to further define theepitope. The TCT-3 T-cells line exhibited a strong proliferativeresponse to the overlapping peptides CT-TSA #96-15, CT-TSA #101-120 andCT-TSA #106-125 (SEQ ID NO: 254-256, respectively) demonstrating animmunoreactive epitope in the thiol specific antioxidant gene of C.trachomatis serovar LGVII.

EXAMPLE 3 PREPARATION OF SYNTHETIC POLYPEPTIDES

Polypeptides may be synthesized on a Millipore 9050 peptide synthesizerusing FMOC chemistry with HPTU(O-Benzotriazole-N,N,N′,N′-tetramethyluronium hexafluorophosphate)activation. A Gly-Cys-Gly sequence may be attached to the amino terminusof the peptide to provide a method of conjugating or labeling of thepeptide. Cleavage of the peptides from the solid support may be carriedout using the following cleavage mixture: trifluoroaceticacid:ethanedithiol:thioanisole:water:phenol (40:1:2:2:3). After cleavingfor 2 hours, the peptides may be precipitated in coldmethyl-t-butyl-ether. The peptide pellets may then be dissolved in watercontaining 0.1% trifluoroacetic acid (TFA) and lyophilized prior topurification by C18 reverse phase HPLC. A gradient of 0-60% acetonitrile(containing 0.1% TFA) in water (containing 0.1% TFA) may be used toelute the peptides. Following lyophilization of the pure fractions, thepeptides may be characterized using electrospray mass spectrometry andby amino acid analysis.

EXAMPLE 4 ISOLATION AND CHARACTERIZATION OF DNA SEQUENCES ENCODINGCHLAMYDIA ANTIGENS USING RETROVIRAL EXPRESSION VECTOR SYSTEMS ANDSUBSEQUENT IMMUNOLOGICAL ANALYSIS

A genomic library of Chlamydia trachomatis LGV II was constructed bylimited digests using BamHI, BglII, BstYi and MboI restriction enzymes.The restriction digest fragments were subsequently ligated into theBamHI site of the retroviral vectors pBIB-KS1,2,3. This vector set wasmodified to contain a Kosak translation initiation site and stop codonsin order to allow expression of proteins from short DNA genomicfragments, as shown in FIG. 2. DNA pools of 80 clones were prepared andtransfected into the retroviral packaging line Phoenix-Ampho, asdescribed in Pear, W. S., Scott, M. L. and Nolan, G. P., Generation ofHigh Titre, Helper-free Retroviruses by Transient Transfection. Methodsin Molecular Medicine: Gene Therapy Protocols, Humana Press, Totowa,N.J., pp. 41-57. The Chlamydia library in retroviral form was thentransduced into H2-Ld expressing P815 cells, which were then used astarget cells to stimulate an antigen specific T-cell line.

A Chlamydia-specific, murine H2^(d) restricted CD8+ T-cell line wasexpanded in culture by repeated rounds of stimulation with irradiated C.trachomatis-infected J774 cells and irradiated syngeneic spleen cells,as described by Stambach, M., in J. Immunol., 153:5183, 1994. ThisChlamydia-specific T-cell line was used to screen the above Chlamydiagenomic library expressed by the retrovirally-transduced P815 cells.Positive DNA pools were identified by detection of INF-γ productionusing Elispot analysis (SEE Lalvani et al., J. Experimental Medicine186:859-865, 1997).

Two positive pools, referred to as 2C7 and 2E10, were identified byIFN-γ Elispot assays. Stable transductants of P815 cells from pool 2C7were cloned by limiting dilution and individual clones were selectedbased upon their capacity to elicit IFN-γ production from theChlamydia-specific CTL line. From this screening process, four positiveclones were selected, referred to as 2C7-8, 2C7-9, 2C7-19 and 2C7-21.Similarly, the positive pool 2E10 was further screened, resulting in anadditional positive clone, which contains three inserts. The threeinserts are fragments of the CT016, tRNA syntase and clpX genes (SEQ IDNO: 268-270, respectively).

Transgenic DNA from these four positive 2C7 clones were PCR amplifiedusing pBIB-KS specific primers to selectively amplify the Chlamydia DNAinsert. Amplified inserts were gel purified and sequenced. Oneimmunoreactive clone, 2C7-8 (SEQ ID NO: 15, with the predicted aminoacid sequence provided in SEQ ID NO: 32), is a 160 bp fragment withhomology to nucleotides 597304-597145 of Chlamydia trachomatis, serovarD (NCBI, BLASTN search; SEQ ID NO: 33, with the predicted amino acidsequence provided in SEQ ID NO: 34). The sequence of clone 2C7-8 mapswithin two putative open reading frames from the region of high homologydescribed immediately above, and in particular, one of these putativeopen reading frames, consisting of a 298 amino acid fragment (SEQ ID NO:16, with the predicted amino acid sequence provided in SEQ ID NO: 17),was demonstrated to exhibit immunological activity.

Full-length cloning of the 298 amino acid fragment (referred to as CT529and/or the Cap1 gene) from serovar L2 was obtained by PCR amplificationusing 5′-ttttgaagcaggtaggtgaatatg (forward) (SEQ ID NO: 159) and5′-ttaagaaatttaaaaaatccctta (reverse) (SEQ ID NO: 160) primers, usingpurified C. trachomatis L2 genomic DNA as template. This PCR product wasgel-purified, cloned into pCRBlunt (Invitrogen, Carlsbad, Calif.) forsequencing, and then subcloned into the EcoRI site of pBIB-KMS, aderivative of pBIB-KS for expression. The Chlamydia pnuemoniae homlogueof CT529 is provided in SEQ ID NO: 291, with the corresponding aminoacid sequence provided in SEQ ID NO: 292.

Full-length DNA encoding various CT529 serovars were amplified by PCRfrom bacterial lysates containing 10⁵ IFU, essentially as described(Denamur, E., C. Sayada, A. Souriau, J. Orfila, A. Rodolakis and J.Elion. 1991. J. Gen. Microbiol. 137: 2525). The following serovars wereamplified as described: Ba (SEQ ID NO: 134, with the correspondingpredicted amino acid sequence provided in SEQ ID NO: 135); E (BOUR) andE (MTW447) (SEQ ID NO: 122, with the corresponding predicted amino acidsequence provided in SEQ ID NO: 123); F (NI1) (SEQ ID NO: 128, with thecorresponding predicted amino acid sequence provided in SEQ ID NO: 129);G; (SEQ ID NO: 126, with the corresponding predicted amino acid sequenceprovided in SEQ ID NO: 127); Ia (SEQ ID NO: 124, with the correspondingpredicted amino acid sequence provided in SEQ ID NO: 125); L1 (SEQ IDNO: 130, with the corresponding predicted amino acid sequence providedin SEQ ID NO: 131); L3 (SEQ ID NO: 132, with the corresponding predictedamino acid sequence provided in SEQ ID NO: 133); I (SEQ ID NO: 263, withthe corresponding predicted amino acid sequence provided in SEQ ID NO:264); K (SEQ ID NO: 265, with the corresponding predicted amino acidsequence provided in SEQ ID NO: 266); and MoPn (SEQ ID NO: 136, with thecorresponding predicted amino acid sequence provided in SEQ ID NO: 137).PCR reactions were performed with Advantage Genomic PCR Kit (Clontech,Palo Alto, Calif.) using primers specific for serovar L2 DNA (externalto the ORF). Primers sequences were 5′-ggtataatatctctctaaattttg(forward-SEQ ID NO: 161) and 5′-agataaaaaaggctgtttc′ (reverse-SEQ ID NO:162) except for MoPn which required 5′-ttttgaagcaggtaggtgaatatg(forward-SEQ ID NO: 163) and 5′-tttacaataagaaaagctaagcactttgt(reverse-SEQ ID NO: 164). PCR amplified DNA was purified with QlAquickPCR purification kit (Qiagen, Valencia, Calif.) and cloned in pCR2.1(Invitrogen, Carlsbad, Calif.) for sequencing.

Sequencing of DNA derived from PCR amplified inserts of immunoreactiveclones was done on an automated sequencer (ABI 377) using both a pBIB-KSspecific forward primer 5′-ccttacacagtcctgctgac (SEQ ID NO: 165) and areverse primer 3′-gtttccgggccctcacattg (SEQ ID NO: 166). PCRBlunt clonedDNA coding for CT529 serovar L2 and pCR2.1 cloned DNA coding for CT529serovar Ba, E (BOUR), E (MTW447), F (NI1), G, Ia, K, L1, L3 and MoPnwere sequenced using T7 promoter primer and universal M13 forward andM13 reverse primers.

To determine if these two putative open reading frames (SEQ ID NO: 16and 20) encoded a protein with an associated immunological function,overlapping peptides (17-20 amino acid lengths) spanning the lengths ofthe two open reading frames were synthesized, as described in Example 3.A standard chromium release assay was utilized to determine the per centspecific lysis of peptide-pulsed H2^(d) restricted target cells. In thisassay, aliquots of P815 cells (H2^(d)) were labeled at 37° C. for onehour with 100 μCi of ⁵¹Cr in the presence or absence of 1 μg/ml of theindicated peptides. Following this incubation, labeled P815 cells werewashed to remove excess ⁵¹Cr and peptide, and subsequently plated induplicate in microculture plates at a concentration of 1,000 cells/well.Effector CTL (Chlamydia-specific CD8 T cells) were added at theindicated effector:target ratios. Following a 4 hour incubation,supernatants were harvested and measured by gamma-counter for release of⁵¹C into the supernatant. Two overlapping peptides from the 298 aminoacid open reading frame did specifically stimulate the CTL line. Thepeptides represented in SEQ ID NO: 138-156 were synthesized,representing the translation of the L2 homologue of the serovar D openreading frame for CT529 (Cap1 gene) and 216 amino acid open readingframe. As shown in FIG. 3, peptides CtC7.8-12 (SEQ ID NO: 18, alsoreferred to as Cap1#132-147, SEQ ID NO: 139) and CtC7.8-13 (SEQ ID NO:19, also referred to as Cap1#138-155, SEQ ID NO: 140) were able toelicit 38 to 52% specific lysis, respectively, at an effector to targetratio of 10:1. Notably, the overlap between these two peptides containeda predicted H2^(d) (K^(d) and L^(d)) binding peptide. A 10 amino acidpeptide was synthesized to correspond to this overlapping sequence (SEQID NO: 31) and was found to generate a strong immune response from theanti-Chlamytdia CTL line by elispot assay. Significantly, a search ofthe most recent Genbank database revealed no proteins have previouslybeen described for this gene. Therefore, the putative open reading frameencoding clone 2C7-8 (SEQ ID NO: 15) defines a gene which encompasses anantigen from Chlamydia capable of stimulating antigen-specific CD8+T-cells in a MHC-I restricted manner, demonstrating this antigen couldbe used to develop a vaccine against Chlamydia.

To confirm these results and to further map the epitope, truncatedpeptides (SEQ ID NO: 138-156) were made and tested for recognition bythe T-cells in an IFN-g ELISPOT assay. Truncations of either Ser139(Cap1#140-147, SEQ ID NO: 146) or Leu147 (Cap1#138-146, SEQ ID NO: 147)abrogate T-cell recognition. These results indicate that the 9-merpeptide Cap1#139-147 (SFIGGITYL, SEQ ID NO: 145) is the minimal epitoperecognized by the Chlamydia-specific T-cells.

Sequence alignments of Cap1 (CT529) from selected serovars of C.trachomatis (SEQ ID NO: 121, 123, 125, 127, 129, 131, 133, 135, 137 and139) shows one of the amino acid differences is found in position 2 ofthe proposed epitope. The homologous serovar D peptide is SIIGGITYL (SEQID NO: 168). The ability of SFIGGITYL and SIIGGITYL to target cells forrecognition by the Chlamydia specific T-cells was compared. Serialdilutions of each peptide were incubated with P815 cells and tested forrecognition by the T-cells in a ⁵¹Cr release assay, as described above.The Chlamydia-specific T-cells recognize the serovar L2 peptide at aminimum concentration of 1 nM and the serovar D peptide at a minimumconcentration of 10 nM.

Further studies have shown that a Cap1#139-147-specific T-cell clonerecognizes C. trachomatis infected cells. To confirm that Cap1₁₃₉₋₁₄₇ ispresented on the surface of Chlamydia infected cells, Balb-3T3 (H-2^(d))cells were infected with C. trachomatis serovar L2 and tested todetermnine whether these cells are recognized by a CD8+ T-cell clonespecific for Cap1#139-147 epitope (SEQ ID NO: 145). The T-cell clonespecific for Cap1#139-147 epitope was obtained by limiting dilution ofthe line 69 T-cells. The T-cell clone specifically recognized theChlamydia infected cells. In these experiments, target cells were C.trachomatis infected (positive control) or uninfected Balb/3T3 cells,showing 45%, 36% and 30% specific lysis at 30:1, 10:1 and 3:1 effectorto target ratios, respectively; or Cap1#139-147 epitope (SEQ ID NO: 145)coated, or untreated P815 cells, showing 83%, 75% and 58% specific lysisat 30:1, 10:1 and 3:1 effector to target ratios, respectively (negativecontrols having less than 5% lysis in all cases). This data suggeststhat the epitope is presented during infection.

In vivo studies show Cap1#139-147 epitope-specific T-cells are primedduring murine infection with C. trachomatis. To determine if infectionwith C. trachomatis primes a Cap1#139-147 epitope-specific T-cellresponse, mice were infected i.p. with 10⁸ IFU of C. trachomatis serovarL2. Two weeks after infection, the mice were sacrificed and spleen cellswere stimulated on irradiated syngeneic spleen cells pulsed withCap1#139-147 epitope peptide. After 5 days of stimulation, the cultureswere used in a standard ⁵¹Cr release assay to determine if there wereCap1#139-147 epitope-specific T-cells present in the culture.Specifically, spleen cells from a C. trachomatis serovar L2 immunizedmouse or a control mouse injected with PBS after a 5 days culture withCap1#139-147 peptide-coated syngeneic spleen cells and CD8+ T-cells ableto specifically recognize Cap1#139-147 epitope gave 73%, 60% and 32%specific lysis at a 30:1, 10:1 and 3:1 effector to target ratios,respectively. The control mice had a percent lysis of approximately 10%at a 30:1 effector to target ratio, and steadily declining with loweringE:T ratios. Target cells were Capl#139-147 peptide-coated, or untreatedP815 cells. These data suggest that Cap1#139-147 peptide-specificT-cells are primed during murine infection with C. trachomatis.

Studies were performed demonstrating that Ct529 (referred to herein asCap-1) localizes to the inclusion membrane of C. trachomatis-infectedcells and is not associated with elementary bodies or reticulate bodies.As described above, Cap-1 was identified as a product from Chlamydiathat stimulates CD8+ CTL. These CTL are protective in a murine model ofinfection, thus making Cap-1 a good vaccine candidate. Further, sincethese CTL are MHC-I restricted, the Cap-1 gene must have access to thecytosol of infected cells, which may be a unique characteristic ofspecific Chlamydial gene products. Therefore, determination of thecellular localization of the gene products would be useful incharacterizing Cap-1 as a vaccine candidate. To detect the intracellularlocalization of Cap-1, rabbit polyclonal antibodies directed against arecombinant polypeptide encompassing the N-terminal 125 amino acids ofCap-1 (SEQ ID NO: 305, with the amino acid sequence including theN-terminal 6-His tag provided in SEQ ID NO: 304) were used to stainMcCoy cells infected with Chlamydiae.

Rabbit-anti-Cap-1 polyclonal antibodies were obtained byhyper-immunization of rabbits with a recombinant polypeptide,rCt529c1-125 (SEQ ID NO: 305) encompassing the N-terminal portion ofCap-1. Recombinant rCt529e1-125 protein was obtained from E. colitransformed with a pET expression plasmid (as described above) encodingthe nucleotides 1-375 encoding the N-terminal 1-125 amino acids ofCap-1. Recombinant protein was purified by Ni-NTA using techniques wellknown in the art. For a positive control antiserum, polyclonal antiseradirected against elementary bodies were made by immunization of rabbitswith purified C. trachomatis elementary bodies (Biodesign, Sacco, Ma.).Pre-immune sera derived from rabbits prior to immunization with theCap-1 polypeptide was used as a negative control.

Immunocytochemistry was performed on McCoy cell monolayers grown onglass coverslips inoculated with either C. trachomatis serovar L2 or C.psitacci, strain 6BC, at a concentration of 10⁶ IFU (Inclusion FormingUnits) per ml. After 2 hours, medium was aspirated and replaced withfresh RP-10 medium supplemented with cycloheximide (1.0 μg/ml). Infectedcells were incubated at in 7%. CO₂ for 24 hours and fixed by aspiratingmedium, rinsing cells once with PBS and methanol fixation for 5 minutes.For antigen staining, fixed cell monolayers were washed with PBS andincubated at 37° C. for 2 hours with 1:100 dilutions of specific orcontrol antisera. Cells were rinsed with PBS and incubated for 1 hourwith fluorescein isothiocyanate (FITC)-labeled, anti-rabbit IgG (KPL,Gaithersburg) and stained with Evans blue (0.05%) in PBS. Fluorescencewas observed with a 100× objective (Zeiss epifluorescence microscope),and photographed (Nikon UFX-11A camera).

Results from this study show Cap-1 localizes to the inclusion membraneof C. trachomatis-infected cells. Cap-1 specific antibody labeled theinclusion membranes of C. trachomatis-infected cells, but not Chlamydialelementary bodies contained in these inclusions or released by thefixation process. Conversely, the anti-elementary body antibody clearlylabeled the bacterial bodies, not only within the inclusions, but thosereleased by the fixation process. Specificity of the anti-Cap-1 antibodyis demonstrated by the fact that it does not stain C. psittaci-infectedcells. Specificity of the Cap-1 labeling is also shown by the absence ofreactivity in pre-immune sera. These results suggest that Cap-1 isreleased from the bacteria and becomes associated with the Chlamydialinclusion membrane. Therefore, Cap-1 is a gene product which may beuseful for stimulating CD8+ T cells in the development of a vaccineagainst infections caused by Chlamydia.

The relevance of the Cap-1 gene as a potential CTL antigen in a vaccineagainst Chlamydia infection is further illustrated by two additionalseries of studies. First, CTL specific for the MHC-I epitope of Cap-1CT529 #138-147 peptide of C. trachomatis (SEQ ID NO: 144) have beenshown to be primed to a high frequency during natural infection.Specifically, Balb/C mice were inoculated with 10⁶ I.F.U. of C.trachomatis, serova L2. After 2 weeks, spleens were harvested andquantified by Elispot analysis for the number of INF-γ secreting cellsin response to Cap-1 #138-147 peptide-pulsed antigen presenting cells.In two experiments, the number of INF-γ -secreting cells in 10⁵splenocytes was about 1% of all CD8+ T-cells. This high frequency ofresponding CD8+ CTL to the MHC-1 epitope (Cap-1 CT529 #138-147 peptide)suggest that Cap-1 is highly immunogenic in infections.

Results from a second series of studies have shown that the Cap-1protein is almost immediately accessible to the cytosol of the host cellupon infection. This is shown in a time-course of Cap-1 CT529 #138-147peptide presentation. Briefly, 3T3 cells were infected with C.trachomatis serovar L2 for various lengths of time, and then tested forrecognition by Cap-1 CT529 #138-147 peptide-specific CTL. The resultsshow that C. trachomatis-infected 3T3 cells are targeted for recognitionby the antigen-specific CTL after only 2 hours of infection. Theseresults suggest that Cap-1 is an early protein synthesized in thedevelopment of C. trachomatis elementary bodies to reticulate bodies. ACD8+ CTL immune response directed against a gene product expressed earlyin infection may be particularly efficacious in a vaccine againstChlamydia infection.

EXAMPLE 5 GENERATION OF ANTIBODY AND T-CELL RESPONSES IN MICE IMMUNIZEDWITH CHLAMYDIA ANTIGENS

Immunogenicity studies were conducted to determine the antibody and CD4+T cell responses in mice immunized with either purified SWIB or S13proteins formulated with Montanide adjuvant, or DNA-based immunizationswith pcDNA-3 expression vectors containing the DNA sequences for SWIB orS13. SWIB is also referred to as clone 1-B1-66 (SEQ ID NO: 1, with thecorresponding amino acid sequence provided in SEQ ID NO: 5), and S13ribosomal protein is also referred to as clone 10-C10-31 (SEQ ID NO: 4,with the corresponding amino acid sequence provided in SEQ ID NO: 12).In the first experiment, groups of three C57BL/6 mice were immunizedtwice and monitored for antibody and CD4+ T-cell responses. DNAimmunizations were intradermal at the base of the tail and polypeptideimmunizations were administered by subcutaneous route. Results fromstandard ³H-incorporation assays of spleen cells from immunized miceshows a strong proliferative response from the group immunized withpurified recombinant SWIB polypeptide (SEQ ID NO: 5). Further analysisby cytokine induction assays, as previously described, demonstrated thatthe group immunized with SWIB polypeptide produced a measurable INF-γand IL-4 response. Subsequent ELISA-based assays to determine thepredominant antibody isotype response in the experimental groupimmunized with the SWIB polypeptide were performned. FIG. 4 illustratesthe SWIB-immunized group gave a humoral response that was predominantlyIgG1.

In a second experiment, C3H mice were immunized three times with 10 μgpurified SWIB protein (also referred to as clone 1-B1-66, SEQ ID NO: 5)formulated in either PBS or Montanide at three week intervals andharvested two weeks after the third immunization. Antibody titersdirected against the SWIB protein were determined by standardELISA-based techniques well known in the art, demonstrating the SWIBprotein formulated with Montanide adjuvant induced a strong humoralimmune response. T-cell proliferative responses were determined by aXTT-based assay (Scudiero, et al, Cancer Research, 1988, 48:4827). Asshown in FIG. 5, splenocytes from mice immunized with the SWIBpolypeptide plus Montanide elicited an antigen specific proliferativeresponse. In addition, the capacity of splenocytes from immunizedanimals to secrete IFN-γ in response to soluble recombinant SWIBpolypeptide was determined using the cytokine induction assay previouslydescribed. The splenocytes from all animals in the group immunized withSWIB polypeptide formulated with montanide adjuvant secreted INF-γ inresponse to exposure to the SWIB Chlamydia antigen, demonstrating anChliamydia-specific immune response.

In a further experiment, C3H mice were immunized at three separate timepoints at the base of the tail with 10 μg of purified SWIB or S13protein (C. trachomatis, SWIB protein, clone 1-B1-66, SEQ ID NO: 5, andS13 protein, clone. 10-C10-31, SEQ ID NO: 4) formulated with the SBAS2adjuvant (SmithKline Beecham, London, England). Antigen-specificantibody titers were measured by ELISA, showing both polypeptidesinduced a strong IgG response, ranging in titers from 1×10⁻⁴ to 1×10⁻⁵.The IgG1 and IgG2a components of this response were present in fairlyequal amounts. Antigen-specific T-cell proliferative responses,determined by standard ³H-incorporation assays on spleen cells isolatedfrom immunized mice, were quite strong for SWIB (50,000 cpm above thenegative control) and even stronger for s13 (100,000 cpm above thenegative control). The IFNγ production was assayed by standard ELISAtechniques from supernatant from the proliferating culture. In vitrorestimulation of the culture with S13 protein induced high levels ofIFNγ production, approximately 25 ng/ml versus 2 ng/ml for the negativecontrol. Restimulation with the SWIB protein also induced IFNγ, althoughto a lesser extent.

In a related experiment, C3H mice were immunized at three separate timepoints with 10 μg of purified SWIB or S13 protein (C. trachomatis, SWIBprotein, clone 1-B1-66, SEQ ID NO: 5, and S13 protein, clone 10-C10-31,SEQ ID NO: 4) mixed with 10 μg of Cholera Toxin. Mucosal immunizationwas through intranasal inoculation. Antigen-specific antibody responseswere determined by standard ELISA techniques. Antigen-specific IgGantibodies were present in the blood of SWIB-immunized mice, with titersranging from 1×10⁻³ to 1×10⁻⁴, but non-detectable in the S13-immunizedanimals. Antigen-specific T-cell responses from isolated splenocytes, asmeasured by IFNγ production, gave similar results to those describedimmediately above for systemic immunization.

An animal study was conducted to determine the immunogenicity of theCT529 serovar LGVII CTL epitope, defined by the CT5290 1 mer consensuspeptide (CSFIGGITYL—SEQ ID NO: 31), which was identified as an H2-Kdrestricted CTL epitope. BALB/c mice (3 mice per group) were immunizedthree times with 25 μg of peptide combined with various adjuvants. Thepeptide was administered systemically at the base of the tail in eitherSKB Adjuvant System SBAS-2″, SBAS-7 (SmithKline Beecham, London,England) or Montanide. The peptide was also administered intranasallymixed with 10 μg of Cholera Toxin (CT). Naive mice were used as acontrol. Four weeks after the 3rd immunization, spleen cells wererestimulated with LPS-blasts pulsed with 10 ug/ml CT529 10 mer consensuspeptide at three different effector to LPS-blasts ratios: 6, 1.5 and 0.4at 1×10⁶ cell/ml. After 2 restimulations, effector cells were tested fortheir ability to lyse peptide pulsed P815 cells using a standardchromium release assay. A non-relevant peptide from chicken eggovalbumin was used as a negative control. The results demonstrate that asignificant immune response was elicited towards the CT529 10 merconsensus peptide and that antigen-specific T-cells capable of lysingpeptide-pulsed targets were elicited in response to immunization withthe peptide. Specifically, antigen-specific lytic activities were foundin the SBAS-7 and CT adjuvanted group while Montanide and SBAS-2″ failedto adjuvant the CTL epitope immunization.

EXAMPLE 6 EXPRESSION AND CHARACTERIZATION OF CHLAMYDIA PNEUMONIAE GENES

The human T-cell line, TCL-8, described in Example 1, recognizesChlamydia trachomatis as well as Chlamydia pneumonia infectedmonocyte-derived dendritic cells, suggesting Chlamydia trachomatis andpneumonia may encode cross-reactive T-cell epitopes. To isolate theChlamydia pneumonia genes homologous to Chlamydia trachomatis LGV IIclones 1B1-66, also referred to as SWIB (SEQ ID NO: 1) and clone10C10-31, also referred to as S13 ribosomal protein (SEQ ID NO: 4), HeLa229 cells were infected with C. pneumonia strain TWAR (CDC/CWL-029).After three days incubation, the C. pneumonia-infected HeLa cells wereharvested, washed and resuspended in 200 μl water and heated in aboiling water bath for 20 minutes. Ten microliters of the disrupted cellsuspension was used as the PCR template.

C. pneumonia specific primers were designed for clones 1B1-66 and10C10-31 such that the 5′ end had a 6×-Histidine tag and a Nde I siteinserted, and the 3′ end had a stop codon and a BamHI site included(FIG. 6). The PCR products were amplified and sequenced by standardtechniques well known in the art. The C. pneumonia-specific PCR productswere cloned into expression vector pET17B (Novagen, Madison, Wis.) andtransfected into E. coli BL21 pLysS for expression and subsequentpurification utilizing the histidine-nickel chromatographic methodologyprovided by Novagen. Two proteins from C. pneumonia were thus generated,a 10-11 kDa protein referred to as CpSWIB (SEQ ID NO: 27, and SEQ ID NO:78 having a 6×His tag, with the corresponding amino acid sequenceprovided in SEQ ID NO: 28, respectively), a 15 kDa protein referred toas CpS13 (SEQ ID NO: 29, and SEQ ID NO: 77, having a 6×His tag, with thecorresponding amino acid sequence provided in SEQ ID NO: 30 and 91,respectively).

EXAMPLE 7 INDUCTION OF T CELL PROLIFERATION AND INTERFERON-γ PRODUCTIONBY CHLAMYDIA PNEUMONIAE ANTIGENS

The ability of recombinant Chlamydia pneumoniae antigens to induce Tcell proliferation and interferon-y production is determined as follows.

Proteins are induced by IPTG and purified by Ni-NTA agarose affinitychromatography (Webb et al., J. Immuology 157:5034-5041, 1996). Thepurified polypeptides are then screened for the ability to induce T-cellproliferation in PBMC preparations. PBMCs from C. pneumoniae patients aswell as from normal donors whose T-cells are known to proliferate inresponse to Chlamydia antigens, are cultured in medium comprising RPMI1640 supplemented with 10% pooled human serum and 50 μg/ml gentamicin.Purified polypeptides are added in duplicate at concentrations of 0.5 to10 μg/mL. After six days of culture in 96-well round-bottom plates in avolume of 200 μl, 50 μl of medium is removed from each well fordetermination of INF-γ levels, as described below. The plates are thenpulsed with 1 μCi/well of tritiated thymidine for a further 18 hours,harvested and tritium uptake determined using a gas scintillationcounter. Fractions that result in proliferation in both replicates threefold greater than the proliferation observed in cells cultured in mediumalone are considered positive.

INF-γ was measured using an enzyme-linked immunosorbent assay (ELISA).ELISA plates are coated with a mouse monoclonal antibody directed tohuman INF-γ (PharMingen, San Diego, Calif.) in PBS for four hours atroom temperature. Wells. are then blocked with PBS containing 5% (W/V)non-fat dried milk for 1 hour at room temperature. The plates are washedsix times in PBS/0.2% TWEEN-20 and samples diluted 1:2 in culture mediumin the ELISA plates are incubated overnight at room temperature. Theplates are again washed and a polyclonal rabbit anti-human INF-γ serumdiluted 1:3000 in PBS/10% normal goat serum is added to each well. Theplates are then incubated for two hours at room temperature, washed andhorseradish peroxidase-coupled anti-rabbit IgG (Sigma Chemical So., St.Louis, Mo.) is added at a 1:2000 dilution in PBS/5% non-fat dried milk.After a further two hour incubation at room temperature, the plates arewashed and TMB substrate added. The reaction is stopped after 20 minwith 1 N sulfuric acid. Optical density is determined at 450 nm using570 nm as a reference wavelength. Fractions that result in bothreplicates giving an OD two fold greater than the mean OD from cellscultured in medium alone, plus 3 standard deviations, are consideredpositive.

A human anti-Chlamydia T-cell line (TCL-8) capable of cross-reacting toC. trachomatis and C. pneumonia was used to determine whether theexpressed proteins described in the example above, (i.e., CpSWIB, SEQ IDNO: 27, and SEQ ID NO: 78 having a 6×His tag, with the correspondingamino acid sequence provided in SEQ ID NO: 28, respectively, and the 15kDa protein referred to as CpS13 SEQ ID NO: 29, and SEQ ID NO: 77,having a 6×His tag, with the corresponding amino acid sequence providedin SEQ ID NO: 30 and 91, respectively), possessed T-cell epitopes commonto both C. trachomatis and C. pneumonia. Briefly, E. coli expressingChlamydial proteins were titered on 1×10⁴ monocyte-derived dendriticcells. After two hours, the dendritic cells cultures were washed and2.5×10⁴ T cells (TCL-8) added and allowed to incubate for an additional72 hours. The amount of INF-γ in the culture supernatant was thendetermined by ELISA. As shown in FIGS. 7A and 7B, the TCL-8 T-cell linespecifically recognized the S13 ribosomal protein from both C.trachomatis and C. pneumonia as demonstrated by the antigen-specificinduction of INF-γ, whereas only the SWIB protein from C. trachomatiswas recognized by the T-cell line. To validate these results, the T cellepitope of C. trachomatis SWIB was identified by epitope mapping usingtarget cells pulsed with a senres of overlapping peptides and the T-cellline TCL-8. 3H-thymidine incorporation assays demonstrated that thepeptide, referred to as C.t.SWIB 52-67, of SEQ ID NO: 39 gave thestrongest proliferation of the TCL-8 line. The homologous peptidescorresponding to the SWIB of C. pneumoniae sequence (SEQ ID NO: 40), thetopoisomerase-SWIB fusion of C. pneumoniae (SEQ ID NO: 43) and C.trachomatis (SEQ ID NO: 42) as well as the human SWI domain (SEQ ID NO:41) were synthesized and tested in the above assay. The T-cell lineTCL-8 only recognized the C. trachomatis peptide of SEQ ID NO: 39 andnot the corresponding C. pneumoniae peptide (SEQ ID NO: 40), or theother corresponding peptides described above (SEQ ID NO; 41-43).

Chlamydia-specific T cell lines were generated from donor CP-21 with apositive serum titer against C. pneumoniae by stimulating donor PBMCwith either C. trachomatis or C. pneumoniae-infected monocyte-deriveddendritic cells, respectively. T-cells generated against C. pneumoniaeresponded to recombinant C. pneumoniae-SWIB but not C. trachomatis-SWIB,whereas the T-cell line generated against C. trachomatis did not respondto either C. trachomatis- or C. pneumoniae-SWIB (see FIG. 9). The C.pneumoniae-SWIB specific immune response of donor CP-21 confirms the C.pneumoniae infection and indicates the elicitation of C. pneumoniae-SWIBspecific T-cells during in vivo C. pneumoniae infection.

Epitope mapping of the T-cell response to C. pneumoniae-SWIB has shownthat Cp-SWIB-specific T-cells responded to the overlapping peptidesCp-SWIB 32-51 (SEQ ID NO: 101) and Cp-SWIB 37-56 (SEQ ID NO: 102),indicating a C. pneumoniae-SWIB-specific T-cell epitope Cp-SWIB 37-51(SEQ ID NO: 100).

In additional experiments, T-cell lines were generated from donor CP1,also a C. pneumoniae seropositive donor, by stimulating PBMC withnon-infectious elementary bodies from C. trachomatis and C. pneumoniae,respectively. In particular, proliferative responses were determined bystimulating 2.5×10⁴ T-cells in the presence of 1×10⁴ monocyte-deriveddendritic cells and non-infectious elementary bodies derived from C.trachomatis and C. pneumoniae, or either recombinant C. trachomatis orC. pneumoniae SWIB protein. The T-cell response against SWIB resembledthe data obtained with T-cell lines from CP-21 in that C.pneumoniae-SWIB, but not C. trachomatis-SWIB elicited a response by theC. pneumoniae T-cell line. In addition, the C. trachomatis T-cell linedid not proliferate in response to either C. trachomatis or C.pneumoniae SWIB, though it did proliferate in response to both CT and CPelementary bodies.As described in Example 1, Clone 11-C12-91 (SEQ ID NO:63), identified using the TCP-21 cell line, has a 269 bp insert that ispart of the OMP2 gene (CT443) and shares homology with the 60 kDacysteine rich outer membrane protein of C. pneumoniae, referred to asOMCB. To further define the reactive epitope(s), epitope mapping wasperformed using a series of overlapping peptides and the immunoassaypreviously described. Briefly, proliferative responses were determinedby stimulating 2.5×10⁴ TCP-21 T-cells in the presence of 1×10⁴monocyte-derived dendritic cells with either non-infectious elementarybodies derived from C. trachomatis and C. pneumoniae, or peptidesderived from the protein sequence of C. trachomatis or C. pneumoniaeOMCB protein (0.1 μg/ml). The TCP-21 T-cells responded to epitopesCT-OMCB #167-186, CT-OMCB #171-190, CT-OMCB #171-186, and to a lesserextent, CT-OMCB #175-186 (SEQ ID NO: 249-252, respectively). Notably,the TCP-21 T-cell line also gave a proliferative response to thehomologous C. pneumoniae peptide CP-OMCB #171-186 (SEQ ID NO: 253),which was equal to or greater than the response to the to the C.trachomatis peptides. The amino acid substitutions in position two(i.e., Asp for Glu) and position four (i.e., Cys for Ser) did not alterthe proliferative response of the T-cells and therefore demonstratingthis epitope to be a cross-reactive epitope between C. trachomatis andC. pneumoniae.

EXAMPLE 8 IMMUNE RESPONSES OF HUMAN PBMC AND T-CELL LINES AGAINSTCHLAMYDIA ANTIGENS

The examples provided herein suggest that there is a population ofhealthy donors among the general population that have been infected withC. trachomatis and generated a protective immune response controllingthe C. trachomatis infection. These donors remained clinicallyasymptomatic and seronegative for C. trachomatis. To characterize theimmune responses of normal donors against chlamydial antigens which hadbeen identified by CD4 expression cloning, PBMC obtained from 12 healthydonors were tested against a panel of recombinant chlamydial antigensincluding C. trachomatis-, C. pneumoniae-SWIB and C. trachomatis-, C.pneumoniae-S13. The data are summarized in Table I below. All donorswere seronegative for C. trachomatis, whereas 6/12 had a positive C.pneumoniae titer. Using a stimulation index of >4 as a positiveresponse, 11/12 of the subjects responded to C. trachomatis elementarybodies and 12/12 responded to C. pneumoniae elementary bodies. Onedonor, AD104, responded to recombinant C. pneumoniae-S13 protein, butnot to recombinant C. trachomatis-S13 protein, indicating a C.pneumoniae-specific response. Three out of 12 donors had a C.trachomatis-SWIB, but not a C. pneumoniae-SWIB specific response,confirming a C. trachomatis infection. C. trachomatis and C.pneumoniae-S13 elicited a response in 8/12 donors suggesting achlamydial infection. These data demonstrate the ability of SWIB and SI3 to elicit a T-cell response in PBMC of normal study subjects.

TABLE I Immune response of normal study subjects against ChlamydiaChlamydia CT CP CT CP CT CP CT CT Donor Sex IgG titer EB EB Swib SwibS13 S13 lpdA TSA AD100 male negative ++ +++ + − ++ ++ − n.t. AD104female negative +++ ++ − − − ++ − n.t. AD108 male CP 1:256 ++ ++ ++/− + + + n.t. AD112 female negative ++ ++ + − + − +/− n.t. AD120 malenegative − + − − − − − n.t. AD124 female CP 1:128 ++ ++ − − − − − n.t.AD128 male CP 1:512 + ++ − − ++ + ++ − AD132 female negative ++ ++ −− + + − − AD136 female CP 1:128 + ++ − − +/− − − − AD140 male CP 1:256++ ++ − − + + − − AD142 female CP 1:512 ++ ++ − − + + + − AD146 femalenegative ++ ++ − − ++ + + − CT = Chlamydia trachomatis; CP = Chlamydiapneumoniae; EB = Chlamydia elementary bodies; Swib = recombinantChlamydia Swib protein; S13 = recombinant Chlamydia S13 protein; lpdA =recombinant Chlamydia lpdA protein; TSA = recombinant Chlamydia TSAprotein. Values represent results from standard proliferation assays.Proliferative responses were determined by stimulating 3 × 10⁵ PBMC with1 × 10⁴ monocyte-derived dendritic cells pre-incubated with therespective recombinant antigens or elementary bodies (EB). Assays wereharvested after 6 days with a ³H-thymidine pulse for the last 18 h. SI:Stimulation index +/−: SI ˜ 4 +: SI > 4 ++: SI 10-30 +++: SI > 30

In a first series of experiments, T-cell lines were generated from ahealthy female individual (CT-10) with a history of genital exposure toC. trachomatis by stimulating T-cells with C. trachomatis LGV IIelementary bodies as previously described. Although the study subjectwas exposed to C. trachomatis, she did not seroconvert and did notdevelop clinical symptoms, suggesting donor CT-10 may have developed aprotective immune response against C. trachomatis. As shown in FIG. 10,a primary Chlamydia-specific T-cell line derived from donor CT-10responded to C. trachomatis-SWIB, but not C. pneumoniae-SWIB recombinantproteins, confirming the exposure of CT-10 to C. trachomatis. Epitopemapping of the T-cell response to C. trachomatis-SWIB showed that thisdonor responded to the same epitope Ct-SWIB 52-67 (SEQ ID NO: 39) asT-cell line TCL-8, as shown in FIG. 11.

Additional T-cell lines were generated as described above for various C.trachomatis patients. A summary of the patients' clinical profile andproliferative responses to various C. trachomatis and C. pneumoniaeelementary bodies and recombinant proteins are summarized in Table II.

TABLE II Proliferative response of C. trachomatis patients Clinical CTCP CT CP CT CP CT CT Patients manifestation IgG titer EB EB Swib SwibS13 S13 lpdA TSA CT-1  NGU negative + + − − ++ ++ ++ + CT-2  NGUnegative ++ ++ − − + +/− − − CT-3  asymptomatic Ct 1:512 + + − − + − + −shed Eb Cp 1:1024 Dx was HPV Cps 1:256 CT-4  asymptomatic Ct 1:1024 + +− − − − − − shed Eb CT-5  BV Ct 1:256 ++ ++ − − + − − − Cp 1:256 CT-6 perinial rash Cp 1:1024 + + − − − − − − discharge CT-7  BV Ct 1:512 + +− − + + + − genital ulcer Cp 1:1024 CT-8  Not known Not tested ++ ++ − −− − − − CT-9  asymptomatic Ct 1:128 +++ ++ − − ++ + + − Cp 1:128 CT-10Itch mild vulvar negative ++ ++ − − − − − − CT-11 BV, Ct 1:512 +++ +++ −− +++ +/− ++ + abnormal pap CT-12 asymptomatic Cp 1:512 ++ ++ − − ++ + +− NGU = Non-Gonococcal Urethritis; BV = Bacterial Vaginosis; CT =Chlamydia trachomatis; CP = Chlamydia pneumoniae; EB = Chlamydiaelementary bodies; Swib = recombinant Chlamydia Swib protein; S13 =recombinant Chlamydia S13 protein; lpdA = recombinant Chlamydia lpdAprotein; TSA = recombinant Chlamydia TSA protein Values representresults from standard proliferation assays. Proliferative responses weredetermined by stimulating 3 × 10⁵ PBMC with 1 × 10⁴ monocyte-deriveddendritic cells

pre-incubated with the respective recombinant antigens or elementarybodies (EB). Assays were harvested after 6 days with a ³H-thymidinepulse for the last 18 hours.

SI: Stimulation index +/−: SI ˜ 4 +: SI > 4 ++: SI 10-30 +++: SI > 30

Using the panel of asymptomatic (as defined above) study subjects and C.trachomatis patients, as summarized in Tables I and II, a comprehensivestudy of the immune responses of PBMC derived from the two groups wasconducted. Briefly, PBMCs from C. pneumoniae patients as well as fromnormal donors are cultured in medium comprising RPMI 1640 supplementedwith 10% pooled human serum and 50 μg/ml gentamicin. Purifiedpolypeptides, a panel of recombinant chlamydial antigens including C.trachomatis-, C. pneumoniae-SWIB and S13, as well as C. trachomatis 1pdAand TSA are added in duplicate at concentrations of 0.5 to 10 μg/mL.After six days of culture in 96-well round-bottom plates in a volume of200 μl, 50 μl of medium is removed from each well for determination ofINF-γ levels, as described below. The plates are then pulsed with 1μCi/well of tritiated thymidine for a further 18 hours, harvested andtritium uptake determined using a gas scintillation counter. Fractionsthat result in proliferation in both replicates three fold greater thanthe proliferation observed in cells cultured in medium alone areconsidered positive.

Proliferative responses to the recombinant Chlamydiae antigensdemonstrated that the majority of asymptomatic donors and C. trachomatispatients recognized the C. trachomatis S13 antigen (8/12) and a majorityof the C. trachomatis patients recognized the C. pneumonia S13 antigen(8/12), with 4/12 asymptomatic donors also recognizing the C. pneumoniaS13 antigen. Also, six out of twelve of the C. trachomatis patients andfour out of twelve of the asymptomatic donors gave a proliferativeresponse to the lpdA antigen of C. trachomatis. These resultsdemonstrate that the C. trachomatis and C. pneumonia S13 antigen, C.trachomatis Swib antigen and the C. trachomatis 1pdA antigen arerecognized by the asymptomatic donors, indicating these antigens wererecognized during exposure to Chlamydia and an immune response elicitedagainst them. This implies these antigens may play a role in conferringprotective immunity in a human host. In addition, the C. trachomatis andC. pneumonia S13 antigen is recognized equally well among the C.trachomatis patients, therefore indicating there may be epitopes sharedbetween C. trachomatis and C. pneumonia in the S13 protein. Table IIIsummarizes the results of these studies.

TABLE III Antigen Normal Donors C.t. Patients C.t.-Swib 3/12 0/12C.p.-Swib 0/12 0/12 C.t.-S13 8/12 8/12 C.p.-S13 4/12 8/12 lpdA 4/12 6/12TSA 0/12 2/12

A series of studies were initiated to determine the cellular immuneresponse to short-term T-cell lines generated from asymptomatic donorsand C. trachomatis patients. Cellular immune responses were measured bystandard proliferation assays and INF-γ, as described in Example 7.Specifically, the majority of the antigens were in the form of single E.coli clones expressing Chlamydial antigens, although some recombinantproteins were also used in the assays. The single E. coli clones weretitered on 1×10⁴ monocyte-derived dendritic cells and after two hours,the culture was washed and 2.5×10⁴ T-cells were added. The assay usingthe recombinant proteins were performed as previously described.Proliferation was determined after four days with a standard³H-thymidine pulse for the last 18 hours. Induction of INF-γ wasdetermined from culture supernatants harvested after four days usingstandard ELISA assays, as described above. The results show that all theC. trachomatis antigens tested, except for C. T. Swib, elicited aproliferative response from one or more different T-cell lines derivedform C. trachomatis patients. In addition, proliferative responses wereelicited from both the C. trachomatis patients and asymptomatic donorsfor the following Chlamydia genes, CT622, groEL, pmpD, CT610 and rS13.

The 12G3-83 clone also contains sequences to CT734 and CT764 in additionto CT622, and therfore these gene sequence may also have immunoreactiveepitopes. Similarly, clone 21G12-60 contains sequences to thehypothetical protein genes CT229 and CT228 in addition to CT875; and15H2-76 also cotains sequences from CT812 and CT088, as well as sharinghomology to the sycE gene. Clone 11H3-61 also contains sequences sharinghomology to the PGP6-D virulence protein.

TABLE IV TCL from C. t. Antigen Asymp. TCL from SEQ Clone (putative*)Donors C. t. Patients ID NO:: 1B1-66 (E. coli) Swib 2/2 0/4  5 1B1-66(protein) Swib 2/2 0/4  5 12G3-83 (E. coli) CT622* 2/2 4/4 57 22B3-53(E. coli) groEL 1/2 4/4 111  22B3-53 (protein) groEL 1/2 4/4 111 15H2-76 (E. coli) PmpD* 1/2 3/4 87 11H3-61 (E. coli) rL1* 0/2 3/4 6014H1-4 (E. coli) TSA 0/2 3/4 56 14H1-4 (protein) TSA 0/2 3/4 56 11G10-46(E. coli) CT610 1/2 1/4 62 10C10-17 (E. coli) rS13 1/2 1/4 62 10C10-17(protein) rS13 1/2 1/4 62 21G12-60 (E. coli) CT875* 0/2 2/4 110  11H4-32(E. coli) dnaK 0/2 2/4 59 21C7-8 (E. coli) dnaK 0/2 2/4 115  17C10-31(E. coli) CT858 0/2 2/4 114 

EXAMPLE 9 PROTECTION STUDIES USING CHLAMYDIA ANTIGENS

Protection studies were conducted in mice to determine whetherimmunization with chiamydial antigens can impact on the genital tractdisease resulting from chlamydial inoculation. Two models were utilized;a model of intravaginal inoculation that uses a human isolate containinga strain of Chlamydia psittaci (MTW447), and a model of intrauterineinoculation that involves a human isolate identified as Chlamydiatrachomatis, serovar F (strain NI1). Both strains induce inflammation inthe upper genital tract, which resemble endometritis and salpingitiscaused by Chlamydia trachomatis in women. In the first experiment, C3Hmice (4 mice per group) were immunized three times with 100 μg ofpcDNA-3 expression vector containing C. trachomatis SWIB DNA (SEQ ID NO:1, with the corresponding amino acid sequence provided in SEQ ID NO: 5).Inoculations were at the base of the tail for systemic immunization. Twoweeks after the last immunization, animals were progesterone treated andinfected, either thru the vagina or by injection of the inoculum in theuterus. Two weeks after infection, the mice were sacrificed and genitaltracts sectioned, stained and examined for histopathology. Inflammationlevel was scored (from + for very mild, to +++++ for very severe).Scores attributed to each single oviduct/ovary were summed and dividedby the number of organs examined to get a mean score of inflammation forthe group. In the model of uterine inoculation, negativecontrol-immunized animals receiving empty vector showed consistentinflammation with an ovary/oviduct mean inflammation score of 6.12, incontrast to 2.62 for the DNA-immunized group. In the model of vaginalinoculation and ascending infection, negative control-immunized mice hadan ovary/oviduct mean inflammation score of 8.37, versus 5.00 for theDNA-immunized group. Also, in the later model, vaccinated mice showed nosigns of tubal occlusion while negative control vaccinated groups hadinflammatory cells in the lumen of the oviduct In a second experiment,C3H mice (4 mice per group) were immunized three times with 50 μg ofpcDNA-3 expression vector containing C. trachomatis SWIB DNA (SEQ ID NO:1, with the corresponding amino acid sequence provided in SEQ ID NO: 5)encapsulated in Poly Lactide co-Glycolide microspheres (PLG);immunizations were made intra-peritoneally. Two weeks after the lastimmunization, animal were progesterone treated and infected byinoculation of C. psittaci in the vagina. Two weeks after infection,mice were sacrificed and genital tracts sectioned, stained and examinedfor histopathology. Inflammation level was scored as previouslydescribed. Scores attributed to each single oviduct/ovary were summedand divided by the number of examined organs to get a mean ofinflammation for the group. Negative control-immunized animals receivingPLG-encapsulated empty vector showed consistent infammation with anovary/oviduct mean inflammation score of 7.28, versus 5.71 for thePLG-encapsulated DNA immunized group. Inflammation in the peritoneum was1.75 for the vaccinated group versus 3.75 for the control.

In a third experiment, C3H mice (4 per group) were immunized three timeswith 10 μg of purified recombinant protein, either SWIB (SEQ ID NO: 1,with the corresponding amino acid sequence provided in SEQ ID NO: 5, orS13 (SEQ ID NO: 4, with the corresponding amino acid sequence providedin SEQ ID NO: 12) mixed with Cholera Toxin (CT); the preparation wasadministred intranasally upon anaesthesia in a 20 uL volume. Two weeksafter the last immunization, animal were progesterone treated andinfected, either by vaginal inoculation of C. psittaci or by injectionof C. trachomatis serovar F in the uterus. Two weeks after infection,the mice were sacrificed and genital tracts sectioned, stained andexamined for histopathology. The degree of inflammation was scored asdescribed above. Scores attributed to each single oviduct/ovary weresummed and divided by the number of examined organs to get a mean scoreof inflammation for the group. In the model of uterine inoculation,negative control-immunized animals receiving cholera toxin alone showedan ovary/oviduct mean inflammation score of 4.25 (only 2 mice analyzed;2 other died) versus 5.00 for the s13 plus cholera toxin-immunizedgroup, and 1.00 for the SWIB plus cholera toxin. Untreated infectedanimals had an ovary/oviduct mean inflammation score of 7. In the modelof vaginal inoculation and ascending infection, negativecontrol-immunized mice had an ovary/oviduct mean inflammation score of7.37 versus 6.75 for the s13 plus cholera toxin-immunized group and 5.37for the SWIB plus cholera toxin-immunized group. Untreated infectedanimals had an ovary/oviduct mean inflammation score of 8.

The three experiments described above suggest that SWIB-specificprotection is obtainable. This protective effect is more marked in themodel of homologous infection but is still present when in aheterologous challenge infection with C. psittaci.

EXAMPLE 10 Pmp/Ra12 FUSION PROTEINS

Various Pmp/Ra12 fusion constructs were generated by first synthesizingPCR fragments of a Pmp gene using primers containing a Not I restrictionsite. Each PCR fragment was then ligated into the NotI restriction siteof pCRX1. The pCRX1 vector contains the 6HisRa12 portion of the fusion.The Ra12 portion of the fusion construct encodes a polypeptidecorresponding to amino acid residues 192-323 of Mycobacteriumtuberculosis MTB32A, as described in U.S. patent application 60/158,585,the disclosure of which is incorporated herein by reference. The correctorientation of each insert was determined by its restriction enzymepattern and its sequence was verified. Multiple fusion constructs weremade for PmpA, PmpB, PmpC, PmpF and PmpH, as described further below:

PmpA Fusion Proteins

PmpA is 107 kD protein containing 982 aa and was cloned from serovar E.The PmpA protein was divided into 2 overlapping fragments, thePmpA(N-terminal) and (C-terminal) portions.

PmpA(N-term) was amplified by the sense and antisense primers:

GAGAGCGGCCGCTCATGTTTATAACAAAGGAACTTATG (SEQ ID NO: 306)

GAGAGCGGCCGCTTACTTAGGTGAGAAGAAGGGAGTTTC (SEQ ID NO: 307)

respectively. The resulting fusion construct has a DNA sequence setforth in SEQ ID NO: 308, encoding a 66 kD protein (619 aa) expressingthe segment 1-473 aa of PmpA. The amino acid sequence of the fusionprotein is set forth in SEQ ID NO: 309.

PmpA(C-term) was amplified by the sense and antisense primers:

GAGAGCGGCCGCTCCATTCTATTCATTTCTTTGATCCTG (SEQ ID NO: 310)

GAGAGCGGCCGCTTAGAAGCCAACATAGCCTCC (SEQ ID NO: 311)

respectively. The resulting fusion construct has a DNA sequence setforth in SEQ ID NO: 312, encoding a 74 kD protein (691 aa) expressingthe segment 438-982 aa of PmpA. The amino acid sequence of the fusionprotein is set forth in SEQ ID NO: 313.

PmpF Fusion Proteins

PmpF is 112 kD protein containing 1034 aa and was cloned from theserovar E. PmpF protein was divided into 2 overlapping fragments, thePmpF(N-term) and (C-term) portions.

PmpF(N-tenm) was amplified by the sense and antisense primers:

GAGAGCGGCCGCTCATGATTAAAAGAACTTCTCTATCC (SEQ ID NO: 314)

GAGAGCGGCCGCTTATAATTCTGCATCATCTTCTATGGC (SEQ ID NO: 315)

respectively. The resulting fusion has a DNA sequence set forth in SEQID NO: 316, encoding a 69 kD protein (646 aa) expressing the segment1-499 aa of PmpF. The amino acid sequence of the fusion protein is setforth in SEQ ID NO: 317.

PmpF(C-term) was amplified by the sense and antisense primers:

GAGAGCGGCCGCTCGACATACGAACTCTGATGGG (SEQ ID NO: 318)

GAGAGCGGCCGCTTAAAAGACCAGAGCTCCTCC (SEQ ID NO: 319)

respectively. The resulting fusion has a DNA sequence set forth in SEQID NO: 320, encoding a 77 kD protein (715 aa) expressing the segment466-1034 aa of PmpF. The amino acid sequence of the fusion protein isset forth in SEQ ID NO: 321.

PmpH Fusion Proteins

PmpH is 108 kD protein containing 1016 aa and was cloned from theserovar E. PmpH protein was divided into 2 overlapping fragments, thePmpH(N-term)and (C-term)portions.

PmpH(N-term) was amplified by the sense and antisense primers:

GAGAGCGGCCGCTCATGCCTTTTTCTTTGAGATCTAC (SEQ ID NO: 322)

GAGAGCGGCCGCTTACACAGATCCATTACCGGACTG (SEQ ID NO: 323)

respectively. The resulting fusion has a DNA sequence set forth in SEQID NO: 324, encoding a 64 kD protein (631 aa) expressing the segment1-484 aa of PmpH. The amino acid sequence of the fusion protein is setforth in SEQ ID NO: 325.

PmpH(C-term) was amplified by the sense and antisense primers:

GAGAGCGGCCGCTCGATCCTGTAGTACAAAATAATTCAGC (SEQ ID NO: 326)

GAGAGCGGCCGCTTAAAAGATTCTATTCAAGCC (SEQ ID NO: 327)

respectively. The resulting fusion construct has a DNA sequence setforth in SEQ ID NO: 328, encoding a 77 kD protein (715 aa) expressingthe segment 449-1016 aa of PmpH. The amino acid sequence of the fusionprotein is set forth in SEQ ID NO: 329.

PmpB Fusion Proteins

PmpB is 183 kD protein containing 1750 aa and was cloned from theserovar E. PmpB protein was divided into 4 overlapping fragments,PmpB(1), (2), (3) and (4).

PmpB(1) was amplified by the sense and antisense primers:

GAGAGCGGCCGCTCATGAAATGGCTGTCAGCTACTGCG (SEQ ID NO: 330)

GAGAGCGGCCGCTTACTTAATGCGAATTTCTTCAAG (SEQ ID NO: 331)

respectively. The resulting fusion has a DNA sequence set forth in SEQID NO: 332, and encodes is a 53 kD protein (518 aa) expressing thesegment 1-372 aa of PmpB. The amino acid sequence of the fusion proteinis set forth in SEQ ID NO: 333.

PmpB(2) was amplified by the sense and antisense primers:GAGAGCGGCCGCTCGGTGACCTCTCAATTCAATCTTC (SEQ ID NO: 334)GAGAGCGGCCGCTTAGTTCTCTGTTACAGATAAGGAGAC (SEQ ID NO: 335) respectively.The resulting fusion has a DNA sequence set forth in SEQ ID NO: 336 andencodes a 60 kD protein (585 aa) expressing the segment 330-767 aa ofPmpB. The amino acid sequence of the fusion protein is set forth in SEQID NO: 337.

PmpB(3) was amplified by the sense and antisense primers:

GAGAGCGGCCGCTCGACCAACTGAATATCTCTGAGAAC (SEQ ID NO: 338)

GAGCGGCCGCTTAAGAGACTACGTGGAGTTCTG (SEQ ID NO: 339)

respectively. The resulting fusion has a DNA sequence set forth in SEQID NO: 340 encodes a 67 kD protein (654 aa) expressing the segment732-1236 aa of PmpB. The amino acid sequence of the fusion protein isset forth in SEQ ID NO: 341

PmpB(4) was amplified by the sense and antisense primers:

GAGAGCGGCCGCTCGGAACTATTGTGTTCTCTTCTG (SEQ ID NO: 342)

GAGAGCGGCCGCTTAGAAGATCATGCGAGCACCGC (SEQ ID NO: 343)

respectively. The resulting fusion construct has a DNA sequence setforth in SEQ ID NO: 344 encodes a 76 kD protein (700 aa) expressing thesegment 1160-1750 of PmpB. The amino acid sequence of the fusion proteinis set forth in SEQ ID NO: 345.

PmpC Fusion Proteins

PmpC is 187 kD protein containing 1774 aa and was cloned from theserovar E/L2. PmpC protein was divided into 3 overlapping fragments,PmpC(1), (2) and (3).

PmpC(1) was amplified by the sense and antisense primers:

GAGAGCGGCCGCTCATGAAATTTATGTCAGCTACTGC (SEQ ID NO: 346)

GAGAGCGGCCGCTTACCCTGTAATTCCAGTGATGGTC (SEQ ID NO: 347)

respectively. The resulting fusion construct has a DNA sequence setforth in SEQ ID NO: 348 and encodes a 51 kD protein (487 aa) expressingthe segment 1-340 aa of PmpC. The amino acid sequence of the fusionprotein is set forth in SEQ ID NO: 349.

PmpC(2) was amplified by the sense and antisense primers:

GAGAGCGGCCGCTCGATACACAAGTATCAGAATCACC (SEQ ID NO: 350)

GAGAGCGGCCGCTTAAGAGGACGATGAGACACTCTCG (SEQ ID NO: 351)

respectively. The resulting fusion construct has a DNA sequence setforth in SEQ ID NO: 352 and encodes a 60 kD protein (583 aa) expressingthe segment 305-741 aa of PmpC. The amino acid sequence of the fusionprotein is set forth in SEQ ID NO: 353.

PmpC(3) was amplified by the sense and antisense primers:

GAGAGCGGCCGCTCGATCAATCTAACGAAAACACAGACG (SEQ ID NO: 354)

GAGAGCGGCCGCTTAGACCAAAGCTCCATCAGCAAC (SEQ ID NO: 355)

respectively. The resulting fusion construct has a DNA sequence setforth in SEQ ID NO: 356 and encodes a 70 kD protein (683 aa) expressingthe segment 714-1250 aa of PmpC. The amino acid sequence of the fusionprotein is set forth in SEQ ID NO: 357.

Although the present invention has been described in some detail by wayof illustration and example for purposes of clarity of understanding,changes and modifications can be carried out without departing from thescope of the invention which is intended to be limited only by the scopeof the appended claims.

357 1 481 DNA Chlamydia trachomatis 1 ctgaagactt ggctatgttt tttattttgacgataaacct agttaaggca taaaagagtt 60 gcgaaggaag agccctcaac ttttcttatcaccttcttta actaggagtc atccatgagt 120 caaaataaga actctgcttt catgcagcctgtgaacgtat ccgctgattt agctgccatc 180 gttggtgcag gacctatgcc tcgcacagagatcattaaga aaatgtggga ttacattaag 240 gagaatagtc ttcaagatcc tacaaacaaacgtaatatca atcccgatga taaattggct 300 aaagtttttg gaactgaaaa acctatcgatatgttccaaa tgacaaaaat ggtttctcaa 360 cacatcatta aataaaatag aaattgactcacgtgttcct cgtctttaag atgaggaact 420 agttcattct ttttgttcgt ttttgtgggtattactgtat ctttaacaac tatcttagca 480 g 481 2 183 DNA Chlamydiatrachomatis 2 atcgttggtg caggacctat gcctcgcaca gagatcatta agaaaatgtgggattacatt 60 aaggagaata gtcttcaaga tcctacaaac aaacgtaata tcaatcccgatgataaattg 120 gctaaagttt ttggaactga aaaacctatc gatatgttcc aaatgacaaaaatggtttct 180 caa 183 3 110 DNA Chlamydia trachomatis 3 gctgcgacatcatgcgagct tgcaaaccaa catggacatc tccaatttcc ccttctaact 60 cgctctttggaactaatgct gctaccgagt caatcacaat cacatcgacc 110 4 555 DNA Chlamydiatrachomatis 4 cggcacgagc ctaagatgct tatactactt taagggaggc ccttcgtatgccgcgcatca 60 ttggaataga tattcctgcg aaaaagaaat taaaaataag tcttacatatatttatggaa 120 tagggccagc tctttctaaa gagattattg ctagattgca gttgaatcccgaagctagag 180 ctgcagagtt gactgaggaa gaggttggtc gactaaacgc tcttttacagtcggattacg 240 ttgttgaagg ggatttgcgc cgtcgtgtgc aatctgatat caaacgtctgattactatcc 300 atgcttatcg tggacaaaga catagacttt ctttgcctgt tcgtggtcagagaacaaaaa 360 caaattctcg cacgcgtaag ggtaaacgta aaactattgc aggtaagaagaaataataat 420 ttttaggaga gagtgttttg gttaaaaatc aagcgcaaaa aagaggcgtaaaaagaaaac 480 aagtaaaaaa cattccttcg ggcgttgtcc atgttaaggc tacttttaataatacaattg 540 taaccataac agacc 555 5 86 PRT Chlamydia trachomatis 5 MetSer Gln Asn Lys Asn Ser Ala Phe Met Gln Pro Val Asn Val Ser 1 5 10 15Ala Asp Leu Ala Ala Ile Val Gly Ala Gly Pro Met Pro Arg Thr Glu 20 25 30Ile Ile Lys Lys Met Trp Asp Tyr Ile Lys Glu Asn Ser Leu Gln Asp 35 40 45Pro Thr Asn Lys Arg Asn Ile Asn Pro Asp Asp Lys Leu Ala Lys Val 50 55 60Phe Gly Thr Glu Lys Pro Ile Asp Met Phe Gln Met Thr Lys Met Val 65 70 7580 Ser Gln His Ile Ile Lys 85 6 61 PRT Chlamydia trachomatis 6 Ile ValGly Ala Gly Pro Met Pro Arg Thr Glu Ile Ile Lys Lys Met 1 5 10 15 TrpAsp Tyr Ile Lys Glu Asn Ser Leu Gln Asp Pro Thr Asn Lys Arg 20 25 30 AsnIle Asn Pro Asp Asp Lys Leu Ala Lys Val Phe Gly Thr Glu Lys 35 40 45 ProIle Asp Met Phe Gln Met Thr Lys Met Val Ser Gln 50 55 60 7 36 PRTChlamyida trachomatis 7 Ala Ala Thr Ser Cys Glu Leu Ala Asn Gln His GlyHis Leu Gln Phe 1 5 10 15 Pro Leu Leu Thr Arg Ser Leu Glu Leu Met LeuLeu Pro Ser Gln Ser 20 25 30 Gln Ser His Arg 35 8 18 PRT Chlamydiatrachomatis 8 Leu Arg His His Ala Ser Leu Gln Thr Asn Met Asp Ile SerAsn Phe 1 5 10 15 Pro Phe 9 5 PRT Chlamydia trachomatis 9 Leu Ala LeuTrp Asn 1 5 10 11 PRT Chlamydia trachomatis 10 Cys Cys Tyr Arg Val AsnHis Asn His Ile Asp 1 5 10 11 36 PRT Chlamydia trachomatis 11 Val AspVal Ile Val Ile Asp Ser Val Ala Ala Leu Val Pro Lys Ser 1 5 10 15 GluLeu Glu Gly Glu Ile Gly Asp Val His Val Gly Leu Gln Ala Arg 20 25 30 MetMet Ser Gln 35 12 122 PRT Chlamydia trachomatis 12 Met Pro Arg Ile IleGly Ile Asp Ile Pro Ala Lys Lys Lys Leu Lys 1 5 10 15 Ile Ser Leu ThrTyr Ile Tyr Gly Ile Gly Pro Ala Leu Ser Lys Glu 20 25 30 Ile Ile Ala ArgLeu Gln Leu Asn Pro Glu Ala Arg Ala Ala Glu Leu 35 40 45 Thr Glu Glu GluVal Gly Arg Leu Asn Ala Leu Leu Gln Ser Asp Tyr 50 55 60 Val Val Glu GlyAsp Leu Arg Arg Arg Val Gln Ser Asp Ile Lys Arg 65 70 75 80 Leu Ile ThrIle His Ala Tyr Arg Gly Gln Arg His Arg Leu Ser Leu 85 90 95 Pro Val ArgGly Gln Arg Thr Lys Thr Asn Ser Arg Thr Arg Lys Gly 100 105 110 Lys ArgLys Thr Ile Ala Gly Lys Lys Lys 115 120 13 20 PRT Chlamydia trachomatis13 Asp Pro Thr Asn Lys Arg Asn Ile Asn Pro Asp Asp Lys Leu Ala Lys 1 510 15 Val Phe Gly Thr 20 14 20 PRT Chlamydia trachomatis 14 Asp Asp LysLeu Ala Lys Val Phe Gly Thr Glu Lys Pro Ile Asp Met 1 5 10 15 Phe GlnMet Thr 20 15 161 DNA Chlamydia trachomatis 15 atctttgtgt gtctcataagcgcagagcgg ctgcggctgt ctgtagcttc atcggaggaa 60 ttacctacct cgcgacattcggagctatcc gtccgattct gtttgtcaac aaaatgctgg 120 cgcaaccgtt tctttcttcccaaactaaag caaatatggg a 161 16 897 DNA Chlymidia trachomatis 16atggcttcta tatgcggacg tttagggtct ggtacaggga atgctctaaa agcttttttt 60acacagccca acaataaaat ggcaagggta gtaaataaga cgaagggaat ggataagact 120attaaggttg ccaagtctgc tgccgaattg accgcaaata ttttggaaca agctggaggc 180gcgggctctt ccgcacacat tacagcttcc caagtgtcca aaggattagg ggatgcgaga 240actgttgtcg ctttagggaa tgcctttaac ggagcgttgc caggaacagt tcaaagtgcg 300caaagcttct tctctcacat gaaagctgct agtcagaaaa cgcaagaagg ggatgagggg 360ctcacagcag atctttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtagcatc 420atcggaggaa ttacctacct cgcgacattc ggagctatcc gtccgattct gtttgtcaac 480aaaatgctgg caaaaccgtt tctttcttcc caaactaaag caaatatggg atcttctgtt 540agctatatta tggcggctaa ccatgcagcg tctgtggtgg gtgctggact cgctatcagt 600gcggaaagag cagattgcga agcccgctgc gctcgtattg cgagagaaga gtcgttactc 660gaagtgccgg gagaggaaaa tgcttgcgag aagaaagtcg ctggagagaa agccaagacg 720ttcacgcgca tcaagtatgc actcctcact atgctcgaga agtttttgga atgcgttgcc 780gacgttttca aattggtgcc gctgcctatt acaatgggta ttcgtgcgat tgtggctgct 840ggatgtacgt tcacttctgc aattattgga ttgtgcactt tctgcgccag agcataa 897 17298 PRT Chlamydia trachomatis 17 Met Ala Ser Ile Cys Gly Arg Leu Gly SerGly Thr Gly Asn Ala Leu 1 5 10 15 Lys Ala Phe Phe Thr Gln Pro Asn AsnLys Met Ala Arg Val Val Asn 20 25 30 Lys Thr Lys Gly Met Asp Lys Thr IleLys Val Ala Lys Ser Ala Ala 35 40 45 Glu Leu Thr Ala Asn Ile Leu Glu GlnAla Gly Gly Ala Gly Ser Ser 50 55 60 Ala His Ile Thr Ala Ser Gln Val SerLys Gly Leu Gly Asp Ala Arg 65 70 75 80 Thr Val Val Ala Leu Gly Asn AlaPhe Asn Gly Ala Leu Pro Gly Thr 85 90 95 Val Gln Ser Ala Gln Ser Phe PheSer His Met Lys Ala Ala Ser Gln 100 105 110 Lys Thr Gln Glu Gly Asp GluGly Leu Thr Ala Asp Leu Cys Val Ser 115 120 125 His Lys Arg Arg Ala AlaAla Ala Val Cys Ser Ile Ile Gly Gly Ile 130 135 140 Thr Tyr Leu Ala ThrPhe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn 145 150 155 160 Lys Met LeuAla Lys Pro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met 165 170 175 Gly SerSer Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Ser Val 180 185 190 ValGly Ala Gly Leu Ala Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala 195 200 205Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Leu Leu Glu Val Pro Gly 210 215220 Glu Glu Asn Ala Cys Glu Lys Lys Val Ala Gly Glu Lys Ala Lys Thr 225230 235 240 Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys PheLeu 245 250 255 Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro IleThr Met 260 265 270 Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe ThrSer Ala Ile 275 280 285 Ile Gly Leu Cys Thr Phe Cys Ala Arg Ala 290 29518 18 PRT Chlamydia trachomatis 18 Arg Ala Ala Ala Ala Ala Ala Val CysSer Phe Ile Gly Gly Ile Thr 1 5 10 15 Tyr Leu 19 18 PRT Chlamydiatrachomatis 19 Cys Ser Phe Ile Gly Gly Ile Thr Tyr Leu Ala Thr Phe GlyAla Ile 1 5 10 15 Arg Pro 20 216 PRT Chlamydia trachomatis 20 Met ArgGly Ser Gln Gln Ile Phe Val Cys Leu Ile Ser Ala Glu Arg 1 5 10 15 LeuArg Leu Ser Val Ala Ser Ser Glu Glu Leu Pro Thr Ser Arg His 20 25 30 SerGlu Leu Ser Val Arg Phe Cys Leu Ser Thr Lys Cys Trp Gln Asn 35 40 45 ArgPhe Phe Leu Pro Lys Leu Lys Gln Ile Trp Asp Leu Leu Leu Ala 50 55 60 IleLeu Trp Arg Leu Thr Met Gln Arg Leu Trp Trp Val Leu Asp Ser 65 70 75 80Leu Ser Val Arg Lys Glu Gln Ile Ala Lys Pro Ala Ala Leu Val Leu 85 90 95Arg Glu Lys Ser Arg Tyr Ser Lys Cys Arg Glu Arg Lys Met Leu Ala 100 105110 Arg Arg Lys Ser Leu Glu Arg Lys Pro Arg Arg Ser Arg Ala Ser Ser 115120 125 Met His Ser Ser Leu Cys Ser Arg Ser Phe Trp Asn Ala Leu Pro Thr130 135 140 Phe Ser Asn Trp Cys Arg Cys Leu Leu Gln Trp Val Phe Val ArgLeu 145 150 155 160 Trp Leu Leu Asp Val Arg Ser Leu Leu Gln Leu Leu AspCys Ala Leu 165 170 175 Ser Ala Pro Glu His Lys Gly Phe Phe Lys Phe LeuLys Lys Lys Ala 180 185 190 Val Ser Lys Lys Lys Gln Pro Phe Leu Ser ThrLys Cys Leu Ala Phe 195 200 205 Leu Ile Val Lys Ile Val Phe Leu 210 21521 1256 DNA Chlamydia trachomatis 21 ctcgtgccgg cacgagcaaa gaaatccctcaaaaaatggc cattattggc ggtggtgtga 60 tcggttgcga attcgcttcc ttattccatacgttaggctc cgaagtttct gtgatcgaag 120 caagctctca aatccttgct ttgaataatccagatatttc aaaaaccatg ttcgataaat 180 tcacccgaca aggactccgt ttcgtactagaagcctctgt atcaaatatt gaggatatag 240 gagatcgcgt tcggttaact atcaatgggaatgtcgaaga atacgattac gttctcgtat 300 ctataggacg ccgtttgaat acagaaaatattggcttgga taaagctggt gttatttgtg 360 atgaacgcgg agtcatccct accgatgccacaatgcgcac aaacgtacct aacatttatg 420 ctattggaga tatcacagga aaatggcaacttgcccatgt agcttctcat caaggaatca 480 ttgcagcacg gaatataggt ggccataaagaggaaatcga ttactctgct gtcccttctg 540 tgatctttac cttccctgaa gtcgcttcagtaggcctctc cccaacagca gctcaacaac 600 atctccttct tcgcttactt tttctgaaaaatttgataca gaagaagaat tcctcgcaca 660 cttgcgagga ggagggcgtc tggaagaccagttgaattta gctaagtttt ctgagcgttt 720 tgattctttg cgagaattat ccgctaagcttggttacgat agcgatggag agactgggga 780 tttcttcaac gaggagtacg acgacgaagaagaggaaatc aaaccgaaga aaactacgaa 840 acgtggacgt aagaagagcc gttcataagccttgctttta aggtttggta gttttacttc 900 tctaaaatcc aaatggttgc tgtgccaaaaagtagtttgc gtttccggat agggcgtaaa 960 tgcgctgcat gaaagattgc ttcgagagcggcatcgcgtg ggagatcccg gatactttct 1020 ttcagatacg aataagcata gctgttcccagaataaaaac ggccgacgct aggaacaaca 1080 agatttagat agagcttgtg tagcaggtaaactgggttat atgttgctgg gcgtgttagt 1140 tctagaatac ccaagtgtcc tccaggttgtaatactcgat acacttccct aagagcctct 1200 aatggatagg ataagttccg taatccataggccatagaag ctaaacgaaa cgtatt 1256 22 601 DNA Chlamydia trachomatis 22ctcgtgccgg cacgagcaaa gaaatccctc aaaaaatggc cattattggc ggtggtgtga 60tcggttgcga attcgcttcc ttattccata cgttaggctc cgaagtttct gtgatcgaag 120caagctctca aatccttgct ttgaataatc cagatatttc aaaaaccatg ttcgataaat 180tcacccgaca aggactccgt ttcgtactag aagcctctgt atcaaatatt gaggatatag 240gagatcgcgt tcggttaact atcaatggga atgtcgaaga atacgattac gttctcgtat 300ctataggacg ccgtttgaat acagaaaata ttggcttgga taaagctggt gttatttgtg 360atgaacgcgg agtcatccct accgatgcca caatgcgcac aaacgtacct aacatttatg 420ctattggaga tatcacagga aaatggcaac ttgcccatgt agcttctcat caaggaatca 480ttgcagcacg gaatataggt ggccataaag aggaaatcga ttactctgct gtcccttctg 540tgatctttac cttccctgaa gtcgcttcag taggcctctc cccaacagca gctcaacaac 600 a601 23 270 DNA Chlamydia trachomatis 23 acatctcctt cttcgcttac tttttctgaaaaatttgata cagaagaaga attcctcgca 60 cacttgcgag gaggagggcg tctggaagaccagttgaatt tagctaagtt ttctgagcgt 120 tttgattctt tgcgagaatt atccgctaagcttggttacg atagcgatgg agagactggg 180 gatttcttca acgaggagta cgacgacgaagaagaggaaa tcaaaccgaa gaaaactacg 240 aaacgtggac gtaagaagag ccgttcataa270 24 363 DNA Chlamydia trachomatis 24 ttacttctct aaaatccaaa tggttgctgtgccaaaaagt agtttgcgtt tccggatagg 60 gcgtaaatgc gctgcatgaa agattgcttcgagagcggca tcgcgtggga gatcccggat 120 actttctttc agatacgaat aagcatagctgttcccagaa taaaaacggc cgacgctagg 180 aacaacaaga tttagataga gcttgtgtagcaggtaaact gggttatatg ttgctgggcg 240 tgttagttct agaataccca agtgtcctccaggttgtaat actcgataca cttccctaag 300 agcctctaat ggataggata agttccgtaatccataggcc atagaagcta aacgaaacgt 360 att 363 25 696 DNA Chlamydiatrachomatis 25 gctcgtgccg gcacgagcaa agaaatccct caaaaaatgg ccattattggcggtggtgtg 60 atcggttgcg aattcgcttc cttattccat acgttaggct ccgaagtttctgtgatcgaa 120 gcaagctctc aaatccttgc tttgaataat ccagatattt caaaaaccatgttcgataaa 180 ttcacccgac aaggactccg tttcgtacta gaagcctctg tatcaaatattgaggatata 240 ggagatcgcg ttcggttaac tatcaatggg aatgtcgaag aatacgattacgttctcgta 300 tctataggac gccgtttgaa tacagaaaat attggcttgg ataaagctggtgttatttgt 360 gatgaacgcg gagtcatccc taccgatgcc acaatgcgca caaacgtacctaacatttat 420 gctattggag atatcacagg aaaatggcaa cttgcccatg tagcttctcatcaaggaatc 480 attgcagcac ggaatatagg tggccataaa gaggaaatcg attactctgctgtcccttct 540 gtgatcttta ccttccctga agtcgcttca gtaggcctct ccccaacagcagctcaacaa 600 catctccttc ttcgcttact ttttctgaaa aatttgatac agaagaagaattcctcgcac 660 acttgcgagg aggagggcgt ctggaagacc agttga 696 26 231 PRTChlamydia trachomatis 26 Ala Arg Ala Gly Thr Ser Lys Glu Ile Pro Gln LysMet Ala Ile Ile 1 5 10 15 Gly Gly Gly Val Ile Gly Cys Glu Phe Ala SerLeu Phe His Thr Leu 20 25 30 Gly Ser Glu Val Ser Val Ile Glu Ala Ser SerGln Ile Leu Ala Leu 35 40 45 Asn Asn Pro Asp Ile Ser Lys Thr Met Phe AspLys Phe Thr Arg Gln 50 55 60 Gly Leu Arg Phe Val Leu Glu Ala Ser Val SerAsn Ile Glu Asp Ile 65 70 75 80 Gly Asp Arg Val Arg Leu Thr Ile Asn GlyAsn Val Glu Glu Tyr Asp 85 90 95 Tyr Val Leu Val Ser Ile Gly Arg Arg LeuAsn Thr Glu Asn Ile Gly 100 105 110 Leu Asp Lys Ala Gly Val Ile Cys AspGlu Arg Gly Val Ile Pro Thr 115 120 125 Asp Ala Thr Met Arg Thr Asn ValPro Asn Ile Tyr Ala Ile Gly Asp 130 135 140 Ile Thr Gly Lys Trp Gln LeuAla His Val Ala Ser His Gln Gly Ile 145 150 155 160 Ile Ala Ala Arg AsnIle Gly Gly His Lys Glu Glu Ile Asp Tyr Ser 165 170 175 Ala Val Pro SerVal Ile Phe Thr Phe Pro Glu Val Ala Ser Val Gly 180 185 190 Leu Ser ProThr Ala Ala Gln Gln His Leu Leu Leu Arg Leu Leu Phe 195 200 205 Leu LysAsn Leu Ile Gln Lys Lys Asn Ser Ser His Thr Cys Glu Glu 210 215 220 GluGly Val Trp Lys Thr Ser 225 230 27 264 DNA Chlamydia pneumoniae 27atgagtcaaa aaaataaaaa ctctgctttt atgcatcccg tgaatatttc cacagattta 60gcagttatag ttggcaaggg acctatgccc agaaccgaaa ttgtaaagaa agtttgggaa 120tacattaaaa aacacaactg tcaggatcaa aaaaataaac gtaatatcct tcccgatgcg 180aatcttgcca aagtctttgg ctctagtgat cctatcgaca tgttccaaat gaccaaagcc 240ctttccaaac atattgtaaa ataa 264 28 87 PRT Chlamydia pneumoniae 28 Met SerGln Lys Asn Lys Asn Ser Ala Phe Met His Pro Val Asn Ile 1 5 10 15 SerThr Asp Leu Ala Val Ile Val Gly Lys Gly Pro Met Pro Arg Thr 20 25 30 GluIle Val Lys Lys Val Trp Glu Tyr Ile Lys Lys His Asn Cys Gln 35 40 45 AspGln Lys Asn Lys Arg Asn Ile Leu Pro Asp Ala Asn Leu Ala Lys 50 55 60 ValPhe Gly Ser Ser Asp Pro Ile Asp Met Phe Gln Met Thr Lys Ala 65 70 75 80Leu Ser Lys His Ile Val Lys 85 29 369 DNA Chlamydia pneumoniae 29atgccacgca tcattggaat tgatattcct gcaaagaaaa agttaaaaat aagtctgaca 60tatatttatg gaataggatc agctcgttct gatgaaatca ttaaaaagtt gaagttagat 120cctgaggcaa gagcctctga attaactgaa gaagaagtag gacgactgaa ctctctgcta 180caatcagaat ataccgtaga aggggatttg cgacgtcgtg ttcaatcgga tatcaaaaga 240ttgatcgcca tccattctta tcgaggtcag agacatagac tttctttacc agtaagagga 300caacgtacaa aaactaattc tcgtactcga aaaggtaaaa gaaaaacagt cgcaggtaag 360aagaaataa 369 30 122 PRT Chlamydia pneumoniae 30 Met Pro Arg Ile Ile GlyIle Asp Ile Pro Ala Lys Lys Lys Leu Lys 1 5 10 15 Ile Ser Leu Thr TyrIle Tyr Gly Ile Gly Ser Ala Arg Ser Asp Glu 20 25 30 Ile Ile Lys Lys LeuLys Leu Asp Pro Glu Ala Arg Ala Ser Glu Leu 35 40 45 Thr Glu Glu Glu ValGly Arg Leu Asn Ser Leu Leu Gln Ser Glu Tyr 50 55 60 Thr Val Glu Gly AspLeu Arg Arg Arg Val Gln Ser Asp Ile Lys Arg 65 70 75 80 Leu Ile Ala IleHis Ser Tyr Arg Gly Gln Arg His Arg Leu Ser Leu 85 90 95 Pro Val Arg GlyGln Arg Thr Lys Thr Asn Ser Arg Thr Arg Lys Gly 100 105 110 Lys Arg LysThr Val Ala Gly Lys Lys Lys 115 120 31 10 PRT Artificial Sequence Madein the lab 31 Cys Ser Phe Ile Gly Gly Ile Thr Tyr Leu 1 5 10 32 53 PRTChlamydia trachomatis 32 Leu Cys Val Ser His Lys Arg Arg Ala Ala Ala AlaVal Cys Ser Phe 1 5 10 15 Ile Gly Gly Ile Thr Tyr Leu Ala Thr Phe GlyAla Ile Arg Pro Ile 20 25 30 Leu Phe Val Asn Lys Met Leu Ala Gln Pro PheLeu Ser Ser Gln Thr 35 40 45 Lys Ala Asn Met Gly 50 33 161 DNA Chlamydiatrachomatis 33 atctttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtagcatcatcggaggaa 60 ttacctacct cgcgacattc ggagctatcc gtccgattct gtttgtcaacaaaatgctgg 120 caaaaccgtt tctttcttcc caaactaaag caaatatggg a 161 34 53PRT Chlamydia trachomatis 34 Leu Cys Val Ser His Lys Arg Arg Ala Ala AlaAla Val Cys Ser Ile 1 5 10 15 Ile Gly Gly Ile Thr Tyr Leu Ala Thr PheGly Ala Ile Arg Pro Ile 20 25 30 Leu Phe Val Asn Lys Met Leu Ala Lys ProPhe Leu Ser Ser Gln Thr 35 40 45 Lys Ala Asn Met Gly 50 35 55 DNAChlamydia pneumoniae 35 gatatacata tgcatcacca tcaccatcac atgagtcaaaaaaaataaaa actct 55 36 33 DNA Chlamydia pneumoniae 36 ctcgaggaattcttatttta caatatgttt gga 33 37 53 DNA Chlamydia pneumoniae 37gatatacata tgcatcacca tcaccatcac atgccacgca tcattggaat gat 53 38 30 DNAChlamydia pneumoniae 38 ctcgaggaat tcttatttct tcttacctgc 30 39 16 PRTArtificial Sequence Made in the lab 39 Lys Arg Asn Ile Asn Pro Asp AspLys Leu Ala Lys Val Phe Gly Thr 1 5 10 15 40 16 PRT Artificial Sequencemade in the lab 40 Lys Arg Asn Ile Leu Pro Asp Ala Asn Leu Ala Lys ValPhe Gly Ser 1 5 10 15 41 15 PRT Artificial Sequence made in the lab 41Lys Glu Tyr Ile Asn Gly Asp Lys Tyr Phe Gln Gln Ile Phe Asp 1 5 10 15 4216 PRT Artificial Sequence made in the lab 42 Lys Lys Ile Ile Ile ProAsp Ser Lys Leu Gln Gly Val Ile Gly Ala 1 5 10 15 43 15 PRT ArtificialSequence made in the lab 43 Lys Lys Leu Leu Val Pro Asp Asn Asn Leu AlaThr Ile Ile Gly 1 5 10 15 44 509 DNA Chlamydia 44 ggagctcgaa ttcggcacgagagtgcctat tgttttgcag gctttgtctg atgatagcga 60 taccgtacgt gagattgctgtacaagtagc tgttatgtat ggttctagtt gcttactgcg 120 cgccgtgggc gatttagcgaaaaatgattc ttctattcaa gtacgcatca ctgcttatcg 180 tgctgcagcc gtgttggagatacaagatct tgtgcctcat ttacgagttg tagtccaaaa 240 tacacaatta gatggaacggaaagaagaga agcttggaga tctttatgtg ttcttactcg 300 gcctcatagt ggtgtattaactggcataga tcaagcttta atgacctgtg agatgttaaa 360 ggaatatcct gaaaagtgtacggaagaaca gattcgtaca ttattggctg cagatcatcc 420 agaagtgcag gtagctactttacagatcat tctgagagga ggtagagtat tccggtcatc 480 ttctataatg gaatcggttctcgtgccgg 509 45 481 DNA Chlamydia unsure (23) n=A,T,C or G 45gatccgaatt cggcacgagg cantatttac tcccaacatt acggttccaa ataagcgata 60aggtcttcta ataaggaagt taatgtaaga ggctttttta ttgcttttcg taaggtagta 120ttgcaaccgc acgcgattga atgatacgca agccatttcc atcatggaaa agaacccttg 180gacaaaaata caaaggaggt tcactcctaa ccagaaaaag ggagagttag tttccatggg 240ttttccttat atacacccgt ttcacacaat taggagccgc gtctagtatt tggaatacaa 300attgtcccca agcgaatttt gttcctgttt cagggatttc tcctaattgt tctgtcagcc 360atccgcctat ggtaacgcaa ttagctgtag taggaagatc aactccaaac aggtcataga 420aatcagaaag ctcataggtg cctgcagcaa taacaacatt cttgtctgag tgagcgaatt 480 g481 46 427 DNA Chlamydia unsure (20) n=A,T,C or G 46 gatccgaattcggcacgagn tttttcctgt tttttcttag tttttagtgt tcccggagca 60 ataacacagatcaaagaacg gccattcagt ttaggctctg actcaacaaa acctatgtcc 120 tctaagccctgacacattct ttgaacaacc ttatgcccgt gttcgggata agccaactct 180 cgcccccgaaacatacaaga aacctttact ttatttcctt tctcaataaa ggctctagct 240 tgctttgctttcgtaagaaa gtcgttatca tcgatattag gcttaagctt aacctctttg 300 atacgcacttggtgctgtgc tttcttacta tctttttctt ttttagttat gtcgtaacga 360 tacttcccgtagtccatgat tttgcacaca ggaggctctg agtttgaagc aacctcgtgc 420 cgaattc 42747 600 DNA Chlamydia unsure (522) n=A,T,C or G 47 gatccgaatt cggcacgagatgcttctatt acaattggtt tggatgcgga aaaagcttac 60 cagcttattc tagaaaagttgggagatcaa attcttggtg gaattgctga tactattgtt 120 gatagtacag tccaagatattttagacaaa atcacaacag acccttctct aggtttgttg 180 aaagctttta acaactttccaatcactaat aaaattcaat gcaacgggtt attcactccc 240 aggaacattg aaactttattaggaggaact gaaataggaa aattcacagt cacacccaaa 300 agctctggga gcatgttcttagtctcagca gatattattg catcaagaat ggaaggcggc 360 gttgttctag ctttggtacgagaaggtgat tctaagccct acgcgattag ttatggatac 420 tcatcaggcg ttcctaatttatgtagtcta agaaccagaa ttattaatac aggattgact 480 ccgacaacgt attcattacgtgtaggcggt ttagaaagcg gngtggtatg ggttaatgcc 540 ctttctaatg gcaatgatattttaggaata acaaatcttc taatgtatct tttttggagg 600 48 600 DNA Chlamydia 48ggagctcgaa ttcggcacga gctctatgaa tatccaattc tctaaactgt tcggataaaa 60atgatgcagg aattaggtcc acactatctt tttttgtttc gcaaatgatt gattttaaat 120cgtttgatgt gtatactatg tcgtgtaagc ctttttggtt acttctgaca ctagccccca 180atccagaaga taaattggat tgcgggtcta ggtcagcaag taacactttt ttccctaaaa 240attgggccaa gttgcatccc acgtttagag aaagtgttgt ttttccagtt cctcccttaa 300aagagcaaaa aactaaggtg tgcaaatcaa ctccaacgtt agagtaagtt atctattcag 360ccttggaaaa catgtctttt ctagacaaga taagcataat caaagccttt tttagcttta 420aactgttatc ctctaatttt tcaagaacag gagagtctgg gaataatcct aaagagtttt 480ctatttgttg aagcagtcct agaattagtg agacactttt atggtagagt tctaagggag 540aatttaagaa agttactttt tccttgttta ctcgtatttt taggtctaat tcggggaaat 600 49600 DNA Chlamydia 49 gatccgaatt cggcacgaga tgcttctatt acaattggtttggatgcgga aaaagcttac 60 cagcttattc tagaaaagtt gggagatcaa attcttggtggaattgctga tactattgtt 120 gatagtacag tccaagatat tttagacaaa atcacaacagacccttctct aggtttgttg 180 aaagctttta acaactttcc aatcactaat aaaattcaatgcaacgggtt attcactccc 240 aggaacattg aaactttatt aggaggaact gaaataggaaaattcacagt cacacccaaa 300 agctctggga gcatgttctt agtctcagca gatattattgcatcaagaat ggaaggcggc 360 gttgttctag ctttggtacg agaaggtgat tctaagccctacgcgattag ttatggatac 420 tcatcaggcg ttcctaattt atgtagtcta agaaccagaattattaatac aggattgact 480 ccgacaacgt attcattacg tgtaggcggt ttagaaagcggtgtggtatg ggttaatgcc 540 ctttctaatg gcaatgatat tttaggaata acaaatacttctaatgtatc ttttttggag 600 50 406 DNA Chlamydia 50 gatccgaatt cggcacgagttcttagcttg cttaattacg taattaacca aactaaaggg 60 gctatcaaat agcttattcagtctttcatt agttaaacga tcttttctag ccatgactca 120 tcctatgttc ttcagctataaaaatacttc ttaaaacttg atatgctgta atcaaatcat 180 cattaaccac aacataatcaaattcgctag cggcagcaat ttcgacagcg ctatgctcta 240 atctttcttt cttctggaaatctttctctg aatcccgagc attcaaacgg cgctcaagtt 300 cttcttgaga gggagcttgaataaaaatgt gactgccggc atttgcttct tcagagccaa 360 agctccttgt acatcaatcacggctatgca gtctcgtgcc gaattc 406 51 602 DNA Chlamydia 51 gatccgaattcggcacgaga tattttagac aaaatcacaa cagacccttc tctaggtttg 60 ttgaaagcttttaacaactt tccaatcact aataaaattc aatgcaacgg gttattcact 120 cccaggaacattgaaacttt attaggagga actgaaatag gaaaattcac agtcacaccc 180 aaaagctctgggagcatgtt cttagtctca gcagatatta ttgcatcaag aatggaaggc 240 ggcgttgttctagctttggt acgagaaggt gattctaagc cctacgcgat tagttatgga 300 tactcatcaggcgttcctaa tttatgtagt ctaagaacca gaattattaa tacaggattg 360 actccgacaacgtattcatt acgtgtaggc ggtttagaaa gcggtgtggt atgggttaat 420 gccctttctaatggcaatga tattttagga ataacaaata cttctaatgt atcttttttg 480 gaggtaatacctcaaacaaa cgcttaaaca atttttattg gatttttctt ataggtttta 540 tatttagagaaaaaagttcg aattacgggg tttgttatgc aaaataaact cgtgccgaat 600 tc 602 52 145DNA Chlamydia 52 gatccgaatt cggcacgagc tcgtgccgat gtgttcaaca gcatccataggatgggcagt 60 caaatatact ccaagtaatt ctttttctct tttcaacaac tccttaggagagcgttggat 120 aacattttca gctcgtgccg aattc 145 53 450 DNA Chlamydia 53gatccgaatt cggcacgagg taatcggcac cgcactgctg acactcatct cctcgagctc 60gatcaaaccc acacttggga caagtaccta caacataacg gtccgctaaa aacttccctt 120cttcctcaga atacagctgt tcggtcacct gattctctac cagtccgcgt tcctgcaagt 180ttcgatagaa atcttgcaca atagcaggat gataagcgtt cgtagttctg gaaaagaaat 240ctacagaaat tcccaatttc ttgaaggtat ctttatgaag cttatgatac atgtcgacat 300attcttgata ccccatgcct gccaactctg cattaagggt aattgcgatt ccgtattcat 360cagaaccaca aatatacaaa acctctttgc cttgtagtct ctgaaaacgc gcataaacat 420ctgcaggcaa ataagcctcg tgccgaattc 450 54 716 DNA Chlamydia 54 gatcgaaattcggcacgagc ggcacgagtt ttctgatagc gatttacaat cctttattca 60 acttttgcctagagaggcac actatactaa gaagtttctt gggtgtgtgg cacagtcctg 120 tcgtcaggggattctgctag aggggtaggg gaaaaaaccc ttattactat gaccatgcgc 180 atgtggaattacattccata gactttcgca tcattcccaa catttacaca gctctacacc 240 tcttaagaagaggtgacgtg gattgggtgg ggcagccttg gcaccaaggg attccttttg 300 agcttcggactacctctgct ctctacaccc attaccctgt agatggcaca ttctggctta 360 ttcttaatcccaaagatcct gtactttcct ctctatctaa tcgtcagcga ttgattgctg 420 ccatccaaaaggaaaaactg gtgaagcaag ctttaggaac acaatatcga gtagctgaaa 480 gctctccatctccagaggga atcatagctc atcaagaagc ttctactcct tttcctggga 540 aaattactttgatatatccc aataatatta cgcgctgtca gcgtttggcc gaggtatcca 600 aaaaatgatcgacaaggagc acgctaaatt tgtacatacc ccaaaatcaa tcagccatct 660 aggcaaatggaatatcaaag taaacagtat acaactgggg atctcgtgcc gaattc 716 55 463 DNAChlamydia trachomatis 55 tctcaaatcc ttgctttgaa taatccagat atttcaaaaaccatgttcga taaattcacc 60 cgacaaggac tccgtttcgt actagaagcc tctgtatcaaatattgagga tataggagat 120 cgcgttcggt taactatcaa tgggaatgtc gaagaatacgattacgttct cgtatctata 180 ggacgccgtt tgaatacaga aaatattggc ttggataaagctggtgttat ttgtgatgaa 240 cgcggagtca tccctaccga tgccacaatg cgcacaaacgtacctaacat ttatgctatt 300 ggagatatca caggaaaatg gcaacttgcc catgtagcttctcatcaagg aatcattgca 360 gcacggaata taggtggcca taaagaggaa atcgattactctgctgtccc ttctgtgatc 420 tttaccttcc ctgaagtcgc ttcagtaggc ctctccccaacag 463 56 829 DNA Chlamydia trachomatis 56 gtactatggg atcattagttggaagacagg ctccggattt ttctggtaaa gccgttgttt 60 gtggagaaga gaaagaaatctctctagcag actttcgtgg taagtatgta gtgctcttct 120 tttatcctaa agattttacctatgtttgtc ctacagaatt acatgctttt caagatagat 180 tggtagattt tgaagagcatggtgcagtcg tccttggttg ctccgttgac gacattgaga 240 cacattctcg ttggctcactgtagcgagag atgcaggagg gatagaggga acagaatatc 300 ctctgttagc agacccctcttttaaaatat cagaagcttt tggtgttttg aatcctgaag 360 gatcgctcgc tttaagagctactttcctta tcgataaaca tggggttatt cgtcatgcgg 420 ttatcaatga tcttcctttagggcgttcca ttgacgagga attgcgtatt ttagattcat 480 tgatcttctt tgagaaccacggaatggttt gtccagctaa ctggcgttct ggagagcgtg 540 gaatggtgcc ttctgaagagggattaaaag aatacttcca gacgatggat taagcatctt 600 tgaaagtaag aaagtcgtacagatcttgat ctgaaaagag aagaaggctt tttaattttc 660 tgcagagagc cagcgaggcttcaataatgt tgaagtctcc gacaccaggc aatgctaagg 720 cgacgatatt agttagtgaagtctgagtat taaggaaatg aaggccaaag aaatagctat 780 caataaagaa gccttcttccttgactctaa agaatagtat gtcgtatcc 829 57 1537 DNA Chlamydia trachomatis 57acatcaagaa atagcggact cgcctttagt gaaaaaagct gaggagcaga ttaatcaagc 60acaacaagat attcaaacga tcacacctag tggtttggat attcctatcg ttggtccgag 120tgggtcagct gcttccgcag gaagtgcggc aggagcgttg aaatcctcta acaattcagg 180aagaatttcc ttgttgcttg atgatgtaga caatgaaatg gcagcgattg caatgcaagg 240ttttcgatct atgatcgaac aatttaatgt aaacaatcct gcaacagcta aagagctaca 300agctatggag gctcagctga ctgcgatgtc agatcaactg gttggtgcgg atggcgagct 360cccagccgaa atacaagcaa tcaaagatgc tcttgcgcaa gctttgaaac aaccatcagc 420agatggttta gctacagcta tgggacaagt ggcttttgca gctgccaagg ttggaggagg 480ctccgcagga acagctggca ctgtccagat gaatgtaaaa cagctttaca agacagcgtt 540ttcttcgact tcttccagct cttatgcagc agcactttcc gatggatatt ctgcttacaa 600aacactgaac tctttatatt ccgaaagcag aagcggcgtg cagtcagcta ttagtcaaac 660tgcaaatccc gcgctttcca gaagcgtttc tcgttctggc atagaaagtc aaggacgcag 720tgcagatgct agccaaagag cagcagaaac tattgtcaga gatagccaaa cgttaggtga 780tgtatatagc cgcttacagg ttctggattc tttgatgtct acgattgtga gcaatccgca 840agcaaatcaa gaagagatta tgcagaagct cacggcatct attagcaaag ctccacaatt 900tgggtatcct gctgttcaga attctgtgga tagcttgcag aagtttgctg cacaattgga 960aagagagttt gttgatgggg aacgtagtct cgcagaatct caagagaatg cgtttagaaa 1020acagcccgct ttcattcaac aggtgttggt aaacattgct tctctattct ctggttatct 1080ttcttaacgt gtgattgaag tttgtgaatt gagggggagc caaaaaagaa tttctttttt 1140ggctcttttt tcttttcaaa ggaatctcgt gtctacagaa gtcttttcaa taataagttc 1200ttagttccaa aagaagaaaa tatataaaag aaaaaactcc taattcattt aaaaagtgct 1260cggcagactt cgtggaaaat gtctgtaaag ctggagggga atcagcagaa agatgcaaga 1320tatccgagaa aaaaggctca ggctcgtgcc gaattcggca cgagactacg aaagaaaggt 1380cttttctttc ggaatctgtc attggatctg cgtaagactt aaagttcggc aacacaggct 1440ctgtcttctc tttaggtttc ttgcgcgaga aaaattttct caagtaacaa gaagatttct 1500ttttacagcc ggcatccggc ttctcgcgaa gtataac 1537 58 463 DNA Chlamydiatrachomatis 58 tctcaaatcc ttgctttgaa taatccagat atttcaaaaa ccatgttcgataaattcacc 60 cgacaaggac tccgtttcgt actagaagcc tctgtatcaa atattgaggatataggagat 120 cgcgttcggt taactatcaa tgggaatgtc gaagaatacg attacgttctcgtatctata 180 ggacgccgtt tgaatacaga aaatattggc ttggataaag ctggtgttatttgtgatgaa 240 cgcggagtca tccctaccga tgccacaatg cgcacaaacg tacctaacatttatgctatt 300 ggagatatca caggaaaatg gcaacttgcc catgtagctt ctcatcaaggaatcattgca 360 gcacggaata taggtggcca taaagaggaa atcgattact ctgctgtcccttctgtgatc 420 tttaccttcc ctgaagtcgc ttcagtaggc ctctccccaa cag 463 59552 DNA Chlamydia trachomatis 59 acattcctcc tgctcctcgc ggccatccacaaattgaggt aaccttcgat attgatgcca 60 acggaatttt acacgtttct gctaaagatgctgctagtgg acgcgaacaa aaaatccgta 120 ttgaagcaag ctctggatta aaagaagatgaaattcaaca aatgatccgc gatgcagagc 180 ttcataaaga ggaagacaaa caacgaaaagaagcttctga tgtgaaaaat gaagccgatg 240 gaatgatctt tagagccgaa aaagctgtgaaagattacca cgacaaaatt cctgcagaac 300 ttgttaaaga aattgaagag catattgagaaagtacgcca agcaatcaaa gaagatgctt 360 ccacaacagc tatcaaagca gcttctgatgagttgagtac tcgtatgcaa aaaatcggag 420 aagctatgca ggctcaatcc gcatccgcagcagcatcttc tgcagcgaat gctcaaggag 480 ggccaaacat taactccgaa gatctgaaaaaacatagttt cagcacacga cctccagcag 540 gaggaagcgc ct 552 60 1180 DNAChlamydia trachomatis 60 atcctagcgg taaaactgct tactggtcag ataaaatccatacagaagca acacgtactt 60 cttttaggag aaaaaatcta taatgctaga aaaatcctgagtaaggatca cttctcctca 120 acaacttttt catcttggat agagttagtt tttagaactaagtcttctgc ttacaatgct 180 cttgcatatt acgagctttt tataaacctc cccaaccaaactctacaaaa agagtttcaa 240 tcgatcccct ataaatccgc atatattttg gccgctagaaaaggcgattt aaaaaccaag 300 gtcgatgtga tagggaaagt atgtggaatc tcgtgccgaattcggcacga gcggcacgag 360 gatgtagagt aattagttaa agagctgcat aattatgacaaagcatggaa aacgcattcg 420 tggtatccaa gagacttacg atttagctaa gtcgtattctttgggtgaag cgatagatat 480 tttaaaacag tgtcctactg tgcgtttcga tcaaacggttgatgtgtctg ttaaattagg 540 gatcgatcca agaaagagtg atcagcaaat tcgtggttcggtttctttac ctcacggtac 600 aggtaaagtt ttgcgaattt tagtttttgc tgctggagataaggctgcag aggctattga 660 agcaggagcg gactttgttg gtagcgacga cttggtagaaaaaatcaaag gtggatgggt 720 tgacttcgat gttgcggttg ccactcccga tatgatgagagaggtcggaa agctaggaaa 780 agttttaggt ccaagaaacc ttatgcctac gcctaaagccggaactgtaa caacagatgt 840 ggttaaaact attgcggaac tgcgaaaagg taaaattgaatttaaagctg atcgagctgg 900 tgtatgcaac gtcggagttg cgaagctttc tttcgatagtgcgcaaatca aagaaaatgt 960 tgaagcgttg tgtgcagcct tagttaaagc taagcccgcaactgctaaag gacaatattt 1020 agttaatttc actatttcct cgaccatggg gccaggggttaccgtggata ctagggagtt 1080 gattgcgtta taattctaag tttaaagagg aaaaatgaaagaagagaaaa agttgctgct 1140 tcgcgaggtt gaagaaaaga taaccgcttc tcggcacgag1180 61 1215 DNA Chlamydia trachomatis 61 attacagcgt gtgcaggtaacgacatcatt gcatgatgct tttgatggca ttgatgcggc 60 attccttata gggtcagttcctagaggccc aggaatggag agaagagatc ttctaaagaa 120 aaatggggag attgttgctacgcaaggaaa agctttgaac acaacagcca agcgggatgc 180 aaagattttt gttgttgggaaccctgtgaa taccaattgc tggatagcaa tgaatcatgc 240 tcccagatta ttgagaaagaactttcatgc gatgctacga ttggaccaga atcgtatgca 300 tagcatgtta tcgcatagagcagaagtacc tttatcggct gtatcacaag ttgtggtttg 360 gggaaatcac tccgccaaacaagtgcctga ttttacgcaa gctctgatta atgaccgtcc 420 tatcgcagag acgatagcggatcgtgattg gttagagaat attatggtgc cttctgtaca 480 gagtcgtggt agtgcagtaattgaagcacg agggaagtct tcggcagctt ctgcagcacg 540 agctttagca gaggctgctcgatcaatata tcagccaaaa gaaggactcg tgccgaattc 600 ggcacgagta tcgaaattgcaggcatttct agtgaatggt cgtatgctta taaactacgt 660 ggtacagact tgagctctcaaaagtttgct acagattctt acatcgcaga cccttattct 720 aagaatatct actcccctcaactatttgga tcccctaaac aagaaaagga ttacgcattt 780 agttacctga aatatgaggattttgactgg gaaggcgaca ctcctttgca ccttccaaaa 840 gaaaattact tcatttatgaaatgcatgtt cggtcattca cccgagatcc gtcttcccag 900 gtttcccatc ctggaactttccttggtatc atcgaaaaaa tagaccacct caaacaacta 960 ggcgttcatg cagttgaactccttcctatt ttcgaattcg atgaaaccgt ccatccattt 1020 aaaaatcagg acttcccccacctgtgtaac tattgggggt attcttcggt gaattttttc 1080 tgcccctctc gccgttatacttatggggca gacccttgcg ctccggcccg agagttcaag 1140 actcttgtca aagcgttacaccgtgcggga atcgaagtca ttctcgatgt cgttttcaat 1200 catacaggct ttgaa 121562 688 DNA Chlamydia trachomatis 62 gtggatccaa aaaagaatct aaaaagccatacaaagattg cgttacttct tgcgatgcct 60 ctaacacttt atcagcgtca tctttgagaagcatctcaat gagcgctttt tcttctctag 120 catgccgcac atccgcttct tcatgttctgtgaaatatgc atagtcttca ggattggaaa 180 atccaaagta ctcagtcaat ccacgaattttctctctagc gatacgtgga atttgactct 240 cataagaata caaagcagcc actcctgcagctaaagaatc tcctgtacac caccgcatga 300 aagtagctac tttcgctttt gctgcttcactaggctcatg agcctctaac tcttctggag 360 taactcctag agcaaacaca aactgcttccacaaatcaat atgattaggg taaccgttct 420 cttcatccat caagttatct aacaataacttacgcgcctc taaatcatcg caacgactat 480 gaatcgcaga taaatattta ggaaaggctttgatatgtaa ataatagtct ttggcacgag 540 cctgtaattg ctctttagta agctcccccttcgaccattt cacataaaac gtgtgttcta 600 gcatatgctt attttgaata attaaatctaactgatctaa aaaattcata aacacctcca 660 tcatttcttt tcttgactcc acgtaacc 68863 269 DNA Chlamydia trachomatis 63 atgttgaaat cacacaagct gttcctaaatatgctacggt aggatctccc tatcctgttg 60 aaattactgc tacaggtaaa agggattgtgttgatgttat cattactcag caattaccat 120 gtgaagcaga gttcgtacgc agtgatccagcgacaactcc tactgctgat ggtaagctag 180 tttggaaaat tgaccgctta ggacaaggcgaaaagagtaa aattactgta tgggtaaaac 240 ctcttaaaga aggttgctgc tttacagct 26964 1339 DNA Chlamydia trachomatis 64 cttttattat ggcttctggg gatgatgtcaacgatatcga cctgctatct cgaggagatt 60 ttaaaattgt tatacagacg gctccagaggagatgcatgg attagcggac tttttggctc 120 ccccggcgaa ggatcttggt attctctccgcctgggaagc tggtgagctg cgttacaaac 180 agctagttaa tccttaggaa acatttctggacctatgccc atcacattgg ctccgtgatc 240 cacatagaga gtttctcccg taattgcgctagctagggga gagactaaga aggctgctgc 300 tgcgcctact tgctcagctt ccattggagaaggtagtgga gcccagtctt ggtagtaatc 360 caccattctc tcaataaatc caatagcttttcctgcacgg ctagctaatg gccctgccga 420 gatagtattc actcggactc cccaacgtcggccggcttcc caagccagta cttttgtatc 480 actttctaaa gcagcttttg ctgcgttcattcctccgcca taccctggaa cagcacgcat 540 ggaagcaaga taagttagag agatggtgctagctcctgca ttcataattg ggccaaaatg 600 agagagaagg ctgataaagg agtagctggatgtacttaag gcggcaagat agcctttacg 660 agaggtatca agtaatggtt tagcaatttccggactgttt gctaaagagt gaacaagaat 720 atcaatgtgt ccaaaatctt ttttcacctgttctacaact tcggatacag tgtacccaga 780 aagatctttg taacgtttat tttccaaaatttcctgagga atatcttctg gggtgtcgaa 840 actggcatcc atgggataga ttttagcgaaagttagcaat tctccattgg agagttcacg 900 agatgcattg aattttccta actcccaagattgagagaaa attttataga taggaaccca 960 ggtccccaca agtatggttg cgcctgcttctgctaacatt ttggcaatgc cccagccata 1020 cccgttatca tcgcctatgc cggctatgaaagcaattttt cctgttaaat caattttcaa 1080 catgagctaa ccccattttg tcttcttgagagaggagagt agcagattct ttattattga 1140 gaaacgggcc tcataataca taaggagtagattcactggc tggatccagg tttctagagt 1200 aaagagtttc cttgtcaaat tcttatatgggtagagttaa tcaactgttt tcaagtgatt 1260 tatgtttatt ttaaaataat ttgttttaacaactgtttaa tagttttaat ttttaaagtg 1320 tgaaaaacag gttttatat 1339 65 195PRT Chlamydia trachomatis 65 Met Gly Ser Leu Val Gly Arg Gln Ala Pro AspPhe Ser Gly Lys Ala 5 10 15 Val Val Cys Gly Glu Glu Lys Glu Ile Ser LeuAla Asp Phe Arg Gly 20 25 30 Lys Tyr Val Val Leu Phe Phe Tyr Pro Lys AspPhe Thr Tyr Val Cys 35 40 45 Pro Thr Glu Leu His Ala Phe Gln Asp Arg LeuVal Asp Phe Glu Glu 50 55 60 His Gly Ala Val Val Leu Gly Cys Ser Val AspAsp Ile Glu Thr His 65 70 75 80 Ser Arg Trp Leu Thr Val Ala Arg Asp AlaGly Gly Ile Glu Gly Thr 85 90 95 Glu Tyr Pro Leu Leu Ala Asp Pro Ser PheLys Ile Ser Glu Ala Phe 100 105 110 Gly Val Leu Asn Pro Glu Gly Ser LeuAla Leu Arg Ala Thr Phe Leu 115 120 125 Ile Asp Lys His Gly Val Ile ArgHis Ala Val Ile Asn Asp Leu Pro 130 135 140 Leu Gly Arg Ser Ile Asp GluGlu Leu Arg Ile Leu Asp Ser Leu Ile 145 150 155 160 Phe Phe Glu Asn HisGly Met Val Cys Pro Ala Asn Trp Arg Ser Gly 165 170 175 Glu Arg Gly MetVal Pro Ser Glu Glu Gly Leu Lys Glu Tyr Phe Gln 180 185 190 Thr Met Asp195 66 520 DNA Chlamydia 66 gatccgaatt cggcacgagg aggaatggaa gggccctccgattttaaatc tgctaccatg 60 ccattcacta gaaactccat aacagcggtt ttctctgatggcgagtaaga agcaagcatt 120 tgatgtaaat tagcgcaatt agagggggat gaggttacttggaaatataa ggagcgaagc 180 gatgaaggag atgtatttgc tctggaagca aaggtttctgaagctaacag aacattgcgt 240 cctccaacaa tcgcctgagg attctggctc atcagttgatgctttgcctg aatgagagcg 300 gacttaagtt tcccatcaga gggagctatt tgaattagataatcaagagc tagatccttt 360 attgtgggat cagaaaattt acttgtgagc gcatcgagaatttcgtcaga agaagaatca 420 tcatcgaacg aatttttcaa tcctcgaaaa tcttctccagagacttcgga aagatcttct 480 gtgaaacgat cttcaagagg agtatcgcct ttttcctctg520 67 276 DNA Chlamydia 67 gatccgaatt cggcacgagg tattgaagga gaaggatctgactcgatcta tgaaatcatg 60 atgcctatct atgaagttat gaatatggat ctagaaacacgaagatcttt tgcggtacag 120 caagggcact atcaggaccc aagagcttca gattatgacctcccacgtgc tagcgactat 180 gatttgccta gaagcccata tcctactcca cctttgccttctagatatca gctacagaat 240 atggatgtag aagcagggtt ccgtgaggca gtttat 276 68248 DNA Chlamydia 68 gatccgaatt cggcacgagg tgttcaagaa tatgtccttcaagaatgggt taaattgaaa 60 gatctaccgg tagaagagtt gctagaaaaa cgatatcagaaattccgaac gataggtcta 120 tatgaaactt cttctgaaag cgattctgag gcataagaagcatttagttt tattcggttt 180 ttctctttta tccatattag ggctaacgat aacgtctcaagcagaaattt tttctctagg 240 tcttattg 248 69 715 DNA Chlamydia unsure (34)n=A,T,C or G 69 gatccgaatt cggcacgaga aggtagatcc gatntcagca aaagtgctcctaaaggaaga 60 ttccttcggt atcctgcagc aaataaggtg gcacactcca tctcggacagtttgagcttt 120 attttcatat agttttcgac ggaactcttt attaaactcc caaaaccgaatgttagtcgt 180 gtgggtgatg cctatatggt aagggaggtt tttggcttcg agaatattggtgatcatttt 240 ttgtacgaca aaattagcta atgcagggac ctctgggggg aagtatgcatctgatgttcc 300 atcttttcgg atgctagcaa cagggacaaa ataatctcct atttggtagtgggatcttaa 360 gcctccgcac atgcccaaca tgatcgctgc tgtagcattg ggaaggaaagaacacagatc 420 tacggtaaga gctgctcctg gagagcctaa tttaaaatcg atgattgaggtgtgaatttg 480 aggcgcatgc gctgccgaaa acatggatcc tcgagaaaca gggacctgatagatttcagc 540 gaaaacatcc acggtaatac ccmaaattag taagaaggag atagggctggaactcttgaa 600 tggtagagcc ggtatagcgc tctagcatgt cacaggcgat tgtttcttcgctgatttttt 660 tatgttgatg ggtcataaat cacagatatt ataatggtta gagaatctttttttc 715 70 323 DNA Chlamydia 70 gatccgaatt cggcacgagc agaacgtaaacagcacactt aaaccgtgta tgaggtttaa 60 cactgtttgg caagcaaaca accattcctctttccacatc gttcttacca atacctctga 120 ggagcaatcc aacattctct cctgcacgaccttctgggag ttcttttctg aacatttcaa 180 ccccagtaac aatcgtttct ttagtatctctaagaccgac caactgaact ttatcggaaa 240 ctttaacaat tccacgctca atacgtccagttactacagt tcctcgtccg gagatagaga 300 acacgtcctc aatgggcatt aag 323 71715 DNA Chlamydia 71 gatccgaatt cggcacgagg aaaaaaagat tctctaaccattataatatc tgtgatttat 60 gacccatcaa cataaaaaaa tcagcgaaga aacaatcgcctgtgacatgc tagagcggct 120 ataccggctc taccattcaa gagttccagc cctatctccttcttactaat tttgggtatt 180 acgtggatgt tttcgctgaa atctatcagg tccctgtttctcgaggatcc atgttttcgg 240 gcagcgcatg cgcctcaaat tcacacctca atcatcgattttaaattagg ctctccagga 300 gcagctctta ccgtagatct gtgttctttc cttcccaatgctacagcagc gatcatgttg 360 ggcatgtgcg gaggcttaag atcccactac caaataggagattattttgt ccctgttgct 420 agcatccgaa aagatggaac atcagatgca tacttccccccagaggtccc tgcattagct 480 aattttgtcg tacaaaaaat gatcaccaat attctcgaagccaaaaacct cccttaccat 540 ataggcatca cccacacgac taacattcgg ttttgggagtttaataaaga gttccgtcga 600 aaactatatg aaaataaagc tcaaactgtc gagatggagtgtgccacctt atttgctgca 660 ggataccgaa ggaatcttcc tttaggagca cttttgctgatatcggatct acctt 715 72 641 DNA Chlamydia unsure (550) n=A,T,C or G 72gatccgaatt cggcacgaga tctcctcgag ctcgatcaaa cccacacttg ggacaagtac 60ctacaacata acggtccgct aaaaacttcc cttcttcctc agaatacagc tgttcggtca 120cctgattctc taccagtccg cgttcctgca agtttcgata gaaatcttgc acaatagcag 180gatgataagc gttcgtagtt ctggaaaaga aatctacaga aattcccaat ttcttgaagg 240tatctttatg aagcttatga tacatgtcga catattcttg ataccccatg cctgccaact 300ctgcattaag ggtaattgcg attccgtatt catcagaacc acaaatatac aaaacctctt 360tgccttgtag tctctgaaaa cgcgcataaa catctgcagg caaataagca ccggtaatat 420gtccaaaatg caaaggacca tttgcgtaag gcaacgcaga agtaataaga atacgggaag 480attccactat ttcacgtcgc tccagttgta cagagaagga tcttttcttc tggatgttcc 540gaaaccttgn tctcttcgnc tctctcctgt agcanacaaa tgnctctctc gacatctctt 600tcagcgtatt cggactgatg ccctaaagat cccnggangt t 641 73 584 DNA Chlamydiaunsure (460) n=A,T,C or G 73 gaattcggca cgagacattt ctagaatgga accggcaacaaacaaaaact ttgtatctga 60 agatgacttt aagcaatctt tagataggga agattttttggaatgggtct ttttatttgg 120 gacttattac ggaacgagta aggcggagat ttctagagttctgcaaaagg gtaagcactg 180 catagccgtg attgatgtac aaggagcttt ggctctgaagaagcaaatgc cggcagtcac 240 tatttttatt caagctccct ctcaagaaga acttgagcgccgtttgaatg ctcgggattc 300 agagaaagat ttccagaaga aagaaagatt agagcatagcgctgtcgaaa ttgctgccgc 360 tagcgaattt gattatgttg tggttaatga tgatttgattacagcatatc aagttttaag 420 aagtattttt atagctgaag aacataggat gagtcatggntagaaaagat cgtttaacta 480 atgaaagact gaataagcta tttgatagcc cctttagtttggntaattac gtaattaagc 540 nagctnagaa caaaattgct agaggagatg ttcgttcttctaac 584 74 465 DNA Chlamydia 74 gatccgaatt cggcacgagc tcgtgccgtttgggatcgtg taatcgcatc ggagaatggt 60 taagaaatta ttttcgagtg aaagagctaggcgtaatcat tacagatagc catactactc 120 caatgcggcg tggagtactg ggtatcgggctgtgttggta tggattttct ccattacaca 180 actatatagg atcgctagat tgtttcggtcgtcccttaca gatgacgcaa agtaatcttg 240 tagatgcctt agcagttgcg gctgttgtttgtatgggaga ggggaatgag caaacaccgt 300 tagcggtgat agagcaggca cctaatatggtctaccattc atatcctact tctcgagaag 360 agtattgttc tttgcgcata gatgaaacagaggacttata cggacctttt ttgcaagcgg 420 ttaccgtgga gtcaagaaaa gaaatgatggaggtgtttat gaatt 465 75 545 DNA Chlamydia 75 gaattcggca cgagatgaaaagttagcgtc acaggggatt ctcctaccaa agaattccga 60 aaagttttct tccaaaaacctcttcctctc ttgattagtg atccctctgc aactacttta 120 ctatatgttc tgtgaaatatgcatagtctt caggattgga aaatccaaag tactcagtca 180 atccacgaat tttctctctagcgatacgtg gaatttgact ctcataagaa tacaaagcag 240 ccactcctgc agctaaagaatctcctgtac accaccgcat gaaagtagct actttcgctt 300 ttgctgcttc actaggctcatgagcctcta actcttctgg agtaactcct agagcaaaca 360 caaactgctt ccacaaatcaatatgattag ggtaaccgtt ctcttcatcc atcaagttat 420 ctaacaataa cttacgcgcctctaaatcat cgcaacgact atgaatcgca gataaatatt 480 taggaaaggc tttgatatgtaaataatagt ctttggcata cgcctgtaat tgctctttag 540 taagc 545 76 797 DNAChlamydia unsure (788) n=A,T,C or G 76 gatccgaatt cggcacgaga tacgctagatgcgataaatg cggataatga ggattatcct 60 aaaccaggtg acttcccacg atcttccttctctagtacgc ctcctcatgc tccagtacct 120 caatctgaga ttccaacgtc acctacctcaacacagcctc catcacccta acttgtaaaa 180 actgtaataa aaagagcgcg cttcctttatgcaaaatcaa tttgaacaac tccttactga 240 attagggact caaatcaaca gccctcttactcctgattcc aataatgcct gtatagttcg 300 ctttggatac aacaatgttg ctgtacaaattgaagaggat ggtaattcag gatttttagt 360 tgctggagtc atgcttggaa aacttccagagaataccttt agacaaaaaa ttttcaaagc 420 tgctttgtct atcaatggat ctccgcaatctaatattaaa ggcactctag gatacggtga 480 aatctctaac caactctatc tctgtgatcggcttaacatg acctatctaa atggagaaaa 540 gctcgcccgt tacttagttc ttttttcgcagcatgccaat atctggatgc aatctatctc 600 aaaaggagaa cttccagatt tacatgctctaggtatgtat cacctgtaaa ttatgccgtc 660 attatcccaa tcccgacgta tcatccagcaatcttccatt cgaaagattt ggaatcagat 720 agatacttct cctaagcatg ggggtatgcgtaccggttat ttttctcttc atactcaaaa 780 aaagttgnng gggaata 797 77 399 DNAChlamydia 77 catatgcatc accatcacca tcacatgcca cgcatcattg gaattgatattcctgcaaag 60 aaaaagttaa aaataagtct gacatatatt tatggaatag gatcagctcgttctgatgaa 120 atcattaaaa agttgaagtt agatcctgag gcaagagcct ctgaattaactgaagaagaa 180 gtaggacgac tgaactctct gctacaatca gaatataccg tagaaggggatttgcgacgt 240 cgtgttcaat cggatatcaa aagattgatc gccatccatt cttatcgaggtcagagacat 300 agactttctt taccagtaag aggacaacgt acaaaaacta attctcgtactcgaaaaggt 360 aaaagaaaaa cagtcgcagg taagaagaaa taagaattc 399 78 285 DNAChlamydia 78 atgcatcacc atcaccatca catgagtcaa aaaaataaaa actctgcttttatgcatccc 60 gtgaatattt ccacagattt agcagttata gttggcaagg gacctatgcccagaaccgaa 120 attgtaaaga aagtttggga atacattaaa aaacacaact gtcaggatcaaaaaaataaa 180 cgtaatatcc ttcccgatgc gaatcttgcc aaagtctttg gctctagtgatcctatcgac 240 atgttccaaa tgaccaaagc cctttccaaa catattgtaa aataa 285 79950 DNA Chlamydia 79 aaattaactc gagcacaaat tacggcaatt gctgagcaaaagatgaagga catggatgtc 60 gttcttttag agtccgccga gagaatggtt gaagggactgcccgaagcat gggtgtagat 120 gtagagtaat tagttaaaga gctgcataat tatgacaaagcatggaaaac gcattcgtgg 180 tatccaagag acttacgatt tagctaagtc gtattctttgggtgaagcga tagatatttt 240 aaaacagtgt cctactgtgc gtttcgatca aacggttgatgtgtctgtta aattagggat 300 cgatccaaga aagagtgatc agcaaattcg tggttcggtttctttacctc acggtacagg 360 taaagttttg cgaattttag tttttgctgc tggagataaggctgcagagg ctattgaagc 420 aggagcggac tttgttggta gcgacgactt ggtagaaaaaatcaaaggtg gatgggttga 480 cttcgatgtt gcggttgcca ctcccgatat gatgagagaggtcggaaagc taggaaaagt 540 tttaggtcca agaaacctta tgcctacgcc taaagccggaactgtaacaa cagatgtggt 600 taaaactatt gcggaactgc gaaaaggtaa aattgaatttaaagctgatc gagctggtgt 660 atgcaacgtc ggagttgcga agctttcttt cgatagtgcgcaaatcaaag aaaatgttga 720 agcgttgtgt gcagccttag ttaaagctaa gcccgcaactgctaaaggac aatatttagt 780 taatttcact atttcctcga ccatggggcc aggggttaccgtggatacta gggagttgat 840 tgcgttataa ttctaagttt aaagaggaaa aatgaaagaagagaaaaagt tgctgcttcg 900 cgaggttgaa gaaaagataa ccgcttctca aggttttattttgttgagat 950 80 395 DNA Chlamydia 80 81 2085 DNA Chlamydia 81atttggcgaa ggagtttggg ctacggctat taataaatca ttcgtgttcg ctgcctccaa 60gaccagattg tgtactttct tatgaagaat ctcctattga gcaaatgttg cgttggggag 120agtctcagtt agaacaattt gctcaagtag gtttagatac aagttggcaa gttgttttcg 180atccaggaat aggatttggg aagactcccg ttcagtcgat gttattgatg gatggagtaa 240agcagtttaa acgtgtttta gagtgtcctg tattaatagg ccattctaga aaatcgtgtt 300tgagtatgtt gggccgattt aatagtgacg atcgtgattg ggaaacgatc ggctgttctg 360tatctcttca tgatcgagga gttgattatc tacgtgtgca tcaggttgaa ggtaacagac 420gtgccttagc cgctgctgct tgggctggta tgtttgtatg atccaagcaa caggtatcgt 480tgctattgat cccagaggag tgatgggagc tttaggcaag ctcccttgga gttatcccga 540agatctacgt ttttttgcag aaaccattcg aaatcatccc atcattatgg gacgaaagac 600ttgggagtct cttccagaca agtataagca tgggcgggat atcgttgtct tttctcgcag 660gatgcatcca ccacaatgca taggagtttc ttcctttgca gagtatggga cactatcttt 720gaatcatccg tttttaattg ggggagcgga gctctttgaa agttttttcc aacaaaacct 780tctgaaagct tgttttgtca cacatatcaa aaagaaatat tggggcgata ctttcttccc 840tatcacgcga ttatcaggat ggaagaagga atgtatttgt aatacagagg atttcagtat 900ttattattat gaaaataact ccgatcaaaa cacgtaaagt atttgcacat gattcgcttc 960aagagatctt gcaagaggct ttgccgcctc tgcaagaacg gagtgtggta gttgtctctt 1020caaagattgt gagtttatgt gaaggcgctg tcgctgatgc aagaatgtgc aaagcagagt 1080tgataaaaaa agaagcggat gcttatttgt tttgtgagaa aagcgggata tatctaacga 1140aaaaagaagg tattttgatt ccttctgcag ggattgatga atcgaatacg gaccagcctt 1200ttgttttata tcctaaagat attttgggat cgtgtaatcg catcggagaa tggttaagaa 1260attattttcg agtgaaagag ctaggcgtaa tcattacaga tagccatact actccaatgc 1320ggcgtggagt actgggtatc gggctgtgtt ggtatggatt ttctccatta cacaactata 1380taggatcgct agattgtttc ggtcgtccct tacagatgac gcaaagtaat cttgtagatg 1440ccttagcagt tgcggctgtt gtttgtatgg gagaggggaa tgagcaaaca ccgttagcgg 1500tgatagagca ggcacctaat atggtctacc attcatatcc tacttctcga gaagagtatt 1560gttctttgcg catagatgaa acagaggact tatacggacc ttttttgcaa gcggttacgt 1620ggagtcaaga aaagaaatga tggaggtgtt tatgaatttt ttagatcagt tagatttaat 1680tattcaaaat aagcatatgc tagaacacac gttttatgtg aaatggtcga agggggagct 1740tactaaagag caattacagg cgtatgccaa agactattat ttacatatca aagcctttcc 1800taaatattta tctgcgattc atagtcgttg cgatgattta gaggcgcgta agttattgtt 1860agataacttg atggatgaag agaacggtta ccctaatcat attgatttgt ggaagcagtt 1920tgtgtttgct ctaggagtta ctccagaaga gttagaggct catgagccta gtgaagcagc 1980aaaagcgaaa gtagctactt tcatgcggtg gtgtacagga gattctttag ctgcaggagt 2040ggctgctttg tattcttatg agagtcaaat tccacgtatc gcctc 2085 82 405 DNAChlamydia 82 ttcatcggtc tagttcgcta ttctactctc caatggttcc gcatttttgggcagagcttc 60 gcaatcatta tgcaacgagt ggtttgaaaa gcgggtacaa tattgggagtaccgatgggt 120 ttctccctgt cattgggcct gttatatggg agtcggaggg tcttttccgcgcttatattt 180 cttcggtgac tgatggggat ggtaagagcc ataaagtagg atttctaagaattcctacat 240 atagttggca ggacatggaa gattttgatc cttcaggacc gcctccttgggaagaattgt 300 attggctcca taaagggagg agaaaacttc gatataggga atcgtatcaaggtgaaagta 360 gcaaaaaata aattagctcc tccattccga actgcagaat ttgat 405 83379 DNA Chlamydia 83 tataccattc gtttgaaagt gcctttgacg ggagaaagtgtttttgaaga tcaatgcaaa 60 ggtcgtgtcg ttttcccttg ggcagatgtt gacgatcaagttttggttaa atcagacggg 120 ttccctacgt atcactttgc taatgtagtt gatgatcatttgatggggat tacccatgtg 180 ttgcgagggg aagagtggtt aagttctaca cctaaacaccttcttcttta caaagctttt 240 gggtgggagc ctccgcagtt tttccatatg ccgcttcttctaaatcctga tggaagtaag 300 ctttccaaga gaaagaatcc tacttctatt ttttactatcgggatgctgg atacaaaaaa 360 gaagcgttca tgaatttcc 379 84 715 DNA Chlamydia84 tcaatcctgt attaataatt ctggttctta gactacataa attaggaacg cctgatgagt 60atccataact aatcgcgtag ggcttagaat caccttctcg taccaaagct agaacaacgc 120cgccttccat tcttgatgca ataatatctg ctgagactaa gaacatgctc ccagagcttt 180tgggtgtgac tgtgaatttt cctatttcag ttcctcctaa taaagtttca atgttcctgg 240gagtgaataa cccgttgcat tgaattttat tagtgattgg aaagttgtta aaagctttca 300acaaacctag agaagggtct gttgtgattt tgtctaaaat atcttggact gtactatcaa 360caatagtatc agcaattcca ccaagaattt gatctcccaa cttttctaga ataagctggt 420aagctttttc cgcatccaaa ccaattgtaa tagaagcatt ggttgatgga ttattggaga 480ctgttaaaga tattccatca gaagctgtca ttttggctgc gacaggtgtt gatgttgtcc 540caaggattat ttgctggtcc ttgagcggct ctgtcatttg cccaactttg atattatcag 600caaagacgca gttttgagtg ttatacaaat aaaaaccaga atttcccatt ttaaaactct 660tttttatttt gagctttaaa taaattaggt ttttagtttc aagtttgcta ttaat 715 85 476DNA Chlamydia 85 ctcgtgccgc tcgtgccgct cgtgccggtc ttttagaaga gcgtgaagctttaaataatt 60 cgattacgtt tatcatggat aagcgtaatt ggatagaaac cgagtctgaacaggtacaag 120 tggttttcag agatagtaca gcttgcttag gaggaggcgc tattgcagctcaagaaattg 180 tttctattca gaacaatcag gctgggattt ccttcgaggg aggtaaggctagtttcggag 240 gaggtattgc gtgtggatct ttttcttccg caggcggtgc ttctgttttagggactattg 300 atatttcgaa gaatttaggc gcgatttcgt tctctcgtac tttatgtacgacctcagatt 360 taggacaaat ggagtaccag ggaggaggag ctctatttgg tgaaaatatttctctttctg 420 agaatgctgg tgtgctcacc tttaaagaca acattgtgaa gacttttgcttcgaat 476 86 1551 DNA Chlamydia 86 gcgtatcgat atttcttctg ttacattctttatagggatt ctgttggctg ttaatgcgct 60 aacctactct catgtattac gggatttatctgtgagtatg gatgcgctgt tttctcgtaa 120 cacgcttgct gttcttttag gtttagtctctagcgtttta gataatgtgc cattagtcgc 180 tgcaacaata ggtatgtatg acttacctatgaacgatcct ctttggaaac tcattgccta 240 tacagcaggc acagggggaa gtattctcatcattggatcc gctgcaggtg ttgcctacat 300 gggaatggaa aaagtgagtt tcggctggtatgtcaaacac gcttcttgga ttgctttagc 360 cagttatttt ggaggtctag cagtctattttctaatggaa aattgtgtga atttgttcgt 420 ttgaggtagt cagtatggca gagtttctttaaaaattctt ttaataaaag ggttctctgc 480 ctattctagg cccctttttg aatggaaaaatgggtttttg gagaacatcg attatgaaaa 540 tgaataggat ttggctatta ctgcttaccttttcttctgc catacattct cctgtacgag 600 gagaaagctt ggtttgcaag aatgctcttcaagatttgag ttttttagag catttattac 660 aggttaaata tgctcctaaa acatggaaagagcaatactt aggatgggat cttgttcaaa 720 gctccgtttc tgcacagcag aagcttcgtacacaagaaaa tccatcaaca agtttttgcc 780 agcaggtcct tgctgatttt atcggaggattaaatgactt tcacgctgga gtaactttct 840 ttgcgataga aagtgcttac cttccttataccgtacaaaa aagtagtgac ggccgtttct 900 actttgtaga tatcatgact ttttcttcagagatccgtgt tggagatgag ttgctagagg 960 tggatggggc gcctgtccaa gatgtgctcgctactctata tggaagcaat cacaaaggga 1020 ctgcagctga agagtcggct gctttaagaacactattttc tcgcatggcc tctttagggc 1080 acaaagtacc ttctgggcgc actactttaaagattcgtcg tccttttggt actacgagag 1140 aagttcgtgt gaaatggcgt tatgttcctgaaggtgtagg agatttggct accatagctc 1200 cttctatcag ggctccacag ttacagaaatcgatgagaag ctttttccct aagaaagatg 1260 atgcgtttca tcggtctagt tcgctattctactctccaat ggttccgcat ttttgggcag 1320 agcttcgcaa tcattatgca acgagtggtttgaaaagcgg gtacaatatt gggagtaccg 1380 atgggtttct ccctgtcatt gggcctgttatatgggagtc ggagggtctt ttccgcgctt 1440 atatttcttc ggtgactgat ggggatggtaagagccataa agtaggattt ctaagaattc 1500 ctacatatag ttggcaggac atggaagattttgatccttc aggaccgcct c 1551 87 3031 DNA Chlamydia 87 atgtaggccctcaagcggtt ttattgttag accaaattcg agatctattc gttgggtcta 60 aagatagtcaggctgaagga cagtataggt taattgtagg agatccaagt tctttccaag 120 agaaagatgcagatactctt cccgggaagg tagagcaaag tactttgttc tcagtaacca 180 atcccgtggttttccaaggt gtggaccaac aggatcaagt ctcttcccaa gggttaattt 240 gtagttttacgagcagcaac cttgattctc cccgtgacgg agaatctttt ttaggtattg 300 cttttgttggggatagtagt aaggctggaa tcacattaac tgacgtgaaa gcttctttgt 360 ctggagcggctttatattct acagaagatc ttatctttga aaagattaag ggtggattgg 420 aatttgcatcatgttcttct ctagaacagg ggggagcttg tgcagctcaa agtattttga 480 ttcatgattgtcaaggattg caggttaaac actgtactac agccgtgaat gctgaggggt 540 ctagtgcgaatgatcatctt ggatttggag gaggcgcttt ctttgttacg ggttctcttt 600 ctggagagaaaagtctctat atgcctgcag gagatatggt agttgcgaat tgtgatgggg 660 ctatatcttttgaaggaaac agcgcgaact ttgctaatgg aggagcgatt gctgcctctg 720 ggaaagtgctttttgtcgct aatgataaaa agacttcttt tatagagaac cgagctttgt 780 ctggaggagcgattgcagcc tcttctgata ttgcctttca aaactgcgca gaactagttt 840 tcaaaggcaattgtgcaatt ggaacagagg ataaaggttc tttaggtgga ggggctatat 900 cttctctaggcaccgttctt ttgcaaggga atcacgggat aacttgtgat aataatgagt 960 ctgcttcgcaaggaggcgcc atttttggca aaaattgtca gatttctgac aacgaggggc 1020 cagtggttttcagagatagt acagcttgct taggaggagg cgctattgca gctcaagaaa 1080 ttgtttctattcagaacaat caggctggga tttccttcga gggaggtaag gctagtttcg 1140 gaggaggtattgcgtgtgga tctttttctt ccgcaggcgg tgcttctgtt ttagggacta 1200 ttgatatttcgaagaattta ggcgcgattt cgttctctcg tactttatgt acgacctcag 1260 atttaggacaaatggagtac cagggaggag gagctctatt tggtgaaaat atttctcttt 1320 ctgagaatgctggtgtgctc acctttaaag acaacattgt gaagactttt gcttcgaatg 1380 ggaaaattctgggaggagga gcgattttag ctactggtaa ggtggaaatt accaataatt 1440 ccggaggaatttcttttaca ggaaatgcga gagctccaca agctcttcca actcaagagg 1500 agtttcctttattcagcaaa aaagaagggc gaccactctc ttcaggatat tctgggggag 1560 gagcgattttaggaagagaa gtagctattc tccacaacgc tgcagtagta tttgagcaaa 1620 atcgtttgcagtgcagcgaa gaagaagcga cattattagg ttgttgtgga ggaggcgctg 1680 ttcatgggatggatagcact tcgattgttg gcaactcttc agtaagattt ggtaataatt 1740 acgcaatgggacaaggagtc tcaggaggag ctcttttatc taaaacagtg cagttagctg 1800 gaaatggaagcgtcgatttt tctcgaaata ttgctagttt gggaggacgc aatgttctgt 1860 tagcttcagaaacctttgct tccagagcaa atacatctcc ttcatcgctt cgctccttat 1920 atttccaagtaacctcatcc ccctctaatt gcgctaattt acatcaaatg cttgcttctt 1980 actcgccatcagagaaaacc gctgttatgg agtttctagt gaatggcatg gtagcagatt 2040 taaaatcggagggcccttcc attcctcctg caaaattgca agtatatatg acggaactaa 2100 gcaatctccaagccttacac tctgtagata gcttttttga tagaaatatt gggaacttgg 2160 aaaatagcttaaagcatgaa ggacatgccc ctattccatc cttaacgaca ggaaatttaa 2220 ctaaaaccttcttacaatta gtagaagata aattcccttc ctcttccaaa gctcaaaagg 2280 cattaaatgaactggtaggc ccagatactg gtcctcaaac tgaagtttta aacttattct 2340 tccgcgctcttaatggctgt tcgcctagaa tattctctgg agctgaaaaa aaacagcagc 2400 tggcatcggttatcacaaat acgctagatg cgataaatgc ggataatgag gattatccta 2460 aaccaggtgacttcccacga tcttccttct ctagtacgcc tcctcatgct ccagtacctc 2520 aatctgagattccaacgtca cctacctcaa cacagcctcc atcaccctaa cttgtaaaaa 2580 ctgtaataaaaagagcgcgc ttcctttatg caaaatcaat ttgaacaact ccttactgaa 2640 ttagggactcaaatcaacag ccctcttact cctgattcca ataatgcctg tatagttcgc 2700 tttggatacaacaatgttgc tgtacaaatt gaagaggatg gtaattcagg atttttagtt 2760 gctggagtcatgcttggaaa acttccagag aataccttta gacaaaaaat tttcaaagct 2820 gctttgtctatcaatggatc tccgcaatct aatattaaag gcactctagg atacggtgaa 2880 atctctaaccaactctatct ctgtgatcgg cttaacatga cctatctaaa tggagaaaag 2940 ctcgcccgttacttagttct tttttcgcag catgccaata tctggatgca atctatctca 3000 aaaggagaacttccagattt acatgctcta g 3031 88 976 DNA Chlamydia 88 aggtggatggggcgcctgtc caagatgtgc tcgctactct atatggaagc aatcacaaag 60 ggactgcagctgaagagtcg gctgctttaa gaacactatt ttctcgcatg gcctctttag 120 ggcacaaagtaccttctggg cgcactactt taaagattcg tcgtcctttt ggtactacga 180 gagaagttcgtgtgaaatgg cgttatgttc ctgaaggtgt aggagatttg gctaccatag 240 ctccttctatcagggctcca cagttacaga aatcgatgag aagctttttc cctaagaaag 300 atgatgcgtttcatcggtct agttcgctat tctactctcc aatggttccg catttttggg 360 cagagcttcgcaatcattat gcaacgagtg gtttgaaaag cgggtacaat attgggagta 420 ccgatgggtttctccctgtc attgggcctg ttatatggga gtcggagggt cttttccgcg 480 cttatatttcttcggtgact gatggggatg gtaagagcca taaagtagga tttctaagaa 540 ttcctacatatagttggcag gacatggaag attttgatcc ttcaggaccg cctccttggg 600 aagaatttgctaagattatt caagtatttt cttctaatac agaagctttg attatcgacc 660 aaacgaacaacccaggtggt agtgtccttt atctttatgc actgctttcc atgttgacag 720 accgtcctttagaacttcct aaacatagaa tgattctgac tcaggatgaa gtggttgatg 780 ctttagattggttaaccctg ttggaaaacg tagacacaaa cgtggagtct cgccttgctc 840 tgggagacaacatggaagga tatactgtgg atctacaggt tgccgagtat ttaaaaagct 900 ttggacgtcaagtattgaat tgttggagta aaggggatat cgagttatca acacctattc 960 ctctttttggttttga 976 89 94 PRT Chlamydia 89 Met His His His His His His Met SerGln Lys Asn Lys Asn Ser Ala 5 10 15 Phe Met His Pro Val Asn Ile Ser ThrAsp Leu Ala Val Ile Val Gly 20 25 30 Lys Gly Pro Met Pro Arg Thr Glu IleVal Lys Lys Val Trp Glu Tyr 35 40 45 Ile Lys Lys His Asn Cys Gln Asp GlnLys Asn Lys Arg Asn Ile Leu 50 55 60 Pro Asp Ala Asn Leu Ala Lys Val PheGly Ser Ser Asp Pro Ile Asp 65 70 75 80 Met Phe Gln Met Thr Lys Ala LeuSer Lys His Ile Val Lys 85 90 90 474 PRT Chlamydia 90 Met Ala Ser HisHis His His His His Met Asn Glu Ala Phe Asp Cys 5 10 15 Val Val Ile GlyAla Gly Pro Gly Gly Tyr Val Ala Ala Ile Thr Ala 20 25 30 Ala Gln Ala GlyLeu Lys Thr Ala Leu Ile Glu Lys Arg Glu Ala Gly 35 40 45 Gly Thr Cys LeuAsn Arg Gly Cys Ile Pro Ser Lys Ala Leu Leu Ala 50 55 60 Gly Ala Glu ValVal Thr Gln Ile Arg His Ala Asp Gln Phe Gly Ile 65 70 75 80 His Val GluGly Phe Ser Ile Asn Tyr Pro Ala Met Val Gln Arg Lys 85 90 95 Asp Ser ValVal Arg Ser Ile Arg Asp Gly Leu Asn Gly Leu Ile Arg 100 105 110 Ser AsnLys Ile Thr Val Phe Ser Gly Arg Gly Ser Leu Ile Ser Ser 115 120 125 ThrGlu Val Lys Ile Leu Gly Glu Asn Pro Ser Val Ile Lys Ala His 130 135 140Ser Ile Ile Leu Ala Thr Gly Ser Glu Pro Arg Ala Phe Pro Gly Ile 145 150155 160 Pro Phe Ser Ala Glu Ser Pro Arg Ile Leu Cys Ser Thr Gly Val Leu165 170 175 Asn Leu Lys Glu Ile Pro Gln Lys Met Ala Ile Ile Gly Gly GlyVal 180 185 190 Ile Gly Cys Glu Phe Ala Ser Leu Phe His Thr Leu Gly SerGlu Val 195 200 205 Ser Val Ile Glu Ala Ser Ser Gln Ile Leu Ala Leu AsnAsn Pro Asp 210 215 220 Ile Ser Lys Thr Met Phe Asp Lys Phe Thr Arg GlnGly Leu Arg Phe 225 230 235 240 Val Leu Glu Ala Ser Val Ser Asn Ile GluAsp Ile Gly Asp Arg Val 245 250 255 Arg Leu Thr Ile Asn Gly Asn Val GluGlu Tyr Asp Tyr Val Leu Val 260 265 270 Ser Ile Gly Arg Arg Leu Asn ThrGlu Asn Ile Gly Leu Asp Lys Ala 275 280 285 Gly Val Ile Cys Asp Glu ArgGly Val Ile Pro Thr Asp Ala Thr Met 290 295 300 Arg Thr Asn Val Pro AsnIle Tyr Ala Ile Gly Asp Ile Thr Gly Lys 305 310 315 320 Trp Gln Leu AlaHis Val Ala Ser His Gln Gly Ile Ile Ala Ala Arg 325 330 335 Asn Ile GlyGly His Lys Glu Glu Ile Asp Tyr Ser Ala Val Pro Ser 340 345 350 Val IlePhe Thr Phe Pro Glu Val Ala Ser Val Gly Leu Ser Pro Thr 355 360 365 AlaAla Gln Gln Gln Lys Ile Pro Val Lys Val Thr Lys Phe Pro Phe 370 375 380Arg Ala Ile Gly Lys Ala Val Ala Met Gly Glu Ala Asp Gly Phe Ala 385 390395 400 Ala Ile Ile Ser His Glu Thr Thr Gln Gln Ile Leu Gly Ala Tyr Val405 410 415 Ile Gly Pro His Ala Ser Ser Leu Ile Ser Glu Ile Thr Leu AlaVal 420 425 430 Arg Asn Glu Leu Thr Leu Pro Cys Ile Tyr Glu Thr Ile HisAla His 435 440 445 Pro Thr Leu Ala Glu Val Trp Ala Glu Ser Ala Leu LeuAla Val Asp 450 455 460 Thr Pro Leu His Met Pro Pro Ala Lys Lys 465 47091 129 PRT Chlamydia 91 Met His His His His His His Met Pro Arg Ile IleGly Ile Asp Ile 5 10 15 Pro Ala Lys Lys Lys Leu Lys Ile Ser Leu Thr TyrIle Tyr Gly Ile 20 25 30 Gly Ser Ala Arg Ser Asp Glu Ile Ile Lys Lys LeuLys Leu Asp Pro 35 40 45 Glu Ala Arg Ala Ser Glu Leu Thr Glu Glu Glu ValGly Arg Leu Asn 50 55 60 Ser Leu Leu Gln Ser Glu Tyr Thr Val Glu Gly AspLeu Arg Arg Arg 65 70 75 80 Val Gln Ser Asp Ile Lys Arg Leu Ile Ala IleHis Ser Tyr Arg Gly 85 90 95 Gln Arg His Arg Leu Ser Leu Pro Val Arg GlyGln Arg Thr Lys Thr 100 105 110 Asn Ser Arg Thr Arg Lys Gly Lys Arg LysThr Val Ala Gly Lys Lys 115 120 125 Lys 92 202 PRT Chlamydia 92 Met HisHis His His His His Met Gly Ser Leu Val Gly Arg Gln Ala 5 10 15 Pro AspPhe Ser Gly Lys Ala Val Val Cys Gly Glu Glu Lys Glu Ile 20 25 30 Ser LeuAla Asp Phe Arg Gly Lys Tyr Val Val Leu Phe Phe Tyr Pro 35 40 45 Lys AspPhe Thr Tyr Val Cys Pro Thr Glu Leu His Ala Phe Gln Asp 50 55 60 Arg LeuVal Asp Phe Glu Glu His Gly Ala Val Val Leu Gly Cys Ser 65 70 75 80 ValAsp Asp Ile Glu Thr His Ser Arg Trp Leu Thr Val Ala Arg Asp 85 90 95 AlaGly Gly Ile Glu Gly Thr Glu Tyr Pro Leu Leu Ala Asp Pro Ser 100 105 110Phe Lys Ile Ser Glu Ala Phe Gly Val Leu Asn Pro Glu Gly Ser Leu 115 120125 Ala Leu Arg Ala Thr Phe Leu Ile Asp Lys His Gly Val Ile Arg His 130135 140 Ala Val Ile Asn Asp Leu Pro Leu Gly Arg Ser Ile Asp Glu Glu Leu145 150 155 160 Arg Ile Leu Asp Ser Leu Ile Phe Phe Glu Asn His Gly MetVal Cys 165 170 175 Pro Ala Asn Trp Arg Ser Gly Glu Arg Gly Met Val ProSer Glu Glu 180 185 190 Gly Leu Lys Glu Tyr Phe Gln Thr Met Asp 195 20093 19 PRT Artificial Sequence made in a lab 93 Glu Asn Ser Leu Gln AspPro Thr Asn Lys Arg Asn Ile Asn Pro Asp 1 5 10 15 Asp Lys Leu 94 20 PRTArtificial Sequence Made in a lab 94 Asp Pro Thr Asn Lys Arg Asn Ile AsnPro Asp Asp Lys Leu Ala Lys 1 5 10 15 Val Phe Gly Thr 20 95 20 PRTArtificial Sequence Made in a lab 95 Lys Arg Asn Ile Asn Pro Asp Asp LysLeu Ala Lys Val Phe Gly Thr 1 5 10 15 Glu Lys Pro Ile 20 96 20 PRTArtificial Sequence Made in a lab 96 Asp Asp Lys Leu Ala Lys Val Phe GlyThr Glu Lys Pro Ile Asp Met 1 5 10 15 Phe Gln Met Thr 20 97 20 PRTArtificial Sequence Made in a lab 97 Lys Val Phe Gly Thr Glu Lys Pro IleAsp Met Phe Gln Met Thr Lys 1 5 10 15 Met Val Ser Gln 20 98 20 PRTArtificial Sequence Made in a lab 98 Asn Lys Arg Asn Ile Asn Pro Asp AspLys Leu Ala Lys Val Phe Gly 1 5 10 15 Thr Glu Lys Pro 20 99 16 PRTArtificial Sequence Made in a lab 99 Asn Lys Arg Asn Ile Leu Pro Asp AlaAsn Leu Ala Lys Val Phe Gly 1 5 10 15 100 15 PRT Artificial SequenceMade in a lab 100 Lys Met Trp Asp Tyr Ile Lys Glu Asn Ser Leu Gln AspPro Thr 1 5 10 15 101 20 PRT Artificial Sequence Made in a lab 101 ThrGlu Ile Val Lys Lys Val Trp Glu Tyr Ile Lys Lys His Asn Cys 1 5 10 15Gln Asp Gln Lys 20 102 20 PRT Artificial Sequence Made in a lab 102 LysVal Trp Glu Tyr Ile Lys Lys His Asn Cys Gln Asp Gln Lys Asn 1 5 10 15Lys Arg Asn Ile 20 103 15 PRT Artificial Sequence Made in a lab 103 LysVal Trp Glu Tyr Ile Lys Lys His Asn Cys Gln Asp Gln Lys 1 5 10 15 104 20PRT Artificial Sequence Made in a lab 104 Ala Glu Leu Thr Glu Glu GluVal Gly Arg Leu Asn Ala Leu Leu Gln 1 5 10 15 Ser Asp Tyr Val 20 105 21PRT Artificial Sequence Made in a lab 105 Leu Gln Ser Asp Tyr Val ValGlu Gly Asp Leu Arg Arg Arg Val Gln 1 5 10 15 Ser Asp Ile Lys Arg 20 10620 PRT Artificial Sequence Made in a lab 106 Met Pro Arg Ile Ile Gly IleAsp Ile Pro Ala Lys Lys Lys Leu Lys 1 5 10 15 Ile Ser Leu Thr 20 107 20PRT Artificial Sequence Made in a lab 107 Ala Glu Leu Thr Glu Glu GluVal Gly Arg Leu Asn Ala Leu Leu Gln 1 5 10 15 Ser Asp Tyr Val 20 108 20PRT Artificial Sequence Made in a lab 108 Leu Asn Ala Leu Leu Gln SerAsp Tyr Val Val Glu Gly Asp Leu Arg 1 5 10 15 Arg Arg Val Gln 20 109 20PRT Artificial Sequence Made in a lab 109 Leu Asn Ser Leu Leu Gln SerGlu Tyr Thr Val Glu Gly Asp Leu Arg 1 5 10 15 Arg Arg Val Gln 20 1101461 DNA Chlamydia 110 ctatctatga agttatgaat atggatctag aaacacgaagatcttttgcg gtacagcaag 60 ggcactatca ggacccaaga gcttcagatt atgacctcccacgtgctagc gactatgatt 120 tgcctagaag cccatatcct actccacctt tgccttctagatatcagcta cagaatatgg 180 atgtagaagc agggttccgt gaggcagttt atgcttcttttgtagcagga atgtacaatt 240 atgtagtgac acagccgcaa gagcgtattc ccaatagtcagcaggtggaa gggattctgc 300 gtgatatgct taccaacggg tcacagacat ttagcaacctgatgcagcgt tgggatagag 360 aagtcgatag ggaataaact ggtatctacc ataggtttgtatcaaaaaac taagcccacc 420 aagaagaaat tctctttggt gggcttcttt ttttattcaaaaaagaaagc cctcttcaag 480 attatctcgt gccgctcgtg ccgaattcgg cacgagcggcacgaggagct gtaagtaagt 540 attgccaaga gttggaagaa aaaatattag atttgtgtaagcgtcatgcc gcaacaattt 600 gctccattga ggaggatgct aaacaagaaa ttcgtcatcagacagaaagg tttaaacagc 660 ggttgcaaca aaatcagaac acttgcagtc aattaacagcagagttgtgt aaattgagat 720 ctgagaataa ggcattatcg gagcggctgc aggtgcaggcatcccgtcgt aaaaaataat 780 taaagactcc tcagatattg catctgagag ttaggggttccttttgctta cggcgcttta 840 gttctgcatg ttgcggattt atagtgattt gcgagtaaagcgccgttctg atacagtttt 900 tccgctttaa aaataaaaag gtggaaaaat gagtactactattagcggag acgcttcttc 960 tttaccgttg ccaacagctt cctgcgtaga gacaaaatctacttcgtctt caacaaaagg 1020 gaatacttgt tccaaaattt tggatatagc tttagctatcgtaggcgctt tagttgttgt 1080 cgctggggta ttagctttgg ttttgtgcgc tagcaatgtcatatttactg taataggtat 1140 tcctgcatta attattggat ctgcttgtgt gggtgcgggaatatctcgtc ttatgtatcg 1200 atcctcttat gctagcttag aagcaaaaaa tgttttggctgagcaacgtt tgcgtaatct 1260 ttcagaagag aaggacgctt tggcctccgt ctctttcattaataagatgt ttctgcgagg 1320 tcttacggac gatctccaag ctttggaagc taaggtaatggaatttgaga ttgattgttt 1380 ggacagatta gagaaaaatg agcaagcttt attgtccgatgtgcgcttag ttttatctag 1440 ctacacaaga tggttggata g 1461 111 267 DNAChlamydia 111 gtcctcttct tattatagca gaagacattg aaggcgaagc tttagctactttggtcgtga 60 acagaattcg tggaggattc cgggtttgcg cagttaaagc tccaggctttggagatagaa 120 gaaaagctat gttggaagac atcgctatct taactggcgg tcaactcattagcgaagagt 180 tgggcatgaa attagaaaac gctaacttag ctatgttagg taaagctaaaaaagttatcg 240 tttctaaaga agacacgacc atcgtcg 267 112 698 DNA Chlamydia112 tgataagcaa gcaaccgctc aactagcagc tctaactatt aaaaaaatcc tctgttttga 60tgaaaattcc tacgagaagg agctggcatg cttagaaaag aaacgcagta gcgtacaaaa 120agatctgagc caactgaaaa aatacacagt tctctacatc aagaagctgc tcgaaaccta 180cagacaactc gggcatcgaa agacaaaaat tgcaaaattt gatgacctac ctaccgagag 240agtctccgct cataagaaag caaaagaact cgctgcgctc gatcaagaag agaacttcta 300aaacgtgact cggcccttga gatccttaaa ctctcgggcc aaaaagacta cagtcttctc 360gagaagaaaa acggtgttag aaaatacgcg cgctaagact ttctctaaca atgactcaaa 420aagctgtaaa cgtatacgtt taccgctctt ccataatttc taggctgact ttcacattat 480ctcgacttgc tacggaaacc aataaagtac ggatagcctt aatagtgcgt ccttctttac 540cgataatttt accgatatct cccttagcaa cagtcaattc gtagataatc gtattggttc 600cctgcacctc tttcagatgc acttcctctg gcttatcaac aagatttttt acaatgtacg 660ctaaaaactc tttcatgcga agcaaatcct acacaagc 698 113 1142 DNA Chlamydia 113ctcttcaaag attgtgagtt tatgtgaagg cgctgtcgct gatgcaagaa tgtgcaaagc 60agagttgata aaaaaagaag cggatgctta tttgttttgt gagaaaagcg ggatatatct 120aacgaaaaaa gaaggtattt tgattccttc tgcagggatt gatgaatcga atacggacca 180gccttttgtt ttatatccta aagatatttt gggatcgtgt aatcgcatcg gagaatggtt 240aagaaattat tttcgagtga aagagctagg cgtaatcatt acagatagcc atactactcc 300aatgcggcgt ggagtactgg gtatcgggct gtgttggtat ggattttctc cattacacaa 360ctatatagga tcgctagatt gtttcggtcg tcccttacag atgacgcaaa gtaatcttgt 420agatgcctta gcagttgcgg ctgttgtttg tatgggagag gggaatgagc aaacaccgtt 480agcggtgata gagcaggcac ctaatatggt ctaccattca tatcctactt ctcgagaaga 540gtattgttct ttgcgcatag atgaaacaga ggacttatac ggaccttttt tgcaagcggt 600tacgtggagt caagaaaaga aatgatggag gtgtttatga attttttaga tcagttagat 660ttaattattc aaaataagca tatgctagaa cacacgtttt atgtgaaatg gtcgaagggg 720gagcttacta aagagcaatt acaggcgtat gccaaagact attatttaca tatcaaagcc 780tttcctaaat atttatctgc gattcatagt cgttgcgatg atttagaggc gcgtaagtta 840ttgttagata acttgatgga tgaagagaac ggttacccta atcatattga tttgtggaag 900cagtttgtgt ttgctctagg agttactcca gaagagttag aggctcatga gcctagtgaa 960gcagcaaaag cgaaagtagc tactttcatg cggtggtgta caggagattc tttagctgca 1020ggagtggctg ctttgtattc ttatgagagt caaattccac gtatcgctag agagaaaatt 1080cgtggattga ctgagtactt tggattttcc aatcctgaag actatgcata tttcacagaa 1140ca 1142 114 976 DNA Chlamydia 114 aggtggatgg ggcgcctgtc caagatgtgctcgctactct atatggaagc aatcacaaag 60 ggactgcagc tgaagagtcg gctgctttaagaacactatt ttctcgcatg gcctctttag 120 ggcacaaagt accttctggg cgcactactttaaagattcg tcgtcctttt ggtactacga 180 gagaagttcg tgtgaaatgg cgttatgttcctgaaggtgt aggagatttg gctaccatag 240 ctccttctat cagggctcca cagttacagaaatcgatgag aagctttttc cctaagaaag 300 atgatgcgtt tcatcggtct agttcgctattctactctcc aatggttccg catttttggg 360 cagagcttcg caatcattat gcaacgagtggtttgaaaag cgggtacaat attgggagta 420 ccgatgggtt tctccctgtc attgggcctgttatatggga gtcggagggt cttttccgcg 480 cttatatttc ttcggtgact gatggggatggtaagagcca taaagtagga tttctaagaa 540 ttcctacata tagttggcag gacatggaagattttgatcc ttcaggaccg cctccttggg 600 aagaatttgc taagattatt caagtattttcttctaatac agaagctttg attatcgacc 660 aaacgaacaa cccaggtggt agtgtcctttatctttatgc actgctttcc atgttgacag 720 accgtccttt agaacttcct aaacatagaatgattctgac tcaggatgaa gtggttgatg 780 ctttagattg gttaaccctg ttggaaaacgtagacacaaa cgtggagtct cgccttgctc 840 tgggagacaa catggaagga tatactgtggatctacaggt tgccgagtat ttaaaaagct 900 ttggacgtca agtattgaat tgttggagtaaaggggatat cgagttatca acacctattc 960 ctctttttgg ttttga 976 115 995 DNAChlamydia 115 ttatcctaga aatttggtgt tcaatatgag cgaaaaaaga aagtctaacaaaattattgg 60 tatcgaccta gggacgacca actcttgcgt ctctgttatg gaaggtggccaacctaaagt 120 tattgcctct tctgaaggaa ctcgtactac tccttctatc gttgcttttaaaggtggcga 180 aactcttgtt ggaattcctg caaaacgtca ggcagtaacc aatcctgaaaaaacattggc 240 ttctactaag cgattcatcg gtagaaaatt ctctgaagtc gaatctgaaattaaaacagt 300 cccctacaaa gttgctccta actcgaaagg agatgcggtc tttgatgtggaacaaaaact 360 gtacactcca gaagaaatcg gcgctcagat cctcatgaag atgaaggaaactgctgaggc 420 ttatctcgga gaaacagtaa cggaagcagt cattaccgta ccagcttactttaacgattc 480 tcaaagagct tctacaaaag atgctggacg tatcgcagga ttagatgttaaacgcattat 540 tcctgaacca acagcggccg ctcttgctta tggtattgat aaggaaggagataaaaaaat 600 cgccgtcttc gacttaggag gaggaacttt cgatatttct atcttggaaatcggtgacgg 660 agtttttgaa gttctctcaa ccaacgggga tactcacttg ggaggagacgacttcgacgg 720 agtcatcatc aactggatgc ttgatgaatt caaaaaacaa gaaggcattgatctaagcaa 780 agataacatg gctttgcaaa gattgaaaga tgctgctgaa aaagcaaaaatagaattgtc 840 tggtgtatcg tctactgaaa tcaatcagcc attcatcact atcgacgctaatggacctaa 900 acatttggct ttaactctaa ctcgcgctca attcgaacac ctagcttcctctctcattga 960 gcgaaccaaa caaccttgtg ctcaggcttt aaaag 995 116 437 DNAChlamydia 116 gtcacagcta aaggcggtgg gctttatact gataagaatc tttcgattactaacatcaca 60 ggaattatcg aaattgcaaa taacaaagcg acagatgttg gaggtggtgcttacgtaaaa 120 ggaaccctta cttgtaaaaa ctctcaccgt ctacaatttt tgaaaaactcttccgataaa 180 caaggtggag gaatctacgg agaagacaac atcaccctat ctaatttgacagggaagact 240 ctattccaag agaatactgc caaaaaagag ggcggtggac tcttcataaaaggtacagat 300 aaagctctta caatgacagg actggatagt ttctgtttaa ttaataacacatcagaaaaa 360 catggtggtg gagcctttgt taccaaagaa atctctcaga cttacacctctgatgtggaa 420 acaattccag gaatcac 437 117 446 DNA Chlamydia 117aagtttacct agaccaaact gaagatgacg aaggaaaagt tgttttatcc agagaaaaag 60caacaagaca acgacaatgg gaatacattc ttgctcactg cgaggaaggt tctattgtta 120agggacaaat tacccgaaaa gttaagggtg gtttgatcgt agatattggt atggaagcct 180tccttccagg atcccaaata gacaataaga agatcaagaa cttagatgat tacgtaggca 240aggtttgtga gttcaaaatt ctcaaaatca acgtggatcg tcggaacgtt gttgtatcta 300gaagagaact tctcgaagct gaacgcattt ctaagaaagc agagttgatc gagcaaatca 360ctatcggtga acgtcgcaaa ggtatcgtta agaatatcac agatttcgga gtattcttgg 420atcttgatgg cattgacggc ctactc 446 118 951 DNA Chlamydia 118 agtattgcgaaatattactg tgagaagcaa tgctgagagc ggttctagta aaagtgaggg 60 gagagctgtcagaagggatc gctcaggaag cgagacaacg tgtggctgat ttattaggaa 120 gattccctctttatcctgaa atcgatctgg aaacgctagt ttagtgggag actctatgcc 180 tgaaggggaaatgatgcata agttgcaaga tgtcatagat agaaagttgt tggattctcg 240 tcgtattttcttctccgaac ctgtaacgga gaaaagtgct gcagaagcca tcaaaaagct 300 ttggtatttggaactcacca atcctgggca gccaattgta tttgtcatta atagccctgg 360 agggtctgttgatgctgggt ttgctgtttg ggaccaaatt aaaatgatct cttctccttt 420 gactacagttgttacaggtt tagcagcatc tatgggatct gtattgagtt tgtgtgctgt 480 tccaggaagacgttttgcta cgcctcatgc gcgcattatg attcaccagc cttctattgg 540 aggaaccattactggtcaag ccacggactt ggatattcat gctcgtgaaa ttttaaaaac 600 aaaagcacgcattattgatg tgtatgtcga ggcaactgga caatctccag aggtgataga 660 gaaagctatcgatcgagata tgtggatgag tgcaaatgaa gcaatggagt ttggactgtt 720 agatgggattctcttctctt ttaacgactt gtagatatct tttatattct ggagcaggaa 780 acagtttcattttgggagaa tcgatgcctt ctcttgagga tgttctgttt ttatgccagg 840 aagagatggttgatgggttt ttatgtgtag agtcttctga aatagcagat gctaaactca 900 ctgtttttaatagtgatgga tctatcgcgt ctatgtgcgg gaatgggttg c 951 119 953 DNA Chlamydia119 atatcaaagt tgggcaaatg acagagccgc tcaaggacca gcaaataatc cttgggacaa 60catcaacacc tgtcgcagcc aaaatgacag cttctgatgg aatatcttta acagtctcca 120ataatccatc aaccaatgct tctattacaa ttggtttgga tgcggaaaaa gcttaccagc 180ttattctaga aaagttggga gatcaaattc ttggtggaat tgctgatact attgttgata 240gtacagtcca agatatttta gacaaaatca caacagaccc ttctctaggt ttgttgaaag 300cttttaacaa ctttccaatc actaataaaa ttcaatgcaa cgggttattc actcccagga 360acattgaaac tttattagga ggaactgaaa taggaaaatt cacagtcaca cccaaaagct 420ctgggagcat gttcttagtc tcagcagata ttattgcatc aagaatggaa ggcggcgttg 480ttctagcttt ggtacgagaa ggtgattcta agccctacgc gattagttat ggatactcat 540caggcgttcc taatttatgt agtctaagaa ccagaattat taatacagga ttgactccga 600caacgtattc attacgtgta ggcggtttag aaagcggtgt ggtatgggtt aatgcccttt 660ctaatggcaa tgatatttta ggaataacaa atacttctaa tgtatctttt ttggaggtaa 720tacctcaaac aaacgcttaa acaattttta ttggattttt cttataggtt ttatatttag 780agaaaaaagt tcgaattacg gggtttgtta tgcaaaataa aagcaaagtg agggacgatt 840ttattaaaat tgttaaagat tcctggtatc ggtctgcgat tccgactcgt ccaacatcaa 900tacaacctat taatttcccc tcgtcaaaaa taaggttatc aagtgagaaa tca 953 120 897DNA Chlamydia 120 atggcttcta tatgcggacg tttagggtct ggtacaggga atgctctaaaagcttttttt 60 acacagccca gcaataaaat ggcaagggta gtaaataaga cgaagggaatggataagact 120 gttaaggtcg ccaagtctgc tgccgaattg accgcaaata ttttggaacaagctggaggc 180 gcgggctctt ccgcacacat tacagcttcc caagtgtcca aaggattaggggatgcgaga 240 actgttctcg ctttagggaa tgcctttaac ggagcgttgc caggaacagttcaaagtgcg 300 caaagcttct tctcttacat gaaagctgct agtcagaaac cgcaagaaggggatgagggg 360 ctcgtagcag atctttgtgt gtctcataag cgcanagcgg ctgcggctgtctgtagcttc 420 atcggaggaa ttacctacct cgcgacattc ggagctatcc gtccgattctgtttgtcaac 480 aaaatgctgg cgcaaccgtt tctttcttcc caaattaaag caaatatgggatcttctgtt 540 agctatatta tggcggctaa ccatgcagcg tttgtggtgg gttctggactcgctatcagt 600 gcggaaagag cagattgcga agcccgctgc gctcgtattg cgagagaagagtcgtcactc 660 gaattgtcgg gagaggaaaa tgcttgcgag aggagagtcg ctggagagaaagccaagacg 720 ttcacgcgca tcaagtatgc actcctcact atgctcgaga agtttttggaatgcgttgcc 780 gacgttttca aattggtgcc gttgcctatt acaatgggta ttcgtgcaattgtggctgcg 840 ggatgtacgt tcacttctgc agttattgga ttgtggactt tctgcgccagagcataa 897 121 298 PRT Chlamydia 121 Met Ala Ser Ile Cys Gly Arg LeuGly Ser Gly Thr Gly Asn Ala Leu 1 5 10 15 Lys Ala Phe Phe Thr Gln ProSer Asn Lys Met Ala Arg Val Val Asn 20 25 30 Lys Thr Lys Gly Met Asp LysThr Val Lys Val Ala Lys Ser Ala Ala 35 40 45 Glu Leu Thr Ala Asn Ile LeuGlu Gln Ala Gly Gly Ala Gly Ser Ser 50 55 60 Ala His Ile Thr Ala Ser GlnVal Ser Lys Gly Leu Gly Asp Ala Arg 65 70 75 80 Thr Val Leu Ala Leu GlyAsn Ala Phe Asn Gly Ala Leu Pro Gly Thr 85 90 95 Val Gln Ser Ala Gln SerPhe Phe Ser Tyr Met Lys Ala Ala Ser Gln 100 105 110 Lys Pro Gln Glu GlyAsp Glu Gly Leu Val Ala Asp Leu Cys Val Ser 115 120 125 His Lys Arg ArgAla Ala Ala Ala Val Cys Ser Phe Ile Gly Gly Ile 130 135 140 Thr Tyr LeuAla Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn 145 150 155 160 LysMet Leu Ala Gln Pro Phe Leu Ser Ser Gln Ile Lys Ala Asn Met 165 170 175Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Phe Val 180 185190 Val Gly Ser Gly Leu Ala Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala 195200 205 Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Ser Leu Glu Leu Ser Gly210 215 220 Glu Glu Asn Ala Cys Glu Arg Arg Val Ala Gly Glu Lys Ala LysThr 225 230 235 240 Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu GluLys Phe Leu 245 250 255 Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro LeuPro Ile Thr Met 260 265 270 Gly Ile Arg Ala Ile Val Ala Ala Gly Cys ThrPhe Thr Ser Ala Val 275 280 285 Ile Gly Leu Trp Thr Phe Cys Ala Arg Ala290 295 122 897 DNA Chlamydia 122 atggcttcta tatgcggacg tttagggtctggtacaggga atgctctaaa agcttttttt 60 acacagccca gcaataaaat ggcaagggtagtaaataaga cgaagggaat ggataagact 120 gttaaggtcg ccaagtctgc tgccgaattgaccgcaaata ttttggaaca agctggaggc 180 gcgggctctt ccgcacacat tacagcttcccaagtgtcca aaggattagg ggatacgaga 240 actgttgtcg ctttagggaa tgcctttaacggagcgttgc caggaacagt tcaaagtgcg 300 caaagcttct tctctcacat gaaagctgctagtcagaaaa cgcaagaagg ggatgagggg 360 ctcacagcag atctttgtgt gtctcataagcgcagagcgg ctgcggctgt ctgtggcttc 420 atcggaggaa ttacctacct cgcgacattcggagttatcc gtccgattct gtttgtcaac 480 aaaatgctgg tgaacccgtt tctttcttcccaaactaaag caaatatggg atcttctgtt 540 agctatatta tggcggctaa ccatgcagcgtctgtggtgg gtgctggact cgctatcagt 600 gcggaaagag cagattgcga agcccgctgcgctcgtattg cgagagaaga gtcgttactc 660 gaagtgtcgg gagaggaaaa tgcttgcgagaagagagtcg ctggagagaa agccaagacg 720 ttcacgcgca tcaagtatgc actcctcactatgctcgaga agtttttgga atgcgttgcc 780 gacgttttca aattggtgcc gctgcctattacaatgggta ttcgtgcgat tgtggctgct 840 ggatgtacgt tcacttctgc aattattggattgtgcactt tctgcgccag agcataa 897 123 298 PRT Chlamydia 123 Met Ala SerIle Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu 1 5 10 15 Lys AlaPhe Phe Thr Gln Pro Ser Asn Lys Met Ala Arg Val Val Asn 20 25 30 Lys ThrLys Gly Met Asp Lys Thr Val Lys Val Ala Lys Ser Ala Ala 35 40 45 Glu LeuThr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser 50 55 60 Ala HisIle Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Thr Arg 65 70 75 80 ThrVal Val Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr 85 90 95 ValGln Ser Ala Gln Ser Phe Phe Ser His Met Lys Ala Ala Ser Gln 100 105 110Lys Thr Gln Glu Gly Asp Glu Gly Leu Thr Ala Asp Leu Cys Val Ser 115 120125 His Lys Arg Arg Ala Ala Ala Ala Val Cys Gly Phe Ile Gly Gly Ile 130135 140 Thr Tyr Leu Ala Thr Phe Gly Val Ile Arg Pro Ile Leu Phe Val Asn145 150 155 160 Lys Met Leu Val Asn Pro Phe Leu Ser Ser Gln Thr Lys AlaAsn Met 165 170 175 Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His AlaAla Ser Val 180 185 190 Val Gly Ala Gly Leu Ala Ile Ser Ala Glu Arg AlaAsp Cys Glu Ala 195 200 205 Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser LeuLeu Glu Val Ser Gly 210 215 220 Glu Glu Asn Ala Cys Glu Lys Arg Val AlaGly Glu Lys Ala Lys Thr 225 230 235 240 Phe Thr Arg Ile Lys Tyr Ala LeuLeu Thr Met Leu Glu Lys Phe Leu 245 250 255 Glu Cys Val Ala Asp Val PheLys Leu Val Pro Leu Pro Ile Thr Met 260 265 270 Gly Ile Arg Ala Ile ValAla Ala Gly Cys Thr Phe Thr Ser Ala Ile 275 280 285 Ile Gly Leu Cys ThrPhe Cys Ala Arg Ala 290 295 124 897 DNA Chlamydia 124 atggcttctatatgcggacg tttagggtct ggtacaggga atgctctaaa agcttttttt 60 acacagcccaacaataaaat ggcaagggta gtaaataaga cgaagggaat ggataagact 120 attaaggttgccaagtctgc tgccgaattg accgcaaata ttttggaaca agctggaggc 180 gcgggctcttccgcacacat tacagcttcc caagtgtcca aaggattagg ggatgcgaga 240 actgttgtcgctttagggaa tgcctttaac ggagcgttgc caggaacagt tcaaagtgcg 300 caaagcttcttctctcacat gaaagctgct agtcagaaaa cgcaagaagg ggatgagggg 360 ctcacagcagatctttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtagcatc 420 atcggaggaattacctacct cgcgacattc ggagctatcc gtccgattct gtttgtcaac 480 aaaatgctggcaaaaccgtt tctttcttcc caaactaaag caaatatggg atcttctgtt 540 agctatattatggcggctaa ccatgcagcg tctgtggtgg gtgctggact cgctatcagt 600 gcggaaagagcagattgcga agcccgctgc gctcgtattg cgagagaaga gtcgttactc 660 gaagtgccgggagaggaaaa tgcttgcgag aagaaagtcg ctggagagaa agccaagacg 720 ttcacgcgcatcaagtatgc actcctcact atgctcgaga agtttttgga atgcgttgcc 780 gacgttttcaaattggtgcc gctgcctatt acaatgggta ttcgtgcgat tgtggctgct 840 ggatgtacgttcacttctgc aattattgga ttgtgcactt tctgcgccag agcataa 897 125 298 PRTChlamydia 125 Met Ala Ser Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly AsnAla Leu 1 5 10 15 Lys Ala Phe Phe Thr Gln Pro Asn Asn Lys Met Ala ArgVal Val Asn 20 25 30 Lys Thr Lys Gly Met Asp Lys Thr Ile Lys Val Ala LysSer Ala Ala 35 40 45 Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly AlaGly Ser Ser 50 55 60 Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu GlyAsp Ala Arg 65 70 75 80 Thr Val Val Ala Leu Gly Asn Ala Phe Asn Gly AlaLeu Pro Gly Thr 85 90 95 Val Gln Ser Ala Gln Ser Phe Phe Ser His Met LysAla Ala Ser Gln 100 105 110 Lys Thr Gln Glu Gly Asp Glu Gly Leu Thr AlaAsp Leu Cys Val Ser 115 120 125 His Lys Arg Arg Ala Ala Ala Ala Val CysSer Ile Ile Gly Gly Ile 130 135 140 Thr Tyr Leu Ala Thr Phe Gly Ala IleArg Pro Ile Leu Phe Val Asn 145 150 155 160 Lys Met Leu Ala Lys Pro PheLeu Ser Ser Gln Thr Lys Ala Asn Met 165 170 175 Gly Ser Ser Val Ser TyrIle Met Ala Ala Asn His Ala Ala Ser Val 180 185 190 Val Gly Ala Gly LeuAla Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala 195 200 205 Arg Cys Ala ArgIle Ala Arg Glu Glu Ser Leu Leu Glu Val Pro Gly 210 215 220 Glu Glu AsnAla Cys Glu Lys Lys Val Ala Gly Glu Lys Ala Lys Thr 225 230 235 240 PheThr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu 245 250 255Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met 260 265270 Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Ile 275280 285 Ile Gly Leu Cys Thr Phe Cys Ala Arg Ala 290 295 126 897 DNAChlamydia 126 atggcttcta tatgcggacg tttagggtct ggtacaggga atgctctaaaagcttttttt 60 acacagccca acaataaaat ggcaagggta gtaaataaga cgaagggaatggataagact 120 attaaggttg ccaagtctgc tgccgaattg accgcaaata ttttggaacaagctggaggc 180 gcgggctctt ccgcacacat tacagcttcc caagtgtcca aaggattaggggatgcgaga 240 actgttgtcg ctttagggaa tgcctttaac ggagcgttgc caggaacagttcaaagtgcg 300 caaagcttct tctctcacat gaaagctgct agtcagaaaa cgcaagaaggggatgagggg 360 ctcacagcag atctttgtgt gtctcataag cgcagagcgg ctgcggctgtctgtagcatc 420 atcggaggaa ttacctacct cgcgacattc ggagctatcc gtccgattctgtttgtcaac 480 aaaatgctgg caaaaccgtt tctttcttcc caaactaaag caaatatgggatcttctgtt 540 agctatatta tggcggctaa ccatgcagcg tctgtggtgg gtgctggactcgctatcagt 600 gcggaaagag cagattgcga agcccgctgc gctcgtattg cgagagaagagtcgttactc 660 gaagtgccgg gagaggaaaa tgcttgcgag aagaaagtcg ctggagagaaagccaagacg 720 ttcacgcgca tcaagtatgc actcctcact atgctcgaga agtttttggaatgcgttgcc 780 gacgttttca aattggtgcc gctgcctatt acaatgggta ttcgtgcgattgtggctgct 840 ggatgtacgt tcacttctgc aattattgga ttgtgcactt tctgcgccagagcataa 897 127 298 PRT Chlamydia 127 Met Ala Ser Ile Cys Gly Arg LeuGly Ser Gly Thr Gly Asn Ala Leu 1 5 10 15 Lys Ala Phe Phe Thr Gln ProAsn Asn Lys Met Ala Arg Val Val Asn 20 25 30 Lys Thr Lys Gly Met Asp LysThr Ile Lys Val Ala Lys Ser Ala Ala 35 40 45 Glu Leu Thr Ala Asn Ile LeuGlu Gln Ala Gly Gly Ala Gly Ser Ser 50 55 60 Ala His Ile Thr Ala Ser GlnVal Ser Lys Gly Leu Gly Asp Ala Arg 65 70 75 80 Thr Val Val Ala Leu GlyAsn Ala Phe Asn Gly Ala Leu Pro Gly Thr 85 90 95 Val Gln Ser Ala Gln SerPhe Phe Ser His Met Lys Ala Ala Ser Gln 100 105 110 Lys Thr Gln Glu GlyAsp Glu Gly Leu Thr Ala Asp Leu Cys Val Ser 115 120 125 His Lys Arg ArgAla Ala Ala Ala Val Cys Ser Ile Ile Gly Gly Ile 130 135 140 Thr Tyr LeuAla Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn 145 150 155 160 LysMet Leu Ala Lys Pro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met 165 170 175Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Ser Val 180 185190 Val Gly Ala Gly Leu Ala Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala 195200 205 Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Leu Leu Glu Val Pro Gly210 215 220 Glu Glu Asn Ala Cys Glu Lys Lys Val Ala Gly Glu Lys Ala LysThr 225 230 235 240 Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu GluLys Phe Leu 245 250 255 Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro LeuPro Ile Thr Met 260 265 270 Gly Ile Arg Ala Ile Val Ala Ala Gly Cys ThrPhe Thr Ser Ala Ile 275 280 285 Ile Gly Leu Cys Thr Phe Cys Ala Arg Ala290 295 128 897 DNA Chlamydia 128 atggcttcta tatgtggacg tttagggtctggtacaggga atgctctaaa agcttttttt 60 acacagccca gcaataaaat ggcaagggtagtaaataaga cgaagggaat ggataagact 120 gttaaggtcg ccaagtctgc tgccgaattgaccgcaaata ttttggaaca agctggaggc 180 gcgggctctt ccgcacacat tacagcttcccaagtgtcca aaggattagg ggatacgaga 240 actgttgtcg ctttagggaa tgcctttaacggagcgttgc caggaacagt tcaaagtgcg 300 caaagcttct tctctcacat gaaagctgctagtcagaaaa cgcaagaagg ggatgagggg 360 ctcacagcag atctttgtgt gtctcataagcgcagagcgg ctgcggctgt ctgtggcttc 420 atcggaggaa ttacctacct cgcgacattcggagttatcc gtccgattct gtttgtcaac 480 aaaatgctgg tgaacccgtt tctttcttcccaaactaaag caaatatggg atcttctgtt 540 agctatatta tggcggctaa ccatgcagcgtctgtggtgg gtgctggact cgctatcagt 600 gcggaaagag cagattgcga agcccgctgcgctcgtattg cgagagaaga gtcgttactc 660 gaagtgtcgg gagaggaaaa tgcttgcgagaagagagtcg ctggagagaa agccaagacg 720 ttcacgcgca tcaagtatgc actcctcactatgctcgaga agtttttgga atgcgttgcc 780 gacgttttca aattggtgcc gctgcctattacaatgggta ttcgtgcgat tgtggctgct 840 ggatgtacgt tcacttctgc aattattggattgtgcactt tctgcgccag agcataa 897 129 298 PRT Chlamydia 129 Met Ala SerIle Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu 1 5 10 15 Lys AlaPhe Phe Thr Gln Pro Ser Asn Lys Met Ala Arg Val Val Asn 20 25 30 Lys ThrLys Gly Met Asp Lys Thr Val Lys Val Ala Lys Ser Ala Ala 35 40 45 Glu LeuThr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser 50 55 60 Ala HisIle Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Thr Arg 65 70 75 80 ThrVal Val Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr 85 90 95 ValGln Ser Ala Gln Ser Phe Phe Ser His Met Lys Ala Ala Ser Gln 100 105 110Lys Thr Gln Glu Gly Asp Glu Gly Leu Thr Ala Asp Leu Cys Val Ser 115 120125 His Lys Arg Arg Ala Ala Ala Ala Val Cys Gly Phe Ile Gly Gly Ile 130135 140 Thr Tyr Leu Ala Thr Phe Gly Val Ile Arg Pro Ile Leu Phe Val Asn145 150 155 160 Lys Met Leu Val Asn Pro Phe Leu Ser Ser Gln Thr Lys AlaAsn Met 165 170 175 Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His AlaAla Ser Val 180 185 190 Val Gly Ala Gly Leu Ala Ile Ser Ala Glu Arg AlaAsp Cys Glu Ala 195 200 205 Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser LeuLeu Glu Val Ser Gly 210 215 220 Glu Glu Asn Ala Cys Glu Lys Arg Val AlaGly Glu Lys Ala Lys Thr 225 230 235 240 Phe Thr Arg Ile Lys Tyr Ala LeuLeu Thr Met Leu Glu Lys Phe Leu 245 250 255 Glu Cys Val Ala Asp Val PheLys Leu Val Pro Leu Pro Ile Thr Met 260 265 270 Gly Ile Arg Ala Ile ValAla Ala Gly Cys Thr Phe Thr Ser Ala Ile 275 280 285 Ile Gly Leu Cys ThrPhe Cys Ala Arg Ala 290 295 130 897 DNA Chlamydia 130 atggctgctatatgtggacg tttagggtct ggtacaggga atgctctaaa agcttttttt 60 acacagcccagcaataaaat ggcaagggta gtaaataaga cgaagggaat ggataagact 120 gttaaggtcgccaagtctgc tgccgaattg accgcaaata ttttggaaca agctggaggc 180 gcgggctcttccgcacacat tacagcttcc caagtgtcca aaggattagg ggatgcgaga 240 actgttctcgctttagggaa tgcctttaac ggagcgttgc caggaacagt tcaaagtgcg 300 caaagcttcttctcttacat gaaagctgct agtcagaaac cgcaagaagg ggatgagggg 360 ctcgtagcagatctttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtagcttc 420 atcggaggaattacctacct cgcgacattc ggagctatcc gtccgattct gtttgtcaac 480 aaaatgctggcgcaaccgtt tctttcttcc caaactaaag caaatatggg atcttctgtt 540 agctatattatggcggctaa ccatgcagcg tttgtggtgg gttctggact cgctatcagt 600 gcggaaagagcagattgcga agcccgctgc gctcgtattg cgagagaaga gtcgtcactc 660 gaattgtcgggagaggaaaa tgcttgcgag aggggagtcg ctggagagaa agccaagacg 720 ttcacgcgcatcaagtatgc actcctcact atgctcgaga agtttttgga atgcgttgcc 780 gacgttttcaaattggtgcc gttgcctatt acaatgggta ttcgtgcaat tgtggctgcg 840 ggatgtacgttcacttctgc agttattgga ttgtggactt tctgcaacag agtataa 897 131 298 PRTChlamydia 131 Met Ala Ala Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly AsnAla Leu 1 5 10 15 Lys Ala Phe Phe Thr Gln Pro Ser Asn Lys Met Ala ArgVal Val Asn 20 25 30 Lys Thr Lys Gly Met Asp Lys Thr Val Lys Val Ala LysSer Ala Ala 35 40 45 Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly AlaGly Ser Ser 50 55 60 Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu GlyAsp Ala Arg 65 70 75 80 Thr Val Leu Ala Leu Gly Asn Ala Phe Asn Gly AlaLeu Pro Gly Thr 85 90 95 Val Gln Ser Ala Gln Ser Phe Phe Ser Tyr Met LysAla Ala Ser Gln 100 105 110 Lys Pro Gln Glu Gly Asp Glu Gly Leu Val AlaAsp Leu Cys Val Ser 115 120 125 His Lys Arg Arg Ala Ala Ala Ala Val CysSer Phe Ile Gly Gly Ile 130 135 140 Thr Tyr Leu Ala Thr Phe Gly Ala IleArg Pro Ile Leu Phe Val Asn 145 150 155 160 Lys Met Leu Ala Gln Pro PheLeu Ser Ser Gln Thr Lys Ala Asn Met 165 170 175 Gly Ser Ser Val Ser TyrIle Met Ala Ala Asn His Ala Ala Phe Val 180 185 190 Val Gly Ser Gly LeuAla Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala 195 200 205 Arg Cys Ala ArgIle Ala Arg Glu Glu Ser Ser Leu Glu Leu Ser Gly 210 215 220 Glu Glu AsnAla Cys Glu Arg Gly Val Ala Gly Glu Lys Ala Lys Thr 225 230 235 240 PheThr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu 245 250 255Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met 260 265270 Gly Ile Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Val 275280 285 Ile Gly Leu Trp Thr Phe Cys Asn Arg Val 290 295 132 897 DNAChlamydia 132 atggctgcta tatgcggacg tttagggtct ggtacaggga atgctctaaaagcttttttt 60 acacagccca gcaataaaat ggcaagggta gtaaataaga cgaagggaatggataagact 120 gttaaggtcg ccaagtctgc tgccgaattg accgcaaata ttttggaacaagctggaggc 180 gcgggctctt ccgcacacat tacagcttcc caagtgtcca aaggattaggggatgcgaga 240 actgttctcg ctttagggaa tgcctttaac ggagcgttgc caggaacagttcaaagtgcg 300 caaagcttct tctcttacat gaaagctgct agtcagaaac cgcaagaaggggatgagggg 360 ctcgtagcag atctttgtgt gtctcataag cgcagagcgg ctgcggctgtctgtagcttc 420 atcggaggaa ttacctacct cgcgacattc ggagctatcc gtccgattctgtttgtcaac 480 aaaatgctgg cgcaaccgtt tctttcttcc caaactaaag caaatatgggatcttctgtt 540 agctatatta tggcggctaa ccatgcagcg tttgtggtgg gttctggactcgctatcagt 600 gcggaaagag cagattgcga agcccgctgc gctcgtattg cgagagaagagtcgtcactc 660 gaattgtcgg gagaggaaaa tgcttgtgag aggagagtcg ctggagagaaagccaagacg 720 ttcacgcgca tcaagtatgc actcctcact atgctcgaga agtttttggaatgcgttgcc 780 gacgttttca aattggtgcc gttgcctatt acaatgggta ttcgtgcaattgtggctgcg 840 ggatgtacgt tcacttctgc agttattgga ttgtggactt tctgcaacagagtataa 897 133 298 PRT Chlamydia 133 Met Ala Ala Ile Cys Gly Arg LeuGly Ser Gly Thr Gly Asn Ala Leu 1 5 10 15 Lys Ala Phe Phe Thr Gln ProSer Asn Lys Met Ala Arg Val Val Asn 20 25 30 Lys Thr Lys Gly Met Asp LysThr Val Lys Val Ala Lys Ser Ala Ala 35 40 45 Glu Leu Thr Ala Asn Ile LeuGlu Gln Ala Gly Gly Ala Gly Ser Ser 50 55 60 Ala His Ile Thr Ala Ser GlnVal Ser Lys Gly Leu Gly Asp Ala Arg 65 70 75 80 Thr Val Leu Ala Leu GlyAsn Ala Phe Asn Gly Ala Leu Pro Gly Thr 85 90 95 Val Gln Ser Ala Gln SerPhe Phe Ser Tyr Met Lys Ala Ala Ser Gln 100 105 110 Lys Pro Gln Glu GlyAsp Glu Gly Leu Val Ala Asp Leu Cys Val Ser 115 120 125 His Lys Arg ArgAla Ala Ala Ala Val Cys Ser Phe Ile Gly Gly Ile 130 135 140 Thr Tyr LeuAla Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn 145 150 155 160 LysMet Leu Ala Gln Pro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met 165 170 175Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala Ala Phe Val 180 185190 Val Gly Ser Gly Leu Ala Ile Ser Ala Glu Arg Ala Asp Cys Glu Ala 195200 205 Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Ser Leu Glu Leu Ser Gly210 215 220 Glu Glu Asn Ala Cys Glu Arg Arg Val Ala Gly Glu Lys Ala LysThr 225 230 235 240 Phe Thr Arg Ile Lys Tyr Ala Leu Leu Thr Met Leu GluLys Phe Leu 245 250 255 Glu Cys Val Ala Asp Val Phe Lys Leu Val Pro LeuPro Ile Thr Met 260 265 270 Gly Ile Arg Ala Ile Val Ala Ala Gly Cys ThrPhe Thr Ser Ala Val 275 280 285 Ile Gly Leu Trp Thr Phe Cys Asn Arg Val290 295 134 897 DNA Chlamydia 134 atggcttcta tatgcggacg tttagggtctggtacaggga atgctctaaa agcttttttt 60 acacagccca acaataaaat ggcaagggtagtaaataaga cgaagggaat ggataagact 120 attaaggttg ccaagtctgc tgccgaattgaccgcaaata ttttggaaca agctggaggc 180 gcgggctctt ccgcacacat tacagcttcccaagtgtcca aaggattagg ggatgcgaga 240 actgttgtcg ctttagggaa tgcctttaacggagcgttgc caggaacagt tcaaagtgcg 300 caaagcttct tctctcacat gaaagctgctagtcagaaaa cgcaagaagg ggatgagggg 360 ctcacagcag atctttgtgt gtctcataagcgcagagcgg ctgcggctgt ctgtagcatc 420 atcggaggaa ttacctacct cgcgacattcggagctatcc gtccgattct gtttgtcaac 480 aaaatgctgg caaaaccgtt tctttcttcccaaactaaag caaatatggg atcttctgtt 540 agctatatta tggcggctaa ccatgcagcgtctgtggtgg gtgctggact cgctatcagt 600 gcggaaagag cagattgcga agcccgctgcgctcgtattg cgagagaaga gtcgttactc 660 gaaatgccgg gagaggaaaa tgcttgcgagaagaaagtcg ctggagagaa agccaagacg 720 ttcacgcgca tcaagtatgc actcctcactatgctcgaga agtttttgga atgcgttgcc 780 gacgttttca aattggtgcc gctgcctattacaatgggta ttcgtgcgat tgtggctgct 840 ggatgtacgt tcacttctgc aattattggattgtgcactt tctgcgccag agcataa 897 135 298 PRT Chlamydia 135 Met Ala SerIle Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu 1 5 10 15 Lys AlaPhe Phe Thr Gln Pro Asn Asn Lys Met Ala Arg Val Val Asn 20 25 30 Lys ThrLys Gly Met Asp Lys Thr Ile Lys Val Ala Lys Ser Ala Ala 35 40 45 Glu LeuThr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser 50 55 60 Ala HisIle Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Ala Arg 65 70 75 80 ThrVal Val Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr 85 90 95 ValGln Ser Ala Gln Ser Phe Phe Ser His Met Lys Ala Ala Ser Gln 100 105 110Lys Thr Gln Glu Gly Asp Glu Gly Leu Thr Ala Asp Leu Cys Val Ser 115 120125 His Lys Arg Arg Ala Ala Ala Ala Val Cys Ser Ile Ile Gly Gly Ile 130135 140 Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn145 150 155 160 Lys Met Leu Ala Lys Pro Phe Leu Ser Ser Gln Thr Lys AlaAsn Met 165 170 175 Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His AlaAla Ser Val 180 185 190 Val Gly Ala Gly Leu Ala Ile Ser Ala Glu Arg AlaAsp Cys Glu Ala 195 200 205 Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser LeuLeu Glu Met Pro Gly 210 215 220 Glu Glu Asn Ala Cys Glu Lys Lys Val AlaGly Glu Lys Ala Lys Thr 225 230 235 240 Phe Thr Arg Ile Lys Tyr Ala LeuLeu Thr Met Leu Glu Lys Phe Leu 245 250 255 Glu Cys Val Ala Asp Val PheLys Leu Val Pro Leu Pro Ile Thr Met 260 265 270 Gly Ile Arg Ala Ile ValAla Ala Gly Cys Thr Phe Thr Ser Ala Ile 275 280 285 Ile Gly Leu Cys ThrPhe Cys Ala Arg Ala 290 295 136 882 DNA Chlamydia 136 atggcttctgtatgtgggcg attaagtgct ggggtgggga acagatttaa cgcatttttc 60 acgcgtcccggtaacaagct atcacggttt gtaaatagcg caaaaggatt agacagatca 120 ataaaggttgggaagtctgc tgctgaatta acggcgagta ttttagagca aactgggggg 180 gcagggactgatgcacatgt tacggcggcc aaggtgtcta aagcacttgg ggacgcgcga 240 acagtaatggctctagggaa tgtcttcaat gggtctgtgc cagcaaccat tcaaagtgcg 300 cgaagctgtctcgcccattt acgagcggcc ggcaaagaag aagaaacatg ctccaaggtg 360 aaagatctctgtgtttctca tagacgaaga gctgcggctg aggcttgtaa tgttattgga 420 ggagcaacttatattacaac tttcggagcg attcgtccga cattactcgt taacaagctt 480 cttgccaaaccattcctttc ctcccaagcc aaagaagggt tgggagcttc tgttggttat 540 atcatggcagcgaaccatgc ggcatctgtg cttgggtctg ctttaagtat tagcgcagaa 600 agagcagactgtgaagagcg gtgtgatcgc attcgatgta gtgaggatgg tgaaatttgc 660 gaaggcaataaattaacagc tatttcggaa gagaaggcta gatcatggac tctcattaag 720 tacagattccttactatgat agaaaaacta tttgagatgg tggcggatat cttcaagtta 780 attcctttgccaatttcgca tggaattcgt gctattgttg ctgcgggatg tacgttgact 840 tctgcagttattggcttagg tactttttgg tctagagcat aa 882 137 293 PRT Chlamydia 137 MetAla Ser Val Cys Gly Arg Leu Ser Ala Gly Val Gly Asn Arg Phe 1 5 10 15Asn Ala Phe Phe Thr Arg Pro Gly Asn Lys Leu Ser Arg Phe Val Asn 20 25 30Ser Ala Lys Gly Leu Asp Arg Ser Ile Lys Val Gly Lys Ser Ala Ala 35 40 45Glu Leu Thr Ala Ser Ile Leu Glu Gln Thr Gly Gly Ala Gly Thr Asp 50 55 60Ala His Val Thr Ala Ala Lys Val Ser Lys Ala Leu Gly Asp Ala Arg 65 70 7580 Thr Val Met Ala Leu Gly Asn Val Phe Asn Gly Ser Val Pro Ala Thr 85 9095 Ile Gln Ser Ala Arg Ser Cys Leu Ala His Leu Arg Ala Ala Gly Lys 100105 110 Glu Glu Glu Thr Cys Ser Lys Val Lys Asp Leu Cys Val Ser His Arg115 120 125 Arg Arg Ala Ala Ala Glu Ala Cys Asn Val Ile Gly Gly Ala ThrTyr 130 135 140 Ile Thr Thr Phe Gly Ala Ile Arg Pro Thr Leu Leu Val AsnLys Leu 145 150 155 160 Leu Ala Lys Pro Phe Leu Ser Ser Gln Ala Lys GluGly Leu Gly Ala 165 170 175 Ser Val Gly Tyr Ile Met Ala Ala Asn His AlaAla Ser Val Leu Gly 180 185 190 Ser Ala Leu Ser Ile Ser Ala Glu Arg AlaAsp Cys Glu Glu Arg Cys 195 200 205 Asp Arg Ile Arg Cys Ser Glu Asp GlyGlu Ile Cys Glu Gly Asn Lys 210 215 220 Leu Thr Ala Ile Ser Glu Glu LysAla Arg Ser Trp Thr Leu Ile Lys 225 230 235 240 Tyr Arg Phe Leu Thr MetIle Glu Lys Leu Phe Glu Met Val Ala Asp 245 250 255 Ile Phe Lys Leu IlePro Leu Pro Ile Ser His Gly Ile Arg Ala Ile 260 265 270 Val Ala Ala GlyCys Thr Leu Thr Ser Ala Val Ile Gly Leu Gly Thr 275 280 285 Phe Trp SerArg Ala 290 138 16 PRT Artificial Sequence Made in a lab 138 Asp Leu CysVal Ser His Lys Arg Arg Ala Ala Ala Ala Val Cys Ser 1 5 10 15 139 16 PRTArtificial Sequence Made in a lab 139 Arg Ala Ala Ala Ala Val Cys SerPhe Ile Gly Gly Ile Thr Tyr Leu 1 5 10 15 140 18 PRT Artificial SequenceMade in a lab 140 Cys Ser Phe Ile Gly Gly Ile Thr Tyr Leu Ala Thr PheGly Ala Ile 1 5 10 15 Arg Pro 141 18 PRT Artificial Sequence Made in alab 141 Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn Lys1 5 10 15 Met Leu 142 18 PRT Artificial Sequence Made in a lab 142 ArgPro Ile Leu Phe Val Asn Lys Met Leu Ala Gln Pro Phe Leu Ser 1 5 10 15Ser Gln 143 17 PRT Artificial Sequence Made in a lab 143 Met Leu Ala GlnPro Phe Leu Ser Ser Gln Thr Lys Ala Asn Met Gly 1 5 10 15 Ser 144 10 PRTArtificial Sequence Made in a lab 144 Cys Ser Phe Ile Gly Gly Ile ThrTyr Leu 1 5 10 145 9 PRT Artificial Sequence Made in a lab 145 Ser PheIle Gly Gly Ile Thr Tyr Leu 1 5 146 8 PRT Artificial Sequence Made in alab 146 Phe Ile Gly Gly Ile Thr Tyr Leu 1 5 147 9 PRT ArtificialSequence Made in a lab 147 Cys Ser Phe Ile Gly Gly Ile Thr Tyr 1 5 148 8PRT Artificial Sequence Made in a lab 148 Cys Ser Phe Ile Gly Gly IleThr 1 5 149 10 PRT Artificial Sequence Made in a lab 149 Cys Ser Ile IleGly Gly Ile Thr Tyr Leu 1 5 10 150 10 PRT Artificial Sequence Made in alab 150 Cys Gly Phe Ile Gly Gly Ile Thr Tyr Leu 1 5 10 151 9 PRTArtificial Sequence Made in a lab 151 Gly Phe Ile Gly Gly Ile Thr TyrLeu 1 5 152 20 PRT Artificial Sequence Made in a lab 152 Gln Ile Phe ValCys Leu Ile Ser Ala Glu Arg Leu Arg Leu Arg Leu 1 5 10 15 Ser Val AlaSer 20 153 20 PRT Artificial Sequence Made in a lab 153 Glu Arg Leu ArgLeu Arg Leu Ser Val Ala Ser Ser Glu Glu Leu Pro 1 5 10 15 Thr Ser ArgHis 20 154 20 PRT Artificial Sequence Made in a lab 154 Ala Ser Ser GluGlu Leu Pro Thr Ser Arg His Ser Glu Leu Ser Val 1 5 10 15 Arg Phe CysLeu 20 155 20 PRT Artificial Sequence Made in a lab 155 Arg His Ser GluLeu Ser Val Arg Phe Cys Leu Ser Thr Lys Cys Trp 1 5 10 15 Arg Asn ArgPhe 20 156 20 PRT Artificial Sequence Made in a lab 156 Leu Ser Thr LysCys Trp Arg Asn Arg Phe Phe Leu Pro Lys Leu Lys 1 5 10 15 Gln Ile TrpAsp 20 157 53 PRT Artificial Sequence Made in a lab 157 Ile Phe Val CysLeu Ile Ser Ala Glu Arg Leu Arg Leu Ser Val Ala 1 5 10 15 Ser Ser GluGlu Leu Pro Thr Ser Arg His Ser Glu Leu Ser Val Arg 20 25 30 Phe Cys LeuSer Thr Lys Cys Trp Arg Asn Arg Phe Phe Leu Pro Lys 35 40 45 Leu Lys GlnIle Trp 50 158 52 PRT Artificial Sequence Made in a lab 158 Leu Cys ValSer His Lys Arg Arg Ala Ala Ala Ala Val Cys Ser Phe 1 5 10 15 Ile GlyGly Ile Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile 20 25 30 Leu PheVal Asn Lys Met Leu Ala Gln Pro Phe Leu Ser Ser Gln Ile 35 40 45 Lys AlaAsn Met 50 159 24 DNA Chlamydia 159 ttttgaagca ggtaggtgaa tatg 24 160 24DNA Chlamydia 160 ttaagaaatt taaaaaatcc ctta 24 161 24 DNA Chlamydia 161ggtataatat ctctctaaat tttg 24 162 19 DNA Chlamydia 162 agataaaaaaggctgtttc 19 163 24 DNA Chlamydia 163 ttttgaagca ggtaggtgaa tatg 24 16429 DNA Chlamydia 164 tttacaataa gaaaagctaa gcactttgt 29 165 20 DNAChlamydia 165 ccttacacag tcctgctgac 20 166 20 DNA Chlamydia 166gtttccgggc cctcacattg 20 167 9 PRT Artificial Sequence Made in a lab 167Ser Phe Ile Gly Gly Ile Thr Tyr Leu 1 5 168 9 PRT Artificial SequenceMade in a lab 168 Ser Ile Ile Gly Gly Ile Thr Tyr Leu 1 5 169 2643 DNAChlamydia 169 gcaatcatgc gacctgatca tatgaacttc tgttgtctat gtgctgctattttgtcatcc 60 acagcggtcc tctttggcca ggatccctta ggtgaaaccg ccctcctcactaaaaatcct 120 aatcatgtcg tctgtacatt ttttgaggac tgtaccatgg agagcctctttcctgctctt 180 tgtgctcatg catcacaaga cgatcctttg tatgtacttg gaaattcctactgttggttc 240 gtatctaaac tccatatcac ggaccccaaa gaggctcttt ttaaagaaaaaggagatctt 300 tccattcaaa actttcgctt cctttccttc acagattgct cttccaaggaaagctctcct 360 tctattattc atcaaaagaa tggtcagtta tccttgcgca ataatggtagcatgagtttc 420 tgtcgaaatc atgctgaagg ctctggagga gccatctctg cggatgccttttctctacag 480 cacaactatc ttttcacagc ttttgaagag aattcttcta aaggaaatggcggagccatt 540 caggctcaaa ccttctcttt atctagaaat gtgtcgccta tttctttcgcccgtaatcgt 600 gcggatttaa atggcggcgc tatttgctgt agtaatctta tttgttcagggaatgtaaac 660 cctctctttt tcactggaaa ctccgccacg aatggaggcg ctatttgttgtatcagcgat 720 ctaaacacct cagaaaaagg ctctctctct cttgcttgta accaagaaacgctatttgca 780 agcaattctg ctaaagaaaa aggcggggct atttatgcca agcacatggtattgcgttat 840 aacggtcctg tttccttcat taacaacagc gctaaaatag gtggagctatcgccatccag 900 tccggaggga gtctctctat ccttgcaggt gaaggatctg ttctgttccagaataactcc 960 caacgcacct ccgaccaagg tctagtaaga aacgccatct acttaragaaagatgcgatt 1020 ctttcttcct tagaagctcg caacggagat attcttttct ttgatcctattgtacaagaa 1080 agtagcagca aagaatcgcc tcttccctcc tctttgcaag ccagcgtgacttctcccacc 1140 ccagccaccg catctccttt agttattcag acaagtgcaa accgttcagtgattttctcg 1200 agcgaacgtc tttctgaaga agaaaaaact cctgataacc tcacttcccaactacagcag 1260 cctatcgaac tgaaatccgg acgcttagtt ttaaaagatc gcgctgtcctttccgcgcct 1320 tctctctctc aggatcctca agctctcctc attatggaag cgggaacttctttaaaaact 1380 tcctctgatt tgaagttagc tacgctaagt attccccttc attccttagatactgaaaaa 1440 agcgtaacta tccacgcccc taatctttct atccaaaaga tcttcctctctaactctgga 1500 gatgagaatt tttatgaaaa tgtagagctt ctcagtaaag agcaaaacaatattcctctc 1560 cttactctcc ctaaagagca atctcattta catcttcctg atgggaacctctcttctcac 1620 tttggatatc aaggagattg gactttttct tggaaagatt ctgatgaagggcattctctg 1680 attgctaatt ggacgcctaa aaactatgtg cctcatccag aacgtcaatctacactcgtt 1740 gcgaacactc tttggaacac ctattccgat atgcaagctg tgcagtcgatgattaataca 1800 acagcgcacg gaggagccta tctatttgga acgtggggat ctgctgtttctaatttattc 1860 tatgttcacg acagctctgg gaaacctatc gataattggc atcatagaagccttggctac 1920 ctattcggta tcagtactca cagtttagat gaccattctt tctgcttggctgcaggacaa 1980 ttactcggga aatcgtccga ttcctttatt acgtctacag aaacgacctcctatatagct 2040 actgtacaag cgcaactcgc tacctctcta atgaaaatct ctgcacaggcatgctacaat 2100 gaaagtatcc atgagctaaa aacaaaatat cgctccttct ctaaagaaggattcggatcc 2160 tggcatagcg ttgcagtatc cggagaagtg tgcgcatcga ttcctattgtatccaatggt 2220 tccggactgt tcagctcctt ctctattttc tctaaactgc aaggattttcaggaacacag 2280 gacggttttg aggagagttc gggagagatt cggtcctttt ctgccagctctttcagaaat 2340 atttcacttc ctataggaat aacatttgaa aaaaaatccc aaaaaacacgaacctactat 2400 tactttctag gagcctacat ccaagacctg aaacgtgatg tggaatcgggacctgtagtg 2460 ttactcaaaa atgccgtctc ctgggatgct cctatggcga acttggattcacgagcctac 2520 atgttccggc ttacgaatca aagagctcta cacagacttc agacgctgttaaatgtgtct 2580 tgtgtgctgc gtgggcaaag ccatagttac tccctggatc tggggaccacttacaggttc 2640 tag 2643 170 2949 DNA Chlamydia 170 atgattcctcaaggaattta cgatggggag acgttaactg tatcatttcc ctatactgtt 60 ataggagatccgagtgggac tactgttttt tctgcaggag agttaacatt aaaaaatctt 120 gacaattctattgcagcttt gcctttaagt tgttttggga acttattagg gagttttact 180 gttttagggagaggacactc gttgactttc gagaacatac ggacttctac aaatggggca 240 gctctaagtaatagcgctgc tgatggactg tttactattg agggttttaa agaattatcc 300 ttttccaattgcaattcatt acttgccgta ctgcctgctg caacgactaa taagggtagc 360 cagactccgacgacaacatc tacaccgtct aatggtacta tttattctaa aacagatctt 420 ttgttactcaataatgagaa gttctcattc tatagtaatt tagtctctgg agatggggga 480 gctatagatgctaagagctt aacggttcaa ggaattagca agctttgtgt cttccaagaa 540 aatactgctcaagctgatgg gggagcttgt caagtagtca ccagtttctc tgctatggct 600 aacgaggctcctattgcctt tgtagcgaat gttgcaggag taagaggggg agggattgct 660 gctgttcaggatgggcagca gggagtgtca tcatctactt caacagaaga tccagtagta 720 agtttttccagaaatactgc ggtagagttt gatgggaacg tagcccgagt aggaggaggg 780 atttactcctacgggaacgt tgctttcctg aataatggaa aaaccttgtt tctcaacaat 840 gttgcttctcctgtttacat tgctgctaag caaccaacaa gtggacaggc ttctaatacg 900 agtaataattacggagatgg aggagctatc ttctgtaaga atggtgcgca agcaggatcc 960 aataactctggatcagtttc ctttgatgga gagggagtag ttttctttag tagcaatgta 1020 gctgctgggaaagggggagc tatttatgcc aaaaagctct cggttgctaa ctgtggccct 1080 gtacaatttttaaggaatat cgctaatgat ggtggagcga tttatttagg agaatctgga 1140 gagctcagtttatctgctga ttatggagat attattttcg atgggaatct taaaagaaca 1200 gccaaagagaatgctgccga tgttaatggc gtaactgtgt cctcacaagc catttcgatg 1260 ggatcgggagggaaaataac gacattaaga gctaaagcag ggcatcagat tctctttaat 1320 gatcccatcgagatggcaaa cggaaataac cagccagcgc agtcttccaa acttctaaaa 1380 attaacgatggtgaaggata cacaggggat attgtttttg ctaatggaag cagtactttg 1440 taccaaaatgttacgataga gcaaggaagg attgttcttc gtgaaaaggc aaaattatca 1500 gtgaattctctaagtcagac aggtgggagt ctgtatatgg aagctgggag tacattggat 1560 tttgtaactccacaaccacc acaacagcct cctgccgcta atcagttgat cacgctttcc 1620 aatctgcatttgtctctttc ttctttgtta gcaaacaatg cagttacgaa tcctcctacc 1680 aatcctccagcgcaagattc tcatcctgca gtcattggta gcacaactgc tggttctgtt 1740 acaattagtgggcctatctt ttttgaggat ttggatgata cagcttatga taggtatgat 1800 tggctaggttctaatcaaaa aatcaatgtc ctgaaattac agttagggac taagccccca 1860 gctaatgccccatcagattt gactctaggg aatgagatgc ctaagtatgg ctatcaagga 1920 agctggaagcttgcgtggga tcctaataca gcaaataatg gtccttatac tctgaaagct 1980 acatggactaaaactgggta taatcctggg cctgagcgag tagcttcttt ggttccaaat 2040 agtttatggggatccatttt agatatacga tctgcgcatt cagcaattca agcaagtgtg 2100 gatgggcgctcttattgtcg aggattatgg gtttctggag tttcgaattt cttctatcat 2160 gaccgcgatgctttaggtca gggatatcgg tatattagtg ggggttattc cttaggagca 2220 aactcctactttggatcatc gatgtttggt ctagcattta ccgaagtatt tggtagatct 2280 aaagattatgtagtgtgtcg ttccaatcat catgcttgca taggatccgt ttatctatct 2340 acccaacaagctttatgtgg atcctatttg ttcggagatg cgtttatccg tgctagctac 2400 gggtttgggaatcagcatat gaaaacctca tatacatttg cagaggagag cgatgttcgt 2460 tgggataataactgtctggc tggagagatt ggagcgggat taccgattgt gattactcca 2520 tctaagctctatttgaatga gttgcgtcct ttcgtgcaag ctgagttttc ttatgccgat 2580 catgaatcttttacagagga aggcgatcaa gctcgggcat tcaagagcgg acatctccta 2640 aatctatcagttcctgttgg agtgaagttt gatcgatgtt ctagtacaca tcctaataaa 2700 tatagctttatggcggctta tatctgtgat gcttatcgca ccatctctgg tactgagaca 2760 acgctcctatcccatcaaga gacatggaca acagatgcct ttcatttagc aagacatgga 2820 gttgtggttagaggatctat gtatgcttct ctaacaagta atatagaagt atatggccat 2880 ggaagatatgagtatcgaga tgcttctcga ggctatggtt tgagtgcagg magtaaagtc 2940 yggttctaa2949 171 2895 DNA Chlamydia 171 atgaaaaaag cgtttttctt tttccttatcggaaactccc tatcaggact agctagagag 60 gttccttcta gaatctttct tatgcccaactcagttccag atcctacgaa agagtcgcta 120 tcaaataaaa ttagtttgac aggagacactcacaatctca ctaactgcta tctcgataac 180 ctacgctaca tactggctat tctacaaaaaactcccaatg aaggagctgc tgtcacaata 240 acagattacc taagcttttt tgatacacaaaaagaaggta tttattttgc aaaaaatctc 300 acccctgaaa gtggtggtgc gattggttatgcgagtccca attctcctac cgtggagatt 360 cgtgatacaa taggtcctgt aatctttgaaaataatactt gttgcagact atttacatgg 420 agaaatcctt atgctgctga taaaataagagaaggcggag ccattcatgc tcaaaatctt 480 tacataaatc ataatcatga tgtggtcggatttatgaaga acttttctta tgtccaagga 540 ggagccatta gtaccgctaa tacctttgttgtgagcgaga atcagtcttg ttttctcttt 600 atggacaaca tctgtattca aactaatacagcaggaaaag gtggcgctat ctatgctgga 660 acgagcaatt cttttgagag taataactgcgatctcttct tcatcaataa cgcctgttgt 720 gcaggaggag cgatcttctc ccctatctgttctctaacag gaaatcgtgg taacatcgtt 780 ttctataaca atcgctgctt taaaaatgtagaaacagctt cttcagaagc ttctgatgga 840 ggagcaatta aagtaactac tcgcctagatgttacaggca atcgtggtag gatctttttt 900 agtgacaata tcacaaaaaa ttatggcggagctatttacg ctcctgtagt taccctagtg 960 gataatggcc ctacctactt tataaacaatatcgccaata ataagggggg cgctatctat 1020 atagacggaa ccagtaactc caaaatttctgccgaccgcc atgctattat ttttaatgaa 1080 aatattgtga ctaatgtaac taatgcaaatggtaccagta cgtcagctaa tcctcctaga 1140 agaaatgcaa taacagtagc aagctcctctggtgaaattc tattaggagc agggagtagc 1200 caaaatttaa ttttttatga tcctattgaagttagcaatg caggggtctc tgtgtccttc 1260 aataaggaag ctgatcaaac aggctctgtagtattttcag gagctactgt taattctgca 1320 gattttcatc aacgcaattt acaaacaaaaacacctgcac cccttactct cagtaatggt 1380 tttctatgta tcgaagatca tgctcagcttacagtgaatc gattcacaca aactgggggt 1440 gttgtttctc ttgggaatgg agcagttctgagttgctata aaaatggtac aggagattct 1500 gctagcaatg cctctataac actgaagcatattggattga atctttcttc cattctgaaa 1560 agtggtgctg agattccttt attgtgggtagagcctacaa ataacagcaa taactataca 1620 gcagatactg cagctacctt ttcattaagtgatgtaaaac tctcactcat tgatgactac 1680 gggaactctc cttatgaatc cacagatctgacccatgctc tgtcatcaca gcctatgcta 1740 tctatttctg aagctagcga taaccagctacaatcagaaa atatagattt ttcgggacta 1800 aatgtccctc attatggatg gcaaggactttggacttggg gctgggcaaa aactcaagat 1860 ccagaaccag catcttcagc aacaatcactgatccacaaa aagccaatag atttcataga 1920 accttactac taacatggct tcctgccgggtatgttccta gcccaaaaca cagaagtccc 1980 ctcatagcta acaccttatg ggggaatatgctgcttgcaa cagaaagctt aaaaaatagt 2040 gcagagctga cacctagtgg tcatcctttctggggaatta caggaggagg actaggcatg 2100 atggtttacc aagatcctcg agaaaatcatcctggattcc atatgcgctc ttccggatac 2160 tctgcgggga tgatagcagg gcagacacacaccttctcat tgaaattcag tcagacctac 2220 accaaactca atgagcgtta cgcaaaaaacaacgtatctt ctaaaaatta ctcatgccaa 2280 ggagaaatgc tcttctcatt gcaagaaggtttcttgctga ctaaattagt tgggctttac 2340 agctatggag accataactg tcaccatttctatactcaag gagaaaatct aacatctcaa 2400 gggacgttcc gcagtcaaac gatgggaggtgctgtctttt ttgatctccc tatgaaaccc 2460 tttggatcaa cgcatatact gacagctccctttttaggtg ctcttggtat ttattctagc 2520 ctgtctcact ttactgaggt gggagcctatccgcgaagct tttctacaaa gactcctttg 2580 atcaatgtcc tagtccctat tggagttaaaggtagcttta tgaatgctac ccacagacct 2640 caagcctgga ctgtagaatt ggcataccaacccgttctgt atagacaaga accagggatc 2700 gcgacccagc tcctagccag taaaggtatttggtttggta gtggaagccc ctcatcgcgt 2760 catgccatgt cctataaaat ctcacagcaaacacaacctt tgagttggtt aactctccat 2820 ttccagtatc atggattcta ctcctcttcaaccttctgta attatctcaa tggggaaatt 2880 gctctgcgat tctag 2895 172 4593 DNAChlamydia 172 atgagttccg agaaagatat aaaaagcacc tgttctaagt tttctttgtctgtagtagca 60 gctatccttg cctctgttag cgggttagct agttgcgtag atcttcatgctggaggacag 120 tctgtaaatg agctggtata tgtaggccct caagcggttt tattgttagaccaaattcga 180 gatctattcg ttgggtctaa agatagtcag gctgaaggac agtataggttaattgtagga 240 gatccaagtt ctttccaaga gaaagatgca gatactcttc ccgggaaggtagagcaaagt 300 actttgttct cagtaaccaa tcccgtggtt ttccaaggtg tggaccaacaggatcaagtc 360 tcttcccaag ggttaatttg tagttttacg agcagcaacc ttgattctccccgtgacgga 420 gaatcttttt taggtattgc ttttgttggg gatagtagta aggctggaatcacattaact 480 gacgtgaaag cttctttgtc tggagcggct ttatattcta cagaagatcttatctttgaa 540 aagattaagg gtggattgga atttgcatca tgttcttctc tagaacaggggggagcttgt 600 gcagctcaaa gtattttgat tcatgattgt caaggattgc aggttaaacactgtactaca 660 gccgtgaatg ctgaggggtc tagtgcgaat gatcatcttg gatttggaggaggcgctttc 720 tttgttacgg gttctctttc tggagagaaa agtctctata tgcctgcaggagatatggta 780 gttgcgaatt gtgatggggc tatatctttt gaaggaaaca gcgcgaactttgctaatgga 840 ggagcgattg ctgcctctgg gaaagtgctt tttgtcgcta atgataaaaagacttctttt 900 atagagaacc gagctttgtc tggaggagcg attgcagcct cttctgatattgcctttcaa 960 aactgcgcag aactagtttt caaaggcaat tgtgcaattg gaacagaggataaaggttct 1020 ttaggtggag gggctatatc ttctctaggc accgttcttt tgcaagggaatcacgggata 1080 acttgtgata agaatgagtc tgcttcgcaa ggaggcgcca tttttggcaaaaattgtcag 1140 atttctgaca acgaggggcc agtggttttc agagatagta cagcttgcttaggaggaggc 1200 gctattgcag ctcaagaaat tgtttctatt cagaacaatc aggctgggatttccttcgag 1260 ggaggtaagg ctagtttcgg aggaggtatt gcgtgtggat ctttttcttccgcaggcggt 1320 gcttctgttt tagggactat tgatatttcg aagaatttag gcgcgatttcgttctctcgt 1380 actttatgta cgacctcaga tttaggacaa atggagtacc agggaggaggagctctattt 1440 ggtgaaaata tttctctttc tgagaatgct ggtgtgctca cctttaaagacaacattgtg 1500 aagacttttg cttcgaatgg gaaaattctg ggaggaggag cgattttagctactggtaag 1560 gtggaaatta ccaataattc cggaggaatt tcttttacag gaaatgcgagagctccacaa 1620 gctcttccaa ctcaagagga gtttccttta ttcagcaaaa aagaagggcgaccactctct 1680 tcaggatatt ctgggggagg agcgatttta ggaagagaag tagctattctccacaacgct 1740 gcagtagtat ttgagcaaaa tcgtttgcag tgcagcgaag aagaagcgacattattaggt 1800 tgttgtggag gaggcgctgt tcatgggatg gatagcactt cgattgttggcaactcttca 1860 gtaagatttg gtaataatta cgcaatggga caaggagtct caggaggagctcttttatct 1920 aaaacagtgc agttagctgg aaatggaagc gtcgattttt ctcgaaatattgctagtttg 1980 ggaggaggag ctcttcaagc ttctgaagga aattgtgagc tagttgataacggctatgtg 2040 ctattcagag ataatcgagg gagggtttat gggggtgcta tttcttgcttacgtggagat 2100 gtagtcattt ctggaaacaa gggtagagtt gaatttaaag acaacatagcaacacgtctt 2160 tatgtggaag aaactgtaga aaaggttgaa gaggtagagc cagctcctgagcaaaaagac 2220 aataatgagc tttctttctt agggagtgta gaacagagtt ttattactgcagctaatcaa 2280 gctcttttcg catctgaaga tggggattta tcacctgagt catccatttcttctgaagaa 2340 cttgcgaaaa gaagagagtg tgctggagga gctatttttg caaaacgggttcgtattgta 2400 gataaccaag aggccgttgt attctcgaat aacttctctg atatttatggcggcgccatt 2460 tttacaggtt ctcttcgaga agaggataag ttagatgggc aaatccctgaagtcttgatc 2520 tcaggcaatg caggggatgt tgttttttcc ggaaattcct cgaagcgtgatgagcatctt 2580 cctcatacag gtgggggagc catttgtact caaaatttga cgatttctcagaatacaggg 2640 aatgttctgt tttataacaa cgtggcctgt tcgggaggag ctgttcgtatagaggatcat 2700 ggtaatgttc ttttagaagc ttttggagga gatattgttt ttaaaggaaattcttctttc 2760 agagcacaag gatccgatgc tatctatttt gcaggtaaag aatcgcatattacagccctg 2820 aatgctacgg aaggacatgc tattgttttc cacgacgcat tagtttttgaaaatctaaaa 2880 gaaaggaaat ctgctgaagt attgttaatc aatagtcgag aaaatccaggttacactgga 2940 tctattcgat ttttagaagc agaaagtaaa gttcctcaat gtattcatgtacaacaagga 3000 agccttgagt tgctaaatgg agctacatta tgtagttatg gttttaaacaagatgctgga 3060 gctaagttgg tattggctgc tggatctaaa ctgaagattt tagattcaggaactcctgta 3120 caagggcatg ctatcagtaa acctgaagca gaaatcgagt catcttctgaaccagagggt 3180 gcacattctc tttggattgc gaagaatgct caaacaacag ttcctatggttgatatccat 3240 actatttctg tagatttagc ctccttctct tctagtcaac aggaggggacagtagaagct 3300 cctcaggtta ttgttcctgg aggaagttat gttcgatctg gagagcttaatttggagtta 3360 gttaacacaa caggtactgg ttatgaaaat catgctttgt tgaagaatgaggctaaagtt 3420 ccattgatgt ctttcgttgc ttctagtgat gaagcttcag ccgaaatcagtaacttgtcg 3480 gtttctgatt tacagattca tgtagcaact ccagagattg aagaagacacatacggccat 3540 atgggagatt ggtctgaggc taaaattcaa gatggaactc ttgtcattaattggaatcct 3600 actggatatc gattagatcc tcaaaaagca ggggctttag tatttaatgcattatgggaa 3660 gaaggggctg tcttgtctgc tctgaaaaat gcacgctttg ctcataatctcactgctcag 3720 cgtatggaat tcgattattc tacaaatgtg tggggattcg cctttggtggtttccgaact 3780 ctatctgcag agaatctggt tgctattgat ggatacaaag gagcttatggtggtgcttct 3840 gctggagtcg atattcaatt gatggaagat tttgttctag gagttagtggagctgctttc 3900 ctaggtaaaa tggatagtca gaagtttgat gcggaggttt ctcggaagggagttgttggt 3960 tctgtatata caggattttt agctggatcc tggttcttca aaggacaatatagccttgga 4020 gaaacacaga acgatatgaa aacgcgttat ggagtactag gagagtcgagtgcttcttgg 4080 acatctcgag gagtactggc agatgcttta gttgaatacc gaagtttagttggtcctgtg 4140 agacctactt tttatgcttt gcatttcaat ccttatgtcg aagtatcttatgcttctatg 4200 aaattccctg gctttacaga acaaggaaga gaagcgcgtt cttttgaagacgcttccctt 4260 accaatatca ccattccttt agggatgaag tttgaattgg cgttcataaaaggacagttt 4320 tcagaggtga actctttggg aataagttat gcatgggaag cttatcgaaaagtagaagga 4380 ggcgcggtgc agcttttaga agctgggttt gattgggagg gagctccaatggatcttcct 4440 agacaggagc tgcgtgtcgc tctggaaaat aatacggaat ggagttcttacttcagcaca 4500 gtcttaggat taacagcttt ttgtggagga tttacttcta cagatagtaaactaggatat 4560 gaggcgaata ctggattgcg attgatcttt taa 4593 173 5331 DNAChlamydia 173 gcaatcatga aatttatgtc agctactgct gtatttgctg cagtactctcctccgttact 60 gaggcgagct cgatccaaga tcaaataaag aataccgact gcaatgttagcaaagtagga 120 tattcaactt ctcaagcatt tactgatatg atgctagcag acaacacagagtatcgagct 180 gctgatagtg tttcattcta tgacttttcg acatcttccg gattacctagaaaacatctt 240 agtagtagta gtgaagcttc tccaacgaca gaaggagtgt cttcatcttcatctggagaa 300 aatactgaga attcacaaga ttcagctccc tcttctggag aaactgataagaaaacagaa 360 gaagaactag acaatggcgg aatcatttat gctagagaga aactaactatctcagaatct 420 caggactctc tctctaatcc aagcatagaa ctccatgaca atagttttttcttcggagaa 480 ggtgaagtta tctttgatca cagagttgcc ctcaaaaacg gaggagctatttatggagag 540 aaagaggtag tctttgaaaa cataaaatct ctactagtag aagtaaatatctcggtcgag 600 aaagggggta gcgtctatgc aaaagaacga gtatctttag aaaatgttaccgaagcaacc 660 ttctcctcca atggtgggga acaaggtggt ggtggaatct attcagaacaagatatgtta 720 atcagtgatt gcaacaatgt acatttccaa gggaatgctg caggagcaacagcagtaaaa 780 caatgtctgg atgaagaaat gatcgtattg ctcacagaat gcgttgatagcttatccgaa 840 gatacactgg atagcactcc agaaacggaa cagactaagt caaatggaaatcaagatggt 900 tcgtctgaaa caaaagatac acaagtatca gaatcaccag aatcaactcctagccccgac 960 gatgttttag gtaaaggtgg tggtatctat acagaaaaat ctttgaccatcactggaatt 1020 acagggacta tagattttgt cagtaacata gctaccgatt ctggagcaggtgtattcact 1080 aaagaaaact tgtcttgcac caacacgaat agcctacagt ttttgaaaaactcggcaggt 1140 caacatggag gaggagccta cgttactcaa accatgtctg ttactaatacaactagtgaa 1200 agtataacta ctccccctct cgtaggagaa gtgattttct ctgaaaatacagctaaaggg 1260 cacggtggtg gtatctgcac taacaaactt tctttatcta atttaaaaacggtgactctc 1320 actaaaaact ctgcaaagga gtctggagga gctattttta cagatctagcgtctatacca 1380 acaacagata ccccagagtc ttctaccccc tcttcctcct cgcctgcaagcactcccgaa 1440 gtagttgctt ctgctaaaat aaatcgattc tttgcctcta cggcagaaccggcagcccct 1500 tctctaacag aggctgagtc tgatcaaacg gatcaaacag aaacttctgatactaatagc 1560 gatatagacg tgtcgattga gaacattttg aatgtcgcta tcaatcaaaacacttctgcg 1620 aaaaaaggag gggctattta cgggaaaaaa gctaaacttt cccgtattaacaatcttgaa 1680 ctttcaggga attcatccca ggatgtagga ggaggtctct gtttaactgaaagcgtagaa 1740 tttgatgcaa ttggatcgct cttatcccac tataactctg ctgctaaagaaggtggggtt 1800 attcattcta aaacggttac tctatctaac ctcaagtcta ccttcacttttgcagataac 1860 actgttaaag caatagtaga aagcactcct gaagctccag aagagattcctccagtagaa 1920 ggagaagagt ctacagcaac agaaaatccg aattctaata cagaaggaagttcggctaac 1980 actaaccttg aaggatctca aggggatact gctgatacag ggactggtgttgttaacaat 2040 gagtctcaag acacatcaga tactggaaac gctgaatctg gagaacaactacaagattct 2100 acacaatcta atgaagaaaa tacccttccc aatagtagta ttgatcaatctaacgaaaac 2160 acagacgaat catctgatag ccacactgag gaaataactg acgagagtgtctcatcgtcc 2220 tctaaaagtg gatcatctac tcctcaagat ggaggagcag cttcttcaggggctccctca 2280 ggagatcaat ctatctctgc aaacgcttgt ttagctaaaa gctatgctgcgagtactgat 2340 agctcccctg tatctaattc ttcaggttca gacgttactg catcttctgataatccagac 2400 tcttcctcat ctggagatag cgctggagac tctgaaggac cgactgagccagaagctggt 2460 tctacaacag aaactcctac tttaatagga ggaggtgcta tctatggagaaactgttaag 2520 attgagaact tctctggcca aggaatattt tctggaaaca aagctatcgataacaccaca 2580 gaaggctcct cttccaaatc taacgtcctc ggaggtgcgg tctatgctaaaacattgttt 2640 aatctcgata gcgggagctc tagacgaact gtcaccttct ccgggaatactgtctcttct 2700 caatctacaa caggtcaggt tgctggagga gctatctact ctcctactgtaaccattgct 2760 actcctgtag tattttctaa aaactctgca acaaacaatg ctaataacgctacagatact 2820 cagagaaaag acacctttgg aggagctatc ggagctactt ctgctgtttctctatcagga 2880 ggggctcatt tcttagaaaa cgttgctgac ctcggatctg ctattgggttggtgccagac 2940 acacaaaata cagaaacagt gaaattagag tctggctcct actactttgaaaaaaataaa 3000 gctttaaaac gagctactat ttacgcacct gtcgtttcca ttaaagcctatactgcgaca 3060 tttaaccaaa acagatctct agaagaagga agcgcgattt actttacaaaagaagcatct 3120 attgagtctt taggctctgt tctcttcaca ggaaacttag taaccccaacgctaagcaca 3180 actacagaag gcacaccagc cacaacctca ggagatgtaa caaaatatggtgctgctatc 3240 tttggacaaa tagcaagctc aaacggatct cagacggata accttcccctgaaactcatt 3300 gcttcaggag gaaatatttg tttccgaaac aatgaatacc gtcctacttcttctgatacc 3360 ggaacctcta ctttctgtag tattgcggga gatgttaaat taaccatgcaagctgcaaaa 3420 gggaaaacga tcagtttctt tgatgcaatc cggacctcta ctaagaaaacaggtacacag 3480 gcaactgcct acgatactct cgatattaat aaatctgagg attcagaaactgtaaactct 3540 gcgtttacag gaacgattct gttctcctct gaattacatg aaaataaatcctatattcca 3600 caaaacgtag ttctacacag tggatctctt gtattgaagc caaataccgagcttcatgtc 3660 atttcttttg agcagaaaga aggctcttct ctcgttatga cacctggatctgttctttcg 3720 aaccagactg ttgctgatgg agctttggtc ataaataaca tgaccattgatttatccagc 3780 gtagagaaaa atggtattgc tgaaggaaat atctttactc ctccagaattgagaatcata 3840 gacactacta caagtggaag cggtggaacc ccatctacag atagtgaaagtaaccagaat 3900 agtgatgata ccaaggagca aaataataat gacgcctcga atcaaggagaaagcgcgaat 3960 ggatcgtctt ctcctgcagt agctgctgca cacacatctc gtacaagaaactttgccgct 4020 gcagctacag ccacacctac gacaacacca acggctacaa ctacaacaagcaaccaagta 4080 atcctaggag gagaaatcaa actcatcgat cctaatggga ccttcttccagaaccctgca 4140 ttaagatccg accaacaaat ctccttgtta gtgctcccta cagactcatcaaaaatgcaa 4200 gctcagaaaa tagtactgac gggtgatatt gctcctcaga aaggatatacaggaacactc 4260 actctggatc ctgatcaact acaaaatgga acgatctcag cgctctggaaatttgactct 4320 tatagacaat gggcttatgt acctagagac aatcatttct atgcgaactcgattctggga 4380 tctcaaatgt caatggtcac agtcaaacaa ggcttgctca acgataaaatgaatctagct 4440 cgctttgatg aagttagcta taacaacctg tggatatcag gactaggaacgatgctatcg 4500 caagtaggaa cacctacttc tgaagaattc acttattaca gcagaggagcttctgttgcc 4560 ttagatgcta aaccagccca tgatgtgatt gttggagctg catttagtaagatgatcggg 4620 aaaacaaaat ccttgaaaag agagaataac tacactcaca aaggatccgaatattcttac 4680 caagcatcgg tatacggagg caaaccattc cactttgtaa tcaataaaaaaacggaaaaa 4740 tcgctaccgc tattgttaca aggagtcatc tcttacggat atatcaaacatgatacagtg 4800 actcactatc caacgatccg tgaacgaaac caaggagaat gggaagacttaggatggctg 4860 acagctctcc gtgtctcctc tgtcttaaga actcctgcac aaggggatactaaacgtatc 4920 actgtttacg gagaattgga atactccagt atccgtcaga aacaattcacagaaacagaa 4980 tacgatcctc gttacttcga caactgcacc tatagaaact tagcaattcctatggggtta 5040 gcattcgaag gagagctctc tggtaacgat attttgatgt acaacagattctctgtagca 5100 tacatgccat caatctatcg aaattctcca acatgcaaat accaagtgctctcttcagga 5160 gaaggcggag aaattatttg tggagtaccg acaagaaact cagctcgcggagaatacagc 5220 acgcagctgt acccgggacc tttgtggact ctgtatggat cctacacgatagaagcagac 5280 gcacatacac tagctcatat gatgaactgc ggtgctcgta tgacattcta a5331 174 5265 DNA Chlamydia 174 gcaatcatga aatggctgtc agctactgcggtgtttgctg ctgttctccc ctcagtttca 60 gggttttgct tcccagaacc taaagaattaaatttctctc gcgtagaaac ttcttcctct 120 accactttta ctgaaacaat tggagaagctggggcagaat atatcgtctc tggtaacgca 180 tctttcacaa aatttaccaa cattcctactaccgatacaa caactcccac gaactcaaac 240 tcctctagct ctagcggaga aactgcttccgtttctgagg atagtgactc tacaacaacg 300 actcctgatc ctaaaggtgg cggcgccttttataacgcgc actccggagt tttgtccttt 360 atgacacgat caggaacaga aggttccttaactctgtctg agataaaaat gactggtgaa 420 ggcggtgcta tcttctctca aggagagctgctatttacag atctgacaag tctaaccatc 480 caaaataact tatcccagct atccggaggagcgatttttg gaggatctac aatctcccta 540 tcagggatta ctaaagcgac tttctcctgcaactctgcag aagttcctgc tcctgttaag 600 aaacctacag aacctaaagc tcaaacagcaagcgaaacgt cgggttctag tagttctagc 660 ggaaatgatt cggtgtcttc ccccagttccagtagagctg aacccgcagc agctaatctt 720 caaagtcact ttatttgtgc tacagctactcctgctgctc aaaccgatac agaaacatca 780 actccctctc ataagccagg atctgggggagctatctatg ctaaaggcga ccttactatc 840 gcagactctc aagaggtact attctcaataaataaagcta ctaaagatgg aggagcgatc 900 tttgctgaga aagatgtttc tttcgagaatattacatcat taaaagtaca aactaacggt 960 gctgaagaaa agggaggagc tatctatgctaaaggtgacc tctcaattca atcttctaaa 1020 cagagtcttt ttaattctaa ctacagtaaacaaggtgggg gggctctata tgttgaagga 1080 ggtataaact tccaagatct tgaagaaattcgcattaagt acaataaagc tggaacgttc 1140 gaaacaaaaa aaatcacttt accttctttaaaagctcaag catctgcagg aaatgcagat 1200 gcttgggcct cttcctctcc tcaatctggttctggagcaa ctacagtctc cgactcagga 1260 gactctagct ctggctcaga ctcggatacctcagaaacag ttccagtcac agctaaaggc 1320 ggtgggcttt atactgataa gaatctttcgattactaaca tcacaggaat tatcgaaatt 1380 gcaaataaca aagcgacaga tgttggaggtggtgcttacg taaaaggaac ccttacttgt 1440 gaaaactctc accgtctaca atttttgaaaaactcttccg ataaacaagg tggaggaatc 1500 tacggagaag acaacatcac cctatctaatttgacaggga agactctatt ccaagagaat 1560 actgccaaag aagagggcgg tggactcttcataaaaggta cagataaagc tcttacaatg 1620 acaggactgg atagtttctg tttaattaataacacatcag aaaaacatgg tggtggagcc 1680 tttgttacca aagaaatctc tcagacttacacctctgatg tggaaacaat tccaggaatc 1740 acgcctgtac atggtgaaac agtcattactggcaataaat ctacaggagg taatggtgga 1800 ggcgtgtgta caaaacgtct tgccttatctaaccttcaaa gcatttctat atccgggaat 1860 tctgcagcag aaaatggtgg tggagcccacacatgcccag atagcttccc aacggcggat 1920 actgcagaac agcccgcagc agcttctgccgcgacgtcta ctcccaaatc tgccccggtc 1980 tcaactgctc taagcacacc ttcatcttctaccgtctctt cattaacctt actagcagcc 2040 tcttcacaag cctctcctgc aacctctaataaggaaactc aagatcctaa tgctgataca 2100 gacttattga tcgattatgt agttgatacgactatcagca aaaacactgc taagaaaggc 2160 ggtggaatct atgctaaaaa agccaagatgtcccgcatag accaactgaa tatctctgag 2220 aactccgcta cagagatagg tggaggtatctgctgtaaag aatctttaga actagatgct 2280 ctagtctcct tatctgtaac agagaaccttgttgggaaag aaggtggagg cttacatgct 2340 aaaactgtaa atatttctaa tctgaaatcaggcttctctt tctcgaacaa caaagcaaac 2400 tcctcatcca caggagtcgc aacaacagcttcagcacctg ctgcagctgc tgcttcccta 2460 caagcagccg cagcagccgc accatcatctccagcaacac caacttattc aggtgtagta 2520 ggaggagcta tctatggaga aaaggttacattctctcaat gtagcgggac ttgtcagttc 2580 tctgggaacc aagctatcga taacaatccctcccaatcat cgttgaacgt acaaggagga 2640 gccatctatg ccaaaacctc tttgtctattggatcttccg atgctggaac ctcctatatt 2700 ttctcgggga acagtgtctc cactgggaaatctcaaacaa cagggcaaat agcgggagga 2760 gcgatctact cccctactgt tacattgaattgtcctgcga cattctctaa caatacagcc 2820 tctatagcta caccgaagac ttcttctgaagatggatcct caggaaattc tattaaagat 2880 accattggag gagccattgc agggacagccattaccctat ctggagtctc tcgattttca 2940 gggaatacgg ctgatttagg agctgcaataggaactctag ctaatgcaaa tacacccagt 3000 gcaactagcg gatctcaaaa tagcattacagaaaaaatta ctttagaaaa cggttctttt 3060 atttttgaaa gaaaccaagc taataaacgtggagcgattt actctcctag cgtttccatt 3120 aaagggaata atattacctt caatcaaaatacatccactc atgatggaag cgctatctac 3180 tttacaaaag atgctacgat tgagtctttaggatctgttc tttttacagg aaataacgtt 3240 acagctacac aagctagttc tgcaacatctggacaaaata caaatactgc caactatggg 3300 gcagccatct ttggagatcc aggaaccactcaatcgtctc aaacagatgc cattttaacc 3360 cttcttgctt cttctggaaa cattacttttagcaacaaca gtttacagaa taaccaaggt 3420 gatactcccg ctagcaagtt ttgtagtattgcaggatacg tcaaactctc tctacaagcc 3480 gctaaaggga agactattag ctttttcgattgtgtgcaca cctctaccaa aaaaacaggt 3540 tcaacacaaa acgtttatga aactttagatattaataaag aagagaacag taatccatat 3600 acaggaacta ttgtgttctc ttctgaattacatgaaaaca aatcttacat cccacagaat 3660 gcaatccttc acaacggaac tttagttcttaaagagaaaa cagaactcca cgtagtctct 3720 tttgagcaga aagaagggtc taaattaattatggaacccg gagctgtgtt atctaaccaa 3780 aacatagcta acggagctct agctatcaatgggttaacga ttgatctttc cagtatgggg 3840 actcctcaag caggggaaat cttctctcctccagaattac gtatcgttgc cacgacctct 3900 agtgcatccg gaggaagcgg ggtcagcagtagtataccaa caaatcctaa aaggatttct 3960 gcagcagtgc cttcaggttc tgccgcaactactccaacta tgagcgagaa caaagttttc 4020 ctaacaggag accttacttt aatagatcctaatggaaact tttaccaaaa ccctatgtta 4080 ggaagcgatc tagatgtacc actaattaagcttccgacta acacaagtga cgtccaagtc 4140 tatgatttaa ctttatctgg ggatcttttccctcagaaag ggtacatggg aacctggaca 4200 ttagattcta atccacaaac agggaaacttcaagccagat ggacattcga tacctatcgt 4260 cgctgggtat acatacctag ggataatcatttttatgcga actctatctt aggctcccaa 4320 aactcaatga ttgttgtgaa gcaagggcttatcaacaaca tgttgaataa tgcccgcttc 4380 gatgatatcg cttacaataa cttctgggtttcaggagtag gaactttctt agctcaacaa 4440 ggaactcctc tttccgaaga attcagttactacagccgcg gaacttcagt tgccatcgat 4500 gccaaaccta gacaagattt tatcctaggagctgcattta gtaagatagt ggggaaaacc 4560 aaagccatca aaaaaatgca taattacttccataagggct ctgagtactc ttaccaagct 4620 tctgtctatg gaggtaaatt cctgtatttcttgctcaata agcaacatgg ttgggcactt 4680 cctttcctaa tacaaggagt cgtgtcctatggacatatta aacatgatac aacaacactt 4740 tacccttcta tccatgaaag aaataaaggagattgggaag atttaggatg gttagcggat 4800 cttcgtatct ctatggatct taaagaaccttctaaagatt cttctaaacg gatcactgtc 4860 tatggggaac tcgagtattc cagcattcgccagaaacagt tcacagaaat cgattacgat 4920 ccaagacact tcgatgattg tgcttacagaaatctgtcgc ttcctgtggg atgcgctgtc 4980 gaaggagcta tcatgaactg taatattcttatgtataata agcttgcatt agcctacatg 5040 ccttctatct acagaaataa tcctgtctgtaaatatcggg tattgtcttc gaatgaagct 5100 ggtcaagtta tctgcggagt gccaactagaacctctgcta gagcagaata cagtactcaa 5160 ctatatcttg gtcccttctg gactctctacggaaactata ctatcgatgt aggcatgtat 5220 acgctatcgc aaatgactag ctgcggtgctcgcatgatct tctaa 5265 175 880 PRT Chlamydia VARIANT (1)...(880) Xaa =Any Amino Acid 175 Ala Ile Met Arg Pro Asp His Met Asn Phe Cys Cys LeuCys Ala Ala 1 5 10 15 Ile Leu Ser Ser Thr Ala Val Leu Phe Gly Gln AspPro Leu Gly Glu 20 25 30 Thr Ala Leu Leu Thr Lys Asn Pro Asn His Val ValCys Thr Phe Phe 35 40 45 Glu Asp Cys Thr Met Glu Ser Leu Phe Pro Ala LeuCys Ala His Ala 50 55 60 Ser Gln Asp Asp Pro Leu Tyr Val Leu Gly Asn SerTyr Cys Trp Phe 65 70 75 80 Val Ser Lys Leu His Ile Thr Asp Pro Lys GluAla Leu Phe Lys Glu 85 90 95 Lys Gly Asp Leu Ser Ile Gln Asn Phe Arg PheLeu Ser Phe Thr Asp 100 105 110 Cys Ser Ser Lys Glu Ser Ser Pro Ser IleIle His Gln Lys Asn Gly 115 120 125 Gln Leu Ser Leu Arg Asn Asn Gly SerMet Ser Phe Cys Arg Asn His 130 135 140 Ala Glu Gly Ser Gly Gly Ala IleSer Ala Asp Ala Phe Ser Leu Gln 145 150 155 160 His Asn Tyr Leu Phe ThrAla Phe Glu Glu Asn Ser Ser Lys Gly Asn 165 170 175 Gly Gly Ala Ile GlnAla Gln Thr Phe Ser Leu Ser Arg Asn Val Ser 180 185 190 Pro Ile Ser PheAla Arg Asn Arg Ala Asp Leu Asn Gly Gly Ala Ile 195 200 205 Cys Cys SerAsn Leu Ile Cys Ser Gly Asn Val Asn Pro Leu Phe Phe 210 215 220 Thr GlyAsn Ser Ala Thr Asn Gly Gly Ala Ile Cys Cys Ile Ser Asp 225 230 235 240Leu Asn Thr Ser Glu Lys Gly Ser Leu Ser Leu Ala Cys Asn Gln Glu 245 250255 Thr Leu Phe Ala Ser Asn Ser Ala Lys Glu Lys Gly Gly Ala Ile Tyr 260265 270 Ala Lys His Met Val Leu Arg Tyr Asn Gly Pro Val Ser Phe Ile Asn275 280 285 Asn Ser Ala Lys Ile Gly Gly Ala Ile Ala Ile Gln Ser Gly GlySer 290 295 300 Leu Ser Ile Leu Ala Gly Glu Gly Ser Val Leu Phe Gln AsnAsn Ser 305 310 315 320 Gln Arg Thr Ser Asp Gln Gly Leu Val Arg Asn AlaIle Tyr Leu Xaa 325 330 335 Lys Asp Ala Ile Leu Ser Ser Leu Glu Ala ArgAsn Gly Asp Ile Leu 340 345 350 Phe Phe Asp Pro Ile Val Gln Glu Ser SerSer Lys Glu Ser Pro Leu 355 360 365 Pro Ser Ser Leu Gln Ala Ser Val ThrSer Pro Thr Pro Ala Thr Ala 370 375 380 Ser Pro Leu Val Ile Gln Thr SerAla Asn Arg Ser Val Ile Phe Ser 385 390 395 400 Ser Glu Arg Leu Ser GluGlu Glu Lys Thr Pro Asp Asn Leu Thr Ser 405 410 415 Gln Leu Gln Gln ProIle Glu Leu Lys Ser Gly Arg Leu Val Leu Lys 420 425 430 Asp Arg Ala ValLeu Ser Ala Pro Ser Leu Ser Gln Asp Pro Gln Ala 435 440 445 Leu Leu IleMet Glu Ala Gly Thr Ser Leu Lys Thr Ser Ser Asp Leu 450 455 460 Lys LeuAla Thr Leu Ser Ile Pro Leu His Ser Leu Asp Thr Glu Lys 465 470 475 480Ser Val Thr Ile His Ala Pro Asn Leu Ser Ile Gln Lys Ile Phe Leu 485 490495 Ser Asn Ser Gly Asp Glu Asn Phe Tyr Glu Asn Val Glu Leu Leu Ser 500505 510 Lys Glu Gln Asn Asn Ile Pro Leu Leu Thr Leu Pro Lys Glu Gln Ser515 520 525 His Leu His Leu Pro Asp Gly Asn Leu Ser Ser His Phe Gly TyrGln 530 535 540 Gly Asp Trp Thr Phe Ser Trp Lys Asp Ser Asp Glu Gly HisSer Leu 545 550 555 560 Ile Ala Asn Trp Thr Pro Lys Asn Tyr Val Pro HisPro Glu Arg Gln 565 570 575 Ser Thr Leu Val Ala Asn Thr Leu Trp Asn ThrTyr Ser Asp Met Gln 580 585 590 Ala Val Gln Ser Met Ile Asn Thr Thr AlaHis Gly Gly Ala Tyr Leu 595 600 605 Phe Gly Thr Trp Gly Ser Ala Val SerAsn Leu Phe Tyr Val His Asp 610 615 620 Ser Ser Gly Lys Pro Ile Asp AsnTrp His His Arg Ser Leu Gly Tyr 625 630 635 640 Leu Phe Gly Ile Ser ThrHis Ser Leu Asp Asp His Ser Phe Cys Leu 645 650 655 Ala Ala Gly Gln LeuLeu Gly Lys Ser Ser Asp Ser Phe Ile Thr Ser 660 665 670 Thr Glu Thr ThrSer Tyr Ile Ala Thr Val Gln Ala Gln Leu Ala Thr 675 680 685 Ser Leu MetLys Ile Ser Ala Gln Ala Cys Tyr Asn Glu Ser Ile His 690 695 700 Glu LeuLys Thr Lys Tyr Arg Ser Phe Ser Lys Glu Gly Phe Gly Ser 705 710 715 720Trp His Ser Val Ala Val Ser Gly Glu Val Cys Ala Ser Ile Pro Ile 725 730735 Val Ser Asn Gly Ser Gly Leu Phe Ser Ser Phe Ser Ile Phe Ser Lys 740745 750 Leu Gln Gly Phe Ser Gly Thr Gln Asp Gly Phe Glu Glu Ser Ser Gly755 760 765 Glu Ile Arg Ser Phe Ser Ala Ser Ser Phe Arg Asn Ile Ser LeuPro 770 775 780 Ile Gly Ile Thr Phe Glu Lys Lys Ser Gln Lys Thr Arg ThrTyr Tyr 785 790 795 800 Tyr Phe Leu Gly Ala Tyr Ile Gln Asp Leu Lys ArgAsp Val Glu Ser 805 810 815 Gly Pro Val Val Leu Leu Lys Asn Ala Val SerTrp Asp Ala Pro Met 820 825 830 Ala Asn Leu Asp Ser Arg Ala Tyr Met PheArg Leu Thr Asn Gln Arg 835 840 845 Ala Leu His Arg Leu Gln Thr Leu LeuAsn Val Ser Cys Val Leu Arg 850 855 860 Gly Gln Ser His Ser Tyr Ser LeuAsp Leu Gly Thr Thr Tyr Arg Phe 865 870 875 880 176 982 PRT ChlamydiaVARIANT (1)...(982) Xaa = Any Amino Acid 176 Met Ile Pro Gln Gly Ile TyrAsp Gly Glu Thr Leu Thr Val Ser Phe 1 5 10 15 Pro Tyr Thr Val Ile GlyAsp Pro Ser Gly Thr Thr Val Phe Ser Ala 20 25 30 Gly Glu Leu Thr Leu LysAsn Leu Asp Asn Ser Ile Ala Ala Leu Pro 35 40 45 Leu Ser Cys Phe Gly AsnLeu Leu Gly Ser Phe Thr Val Leu Gly Arg 50 55 60 Gly His Ser Leu Thr PheGlu Asn Ile Arg Thr Ser Thr Asn Gly Ala 65 70 75 80 Ala Leu Ser Asn SerAla Ala Asp Gly Leu Phe Thr Ile Glu Gly Phe 85 90 95 Lys Glu Leu Ser PheSer Asn Cys Asn Ser Leu Leu Ala Val Leu Pro 100 105 110 Ala Ala Thr ThrAsn Lys Gly Ser Gln Thr Pro Thr Thr Thr Ser Thr 115 120 125 Pro Ser AsnGly Thr Ile Tyr Ser Lys Thr Asp Leu Leu Leu Leu Asn 130 135 140 Asn GluLys Phe Ser Phe Tyr Ser Asn Leu Val Ser Gly Asp Gly Gly 145 150 155 160Ala Ile Asp Ala Lys Ser Leu Thr Val Gln Gly Ile Ser Lys Leu Cys 165 170175 Val Phe Gln Glu Asn Thr Ala Gln Ala Asp Gly Gly Ala Cys Gln Val 180185 190 Val Thr Ser Phe Ser Ala Met Ala Asn Glu Ala Pro Ile Ala Phe Val195 200 205 Ala Asn Val Ala Gly Val Arg Gly Gly Gly Ile Ala Ala Val GlnAsp 210 215 220 Gly Gln Gln Gly Val Ser Ser Ser Thr Ser Thr Glu Asp ProVal Val 225 230 235 240 Ser Phe Ser Arg Asn Thr Ala Val Glu Phe Asp GlyAsn Val Ala Arg 245 250 255 Val Gly Gly Gly Ile Tyr Ser Tyr Gly Asn ValAla Phe Leu Asn Asn 260 265 270 Gly Lys Thr Leu Phe Leu Asn Asn Val AlaSer Pro Val Tyr Ile Ala 275 280 285 Ala Lys Gln Pro Thr Ser Gly Gln AlaSer Asn Thr Ser Asn Asn Tyr 290 295 300 Gly Asp Gly Gly Ala Ile Phe CysLys Asn Gly Ala Gln Ala Gly Ser 305 310 315 320 Asn Asn Ser Gly Ser ValSer Phe Asp Gly Glu Gly Val Val Phe Phe 325 330 335 Ser Ser Asn Val AlaAla Gly Lys Gly Gly Ala Ile Tyr Ala Lys Lys 340 345 350 Leu Ser Val AlaAsn Cys Gly Pro Val Gln Phe Leu Arg Asn Ile Ala 355 360 365 Asn Asp GlyGly Ala Ile Tyr Leu Gly Glu Ser Gly Glu Leu Ser Leu 370 375 380 Ser AlaAsp Tyr Gly Asp Ile Ile Phe Asp Gly Asn Leu Lys Arg Thr 385 390 395 400Ala Lys Glu Asn Ala Ala Asp Val Asn Gly Val Thr Val Ser Ser Gln 405 410415 Ala Ile Ser Met Gly Ser Gly Gly Lys Ile Thr Thr Leu Arg Ala Lys 420425 430 Ala Gly His Gln Ile Leu Phe Asn Asp Pro Ile Glu Met Ala Asn Gly435 440 445 Asn Asn Gln Pro Ala Gln Ser Ser Lys Leu Leu Lys Ile Asn AspGly 450 455 460 Glu Gly Tyr Thr Gly Asp Ile Val Phe Ala Asn Gly Ser SerThr Leu 465 470 475 480 Tyr Gln Asn Val Thr Ile Glu Gln Gly Arg Ile ValLeu Arg Glu Lys 485 490 495 Ala Lys Leu Ser Val Asn Ser Leu Ser Gln ThrGly Gly Ser Leu Tyr 500 505 510 Met Glu Ala Gly Ser Thr Leu Asp Phe ValThr Pro Gln Pro Pro Gln 515 520 525 Gln Pro Pro Ala Ala Asn Gln Leu IleThr Leu Ser Asn Leu His Leu 530 535 540 Ser Leu Ser Ser Leu Leu Ala AsnAsn Ala Val Thr Asn Pro Pro Thr 545 550 555 560 Asn Pro Pro Ala Gln AspSer His Pro Ala Val Ile Gly Ser Thr Thr 565 570 575 Ala Gly Ser Val ThrIle Ser Gly Pro Ile Phe Phe Glu Asp Leu Asp 580 585 590 Asp Thr Ala TyrAsp Arg Tyr Asp Trp Leu Gly Ser Asn Gln Lys Ile 595 600 605 Asn Val LeuLys Leu Gln Leu Gly Thr Lys Pro Pro Ala Asn Ala Pro 610 615 620 Ser AspLeu Thr Leu Gly Asn Glu Met Pro Lys Tyr Gly Tyr Gln Gly 625 630 635 640Ser Trp Lys Leu Ala Trp Asp Pro Asn Thr Ala Asn Asn Gly Pro Tyr 645 650655 Thr Leu Lys Ala Thr Trp Thr Lys Thr Gly Tyr Asn Pro Gly Pro Glu 660665 670 Arg Val Ala Ser Leu Val Pro Asn Ser Leu Trp Gly Ser Ile Leu Asp675 680 685 Ile Arg Ser Ala His Ser Ala Ile Gln Ala Ser Val Asp Gly ArgSer 690 695 700 Tyr Cys Arg Gly Leu Trp Val Ser Gly Val Ser Asn Phe PheTyr His 705 710 715 720 Asp Arg Asp Ala Leu Gly Gln Gly Tyr Arg Tyr IleSer Gly Gly Tyr 725 730 735 Ser Leu Gly Ala Asn Ser Tyr Phe Gly Ser SerMet Phe Gly Leu Ala 740 745 750 Phe Thr Glu Val Phe Gly Arg Ser Lys AspTyr Val Val Cys Arg Ser 755 760 765 Asn His His Ala Cys Ile Gly Ser ValTyr Leu Ser Thr Gln Gln Ala 770 775 780 Leu Cys Gly Ser Tyr Leu Phe GlyAsp Ala Phe Ile Arg Ala Ser Tyr 785 790 795 800 Gly Phe Gly Asn Gln HisMet Lys Thr Ser Tyr Thr Phe Ala Glu Glu 805 810 815 Ser Asp Val Arg TrpAsp Asn Asn Cys Leu Ala Gly Glu Ile Gly Ala 820 825 830 Gly Leu Pro IleVal Ile Thr Pro Ser Lys Leu Tyr Leu Asn Glu Leu 835 840 845 Arg Pro PheVal Gln Ala Glu Phe Ser Tyr Ala Asp His Glu Ser Phe 850 855 860 Thr GluGlu Gly Asp Gln Ala Arg Ala Phe Lys Ser Gly His Leu Leu 865 870 875 880Asn Leu Ser Val Pro Val Gly Val Lys Phe Asp Arg Cys Ser Ser Thr 885 890895 His Pro Asn Lys Tyr Ser Phe Met Ala Ala Tyr Ile Cys Asp Ala Tyr 900905 910 Arg Thr Ile Ser Gly Thr Glu Thr Thr Leu Leu Ser His Gln Glu Thr915 920 925 Trp Thr Thr Asp Ala Phe His Leu Ala Arg His Gly Val Val ValArg 930 935 940 Gly Ser Met Tyr Ala Ser Leu Thr Ser Asn Ile Glu Val TyrGly His 945 950 955 960 Gly Arg Tyr Glu Tyr Arg Asp Ala Ser Arg Gly TyrGly Leu Ser Ala 965 970 975 Gly Ser Lys Val Xaa Phe 980 177 964 PRTChlamydia 177 Met Lys Lys Ala Phe Phe Phe Phe Leu Ile Gly Asn Ser LeuSer Gly 1 5 10 15 Leu Ala Arg Glu Val Pro Ser Arg Ile Phe Leu Met ProAsn Ser Val 20 25 30 Pro Asp Pro Thr Lys Glu Ser Leu Ser Asn Lys Ile SerLeu Thr Gly 35 40 45 Asp Thr His Asn Leu Thr Asn Cys Tyr Leu Asp Asn LeuArg Tyr Ile 50 55 60 Leu Ala Ile Leu Gln Lys Thr Pro Asn Glu Gly Ala AlaVal Thr Ile 65 70 75 80 Thr Asp Tyr Leu Ser Phe Phe Asp Thr Gln Lys GluGly Ile Tyr Phe 85 90 95 Ala Lys Asn Leu Thr Pro Glu Ser Gly Gly Ala IleGly Tyr Ala Ser 100 105 110 Pro Asn Ser Pro Thr Val Glu Ile Arg Asp ThrIle Gly Pro Val Ile 115 120 125 Phe Glu Asn Asn Thr Cys Cys Arg Leu PheThr Trp Arg Asn Pro Tyr 130 135 140 Ala Ala Asp Lys Ile Arg Glu Gly GlyAla Ile His Ala Gln Asn Leu 145 150 155 160 Tyr Ile Asn His Asn His AspVal Val Gly Phe Met Lys Asn Phe Ser 165 170 175 Tyr Val Gln Gly Gly AlaIle Ser Thr Ala Asn Thr Phe Val Val Ser 180 185 190 Glu Asn Gln Ser CysPhe Leu Phe Met Asp Asn Ile Cys Ile Gln Thr 195 200 205 Asn Thr Ala GlyLys Gly Gly Ala Ile Tyr Ala Gly Thr Ser Asn Ser 210 215 220 Phe Glu SerAsn Asn Cys Asp Leu Phe Phe Ile Asn Asn Ala Cys Cys 225 230 235 240 AlaGly Gly Ala Ile Phe Ser Pro Ile Cys Ser Leu Thr Gly Asn Arg 245 250 255Gly Asn Ile Val Phe Tyr Asn Asn Arg Cys Phe Lys Asn Val Glu Thr 260 265270 Ala Ser Ser Glu Ala Ser Asp Gly Gly Ala Ile Lys Val Thr Thr Arg 275280 285 Leu Asp Val Thr Gly Asn Arg Gly Arg Ile Phe Phe Ser Asp Asn Ile290 295 300 Thr Lys Asn Tyr Gly Gly Ala Ile Tyr Ala Pro Val Val Thr LeuVal 305 310 315 320 Asp Asn Gly Pro Thr Tyr Phe Ile Asn Asn Ile Ala AsnAsn Lys Gly 325 330 335 Gly Ala Ile Tyr Ile Asp Gly Thr Ser Asn Ser LysIle Ser Ala Asp 340 345 350 Arg His Ala Ile Ile Phe Asn Glu Asn Ile ValThr Asn Val Thr Asn 355 360 365 Ala Asn Gly Thr Ser Thr Ser Ala Asn ProPro Arg Arg Asn Ala Ile 370 375 380 Thr Val Ala Ser Ser Ser Gly Glu IleLeu Leu Gly Ala Gly Ser Ser 385 390 395 400 Gln Asn Leu Ile Phe Tyr AspPro Ile Glu Val Ser Asn Ala Gly Val 405 410 415 Ser Val Ser Phe Asn LysGlu Ala Asp Gln Thr Gly Ser Val Val Phe 420 425 430 Ser Gly Ala Thr ValAsn Ser Ala Asp Phe His Gln Arg Asn Leu Gln 435 440 445 Thr Lys Thr ProAla Pro Leu Thr Leu Ser Asn Gly Phe Leu Cys Ile 450 455 460 Glu Asp HisAla Gln Leu Thr Val Asn Arg Phe Thr Gln Thr Gly Gly 465 470 475 480 ValVal Ser Leu Gly Asn Gly Ala Val Leu Ser Cys Tyr Lys Asn Gly 485 490 495Thr Gly Asp Ser Ala Ser Asn Ala Ser Ile Thr Leu Lys His Ile Gly 500 505510 Leu Asn Leu Ser Ser Ile Leu Lys Ser Gly Ala Glu Ile Pro Leu Leu 515520 525 Trp Val Glu Pro Thr Asn Asn Ser Asn Asn Tyr Thr Ala Asp Thr Ala530 535 540 Ala Thr Phe Ser Leu Ser Asp Val Lys Leu Ser Leu Ile Asp AspTyr 545 550 555 560 Gly Asn Ser Pro Tyr Glu Ser Thr Asp Leu Thr His AlaLeu Ser Ser 565 570 575 Gln Pro Met Leu Ser Ile Ser Glu Ala Ser Asp AsnGln Leu Gln Ser 580 585 590 Glu Asn Ile Asp Phe Ser Gly Leu Asn Val ProHis Tyr Gly Trp Gln 595 600 605 Gly Leu Trp Thr Trp Gly Trp Ala Lys ThrGln Asp Pro Glu Pro Ala 610 615 620 Ser Ser Ala Thr Ile Thr Asp Pro GlnLys Ala Asn Arg Phe His Arg 625 630 635 640 Thr Leu Leu Leu Thr Trp LeuPro Ala Gly Tyr Val Pro Ser Pro Lys 645 650 655 His Arg Ser Pro Leu IleAla Asn Thr Leu Trp Gly Asn Met Leu Leu 660 665 670 Ala Thr Glu Ser LeuLys Asn Ser Ala Glu Leu Thr Pro Ser Gly His 675 680 685 Pro Phe Trp GlyIle Thr Gly Gly Gly Leu Gly Met Met Val Tyr Gln 690 695 700 Asp Pro ArgGlu Asn His Pro Gly Phe His Met Arg Ser Ser Gly Tyr 705 710 715 720 SerAla Gly Met Ile Ala Gly Gln Thr His Thr Phe Ser Leu Lys Phe 725 730 735Ser Gln Thr Tyr Thr Lys Leu Asn Glu Arg Tyr Ala Lys Asn Asn Val 740 745750 Ser Ser Lys Asn Tyr Ser Cys Gln Gly Glu Met Leu Phe Ser Leu Gln 755760 765 Glu Gly Phe Leu Leu Thr Lys Leu Val Gly Leu Tyr Ser Tyr Gly Asp770 775 780 His Asn Cys His His Phe Tyr Thr Gln Gly Glu Asn Leu Thr SerGln 785 790 795 800 Gly Thr Phe Arg Ser Gln Thr Met Gly Gly Ala Val PhePhe Asp Leu 805 810 815 Pro Met Lys Pro Phe Gly Ser Thr His Ile Leu ThrAla Pro Phe Leu 820 825 830 Gly Ala Leu Gly Ile Tyr Ser Ser Leu Ser HisPhe Thr Glu Val Gly 835 840 845 Ala Tyr Pro Arg Ser Phe Ser Thr Lys ThrPro Leu Ile Asn Val Leu 850 855 860 Val Pro Ile Gly Val Lys Gly Ser PheMet Asn Ala Thr His Arg Pro 865 870 875 880 Gln Ala Trp Thr Val Glu LeuAla Tyr Gln Pro Val Leu Tyr Arg Gln 885 890 895 Glu Pro Gly Ile Ala ThrGln Leu Leu Ala Ser Lys Gly Ile Trp Phe 900 905 910 Gly Ser Gly Ser ProSer Ser Arg His Ala Met Ser Tyr Lys Ile Ser 915 920 925 Gln Gln Thr GlnPro Leu Ser Trp Leu Thr Leu His Phe Gln Tyr His 930 935 940 Gly Phe TyrSer Ser Ser Thr Phe Cys Asn Tyr Leu Asn Gly Glu Ile 945 950 955 960 AlaLeu Arg Phe 178 1530 PRT Chlamydia 178 Met Ser Ser Glu Lys Asp Ile LysSer Thr Cys Ser Lys Phe Ser Leu 1 5 10 15 Ser Val Val Ala Ala Ile LeuAla Ser Val Ser Gly Leu Ala Ser Cys 20 25 30 Val Asp Leu His Ala Gly GlyGln Ser Val Asn Glu Leu Val Tyr Val 35 40 45 Gly Pro Gln Ala Val Leu LeuLeu Asp Gln Ile Arg Asp Leu Phe Val 50 55 60 Gly Ser Lys Asp Ser Gln AlaGlu Gly Gln Tyr Arg Leu Ile Val Gly 65 70 75 80 Asp Pro Ser Ser Phe GlnGlu Lys Asp Ala Asp Thr Leu Pro Gly Lys 85 90 95 Val Glu Gln Ser Thr LeuPhe Ser Val Thr Asn Pro Val Val Phe Gln 100 105 110 Gly Val Asp Gln GlnAsp Gln Val Ser Ser Gln Gly Leu Ile Cys Ser 115 120 125 Phe Thr Ser SerAsn Leu Asp Ser Pro Arg Asp Gly Glu Ser Phe Leu 130 135 140 Gly Ile AlaPhe Val Gly Asp Ser Ser Lys Ala Gly Ile Thr Leu Thr 145 150 155 160 AspVal Lys Ala Ser Leu Ser Gly Ala Ala Leu Tyr Ser Thr Glu Asp 165 170 175Leu Ile Phe Glu Lys Ile Lys Gly Gly Leu Glu Phe Ala Ser Cys Ser 180 185190 Ser Leu Glu Gln Gly Gly Ala Cys Ala Ala Gln Ser Ile Leu Ile His 195200 205 Asp Cys Gln Gly Leu Gln Val Lys His Cys Thr Thr Ala Val Asn Ala210 215 220 Glu Gly Ser Ser Ala Asn Asp His Leu Gly Phe Gly Gly Gly AlaPhe 225 230 235 240 Phe Val Thr Gly Ser Leu Ser Gly Glu Lys Ser Leu TyrMet Pro Ala 245 250 255 Gly Asp Met Val Val Ala Asn Cys Asp Gly Ala IleSer Phe Glu Gly 260 265 270 Asn Ser Ala Asn Phe Ala Asn Gly Gly Ala IleAla Ala Ser Gly Lys 275 280 285 Val Leu Phe Val Ala Asn Asp Lys Lys ThrSer Phe Ile Glu Asn Arg 290 295 300 Ala Leu Ser Gly Gly Ala Ile Ala AlaSer Ser Asp Ile Ala Phe Gln 305 310 315 320 Asn Cys Ala Glu Leu Val PheLys Gly Asn Cys Ala Ile Gly Thr Glu 325 330 335 Asp Lys Gly Ser Leu GlyGly Gly Ala Ile Ser Ser Leu Gly Thr Val 340 345 350 Leu Leu Gln Gly AsnHis Gly Ile Thr Cys Asp Lys Asn Glu Ser Ala 355 360 365 Ser Gln Gly GlyAla Ile Phe Gly Lys Asn Cys Gln Ile Ser Asp Asn 370 375 380 Glu Gly ProVal Val Phe Arg Asp Ser Thr Ala Cys Leu Gly Gly Gly 385 390 395 400 AlaIle Ala Ala Gln Glu Ile Val Ser Ile Gln Asn Asn Gln Ala Gly 405 410 415Ile Ser Phe Glu Gly Gly Lys Ala Ser Phe Gly Gly Gly Ile Ala Cys 420 425430 Gly Ser Phe Ser Ser Ala Gly Gly Ala Ser Val Leu Gly Thr Ile Asp 435440 445 Ile Ser Lys Asn Leu Gly Ala Ile Ser Phe Ser Arg Thr Leu Cys Thr450 455 460 Thr Ser Asp Leu Gly Gln Met Glu Tyr Gln Gly Gly Gly Ala LeuPhe 465 470 475 480 Gly Glu Asn Ile Ser Leu Ser Glu Asn Ala Gly Val LeuThr Phe Lys 485 490 495 Asp Asn Ile Val Lys Thr Phe Ala Ser Asn Gly LysIle Leu Gly Gly 500 505 510 Gly Ala Ile Leu Ala Thr Gly Lys Val Glu IleThr Asn Asn Ser Gly 515 520 525 Gly Ile Ser Phe Thr Gly Asn Ala Arg AlaPro Gln Ala Leu Pro Thr 530 535 540 Gln Glu Glu Phe Pro Leu Phe Ser LysLys Glu Gly Arg Pro Leu Ser 545 550 555 560 Ser Gly Tyr Ser Gly Gly GlyAla Ile Leu Gly Arg Glu Val Ala Ile 565 570 575 Leu His Asn Ala Ala ValVal Phe Glu Gln Asn Arg Leu Gln Cys Ser 580 585 590 Glu Glu Glu Ala ThrLeu Leu Gly Cys Cys Gly Gly Gly Ala Val His 595 600 605 Gly Met Asp SerThr Ser Ile Val Gly Asn Ser Ser Val Arg Phe Gly 610 615 620 Asn Asn TyrAla Met Gly Gln Gly Val Ser Gly Gly Ala Leu Leu Ser 625 630 635 640 LysThr Val Gln Leu Ala Gly Asn Gly Ser Val Asp Phe Ser Arg Asn 645 650 655Ile Ala Ser Leu Gly Gly Gly Ala Leu Gln Ala Ser Glu Gly Asn Cys 660 665670 Glu Leu Val Asp Asn Gly Tyr Val Leu Phe Arg Asp Asn Arg Gly Arg 675680 685 Val Tyr Gly Gly Ala Ile Ser Cys Leu Arg Gly Asp Val Val Ile Ser690 695 700 Gly Asn Lys Gly Arg Val Glu Phe Lys Asp Asn Ile Ala Thr ArgLeu 705 710 715 720 Tyr Val Glu Glu Thr Val Glu Lys Val Glu Glu Val GluPro Ala Pro 725 730 735 Glu Gln Lys Asp Asn Asn Glu Leu Ser Phe Leu GlySer Val Glu Gln 740 745 750 Ser Phe Ile Thr Ala Ala Asn Gln Ala Leu PheAla Ser Glu Asp Gly 755 760 765 Asp Leu Ser Pro Glu Ser Ser Ile Ser SerGlu Glu Leu Ala Lys Arg 770 775 780 Arg Glu Cys Ala Gly Gly Ala Ile PheAla Lys Arg Val Arg Ile Val 785 790 795 800 Asp Asn Gln Glu Ala Val ValPhe Ser Asn Asn Phe Ser Asp Ile Tyr 805 810 815 Gly Gly Ala Ile Phe ThrGly Ser Leu Arg Glu Glu Asp Lys Leu Asp 820 825 830 Gly Gln Ile Pro GluVal Leu Ile Ser Gly Asn Ala Gly Asp Val Val 835 840 845 Phe Ser Gly AsnSer Ser Lys Arg Asp Glu His Leu Pro His Thr Gly 850 855 860 Gly Gly AlaIle Cys Thr Gln Asn Leu Thr Ile Ser Gln Asn Thr Gly 865 870 875 880 AsnVal Leu Phe Tyr Asn Asn Val Ala Cys Ser Gly Gly Ala Val Arg 885 890 895Ile Glu Asp His Gly Asn Val Leu Leu Glu Ala Phe Gly Gly Asp Ile 900 905910 Val Phe Lys Gly Asn Ser Ser Phe Arg Ala Gln Gly Ser Asp Ala Ile 915920 925 Tyr Phe Ala Gly Lys Glu Ser His Ile Thr Ala Leu Asn Ala Thr Glu930 935 940 Gly His Ala Ile Val Phe His Asp Ala Leu Val Phe Glu Asn LeuLys 945 950 955 960 Glu Arg Lys Ser Ala Glu Val Leu Leu Ile Asn Ser ArgGlu Asn Pro 965 970 975 Gly Tyr Thr Gly Ser Ile Arg Phe Leu Glu Ala GluSer Lys Val Pro 980 985 990 Gln Cys Ile His Val Gln Gln Gly Ser Leu GluLeu Leu Asn Gly Ala 995 1000 1005 Thr Leu Cys Ser Tyr Gly Phe Lys GlnAsp Ala Gly Ala Lys Leu Val 1010 1015 1020 Leu Ala Ala Gly Ser Lys LeuLys Ile Leu Asp Ser Gly Thr Pro Val 1025 1030 1035 1040 Gln Gly His AlaIle Ser Lys Pro Glu Ala Glu Ile Glu Ser Ser Ser 1045 1050 1055 Glu ProGlu Gly Ala His Ser Leu Trp Ile Ala Lys Asn Ala Gln Thr 1060 1065 1070Thr Val Pro Met Val Asp Ile His Thr Ile Ser Val Asp Leu Ala Ser 10751080 1085 Phe Ser Ser Ser Gln Gln Glu Gly Thr Val Glu Ala Pro Gln ValIle 1090 1095 1100 Val Pro Gly Gly Ser Tyr Val Arg Ser Gly Glu Leu AsnLeu Glu Leu 1105 1110 1115 1120 Val Asn Thr Thr Gly Thr Gly Tyr Glu AsnHis Ala Leu Leu Lys Asn 1125 1130 1135 Glu Ala Lys Val Pro Leu Met SerPhe Val Ala Ser Ser Asp Glu Ala 1140 1145 1150 Ser Ala Glu Ile Ser AsnLeu Ser Val Ser Asp Leu Gln Ile His Val 1155 1160 1165 Ala Thr Pro GluIle Glu Glu Asp Thr Tyr Gly His Met Gly Asp Trp 1170 1175 1180 Ser GluAla Lys Ile Gln Asp Gly Thr Leu Val Ile Asn Trp Asn Pro 1185 1190 11951200 Thr Gly Tyr Arg Leu Asp Pro Gln Lys Ala Gly Ala Leu Val Phe Asn1205 1210 1215 Ala Leu Trp Glu Glu Gly Ala Val Leu Ser Ala Leu Lys AsnAla Arg 1220 1225 1230 Phe Ala His Asn Leu Thr Ala Gln Arg Met Glu PheAsp Tyr Ser Thr 1235 1240 1245 Asn Val Trp Gly Phe Ala Phe Gly Gly PheArg Thr Leu Ser Ala Glu 1250 1255 1260 Asn Leu Val Ala Ile Asp Gly TyrLys Gly Ala Tyr Gly Gly Ala Ser 1265 1270 1275 1280 Ala Gly Val Asp IleGln Leu Met Glu Asp Phe Val Leu Gly Val Ser 1285 1290 1295 Gly Ala AlaPhe Leu Gly Lys Met Asp Ser Gln Lys Phe Asp Ala Glu 1300 1305 1310 ValSer Arg Lys Gly Val Val Gly Ser Val Tyr Thr Gly Phe Leu Ala 1315 13201325 Gly Ser Trp Phe Phe Lys Gly Gln Tyr Ser Leu Gly Glu Thr Gln Asn1330 1335 1340 Asp Met Lys Thr Arg Tyr Gly Val Leu Gly Glu Ser Ser AlaSer Trp 1345 1350 1355 1360 Thr Ser Arg Gly Val Leu Ala Asp Ala Leu ValGlu Tyr Arg Ser Leu 1365 1370 1375 Val Gly Pro Val Arg Pro Thr Phe TyrAla Leu His Phe Asn Pro Tyr 1380 1385 1390 Val Glu Val Ser Tyr Ala SerMet Lys Phe Pro Gly Phe Thr Glu Gln 1395 1400 1405 Gly Arg Glu Ala ArgSer Phe Glu Asp Ala Ser Leu Thr Asn Ile Thr 1410 1415 1420 Ile Pro LeuGly Met Lys Phe Glu Leu Ala Phe Ile Lys Gly Gln Phe 1425 1430 1435 1440Ser Glu Val Asn Ser Leu Gly Ile Ser Tyr Ala Trp Glu Ala Tyr Arg 14451450 1455 Lys Val Glu Gly Gly Ala Val Gln Leu Leu Glu Ala Gly Phe AspTrp 1460 1465 1470 Glu Gly Ala Pro Met Asp Leu Pro Arg Gln Glu Leu ArgVal Ala Leu 1475 1480 1485 Glu Asn Asn Thr Glu Trp Ser Ser Tyr Phe SerThr Val Leu Gly Leu 1490 1495 1500 Thr Ala Phe Cys Gly Gly Phe Thr SerThr Asp Ser Lys Leu Gly Tyr 1505 1510 1515 1520 Glu Ala Asn Thr Gly LeuArg Leu Ile Phe 1525 1530 179 1776 PRT Chlamydia 179 Ala Ile Met Lys PheMet Ser Ala Thr Ala Val Phe Ala Ala Val Leu 1 5 10 15 Ser Ser Val ThrGlu Ala Ser Ser Ile Gln Asp Gln Ile Lys Asn Thr 20 25 30 Asp Cys Asn ValSer Lys Val Gly Tyr Ser Thr Ser Gln Ala Phe Thr 35 40 45 Asp Met Met LeuAla Asp Asn Thr Glu Tyr Arg Ala Ala Asp Ser Val 50 55 60 Ser Phe Tyr AspPhe Ser Thr Ser Ser Gly Leu Pro Arg Lys His Leu 65 70 75 80 Ser Ser SerSer Glu Ala Ser Pro Thr Thr Glu Gly Val Ser Ser Ser 85 90 95 Ser Ser GlyGlu Asn Thr Glu Asn Ser Gln Asp Ser Ala Pro Ser Ser 100 105 110 Gly GluThr Asp Lys Lys Thr Glu Glu Glu Leu Asp Asn Gly Gly Ile 115 120 125 IleTyr Ala Arg Glu Lys Leu Thr Ile Ser Glu Ser Gln Asp Ser Leu 130 135 140Ser Asn Pro Ser Ile Glu Leu His Asp Asn Ser Phe Phe Phe Gly Glu 145 150155 160 Gly Glu Val Ile Phe Asp His Arg Val Ala Leu Lys Asn Gly Gly Ala165 170 175 Ile Tyr Gly Glu Lys Glu Val Val Phe Glu Asn Ile Lys Ser LeuLeu 180 185 190 Val Glu Val Asn Ile Ser Val Glu Lys Gly Gly Ser Val TyrAla Lys 195 200 205 Glu Arg Val Ser Leu Glu Asn Val Thr Glu Ala Thr PheSer Ser Asn 210 215 220 Gly Gly Glu Gln Gly Gly Gly Gly Ile Tyr Ser GluGln Asp Met Leu 225 230 235 240 Ile Ser Asp Cys Asn Asn Val His Phe GlnGly Asn Ala Ala Gly Ala 245 250 255 Thr Ala Val Lys Gln Cys Leu Asp GluGlu Met Ile Val Leu Leu Thr 260 265 270 Glu Cys Val Asp Ser Leu Ser GluAsp Thr Leu Asp Ser Thr Pro Glu 275 280 285 Thr Glu Gln Thr Lys Ser AsnGly Asn Gln Asp Gly Ser Ser Glu Thr 290 295 300 Lys Asp Thr Gln Val SerGlu Ser Pro Glu Ser Thr Pro Ser Pro Asp 305 310 315 320 Asp Val Leu GlyLys Gly Gly Gly Ile Tyr Thr Glu Lys Ser Leu Thr 325 330 335 Ile Thr GlyIle Thr Gly Thr Ile Asp Phe Val Ser Asn Ile Ala Thr 340 345 350 Asp SerGly Ala Gly Val Phe Thr Lys Glu Asn Leu Ser Cys Thr Asn 355 360 365 ThrAsn Ser Leu Gln Phe Leu Lys Asn Ser Ala Gly Gln His Gly Gly 370 375 380Gly Ala Tyr Val Thr Gln Thr Met Ser Val Thr Asn Thr Thr Ser Glu 385 390395 400 Ser Ile Thr Thr Pro Pro Leu Val Gly Glu Val Ile Phe Ser Glu Asn405 410 415 Thr Ala Lys Gly His Gly Gly Gly Ile Cys Thr Asn Lys Leu SerLeu 420 425 430 Ser Asn Leu Lys Thr Val Thr Leu Thr Lys Asn Ser Ala LysGlu Ser 435 440 445 Gly Gly Ala Ile Phe Thr Asp Leu Ala Ser Ile Pro ThrThr Asp Thr 450 455 460 Pro Glu Ser Ser Thr Pro Ser Ser Ser Ser Pro AlaSer Thr Pro Glu 465 470 475 480 Val Val Ala Ser Ala Lys Ile Asn Arg PhePhe Ala Ser Thr Ala Glu 485 490 495 Pro Ala Ala Pro Ser Leu Thr Glu AlaGlu Ser Asp Gln Thr Asp Gln 500 505 510 Thr Glu Thr Ser Asp Thr Asn SerAsp Ile Asp Val Ser Ile Glu Asn 515 520 525 Ile Leu Asn Val Ala Ile AsnGln Asn Thr Ser Ala Lys Lys Gly Gly 530 535 540 Ala Ile Tyr Gly Lys LysAla Lys Leu Ser Arg Ile Asn Asn Leu Glu 545 550 555 560 Leu Ser Gly AsnSer Ser Gln Asp Val Gly Gly Gly Leu Cys Leu Thr 565 570 575 Glu Ser ValGlu Phe Asp Ala Ile Gly Ser Leu Leu Ser His Tyr Asn 580 585 590 Ser AlaAla Lys Glu Gly Gly Val Ile His Ser Lys Thr Val Thr Leu 595 600 605 SerAsn Leu Lys Ser Thr Phe Thr Phe Ala Asp Asn Thr Val Lys Ala 610 615 620Ile Val Glu Ser Thr Pro Glu Ala Pro Glu Glu Ile Pro Pro Val Glu 625 630635 640 Gly Glu Glu Ser Thr Ala Thr Glu Asn Pro Asn Ser Asn Thr Glu Gly645 650 655 Ser Ser Ala Asn Thr Asn Leu Glu Gly Ser Gln Gly Asp Thr AlaAsp 660 665 670 Thr Gly Thr Gly Val Val Asn Asn Glu Ser Gln Asp Thr SerAsp Thr 675 680 685 Gly Asn Ala Glu Ser Gly Glu Gln Leu Gln Asp Ser ThrGln Ser Asn 690 695 700 Glu Glu Asn Thr Leu Pro Asn Ser Ser Ile Asp GlnSer Asn Glu Asn 705 710 715 720 Thr Asp Glu Ser Ser Asp Ser His Thr GluGlu Ile Thr Asp Glu Ser 725 730 735 Val Ser Ser Ser Ser Lys Ser Gly SerSer Thr Pro Gln Asp Gly Gly 740 745 750 Ala Ala Ser Ser Gly Ala Pro SerGly Asp Gln Ser Ile Ser Ala Asn 755 760 765 Ala Cys Leu Ala Lys Ser TyrAla Ala Ser Thr Asp Ser Ser Pro Val 770 775 780 Ser Asn Ser Ser Gly SerAsp Val Thr Ala Ser Ser Asp Asn Pro Asp 785 790 795 800 Ser Ser Ser SerGly Asp Ser Ala Gly Asp Ser Glu Gly Pro Thr Glu 805 810 815 Pro Glu AlaGly Ser Thr Thr Glu Thr Pro Thr Leu Ile Gly Gly Gly 820 825 830 Ala IleTyr Gly Glu Thr Val Lys Ile Glu Asn Phe Ser Gly Gln Gly 835 840 845 IlePhe Ser Gly Asn Lys Ala Ile Asp Asn Thr Thr Glu Gly Ser Ser 850 855 860Ser Lys Ser Asn Val Leu Gly Gly Ala Val Tyr Ala Lys Thr Leu Phe 865 870875 880 Asn Leu Asp Ser Gly Ser Ser Arg Arg Thr Val Thr Phe Ser Gly Asn885 890 895 Thr Val Ser Ser Gln Ser Thr Thr Gly Gln Val Ala Gly Gly AlaIle 900 905 910 Tyr Ser Pro Thr Val Thr Ile Ala Thr Pro Val Val Phe SerLys Asn 915 920 925 Ser Ala Thr Asn Asn Ala Asn Asn Ala Thr Asp Thr GlnArg Lys Asp 930 935 940 Thr Phe Gly Gly Ala Ile Gly Ala Thr Ser Ala ValSer Leu Ser Gly 945 950 955 960 Gly Ala His Phe Leu Glu Asn Val Ala AspLeu Gly Ser Ala Ile Gly 965 970 975 Leu Val Pro Asp Thr Gln Asn Thr GluThr Val Lys Leu Glu Ser Gly 980 985 990 Ser Tyr Tyr Phe Glu Lys Asn LysAla Leu Lys Arg Ala Thr Ile Tyr 995 1000 1005 Ala Pro Val Val Ser IleLys Ala Tyr Thr Ala Thr Phe Asn Gln Asn 1010 1015 1020 Arg Ser Leu GluGlu Gly Ser Ala Ile Tyr Phe Thr Lys Glu Ala Ser 1025 1030 1035 1040 IleGlu Ser Leu Gly Ser Val Leu Phe Thr Gly Asn Leu Val Thr Pro 1045 10501055 Thr Leu Ser Thr Thr Thr Glu Gly Thr Pro Ala Thr Thr Ser Gly Asp1060 1065 1070 Val Thr Lys Tyr Gly Ala Ala Ile Phe Gly Gln Ile Ala SerSer Asn 1075 1080 1085 Gly Ser Gln Thr Asp Asn Leu Pro Leu Lys Leu IleAla Ser Gly Gly 1090 1095 1100 Asn Ile Cys Phe Arg Asn Asn Glu Tyr ArgPro Thr Ser Ser Asp Thr 1105 1110 1115 1120 Gly Thr Ser Thr Phe Cys SerIle Ala Gly Asp Val Lys Leu Thr Met 1125 1130 1135 Gln Ala Ala Lys GlyLys Thr Ile Ser Phe Phe Asp Ala Ile Arg Thr 1140 1145 1150 Ser Thr LysLys Thr Gly Thr Gln Ala Thr Ala Tyr Asp Thr Leu Asp 1155 1160 1165 IleAsn Lys Ser Glu Asp Ser Glu Thr Val Asn Ser Ala Phe Thr Gly 1170 11751180 Thr Ile Leu Phe Ser Ser Glu Leu His Glu Asn Lys Ser Tyr Ile Pro1185 1190 1195 1200 Gln Asn Val Val Leu His Ser Gly Ser Leu Val Leu LysPro Asn Thr 1205 1210 1215 Glu Leu His Val Ile Ser Phe Glu Gln Lys GluGly Ser Ser Leu Val 1220 1225 1230 Met Thr Pro Gly Ser Val Leu Ser AsnGln Thr Val Ala Asp Gly Ala 1235 1240 1245 Leu Val Ile Asn Asn Met ThrIle Asp Leu Ser Ser Val Glu Lys Asn 1250 1255 1260 Gly Ile Ala Glu GlyAsn Ile Phe Thr Pro Pro Glu Leu Arg Ile Ile 1265 1270 1275 1280 Asp ThrThr Thr Ser Gly Ser Gly Gly Thr Pro Ser Thr Asp Ser Glu 1285 1290 1295Ser Asn Gln Asn Ser Asp Asp Thr Lys Glu Gln Asn Asn Asn Asp Ala 13001305 1310 Ser Asn Gln Gly Glu Ser Ala Asn Gly Ser Ser Ser Pro Ala ValAla 1315 1320 1325 Ala Ala His Thr Ser Arg Thr Arg Asn Phe Ala Ala AlaAla Thr Ala 1330 1335 1340 Thr Pro Thr Thr Thr Pro Thr Ala Thr Thr ThrThr Ser Asn Gln Val 1345 1350 1355 1360 Ile Leu Gly Gly Glu Ile Lys LeuIle Asp Pro Asn Gly Thr Phe Phe 1365 1370 1375 Gln Asn Pro Ala Leu ArgSer Asp Gln Gln Ile Ser Leu Leu Val Leu 1380 1385 1390 Pro Thr Asp SerSer Lys Met Gln Ala Gln Lys Ile Val Leu Thr Gly 1395 1400 1405 Asp IleAla Pro Gln Lys Gly Tyr Thr Gly Thr Leu Thr Leu Asp Pro 1410 1415 1420Asp Gln Leu Gln Asn Gly Thr Ile Ser Ala Leu Trp Lys Phe Asp Ser 14251430 1435 1440 Tyr Arg Gln Trp Ala Tyr Val Pro Arg Asp Asn His Phe TyrAla Asn 1445 1450 1455 Ser Ile Leu Gly Ser Gln Met Ser Met Val Thr ValLys Gln Gly Leu 1460 1465 1470 Leu Asn Asp Lys Met Asn Leu Ala Arg PheAsp Glu Val Ser Tyr Asn 1475 1480 1485 Asn Leu Trp Ile Ser Gly Leu GlyThr Met Leu Ser Gln Val Gly Thr 1490 1495 1500 Pro Thr Ser Glu Glu PheThr Tyr Tyr Ser Arg Gly Ala Ser Val Ala 1505 1510 1515 1520 Leu Asp AlaLys Pro Ala His Asp Val Ile Val Gly Ala Ala Phe Ser 1525 1530 1535 LysMet Ile Gly Lys Thr Lys Ser Leu Lys Arg Glu Asn Asn Tyr Thr 1540 15451550 His Lys Gly Ser Glu Tyr Ser Tyr Gln Ala Ser Val Tyr Gly Gly Lys1555 1560 1565 Pro Phe His Phe Val Ile Asn Lys Lys Thr Glu Lys Ser LeuPro Leu 1570 1575 1580 Leu Leu Gln Gly Val Ile Ser Tyr Gly Tyr Ile LysHis Asp Thr Val 1585 1590 1595 1600 Thr His Tyr Pro Thr Ile Arg Glu ArgAsn Gln Gly Glu Trp Glu Asp 1605 1610 1615 Leu Gly Trp Leu Thr Ala LeuArg Val Ser Ser Val Leu Arg Thr Pro 1620 1625 1630 Ala Gln Gly Asp ThrLys Arg Ile Thr Val Tyr Gly Glu Leu Glu Tyr 1635 1640 1645 Ser Ser IleArg Gln Lys Gln Phe Thr Glu Thr Glu Tyr Asp Pro Arg 1650 1655 1660 TyrPhe Asp Asn Cys Thr Tyr Arg Asn Leu Ala Ile Pro Met Gly Leu 1665 16701675 1680 Ala Phe Glu Gly Glu Leu Ser Gly Asn Asp Ile Leu Met Tyr AsnArg 1685 1690 1695 Phe Ser Val Ala Tyr Met Pro Ser Ile Tyr Arg Asn SerPro Thr Cys 1700 1705 1710 Lys Tyr Gln Val Leu Ser Ser Gly Glu Gly GlyGlu Ile Ile Cys Gly 1715 1720 1725 Val Pro Thr Arg Asn Ser Ala Arg GlyGlu Tyr Ser Thr Gln Leu Tyr 1730 1735 1740 Pro Gly Pro Leu Trp Thr LeuTyr Gly Ser Tyr Thr Ile Glu Ala Asp 1745 1750 1755 1760 Ala His Thr LeuAla His Met Met Asn Cys Gly Ala Arg Met Thr Phe 1765 1770 1775 180 1752PRT Chlamydia 180 Met Lys Trp Leu Ser Ala Thr Ala Val Phe Ala Ala ValLeu Pro Ser 1 5 10 15 Val Ser Gly Phe Cys Phe Pro Glu Pro Lys Glu LeuAsn Phe Ser Arg 20 25 30 Val Glu Thr Ser Ser Ser Thr Thr Phe Thr Glu ThrIle Gly Glu Ala 35 40 45 Gly Ala Glu Tyr Ile Val Ser Gly Asn Ala Ser PheThr Lys Phe Thr 50 55 60 Asn Ile Pro Thr Thr Asp Thr Thr Thr Pro Thr AsnSer Asn Ser Ser 65 70 75 80 Ser Ser Ser Gly Glu Thr Ala Ser Val Ser GluAsp Ser Asp Ser Thr 85 90 95 Thr Thr Thr Pro Asp Pro Lys Gly Gly Gly AlaPhe Tyr Asn Ala His 100 105 110 Ser Gly Val Leu Ser Phe Met Thr Arg SerGly Thr Glu Gly Ser Leu 115 120 125 Thr Leu Ser Glu Ile Lys Met Thr GlyGlu Gly Gly Ala Ile Phe Ser 130 135 140 Gln Gly Glu Leu Leu Phe Thr AspLeu Thr Ser Leu Thr Ile Gln Asn 145 150 155 160 Asn Leu Ser Gln Leu SerGly Gly Ala Ile Phe Gly Gly Ser Thr Ile 165 170 175 Ser Leu Ser Gly IleThr Lys Ala Thr Phe Ser Cys Asn Ser Ala Glu 180 185 190 Val Pro Ala ProVal Lys Lys Pro Thr Glu Pro Lys Ala Gln Thr Ala 195 200 205 Ser Glu ThrSer Gly Ser Ser Ser Ser Ser Gly Asn Asp Ser Val Ser 210 215 220 Ser ProSer Ser Ser Arg Ala Glu Pro Ala Ala Ala Asn Leu Gln Ser 225 230 235 240His Phe Ile Cys Ala Thr Ala Thr Pro Ala Ala Gln Thr Asp Thr Glu 245 250255 Thr Ser Thr Pro Ser His Lys Pro Gly Ser Gly Gly Ala Ile Tyr Ala 260265 270 Lys Gly Asp Leu Thr Ile Ala Asp Ser Gln Glu Val Leu Phe Ser Ile275 280 285 Asn Lys Ala Thr Lys Asp Gly Gly Ala Ile Phe Ala Glu Lys AspVal 290 295 300 Ser Phe Glu Asn Ile Thr Ser Leu Lys Val Gln Thr Asn GlyAla Glu 305 310 315 320 Glu Lys Gly Gly Ala Ile Tyr Ala Lys Gly Asp LeuSer Ile Gln Ser 325 330 335 Ser Lys Gln Ser Leu Phe Asn Ser Asn Tyr SerLys Gln Gly Gly Gly 340 345 350 Ala Leu Tyr Val Glu Gly Gly Ile Asn PheGln Asp Leu Glu Glu Ile 355 360 365 Arg Ile Lys Tyr Asn Lys Ala Gly ThrPhe Glu Thr Lys Lys Ile Thr 370 375 380 Leu Pro Ser Leu Lys Ala Gln AlaSer Ala Gly Asn Ala Asp Ala Trp 385 390 395 400 Ala Ser Ser Ser Pro GlnSer Gly Ser Gly Ala Thr Thr Val Ser Asp 405 410 415 Ser Gly Asp Ser SerSer Gly Ser Asp Ser Asp Thr Ser Glu Thr Val 420 425 430 Pro Val Thr AlaLys Gly Gly Gly Leu Tyr Thr Asp Lys Asn Leu Ser 435 440 445 Ile Thr AsnIle Thr Gly Ile Ile Glu Ile Ala Asn Asn Lys Ala Thr 450 455 460 Asp ValGly Gly Gly Ala Tyr Val Lys Gly Thr Leu Thr Cys Glu Asn 465 470 475 480Ser His Arg Leu Gln Phe Leu Lys Asn Ser Ser Asp Lys Gln Gly Gly 485 490495 Gly Ile Tyr Gly Glu Asp Asn Ile Thr Leu Ser Asn Leu Thr Gly Lys 500505 510 Thr Leu Phe Gln Glu Asn Thr Ala Lys Glu Glu Gly Gly Gly Leu Phe515 520 525 Ile Lys Gly Thr Asp Lys Ala Leu Thr Met Thr Gly Leu Asp SerPhe 530 535 540 Cys Leu Ile Asn Asn Thr Ser Glu Lys His Gly Gly Gly AlaPhe Val 545 550 555 560 Thr Lys Glu Ile Ser Gln Thr Tyr Thr Ser Asp ValGlu Thr Ile Pro 565 570 575 Gly Ile Thr Pro Val His Gly Glu Thr Val IleThr Gly Asn Lys Ser 580 585 590 Thr Gly Gly Asn Gly Gly Gly Val Cys ThrLys Arg Leu Ala Leu Ser 595 600 605 Asn Leu Gln Ser Ile Ser Ile Ser GlyAsn Ser Ala Ala Glu Asn Gly 610 615 620 Gly Gly Ala His Thr Cys Pro AspSer Phe Pro Thr Ala Asp Thr Ala 625 630 635 640 Glu Gln Pro Ala Ala AlaSer Ala Ala Thr Ser Thr Pro Lys Ser Ala 645 650 655 Pro Val Ser Thr AlaLeu Ser Thr Pro Ser Ser Ser Thr Val Ser Ser 660 665 670 Leu Thr Leu LeuAla Ala Ser Ser Gln Ala Ser Pro Ala Thr Ser Asn 675 680 685 Lys Glu ThrGln Asp Pro Asn Ala Asp Thr Asp Leu Leu Ile Asp Tyr 690 695 700 Val ValAsp Thr Thr Ile Ser Lys Asn Thr Ala Lys Lys Gly Gly Gly 705 710 715 720Ile Tyr Ala Lys Lys Ala Lys Met Ser Arg Ile Asp Gln Leu Asn Ile 725 730735 Ser Glu Asn Ser Ala Thr Glu Ile Gly Gly Gly Ile Cys Cys Lys Glu 740745 750 Ser Leu Glu Leu Asp Ala Leu Val Ser Leu Ser Val Thr Glu Asn Leu755 760 765 Val Gly Lys Glu Gly Gly Gly Leu His Ala Lys Thr Val Asn IleSer 770 775 780 Asn Leu Lys Ser Gly Phe Ser Phe Ser Asn Asn Lys Ala AsnSer Ser 785 790 795 800 Ser Thr Gly Val Ala Thr Thr Ala Ser Ala Pro AlaAla Ala Ala Ala 805 810 815 Ser Leu Gln Ala Ala Ala Ala Ala Ala Pro SerSer Pro Ala Thr Pro 820 825 830 Thr Tyr Ser Gly Val Val Gly Gly Ala IleTyr Gly Glu Lys Val Thr 835 840 845 Phe Ser Gln Cys Ser Gly Thr Cys GlnPhe Ser Gly Asn Gln Ala Ile 850 855 860 Asp Asn Asn Pro Ser Gln Ser SerLeu Asn Val Gln Gly Gly Ala Ile 865 870 875 880 Tyr Ala Lys Thr Ser LeuSer Ile Gly Ser Ser Asp Ala Gly Thr Ser 885 890 895 Tyr Ile Phe Ser GlyAsn Ser Val Ser Thr Gly Lys Ser Gln Thr Thr 900 905 910 Gly Gln Ile AlaGly Gly Ala Ile Tyr Ser Pro Thr Val Thr Leu Asn 915 920 925 Cys Pro AlaThr Phe Ser Asn Asn Thr Ala Ser Ile Ala Thr Pro Lys 930 935 940 Thr SerSer Glu Asp Gly Ser Ser Gly Asn Ser Ile Lys Asp Thr Ile 945 950 955 960Gly Gly Ala Ile Ala Gly Thr Ala Ile Thr Leu Ser Gly Val Ser Arg 965 970975 Phe Ser Gly Asn Thr Ala Asp Leu Gly Ala Ala Ile Gly Thr Leu Ala 980985 990 Asn Ala Asn Thr Pro Ser Ala Thr Ser Gly Ser Gln Asn Ser Ile Thr995 1000 1005 Glu Lys Ile Thr Leu Glu Asn Gly Ser Phe Ile Phe Glu ArgAsn Gln 1010 1015 1020 Ala Asn Lys Arg Gly Ala Ile Tyr Ser Pro Ser ValSer Ile Lys Gly 1025 1030 1035 1040 Asn Asn Ile Thr Phe Asn Gln Asn ThrSer Thr His Asp Gly Ser Ala 1045 1050 1055 Ile Tyr Phe Thr Lys Asp AlaThr Ile Glu Ser Leu Gly Ser Val Leu 1060 1065 1070 Phe Thr Gly Asn AsnVal Thr Ala Thr Gln Ala Ser Ser Ala Thr Ser 1075 1080 1085 Gly Gln AsnThr Asn Thr Ala Asn Tyr Gly Ala Ala Ile Phe Gly Asp 1090 1095 1100 ProGly Thr Thr Gln Ser Ser Gln Thr Asp Ala Ile Leu Thr Leu Leu 1105 11101115 1120 Ala Ser Ser Gly Asn Ile Thr Phe Ser Asn Asn Ser Leu Gln AsnAsn 1125 1130 1135 Gln Gly Asp Thr Pro Ala Ser Lys Phe Cys Ser Ile AlaGly Tyr Val 1140 1145 1150 Lys Leu Ser Leu Gln Ala Ala Lys Gly Lys ThrIle Ser Phe Phe Asp 1155 1160 1165 Cys Val His Thr Ser Thr Lys Lys ThrGly Ser Thr Gln Asn Val Tyr 1170 1175 1180 Glu Thr Leu Asp Ile Asn LysGlu Glu Asn Ser Asn Pro Tyr Thr Gly 1185 1190 1195 1200 Thr Ile Val PheSer Ser Glu Leu His Glu Asn Lys Ser Tyr Ile Pro 1205 1210 1215 Gln AsnAla Ile Leu His Asn Gly Thr Leu Val Leu Lys Glu Lys Thr 1220 1225 1230Glu Leu His Val Val Ser Phe Glu Gln Lys Glu Gly Ser Lys Leu Ile 12351240 1245 Met Glu Pro Gly Ala Val Leu Ser Asn Gln Asn Ile Ala Asn GlyAla 1250 1255 1260 Leu Ala Ile Asn Gly Leu Thr Ile Asp Leu Ser Ser MetGly Thr Pro 1265 1270 1275 1280 Gln Ala Gly Glu Ile Phe Ser Pro Pro GluLeu Arg Ile Val Ala Thr 1285 1290 1295 Thr Ser Ser Ala Ser Gly Gly SerGly Val Ser Ser Ser Ile Pro Thr 1300 1305 1310 Asn Pro Lys Arg Ile SerAla Ala Val Pro Ser Gly Ser Ala Ala Thr 1315 1320 1325 Thr Pro Thr MetSer Glu Asn Lys Val Phe Leu Thr Gly Asp Leu Thr 1330 1335 1340 Leu IleAsp Pro Asn Gly Asn Phe Tyr Gln Asn Pro Met Leu Gly Ser 1345 1350 13551360 Asp Leu Asp Val Pro Leu Ile Lys Leu Pro Thr Asn Thr Ser Asp Val1365 1370 1375 Gln Val Tyr Asp Leu Thr Leu Ser Gly Asp Leu Phe Pro GlnLys Gly 1380 1385 1390 Tyr Met Gly Thr Trp Thr Leu Asp Ser Asn Pro GlnThr Gly Lys Leu 1395 1400 1405 Gln Ala Arg Trp Thr Phe Asp Thr Tyr ArgArg Trp Val Tyr Ile Pro 1410 1415 1420 Arg Asp Asn His Phe Tyr Ala AsnSer Ile Leu Gly Ser Gln Asn Ser 1425 1430 1435 1440 Met Ile Val Val LysGln Gly Leu Ile Asn Asn Met Leu Asn Asn Ala 1445 1450 1455 Arg Phe AspAsp Ile Ala Tyr Asn Asn Phe Trp Val Ser Gly Val Gly 1460 1465 1470 ThrPhe Leu Ala Gln Gln Gly Thr Pro Leu Ser Glu Glu Phe Ser Tyr 1475 14801485 Tyr Ser Arg Gly Thr Ser Val Ala Ile Asp Ala Lys Pro Arg Gln Asp1490 1495 1500 Phe Ile Leu Gly Ala Ala Phe Ser Lys Ile Val Gly Lys ThrLys Ala 1505 1510 1515 1520 Ile Lys Lys Met His Asn Tyr Phe His Lys GlySer Glu Tyr Ser Tyr 1525 1530 1535 Gln Ala Ser Val Tyr Gly Gly Lys PheLeu Tyr Phe Leu Leu Asn Lys 1540 1545 1550 Gln His Gly Trp Ala Leu ProPhe Leu Ile Gln Gly Val Val Ser Tyr 1555 1560 1565 Gly His Ile Lys HisAsp Thr Thr Thr Leu Tyr Pro Ser Ile His Glu 1570 1575 1580 Arg Asn LysGly Asp Trp Glu Asp Leu Gly Trp Leu Ala Asp Leu Arg 1585 1590 1595 1600Ile Ser Met Asp Leu Lys Glu Pro Ser Lys Asp Ser Ser Lys Arg Ile 16051610 1615 Thr Val Tyr Gly Glu Leu Glu Tyr Ser Ser Ile Arg Gln Lys GlnPhe 1620 1625 1630 Thr Glu Ile Asp Tyr Asp Pro Arg His Phe Asp Asp CysAla Tyr Arg 1635 1640 1645 Asn Leu Ser Leu Pro Val Gly Cys Ala Val GluGly Ala Ile Met Asn 1650 1655 1660 Cys Asn Ile Leu Met Tyr Asn Lys LeuAla Leu Ala Tyr Met Pro Ser 1665 1670 1675 1680 Ile Tyr Arg Asn Asn ProVal Cys Lys Tyr Arg Val Leu Ser Ser Asn 1685 1690 1695 Glu Ala Gly GlnVal Ile Cys Gly Val Pro Thr Arg Thr Ser Ala Arg 1700 1705 1710 Ala GluTyr Ser Thr Gln Leu Tyr Leu Gly Pro Phe Trp Thr Leu Tyr 1715 1720 1725Gly Asn Tyr Thr Ile Asp Val Gly Met Tyr Thr Leu Ser Gln Met Thr 17301735 1740 Ser Cys Gly Ala Arg Met Ile Phe 1745 1750 181 2601 DNAChlamydia 181 atggctagcc atcaccatca ccatcacctc tttggccagg atcccttaggtgaaaccgcc 60 ctcctcacta aaaatcctaa tcatgtcgtc tgtacatttt ttgaggactgtaccatggag 120 agcctctttc ctgctctttg tgctcatgca tcacaagacg atcctttgtatgtacttgga 180 aattcctact gttggttcgt atctaaactc catatcacgg accccaaagaggctcttttt 240 aaagaaaaag gagatctttc cattcaaaac tttcgcttcc tttccttcacagattgctct 300 tccaaggaaa gctctccttc tattattcat caaaagaatg gtcagttatccttgcgcaat 360 aatggtagca tgagtttctg tcgaaatcat gctgaaggct ctggaggagccatctctgcg 420 gatgcctttt ctctacagca caactatctt ttcacagctt ttgaagagaattcttctaaa 480 ggaaatggcg gagccattca ggctcaaacc ttctctttat ctagaaatgtgtcgcctatt 540 tctttcgccc gtaatcgtgc ggatttaaat ggcggcgcta tttgctgtagtaatcttatt 600 tgttcaggga atgtaaaccc tctctttttc actggaaact ccgccacraatggaggcsct 660 atttgttgta tcagcgatct aaacacctca gaaaaaggct ctctctctcttgcttgtaac 720 caaraaacgc tatttgcaag caattctgct aaagaaaaag gcggggctatttatgccaag 780 cacatggtat tgcgttataa cggtcctgtt tccttcatta acaacagcgctaaaataggt 840 ggagctatcg ccatccagtc cggagggagt ctctctatcc ttgcaggtgaaggatctgtt 900 ctgttccaga ataactccca acgcacctcc gaccaaggtc tagtaagaaacgccatctac 960 ttagagaaag atgcgattct ttcttcctta gaagctcgca acggagatattcttttcttt 1020 gatcctattg tacaagaaag tagcagcaaa gaatcgcctc ttccctcctctttgcaagcc 1080 agcgtgactt ctcccacccc agccaccgca tctcctttag ttattcagacaagtgcaaac 1140 cgttcagtga ttttctcgag cgaacgtctt tctgaagaag aaaaaactcctgataacctc 1200 acttcccaac tacagcagcc tatcgaactg aaatccggac gcttagttttaaaagatcgc 1260 gctgtccttt ccgsgccttc tctctctcag gatcctcaag ctctcctcattatggaagcg 1320 ggaacttctt taaaaacttc ctytgatttg aagttagsta cgstaagtattccccttcat 1380 tccttagata ctgaaaaaag cgtaactatc cacgccccta atctttctatccaaaagatc 1440 ttcctctcta actctggaga tgagaatttt tatgaaaatg tagagcttctcagtaaagag 1500 caaaacaata ttcctctcct tactctccct aaagagcaat ctcatttacatcttcctgat 1560 gggaacctct cttctcactt tggatatcaa ggagattgga ctttttcttggaaagattct 1620 gatgaagggc attctctgat tgctaattgg acgcctaaaa actatgtgcctcatccagaa 1680 cgtcaatcta cactcgttgc gaacactctt tggaacacct attccgatatgcaagctgtg 1740 cagtcgatga ttaatacaac agcgcacgga ggagcctatc tatttggaacgtggggatct 1800 gctgtttcta atttattcta tgttcacgac agctctggga aacctatcgataattggcat 1860 catagaagcc ttggctacct attcggtatc agtactcaca gtttagatgaccattctttc 1920 tgcttggctg caggacaatt actcgggaaa tcgtccgatt cctttattacgtctacagaa 1980 acgacctcct atatagctac tgtacaagcg caactcgcta cctctctaatgaaaatctct 2040 gcacaggcat gctacaatga aagtatccat gagctaaaaa caaaatatcgctccttctct 2100 aaagaaggat tcggatcctg gcatagcgtt gcagtatccg gagaagtgtgcgcatcgatt 2160 cctattgtat ccaatggttc cggactgttc agctccttct ctattttctctaaactgcaa 2220 ggattttcag gaacacagga cggttttgag gagagttcgg gagagattcggtccttttct 2280 gccagctctt tcagaaatat ttcacttcct ataggaataa catttgaaaaaaaatcccaa 2340 aaaacacgaa cctactatta ctttctagga gcctacatcc aagacctgaaacgtgatgtg 2400 gaatcgggac ctgtagtgtt actcaaaaat gccgtctcct gggatgctcctatggcgaac 2460 ttggattcac gagcctacat gttccggctt acgaatcaaa gagctctacacagacttcag 2520 acgctgttaa atgtgtcttg tgtgctgcgt gggcaaagcc atagttactccctggatctg 2580 gggaccactt acaggttcta g 2601 182 3021 DNA Chlamydia 182atggctagca tgactggtgg acagcaaatg ggtcgggatt caagcttggt accgcatcac 60catcaccatc acatgattcc tcaaggaatt tacgatgggg agacgttaac tgtatcattt 120ccctatactg ttataggaga tccgagtggg actactgttt tttctgcagg agagttaaca 180ttaaaaaatc ttgacaattc tattgcagct ttgcctttaa gttgttttgg gaacttatta 240gggagtttta ctgttttagg gagaggacac tcgttgactt tcgagaacat acggacttct 300acaaatgggg cagctctaag taatagcgct gctgatggac tgtttactat tgagggtttt 360aaagaattat ccttttccaa ttgcaattca ttacttgccg tactgcctgc tgcaacgact 420aataagggta gccagactcc gacgacaaca tctacaccgt ctaatggtac tatttattct 480aaaacagatc ttttgttact caataatgag aagttctcat tctatagtaa tttagtctct 540ggagatgggg gagctataga tgctaagagc ttaacggttc aaggaattag caagctttgt 600gtcttccaag aaaatactgc tcaagctgat gggggagctt gtcaagtagt caccagtttc 660tctgctatgg ctaacgaggc tcctattgcc tttgtagcga atgttgcagg agtaagaggg 720ggagggattg ctgctgttca ggatgggcag cagggagtgt catcatctac ttcaacagaa 780gatccagtag taagtttttc cagaaatact gcggtagagt ttgatgggaa cgtagcccga 840gtaggaggag ggatttactc ctacgggaac gttgctttcc tgaataatgg aaaaaccttg 900tttctcaaca atgttgcttc tcctgtttac attgctgcta agcaaccaac aagtggacag 960gcttctaata cgagtaataa ttacggagat ggaggagcta tcttctgtaa gaatggtgcg 1020caagcaggat ccaataactc tggatcagtt tcctttgatg gagagggagt agttttcttt 1080agtagcaatg tagctgctgg gaaaggggga gctatttatg ccaaaaagct ctcggttgct 1140aactgtggcc ctgtacaatt tttaaggaat atcgctaatg atggtggagc gatttattta 1200ggagaatctg gagagctcag tttatctgct gattatggag atattatttt cgatgggaat 1260cttaaaagaa cagccaaaga gaatgctgcc gatgttaatg gcgtaactgt gtcctcacaa 1320gccatttcga tgggatcggg agggaaaata acgacattaa gagctaaagc agggcatcag 1380attctcttta atgatcccat cgagatggca aacggaaata accagccagc gcagtcttcc 1440aaacttctaa aaattaacga tggtgaagga tacacagggg atattgtttt tgctaatgga 1500agcagtactt tgtaccaaaa tgttacgata gagcaaggaa ggattgttct tcgtgaaaag 1560gcaaaattat cagtgaattc tctaagtcag acaggtggga gtctgtatat ggaagctggg 1620agtacattgg attttgtaac tccacaacca ccacaacagc ctcctgccgc taatcagttg 1680atcacgcttt ccaatctgca tttgtctctt tcttctttgt tagcaaacaa tgcagttacg 1740aatcctccta ccaatcctcc agcgcaagat tctcatcctg cagtcattgg tagcacaact 1800gctggttctg ttacaattag tgggcctatc ttttttgagg atttggatga tacagcttat 1860gataggtatg attggctagg ttctaatcaa aaaatcaatg tcctgaaatt acagttaggg 1920actaagcccc cagctaatgc cccatcagat ttgactctag ggaatgagat gcctaagtat 1980ggctatcaag gaagctggaa gcttgcgtgg gatcctaata cagcaaataa tggtccttat 2040actctgaaag ctacatggac taaaactggg tataatcctg ggcctgagcg agtagcttct 2100ttggttccaa atagtttatg gggatccatt ttagatatac gatctgcgca ttcagcaatt 2160caagcaagtg tggatgggcg ctcttattgt cgaggattat gggtttctgg agtttcgaat 2220ttcttctatc atgaccgcga tgctttaggt cagggatatc ggtatattag tgggggttat 2280tccttaggag caaactccta ctttggatca tcgatgtttg gtctagcatt taccgaagta 2340tttggtagat ctaaagatta tgtagtgtgt cgttccaatc atcatgcttg cataggatcc 2400gtttatctat ctacccaaca agctttatgt ggatcctatt tgttcggaga tgcgtttatc 2460cgtgctagct acgggtttgg gaatcagcat atgaaaacct catatacatt tgcagaggag 2520agcgatgttc gttgggataa taactgtctg gctggagaga ttggagcggg attaccgatt 2580gtgattactc catctaagct ctatttgaat gagttgcgtc ctttcgtgca agctgagttt 2640tcttatgccg atcatgaatc ttttacagag gaaggcgatc aagctcgggc attcaagagc 2700ggacatctcc taaatctatc agttcctgtt ggagtgaagt ttgatcgatg ttctagtaca 2760catcctaata aatatagctt tatggcggct tatatctgtg atgcttatcg caccatctct 2820ggtactgaga caacgctcct atcccatcaa gagacatgga caacagatgc ctttcattta 2880gcaagacatg gagttgtggt tagaggatct atgtatgctt ctctaacaag taatatagaa 2940gtatatggcc atggaagata tgagtatcga gatgcttctc gaggctatgg tttgagtgca 3000ggaagtaaag tccggttcta a 3021 183 2934 DNA Chlamydia 183 atggctagcatgactggtgg acagcaaatg ggtcgggatt caagcttggt accgagctcg 60 gatccacatcaccatcacca tcacggacta gctagagagg ttccttctag aatctttctt 120 atgcccaactcagttccaga tcctacgaaa gagtcgctat caaataaaat tagtttgaca 180 ggagacactcacaatctcac taactgctat ctcgataacc tacgctacat actggctatt 240 ctacaaaaaactcccaatga aggagctgct gtcacaataa cagattacct aagctttttt 300 gatacacaaaaagaaggtat ttattttgca aaaaatctca cccctgaaag tggtggtgcg 360 attggttatgcgagtcccaa ttctcctacc gtggagattc gtgatacaat aggtcctgta 420 atctttgaaaataatacttg ttgcagacta tttacatgga gaaatcctta tgctgctgat 480 aaaataagagaaggcggagc cattcatgct caaaatcttt acataaatca taatcatgat 540 gtggtcggatttatgaagaa cttttcttat gtccaaggag gagccattag taccgctaat 600 acctttgttgtgagcgagaa tcagtcttgt tttctcttta tggacaacat ctgtattcaa 660 actaatacagcaggaaaagg tggcgctatc tatgctggaa cgagcaattc ttttgagagt 720 aataactgcgatctcttctt catcaataac gcctgttgtg caggaggagc gatcttctcc 780 cctatctgttctctaacagg aaatcgtggt aacatcgttt tctataacaa tcgctgcttt 840 aaaaatgtagaaacagcttc ttcagaagct tctgatggag gagcaattaa agtaactact 900 cgcctagatgttacaggcaa tcgtggtagg atctttttta gtgacaatat cacaaaaaat 960 tatggcggagctatttacgc tcctgtagtt accctagtgg ataatggccc tacctacttt 1020 ataaacaatatcgccaataa taaggggggc gctatctata tagacggaac cagtaactcc 1080 aaaatttctgccgaccgcca tgctattatt tttaatgaaa atattgtgac taatgtaact 1140 aatgcaaatggtaccagtac gtcagctaat cctcctagaa gaaatgcaat aacagtagca 1200 agctcctctggtgaaattct attaggagca gggagtagcc aaaatttaat tttttatgat 1260 cctattgaagttagcaatgc aggggtctct gtgtccttca ataaggaagc tgatcaaaca 1320 ggctctgtagtattttcagg agctactgtt aattctgcag attttcatca acgcaattta 1380 caaacaaaaacacctgcacc ccttactctc agtaatggtt ttctatgtat cgaagatcat 1440 gctcagcttacagtgaatcg attcacacaa actgggggtg ttgtttctct tgggaatgga 1500 gcagttctgagttgctataa aaatggtaca ggagattctg ctagcaatgc ctctataaca 1560 ctgaagcatattggattgaa tctttcttcc attctgaaaa gtggtgctga gattccttta 1620 ttgtgggtagagcctacaaa taacagcaat aactatacag cagatactgc agctaccttt 1680 tcattaagtgatgtaaaact ctcactcatt gatgactacg ggaactctcc ttatgaatcc 1740 acagatctgacccatgctct gtcatcacag cctatgctat ctatttctga agctagcgat 1800 aaccagctacaatcagaaaa tatagatttt tcgggactaa atgtccctca ttatggatgg 1860 caaggactttggacttgggg ctgggcaaaa actcaagatc cagaaccagc atcttcagca 1920 acaatcactgatccacaaaa agccaataga tttcatagaa ccttactact aacatggctt 1980 cctgccgggtatgttcctag cccaaaacac agaagtcccc tcatagctaa caccttatgg 2040 gggaatatgctgcttgcaac agaaagctta aaaaatagtg cagagctgac acctagtggt 2100 catcctttctggggaattac aggaggagga ctaggcatga tggtttacca agatcctcga 2160 gaaaatcatcctggattcca tatgcgctct tccggatact ctgcggggat gatagcaggg 2220 cagacacacaccttctcatt gaaattcagt cagacctaca ccaaactcaa tgagcgttac 2280 gcaaaaaacaacgtatcttc taaaaattac tcatgccaag gagaaatgct cttctcattg 2340 caagaaggtttcttgctgac taaattagtt gggctttaca gctatggaga ccataactgt 2400 caccatttctatactcaagg agaaaatcta acatctcaag ggacgttccg cagtcaaacg 2460 atgggaggtgctgtcttttt tgatctccct atgaaaccct ttggatcaac gcatatactg 2520 acagctccctttttaggtgc tcttggtatt tattctagcc tgtctcactt tactgaggtg 2580 ggagcctatccgcgaagctt ttctacaaag actcctttga tcaatgtcct agtccctatt 2640 ggagttaaaggtagctttat gaatgctacc cacagacctc aagcctggac tgtagaattg 2700 gcataccaacccgttctgta tagacaagaa ccagggatcg cgacccagct cctagccagt 2760 aaaggtatttggtttggtag tggaagcccc tcatcgcgtc atgccatgtc ctataaaatc 2820 tcacagcaaacacaaccttt gagttggtta actctccatt tccagtatca tggattctac 2880 tcctcttcaaccttctgtaa ttatctcaat ggggaaattg ctctgcgatt ctag 2934 184 2547 DNAChlamydia 184 atggctagcc atcaccatca ccatcacggt gctatttctt gcttacgtggagatgtagtc 60 atttctggaa acaagggtag agttgaattt aaagacaaca tagcaacacgtctttatgtg 120 gaagaaactg tagaaaaggt tgaagaggta gagccagctc ctgagcaaaaagacaataat 180 gagctttctt tcttagggag tgtagaacag agttttatta ctgcagctaatcaagctctt 240 ttcgcatctg aagatgggga tttatcacct gagtcatcca tttcttctgaagaacttgcg 300 aaaagaagag agtgtgctgg aggagctatt tttgcaaaac gggttcgtattgtagataac 360 caagaggccg ttgtattctc gaataacttc tctgatattt atggcggcgccatttttaca 420 ggttctcttc gagaagagga taagttagat gggcaaatcc ctgaagtcttgatctcaggc 480 aatgcagggg atgttgtttt ttccggaaat tcctcgaagc gtgatgagcatcttcctcat 540 acaggtgggg gagccatttg tactcaaaat ttgacgattt ctcagaatacagggaatgtt 600 ctgttttata acaacgtggc ctgttcggga ggagctgttc gtatagaggatcatggtaat 660 gttcttttag aagcttttgg aggagatatt gtttttaaag gaaattcttctttcagagca 720 caaggatccg atgctatcta ttttgcaggt aaagaatcgc atattacagccctgaatgct 780 acggaaggac atgctattgt tttccacgac gcattagttt ttgaaaatctaaaagaaagg 840 aaatctgctg aagtattgtt aatcaatagt cgagaaaatc caggttacactggatctatt 900 cgatttttag aagcagaaag taaagttcct caatgtattc atgtacaacaaggaagcctt 960 gagttgctaa atggagctac attatgtagt tatggtttta aacaagatgctggagctaag 1020 ttggtattgg ctgctggatc taaactgaag attttagatt caggaactcctgtacaaggg 1080 catgctatca gtaaacctga agcagaaatc gagtcatctt ctgaaccagagggtgcacat 1140 tctctttgga ttgcgaagaa tgctcaaaca acagttccta tggttgatatccatactatt 1200 tctgtagatt tagcctcctt ctcttctagt caacaggagg ggacagtagaagctcctcag 1260 gttattgttc ctggaggaag ttatgttcga tctggagagc ttaatttggagttagttaac 1320 acaacaggta ctggttatga aaatcatgct ttgttgaaga atgaggctaaagttccattg 1380 atgtctttcg ttgcttctag tgatgaagct tcagccgaaa tcagtaacttgtcggtttct 1440 gatttacaga ttcatgtagc aactccagag attgaagaag acacatacggccatatggga 1500 gattggtctg aggctaaaat tcaagatgga actcttgtca ttaattggaatcctactgga 1560 tatcgattag atcctcaaaa agcaggggct ttagtattta atgcattatgggaagaaggg 1620 gctgtcttgt ctgctctgaa aaatgcacgc tttgctcata atctcactgctcagcgtatg 1680 gaattcgatt attctacaaa tgtgtgggga ttcgcctttg gtggtttccgaactctatct 1740 gcagagaatc tggttgctat tgatggatac aaaggagctt atggtggtgcttctgctgga 1800 gtcgatattc aattgatgga agattttgtt ctaggagtta gtggagctgctttcctaggt 1860 aaaatggata gtcagaagtt tgatgcggag gtttctcgga agggagttgttggttctgta 1920 tatacaggat ttttagctgg atcctggttc ttcaaaggac aatatagccttggagaaaca 1980 cagaacgata tgaaaacgcg ttatggagta ctaggagagt cgagtgcttcttggacatct 2040 cgaggagtac tggcagatgc tttagttgaa taccgaagtt tagttggtcctgtgagacct 2100 actttttatg ctttgcattt caatccttat gtcgaagtat cttatgcttctatgaaattc 2160 cctggcttta cagaacaagg aagagaagcg cgttcttttg aagacgcttcccttaccaat 2220 atcaccattc ctttagggat gaagtttgaa ttggcgttca taaaaggacagttttcagag 2280 gtgaactctt tgggaataag ttatgcatgg gaagcttatc gaaaagtagaaggaggcgcg 2340 gtgcagcttt tagaagctgg gtttgattgg gagggagctc caatggatcttcctagacag 2400 gagctgcgtg tcgctctgga aaataatacg gaatggagtt cttacttcagcacagtctta 2460 ggattaacag ctttttgtgg aggatttact tctacagata gtaaactaggatatgaggcg 2520 aatactggat tgcgattgat cttttaa 2547 185 2337 DNAChlamydia 185 atgcatcacc atcaccatca cgggttagct agttgcgtag atcttcatgctggaggacag 60 tctgtaaatg agctggtata tgtaggccct caagcggttt tattgttagaccaaattcga 120 gatctattcg ttgggtctaa agatagtcag gctgaaggac agtataggttaattgtagga 180 gatccaagtt ctttccaaga gaaagatgca gatactcttc ccgggaaggtagagcaaagt 240 actttgttct cagtaaccaa tcccgtggtt ttccaaggtg tggaccaacaggatcaagtc 300 tcttcccaag ggttaatttg tagttttacg agcagcaacc ttgattctccccgtgacgga 360 gaatcttttt taggtattgc ttttgttggg gatagtagta aggctggaatcacattaact 420 gacgtgaaag cttctttgtc tggagcggct ttatattcta cagaagatcttatctttgaa 480 aagattaagg gtggattgga atttgcatca tgttcttctc tagaacaggggggagcttgt 540 gcagctcaaa gtattttgat tcatgattgt caaggattgc aggttaaacactgtactaca 600 gccgtgaatg ctgaggggtc tagtgcgaat gatcatcttg gatttggaggaggcgctttc 660 tttgttacgg gttctctttc tggagagaaa agtctctata tgcctgcaggagatatggta 720 gttgcgaatt gtgatggggc tatatctttt gaaggaaaca gcgcgaactttgctaatgga 780 ggagcgattg ctgcctctgg gaaagtgctt tttgtcgcta atgataaaaagacttctttt 840 atagagaacc gagctttgtc tggaggagcg attgcagcct cttctgatattgcctttcaa 900 aactgcgcag aactagtttt caaaggcaat tgtgcaattg gaacagaggataaaggttct 960 ttaggtggag gggctatatc ttctctaggc accgttcttt tgcaagggaatcacgggata 1020 acttgtgata agaatgagtc tgcttcgcaa ggaggcgcca tttttggcaaaaattgtcag 1080 atttctgaca acgaggggcc agtggttttc agagatagta cagcttgcttaggaggaggc 1140 gctattgcag ctcaagaaat tgtttctatt cagaacaatc aggctgggatttccttcgag 1200 ggaggtaagg ctagtttcgg aggaggtatt gcgtgtggat ctttttcttccgcaggcggt 1260 gcttctgttt tagggactat tgatatttcg aagaatttag gcgcgatttcgttctctcgt 1320 actttatgta cgacctcaga tttaggacaa atggagtacc agggaggaggagctctattt 1380 ggtgaaaata tttctctttc tgagaatgct ggtgtgctca cctttaaagacaacattgtg 1440 aagacttttg cttcgaatgg gaaaattctg ggaggaggag cgattttagctactggtaag 1500 gtggaaatta ccaataattc cggaggaatt tcttttacag gaaatgcgagagctccacaa 1560 gctcttccaa ctcaagagga gtttccttta ttcagcaaaa aagaagggcgaccactctct 1620 tcaggatatt ctgggggagg agcgatttta ggaagagaag tagctattctccacaacgct 1680 gcagtagtat ttgagcaaaa tcgtttgcag tgcagcgaag aagaagcgacattattaggt 1740 tgttgtggag gaggcgctgt tcatgggatg gatagcactt cgattgttggcaactcttca 1800 gtaagatttg gtaataatta cgcaatggga caaggagtct caggaggagctcttttatct 1860 aaaacagtgc agttagctgg aaatggaagc gtcgattttt ctcgaaatattgctagtttg 1920 ggaggaggag ctcttcaagc ttctgaagga aattgtgagc tagttgataacggctatgtg 1980 ctattcagag ataatcgagg gagggtttat gggggtgcta tttcttgcttacgtggagat 2040 gtagtcattt ctggaaacaa gggtagagtt gaatttaaag acaacatagcaacacgtctt 2100 tatgtggaag aaactgtaga aaaggttgaa gaggtagagc cagctcctgagcaaaaagac 2160 aataatgagc tttctttctt agggagtgta gaacagagtt ttattactgcagctaatcaa 2220 gctcttttcg catctgaaga tggggattta tcacctgagt catccatttcttctgaagaa 2280 cttgcgaaaa gaagagagtg tgctggagga gctgactcga gcagatccggctgctaa 2337 186 2847 DNA Chlamydia 186 atggctagca tgcatcacca tcaccatcacgttaagattg agaacttctc tggccaagga 60 atattttctg gaaacaaagc tatcgataacaccacagaag gctcctcttc caaatctaac 120 gtcctcggag gtgcggtcta tgctaaaacattgtttaatc tcgatagcgg gagctctaga 180 cgaactgtca ccttctccgg gaatactgtctcttctcaat ctacaacagg tcaggttgct 240 ggaggagcta tctactctcc tactgtaaccattgctactc ctgtagtatt ttctaaaaac 300 tctgcaacaa acaatgctaa taacgctacagatactcaga gaaaagacac ctttggagga 360 gctatcggag ctacttctgc tgtttctctatcaggagggg ctcatttctt agaaaacgtt 420 gctgacctcg gatctgctat tgggttggtgccagacacac aaaatacaga aacagtgaaa 480 ttagagtctg gctcctacta ctttgaaaaaaataaagctt taaaacgagc tactatttac 540 gcacctgtcg tttccattaa agcctatactgcgacattta accaaaacag atctctagaa 600 gaaggaagcg cgatttactt tacaaaagaagcatctattg agtctttagg ctctgttctc 660 ttcacaggaa acttagtaac cccaacgctaagcacaacta cagaaggcac accagccaca 720 acctcaggag atgtaacaaa atatggtgctgctatctttg gacaaatagc aagctcaaac 780 ggatctcaga cggataacct tcccctgaaactcattgctt caggaggaaa tatttgtttc 840 cgaaacaatg aataccgtcc tacttcttctgataccggaa cctctacttt ctgtagtatt 900 gcgggagatg ttaaattaac catgcaagctgcaaaaggga aaacgatcag tttctttgat 960 gcaatccgga cctctactaa gaaaacaggtacacaggcaa ctgcctacga tactctcgat 1020 attaataaat ctgaggattc agaaactgtaaactctgcgt ttacaggaac gattctgttc 1080 tcctctgaat tacatgaaaa taaatcctatattccacaaa acgtagttct acacagtgga 1140 tctcttgtat tgaagccaaa taccgagcttcatgtcattt cttttgagca gaaagaaggc 1200 tcttctctcg ttatgacacc tggatctgttctttcgaacc agactgttgc tgatggagct 1260 ttggtcataa ataacatgac cattgatttatccagcgtag agaaaaatgg tattgctgaa 1320 ggaaatatct ttactcctcc agaattgagaatcatagaca ctactacaag tggaagcggt 1380 ggaaccccat ctacagatag tgaaagtaaccagaatagtg atgataccaa ggagcaaaat 1440 aataatgacg cctcgaatca aggagaaagcgcgaatggat cgtcttctcc tgcagtagct 1500 gctgcacaca catctcgtac aagaaactttgccgctgcag ctacagccac acctacgaca 1560 acaccaacgg ctacaactac aacaagcaaccaagtaatcc taggaggaga aatcaaactc 1620 atcgatccta atgggacctt cttccagaaccctgcattaa gatccgacca acaaatctcc 1680 ttgttagtgc tccctacaga ctcatcaaaaatgcaagctc agaaaatagt actgacgggt 1740 gatattgctc ctcagaaagg atatacaggaacactcactc tggatcctga tcaactacaa 1800 aatggaacga tctcagcgct ctggaaatttgactcttata gacaatgggc ttatgtacct 1860 agagacaatc atttctatgc gaactcgattctgggatctc aaatgtcaat ggtcacagtc 1920 aaacaaggct tgctcaacga taaaatgaatctagctcgct ttgatgaagt tagctataac 1980 aacctgtgga tatcaggact aggaacgatgctatcgcaag taggaacacc tacttctgaa 2040 gaattcactt attacagcag aggagcttctgttgccttag atgctaaacc agcccatgat 2100 gtgattgttg gagctgcatt tagtaagatgatcgggaaaa caaaatcctt gaaaagagag 2160 aataactaca ctcacaaagg atccgaatattcttaccaag catcggtata cggaggcaaa 2220 ccattccact ttgtaatcaa taaaaaaacggaaaaatcgc taccgctatt gttacaagga 2280 gtcatctctt acggatatat caaacatgatacagtgactc actatccaac gatccgtgaa 2340 cgaaaccaag gagaatggga agacttaggatggctgacag ctctccgtgt ctcctctgtc 2400 ttaagaactc ctgcacaagg ggatactaaacgtatcactg tttacggaga attggaatac 2460 tccagtatcc gtcagaaaca attcacagaaacagaatacg atcctcgtta cttcgacaac 2520 tgcacctata gaaacttagc aattcctatggggttagcat tcgaaggaga gctctctggt 2580 aacgatattt tgatgtacaa cagattctctgtagcataca tgccatcaat ctatcgaaat 2640 tctccaacat gcaaatacca agtgctctcttcaggagaag gcggagaaat tatttgtgga 2700 gtaccgacaa gaaactcagc tcgcggagaatacagcacgc agctgtaccc gggacctttg 2760 tggactctgt atggatccta cacgatagaagcagacgcac atacactagc tcatatgatg 2820 aactgcggtg ctcgtatgac attctaa 2847187 2466 DNA Chlamydia 187 atgcatcacc atcaccatca cgaggcgagc tcgatccaagatcaaataaa gaataccgac 60 tgcaatgtta gcaaagtagg atattcaact tctcaagcatttactgatat gatgctagca 120 gacaacacag agtatcgagc tgctgatagt gtttcattctatgacttttc gacatcttcc 180 ggattaccta gaaaacatct tagtagtagt agtgaagcttctccaacgac agaaggagtg 240 tcttcatctt catctggaga aaatactgag aattcacaagattcagctcc ctcttctgga 300 gaaactgata agaaaacaga agaagaacta gacaatggcggaatcattta tgctagagag 360 aaactaacta tctcagaatc tcaggactct ctctctaatccaagcataga actccatgac 420 aatagttttt tcttcggaga aggtgaagtt atctttgatcacagagttgc cctcaaaaac 480 ggaggagcta tttatggaga gaaagaggta gtctttgaaaacataaaatc tctactagta 540 gaagtaaata tctcggtcga gaaagggggt agcgtctatgcaaaagaacg agtatcttta 600 gaaaatgtta ccgaagcaac cttctcctcc aatggtggggaacaaggtgg tggtggaatc 660 tattcagaac aagatatgtt aatcagtgat tgcaacaatgtacatttcca agggaatgct 720 gcaggagcaa cagcagtaaa acaatgtctg gatgaagaaatgatcgtatt gctcacagaa 780 tgcgttgata gcttatccga agatacactg gatagcactccagaaacgga acagactaag 840 tcaaatggaa atcaagatgg ttcgtctgaa acaaaagatacacaagtatc agaatcacca 900 gaatcaactc ctagccccga cgatgtttta ggtaaaggtggtggtatcta tacagaaaaa 960 tctttgacca tcactggaat tacagggact atagattttgtcagtaacat agctaccgat 1020 tctggagcag gtgtattcac taaagaaaac ttgtcttgcaccaacacgaa tagcctacag 1080 tttttgaaaa actcggcagg tcaacatgga ggaggagcctacgttactca aaccatgtct 1140 gttactaata caactagtga aagtataact actccccctctcgtaggaga agtgattttc 1200 tctgaaaata cagctaaagg gcacggtggt ggtatctgcactaacaaact ttctttatct 1260 aatttaaaaa cggtgactct cactaaaaac tctgcaaaggagtctggagg agctattttt 1320 acagatctag cgtctatacc aacaacagat accccagagtcttctacccc ctcttcctcc 1380 tcgcctgcaa gcactcccga agtagttgct tctgctaaaataaatcgatt ctttgcctct 1440 acggcagaac cggcagcccc ttctctaaca gaggctgagtctgatcaaac ggatcaaaca 1500 gaaacttctg atactaatag cgatatagac gtgtcgattgagaacatttt gaatgtcgct 1560 atcaatcaaa acacttctgc gaaaaaagga ggggctatttacgggaaaaa agctaaactt 1620 tcccgtatta acaatcttga actttcaggg aattcatcccaggatgtagg aggaggtctc 1680 tgtttaactg aaagcgtaga atttgatgca attggatcgctcttatccca ctataactct 1740 gctgctaaag aaggtggggt tattcattct aaaacggttactctatctaa cctcaagtct 1800 accttcactt ttgcagataa cactgttaaa gcaatagtagaaagcactcc tgaagctcca 1860 gaagagattc ctccagtaga aggagaagag tctacagcaacagaaaatcc gaattctaat 1920 acagaaggaa gttcggctaa cactaacctt gaaggatctcaaggggatac tgctgataca 1980 gggactggtg ttgttaacaa tgagtctcaa gacacatcagatactggaaa cgctgaatct 2040 ggagaacaac tacaagattc tacacaatct aatgaagaaaatacccttcc caatagtagt 2100 attgatcaat ctaacgaaaa cacagacgaa tcatctgatagccacactga ggaaataact 2160 gacgagagtg tctcatcgtc ctctaaaagt ggatcatctactcctcaaga tggaggagca 2220 gcttcttcag gggctccctc aggagatcaa tctatctctgcaaacgcttg tttagctaaa 2280 agctatgctg cgagtactga tagctcccct gtatctaattcttcaggttc agacgttact 2340 gcatcttctg ataatccaga ctcttcctca tctggagatagcgctggaga ctctgaagga 2400 ccgactgagc cagaagctgg ttctacaaca gaaactcctactttaatagg aggaggtgct 2460 atctga 2466 188 1578 DNA Chlamydia 188atgcatcacc atcaccatca cacggccgcg tccgataact tccagctgtc ccagggtggg 60cagggattcg ccattccgat cgggcaggcg atggcgatcg cgggccagat caagcttccc 120accgttcata tcgggcctac cgccttcctc ggcttgggtg ttgtcgacaa caacggcaac 180ggcgcacgag tccaacgcgt ggtcgggagc gctccggcgg caagtctcgg catctccacc 240ggcgacgtga tcaccgcggt cgacggcgct ccgatcaact cggccaccgc gatggcggac 300gcgcttaacg ggcatcatcc cggtgacgtc atctcggtga cctggcaaac caagtcgggc 360ggcacgcgta cagggaacgt gacattggcc gagggacccc cggccgaatt cccgctagta 420cctagaggtt caccgctgcc tgtggggaat ccagctgaac caagtttatt aatcgatggc 480actatgtggg aaggtgcttc aggagatcct tgcgatcctt gcgctacttg gtgtgacgcc 540attagcatcc gcgcaggata ctacggagat tatgttttcg atcgtgtatt aaaagttgat 600gtgaataaaa cttttagcgg catggctgca actcctacgc aggctatagg taacgcaagt 660aatactaatc agccagaagc aaatggcaga ccgaacatcg cttacggaag gcatatgcaa 720gatgcagagt ggttttcaaa tgcagccttc ctagccttaa acatttggga tcgcttcgac 780attttctgca ccttaggggc atccaatgga tacttcaaag caagttcggc tgcattcaac 840ttggttgggt taatagggtt ttcagctgca agctcaatct ctaccgatct tccaatgcaa 900cttcctaacg taggcattac ccaaggtgtt gtggaatttt atacagacac atcattttct 960tggagcgtag gtgcacgtgg agctttatgg gaatgtggtt gtgcaacttt aggagctgag 1020ttccaatacg ctcaatctaa tcctaagatt gagatgctca acgtcacttc aagcccagca 1080caatttgtga ttcacaaacc aagaggctat aaaggagcta gctcgaattt tcctttacct 1140ataacggctg gaacaacaga agctacagac accaaatcag ctacaattaa ataccatgaa 1200tggcaagtag gcctcgccct gtcttacaga ttgaatatgc ttgttccata tattggcgta 1260aactggtcaa gagcaacttt tgatgctgat actatccgca ttgctcaacc taaattaaaa 1320tcggagattc ttaacattac tacatggaac ccaagcctta taggatcaac cactgctttg 1380cccaataata gtggtaagga tgttctatct gatgtcttgc aaattgcttc gattcagatc 1440aacaaaatga agtctagaaa agcttgtggt gtagctgttg gtgcaacgtt aatcgacgct 1500gacaaatggt caatcactgg tgaagcacgc ttaatcaatg aaagagctgc tcacatgaat 1560gcacaattcc gcttctaa 1578 189 866 PRT Chlamydia VARIANT (1)...(866) Xaa =Any Amino Acid 189 Met Ala Ser His His His His His His Leu Phe Gly GlnAsp Pro Leu 1 5 10 15 Gly Glu Thr Ala Leu Leu Thr Lys Asn Pro Asn HisVal Val Cys Thr 20 25 30 Phe Phe Glu Asp Cys Thr Met Glu Ser Leu Phe ProAla Leu Cys Ala 35 40 45 His Ala Ser Gln Asp Asp Pro Leu Tyr Val Leu GlyAsn Ser Tyr Cys 50 55 60 Trp Phe Val Ser Lys Leu His Ile Thr Asp Pro LysGlu Ala Leu Phe 65 70 75 80 Lys Glu Lys Gly Asp Leu Ser Ile Gln Asn PheArg Phe Leu Ser Phe 85 90 95 Thr Asp Cys Ser Ser Lys Glu Ser Ser Pro SerIle Ile His Gln Lys 100 105 110 Asn Gly Gln Leu Ser Leu Arg Asn Asn GlySer Met Ser Phe Cys Arg 115 120 125 Asn His Ala Glu Gly Ser Gly Gly AlaIle Ser Ala Asp Ala Phe Ser 130 135 140 Leu Gln His Asn Tyr Leu Phe ThrAla Phe Glu Glu Asn Ser Ser Lys 145 150 155 160 Gly Asn Gly Gly Ala IleGln Ala Gln Thr Phe Ser Leu Ser Arg Asn 165 170 175 Val Ser Pro Ile SerPhe Ala Arg Asn Arg Ala Asp Leu Asn Gly Gly 180 185 190 Ala Ile Cys CysSer Asn Leu Ile Cys Ser Gly Asn Val Asn Pro Leu 195 200 205 Phe Phe ThrGly Asn Ser Ala Thr Asn Gly Gly Xaa Ile Cys Cys Ile 210 215 220 Ser AspLeu Asn Thr Ser Glu Lys Gly Ser Leu Ser Leu Ala Cys Asn 225 230 235 240Gln Xaa Thr Leu Phe Ala Ser Asn Ser Ala Lys Glu Lys Gly Gly Ala 245 250255 Ile Tyr Ala Lys His Met Val Leu Arg Tyr Asn Gly Pro Val Ser Phe 260265 270 Ile Asn Asn Ser Ala Lys Ile Gly Gly Ala Ile Ala Ile Gln Ser Gly275 280 285 Gly Ser Leu Ser Ile Leu Ala Gly Glu Gly Ser Val Leu Phe GlnAsn 290 295 300 Asn Ser Gln Arg Thr Ser Asp Gln Gly Leu Val Arg Asn AlaIle Tyr 305 310 315 320 Leu Glu Lys Asp Ala Ile Leu Ser Ser Leu Glu AlaArg Asn Gly Asp 325 330 335 Ile Leu Phe Phe Asp Pro Ile Val Gln Glu SerSer Ser Lys Glu Ser 340 345 350 Pro Leu Pro Ser Ser Leu Gln Ala Ser ValThr Ser Pro Thr Pro Ala 355 360 365 Thr Ala Ser Pro Leu Val Ile Gln ThrSer Ala Asn Arg Ser Val Ile 370 375 380 Phe Ser Ser Glu Arg Leu Ser GluGlu Glu Lys Thr Pro Asp Asn Leu 385 390 395 400 Thr Ser Gln Leu Gln GlnPro Ile Glu Leu Lys Ser Gly Arg Leu Val 405 410 415 Leu Lys Asp Arg AlaVal Leu Ser Xaa Pro Ser Leu Ser Gln Asp Pro 420 425 430 Gln Ala Leu LeuIle Met Glu Ala Gly Thr Ser Leu Lys Thr Ser Xaa 435 440 445 Asp Leu LysLeu Xaa Thr Xaa Ser Ile Pro Leu His Ser Leu Asp Thr 450 455 460 Glu LysSer Val Thr Ile His Ala Pro Asn Leu Ser Ile Gln Lys Ile 465 470 475 480Phe Leu Ser Asn Ser Gly Asp Glu Asn Phe Tyr Glu Asn Val Glu Leu 485 490495 Leu Ser Lys Glu Gln Asn Asn Ile Pro Leu Leu Thr Leu Pro Lys Glu 500505 510 Gln Ser His Leu His Leu Pro Asp Gly Asn Leu Ser Ser His Phe Gly515 520 525 Tyr Gln Gly Asp Trp Thr Phe Ser Trp Lys Asp Ser Asp Glu GlyHis 530 535 540 Ser Leu Ile Ala Asn Trp Thr Pro Lys Asn Tyr Val Pro HisPro Glu 545 550 555 560 Arg Gln Ser Thr Leu Val Ala Asn Thr Leu Trp AsnThr Tyr Ser Asp 565 570 575 Met Gln Ala Val Gln Ser Met Ile Asn Thr ThrAla His Gly Gly Ala 580 585 590 Tyr Leu Phe Gly Thr Trp Gly Ser Ala ValSer Asn Leu Phe Tyr Val 595 600 605 His Asp Ser Ser Gly Lys Pro Ile AspAsn Trp His His Arg Ser Leu 610 615 620 Gly Tyr Leu Phe Gly Ile Ser ThrHis Ser Leu Asp Asp His Ser Phe 625 630 635 640 Cys Leu Ala Ala Gly GlnLeu Leu Gly Lys Ser Ser Asp Ser Phe Ile 645 650 655 Thr Ser Thr Glu ThrThr Ser Tyr Ile Ala Thr Val Gln Ala Gln Leu 660 665 670 Ala Thr Ser LeuMet Lys Ile Ser Ala Gln Ala Cys Tyr Asn Glu Ser 675 680 685 Ile His GluLeu Lys Thr Lys Tyr Arg Ser Phe Ser Lys Glu Gly Phe 690 695 700 Gly SerTrp His Ser Val Ala Val Ser Gly Glu Val Cys Ala Ser Ile 705 710 715 720Pro Ile Val Ser Asn Gly Ser Gly Leu Phe Ser Ser Phe Ser Ile Phe 725 730735 Ser Lys Leu Gln Gly Phe Ser Gly Thr Gln Asp Gly Phe Glu Glu Ser 740745 750 Ser Gly Glu Ile Arg Ser Phe Ser Ala Ser Ser Phe Arg Asn Ile Ser755 760 765 Leu Pro Ile Gly Ile Thr Phe Glu Lys Lys Ser Gln Lys Thr ArgThr 770 775 780 Tyr Tyr Tyr Phe Leu Gly Ala Tyr Ile Gln Asp Leu Lys ArgAsp Val 785 790 795 800 Glu Ser Gly Pro Val Val Leu Leu Lys Asn Ala ValSer Trp Asp Ala 805 810 815 Pro Met Ala Asn Leu Asp Ser Arg Ala Tyr MetPhe Arg Leu Thr Asn 820 825 830 Gln Arg Ala Leu His Arg Leu Gln Thr LeuLeu Asn Val Ser Cys Val 835 840 845 Leu Arg Gly Gln Ser His Ser Tyr SerLeu Asp Leu Gly Thr Thr Tyr 850 855 860 Arg Phe 865 190 1006 PRTChlamydia 190 Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Asp SerSer Leu 1 5 10 15 Val Pro His His His His His His Met Ile Pro Gln GlyIle Tyr Asp 20 25 30 Gly Glu Thr Leu Thr Val Ser Phe Pro Tyr Thr Val IleGly Asp Pro 35 40 45 Ser Gly Thr Thr Val Phe Ser Ala Gly Glu Leu Thr LeuLys Asn Leu 50 55 60 Asp Asn Ser Ile Ala Ala Leu Pro Leu Ser Cys Phe GlyAsn Leu Leu 65 70 75 80 Gly Ser Phe Thr Val Leu Gly Arg Gly His Ser LeuThr Phe Glu Asn 85 90 95 Ile Arg Thr Ser Thr Asn Gly Ala Ala Leu Ser AsnSer Ala Ala Asp 100 105 110 Gly Leu Phe Thr Ile Glu Gly Phe Lys Glu LeuSer Phe Ser Asn Cys 115 120 125 Asn Ser Leu Leu Ala Val Leu Pro Ala AlaThr Thr Asn Lys Gly Ser 130 135 140 Gln Thr Pro Thr Thr Thr Ser Thr ProSer Asn Gly Thr Ile Tyr Ser 145 150 155 160 Lys Thr Asp Leu Leu Leu LeuAsn Asn Glu Lys Phe Ser Phe Tyr Ser 165 170 175 Asn Leu Val Ser Gly AspGly Gly Ala Ile Asp Ala Lys Ser Leu Thr 180 185 190 Val Gln Gly Ile SerLys Leu Cys Val Phe Gln Glu Asn Thr Ala Gln 195 200 205 Ala Asp Gly GlyAla Cys Gln Val Val Thr Ser Phe Ser Ala Met Ala 210 215 220 Asn Glu AlaPro Ile Ala Phe Val Ala Asn Val Ala Gly Val Arg Gly 225 230 235 240 GlyGly Ile Ala Ala Val Gln Asp Gly Gln Gln Gly Val Ser Ser Ser 245 250 255Thr Ser Thr Glu Asp Pro Val Val Ser Phe Ser Arg Asn Thr Ala Val 260 265270 Glu Phe Asp Gly Asn Val Ala Arg Val Gly Gly Gly Ile Tyr Ser Tyr 275280 285 Gly Asn Val Ala Phe Leu Asn Asn Gly Lys Thr Leu Phe Leu Asn Asn290 295 300 Val Ala Ser Pro Val Tyr Ile Ala Ala Lys Gln Pro Thr Ser GlyGln 305 310 315 320 Ala Ser Asn Thr Ser Asn Asn Tyr Gly Asp Gly Gly AlaIle Phe Cys 325 330 335 Lys Asn Gly Ala Gln Ala Gly Ser Asn Asn Ser GlySer Val Ser Phe 340 345 350 Asp Gly Glu Gly Val Val Phe Phe Ser Ser AsnVal Ala Ala Gly Lys 355 360 365 Gly Gly Ala Ile Tyr Ala Lys Lys Leu SerVal Ala Asn Cys Gly Pro 370 375 380 Val Gln Phe Leu Arg Asn Ile Ala AsnAsp Gly Gly Ala Ile Tyr Leu 385 390 395 400 Gly Glu Ser Gly Glu Leu SerLeu Ser Ala Asp Tyr Gly Asp Ile Ile 405 410 415 Phe Asp Gly Asn Leu LysArg Thr Ala Lys Glu Asn Ala Ala Asp Val 420 425 430 Asn Gly Val Thr ValSer Ser Gln Ala Ile Ser Met Gly Ser Gly Gly 435 440 445 Lys Ile Thr ThrLeu Arg Ala Lys Ala Gly His Gln Ile Leu Phe Asn 450 455 460 Asp Pro IleGlu Met Ala Asn Gly Asn Asn Gln Pro Ala Gln Ser Ser 465 470 475 480 LysLeu Leu Lys Ile Asn Asp Gly Glu Gly Tyr Thr Gly Asp Ile Val 485 490 495Phe Ala Asn Gly Ser Ser Thr Leu Tyr Gln Asn Val Thr Ile Glu Gln 500 505510 Gly Arg Ile Val Leu Arg Glu Lys Ala Lys Leu Ser Val Asn Ser Leu 515520 525 Ser Gln Thr Gly Gly Ser Leu Tyr Met Glu Ala Gly Ser Thr Leu Asp530 535 540 Phe Val Thr Pro Gln Pro Pro Gln Gln Pro Pro Ala Ala Asn GlnLeu 545 550 555 560 Ile Thr Leu Ser Asn Leu His Leu Ser Leu Ser Ser LeuLeu Ala Asn 565 570 575 Asn Ala Val Thr Asn Pro Pro Thr Asn Pro Pro AlaGln Asp Ser His 580 585 590 Pro Ala Val Ile Gly Ser Thr Thr Ala Gly SerVal Thr Ile Ser Gly 595 600 605 Pro Ile Phe Phe Glu Asp Leu Asp Asp ThrAla Tyr Asp Arg Tyr Asp 610 615 620 Trp Leu Gly Ser Asn Gln Lys Ile AsnVal Leu Lys Leu Gln Leu Gly 625 630 635 640 Thr Lys Pro Pro Ala Asn AlaPro Ser Asp Leu Thr Leu Gly Asn Glu 645 650 655 Met Pro Lys Tyr Gly TyrGln Gly Ser Trp Lys Leu Ala Trp Asp Pro 660 665 670 Asn Thr Ala Asn AsnGly Pro Tyr Thr Leu Lys Ala Thr Trp Thr Lys 675 680 685 Thr Gly Tyr AsnPro Gly Pro Glu Arg Val Ala Ser Leu Val Pro Asn 690 695 700 Ser Leu TrpGly Ser Ile Leu Asp Ile Arg Ser Ala His Ser Ala Ile 705 710 715 720 GlnAla Ser Val Asp Gly Arg Ser Tyr Cys Arg Gly Leu Trp Val Ser 725 730 735Gly Val Ser Asn Phe Phe Tyr His Asp Arg Asp Ala Leu Gly Gln Gly 740 745750 Tyr Arg Tyr Ile Ser Gly Gly Tyr Ser Leu Gly Ala Asn Ser Tyr Phe 755760 765 Gly Ser Ser Met Phe Gly Leu Ala Phe Thr Glu Val Phe Gly Arg Ser770 775 780 Lys Asp Tyr Val Val Cys Arg Ser Asn His His Ala Cys Ile GlySer 785 790 795 800 Val Tyr Leu Ser Thr Gln Gln Ala Leu Cys Gly Ser TyrLeu Phe Gly 805 810 815 Asp Ala Phe Ile Arg Ala Ser Tyr Gly Phe Gly AsnGln His Met Lys 820 825 830 Thr Ser Tyr Thr Phe Ala Glu Glu Ser Asp ValArg Trp Asp Asn Asn 835 840 845 Cys Leu Ala Gly Glu Ile Gly Ala Gly LeuPro Ile Val Ile Thr Pro 850 855 860 Ser Lys Leu Tyr Leu Asn Glu Leu ArgPro Phe Val Gln Ala Glu Phe 865 870 875 880 Ser Tyr Ala Asp His Glu SerPhe Thr Glu Glu Gly Asp Gln Ala Arg 885 890 895 Ala Phe Lys Ser Gly HisLeu Leu Asn Leu Ser Val Pro Val Gly Val 900 905 910 Lys Phe Asp Arg CysSer Ser Thr His Pro Asn Lys Tyr Ser Phe Met 915 920 925 Ala Ala Tyr IleCys Asp Ala Tyr Arg Thr Ile Ser Gly Thr Glu Thr 930 935 940 Thr Leu LeuSer His Gln Glu Thr Trp Thr Thr Asp Ala Phe His Leu 945 950 955 960 AlaArg His Gly Val Val Val Arg Gly Ser Met Tyr Ala Ser Leu Thr 965 970 975Ser Asn Ile Glu Val Tyr Gly His Gly Arg Tyr Glu Tyr Arg Asp Ala 980 985990 Ser Arg Gly Tyr Gly Leu Ser Ala Gly Ser Lys Val Arg Phe 995 10001005 191 977 PRT Chlamydia 191 Met Ala Ser Met Thr Gly Gly Gln Gln MetGly Arg Asp Ser Ser Leu 1 5 10 15 Val Pro Ser Ser Asp Pro His His HisHis His His Gly Leu Ala Arg 20 25 30 Glu Val Pro Ser Arg Ile Phe Leu MetPro Asn Ser Val Pro Asp Pro 35 40 45 Thr Lys Glu Ser Leu Ser Asn Lys IleSer Leu Thr Gly Asp Thr His 50 55 60 Asn Leu Thr Asn Cys Tyr Leu Asp AsnLeu Arg Tyr Ile Leu Ala Ile 65 70 75 80 Leu Gln Lys Thr Pro Asn Glu GlyAla Ala Val Thr Ile Thr Asp Tyr 85 90 95 Leu Ser Phe Phe Asp Thr Gln LysGlu Gly Ile Tyr Phe Ala Lys Asn 100 105 110 Leu Thr Pro Glu Ser Gly GlyAla Ile Gly Tyr Ala Ser Pro Asn Ser 115 120 125 Pro Thr Val Glu Ile ArgAsp Thr Ile Gly Pro Val Ile Phe Glu Asn 130 135 140 Asn Thr Cys Cys ArgLeu Phe Thr Trp Arg Asn Pro Tyr Ala Ala Asp 145 150 155 160 Lys Ile ArgGlu Gly Gly Ala Ile His Ala Gln Asn Leu Tyr Ile Asn 165 170 175 His AsnHis Asp Val Val Gly Phe Met Lys Asn Phe Ser Tyr Val Gln 180 185 190 GlyGly Ala Ile Ser Thr Ala Asn Thr Phe Val Val Ser Glu Asn Gln 195 200 205Ser Cys Phe Leu Phe Met Asp Asn Ile Cys Ile Gln Thr Asn Thr Ala 210 215220 Gly Lys Gly Gly Ala Ile Tyr Ala Gly Thr Ser Asn Ser Phe Glu Ser 225230 235 240 Asn Asn Cys Asp Leu Phe Phe Ile Asn Asn Ala Cys Cys Ala GlyGly 245 250 255 Ala Ile Phe Ser Pro Ile Cys Ser Leu Thr Gly Asn Arg GlyAsn Ile 260 265 270 Val Phe Tyr Asn Asn Arg Cys Phe Lys Asn Val Glu ThrAla Ser Ser 275 280 285 Glu Ala Ser Asp Gly Gly Ala Ile Lys Val Thr ThrArg Leu Asp Val 290 295 300 Thr Gly Asn Arg Gly Arg Ile Phe Phe Ser AspAsn Ile Thr Lys Asn 305 310 315 320 Tyr Gly Gly Ala Ile Tyr Ala Pro ValVal Thr Leu Val Asp Asn Gly 325 330 335 Pro Thr Tyr Phe Ile Asn Asn IleAla Asn Asn Lys Gly Gly Ala Ile 340 345 350 Tyr Ile Asp Gly Thr Ser AsnSer Lys Ile Ser Ala Asp Arg His Ala 355 360 365 Ile Ile Phe Asn Glu AsnIle Val Thr Asn Val Thr Asn Ala Asn Gly 370 375 380 Thr Ser Thr Ser AlaAsn Pro Pro Arg Arg Asn Ala Ile Thr Val Ala 385 390 395 400 Ser Ser SerGly Glu Ile Leu Leu Gly Ala Gly Ser Ser Gln Asn Leu 405 410 415 Ile PheTyr Asp Pro Ile Glu Val Ser Asn Ala Gly Val Ser Val Ser 420 425 430 PheAsn Lys Glu Ala Asp Gln Thr Gly Ser Val Val Phe Ser Gly Ala 435 440 445Thr Val Asn Ser Ala Asp Phe His Gln Arg Asn Leu Gln Thr Lys Thr 450 455460 Pro Ala Pro Leu Thr Leu Ser Asn Gly Phe Leu Cys Ile Glu Asp His 465470 475 480 Ala Gln Leu Thr Val Asn Arg Phe Thr Gln Thr Gly Gly Val ValSer 485 490 495 Leu Gly Asn Gly Ala Val Leu Ser Cys Tyr Lys Asn Gly ThrGly Asp 500 505 510 Ser Ala Ser Asn Ala Ser Ile Thr Leu Lys His Ile GlyLeu Asn Leu 515 520 525 Ser Ser Ile Leu Lys Ser Gly Ala Glu Ile Pro LeuLeu Trp Val Glu 530 535 540 Pro Thr Asn Asn Ser Asn Asn Tyr Thr Ala AspThr Ala Ala Thr Phe 545 550 555 560 Ser Leu Ser Asp Val Lys Leu Ser LeuIle Asp Asp Tyr Gly Asn Ser 565 570 575 Pro Tyr Glu Ser Thr Asp Leu ThrHis Ala Leu Ser Ser Gln Pro Met 580 585 590 Leu Ser Ile Ser Glu Ala SerAsp Asn Gln Leu Gln Ser Glu Asn Ile 595 600 605 Asp Phe Ser Gly Leu AsnVal Pro His Tyr Gly Trp Gln Gly Leu Trp 610 615 620 Thr Trp Gly Trp AlaLys Thr Gln Asp Pro Glu Pro Ala Ser Ser Ala 625 630 635 640 Thr Ile ThrAsp Pro Gln Lys Ala Asn Arg Phe His Arg Thr Leu Leu 645 650 655 Leu ThrTrp Leu Pro Ala Gly Tyr Val Pro Ser Pro Lys His Arg Ser 660 665 670 ProLeu Ile Ala Asn Thr Leu Trp Gly Asn Met Leu Leu Ala Thr Glu 675 680 685Ser Leu Lys Asn Ser Ala Glu Leu Thr Pro Ser Gly His Pro Phe Trp 690 695700 Gly Ile Thr Gly Gly Gly Leu Gly Met Met Val Tyr Gln Asp Pro Arg 705710 715 720 Glu Asn His Pro Gly Phe His Met Arg Ser Ser Gly Tyr Ser AlaGly 725 730 735 Met Ile Ala Gly Gln Thr His Thr Phe Ser Leu Lys Phe SerGln Thr 740 745 750 Tyr Thr Lys Leu Asn Glu Arg Tyr Ala Lys Asn Asn ValSer Ser Lys 755 760 765 Asn Tyr Ser Cys Gln Gly Glu Met Leu Phe Ser LeuGln Glu Gly Phe 770 775 780 Leu Leu Thr Lys Leu Val Gly Leu Tyr Ser TyrGly Asp His Asn Cys 785 790 795 800 His His Phe Tyr Thr Gln Gly Glu AsnLeu Thr Ser Gln Gly Thr Phe 805 810 815 Arg Ser Gln Thr Met Gly Gly AlaVal Phe Phe Asp Leu Pro Met Lys 820 825 830 Pro Phe Gly Ser Thr His IleLeu Thr Ala Pro Phe Leu Gly Ala Leu 835 840 845 Gly Ile Tyr Ser Ser LeuSer His Phe Thr Glu Val Gly Ala Tyr Pro 850 855 860 Arg Ser Phe Ser ThrLys Thr Pro Leu Ile Asn Val Leu Val Pro Ile 865 870 875 880 Gly Val LysGly Ser Phe Met Asn Ala Thr His Arg Pro Gln Ala Trp 885 890 895 Thr ValGlu Leu Ala Tyr Gln Pro Val Leu Tyr Arg Gln Glu Pro Gly 900 905 910 IleAla Thr Gln Leu Leu Ala Ser Lys Gly Ile Trp Phe Gly Ser Gly 915 920 925Ser Pro Ser Ser Arg His Ala Met Ser Tyr Lys Ile Ser Gln Gln Thr 930 935940 Gln Pro Leu Ser Trp Leu Thr Leu His Phe Gln Tyr His Gly Phe Tyr 945950 955 960 Ser Ser Ser Thr Phe Cys Asn Tyr Leu Asn Gly Glu Ile Ala LeuArg 965 970 975 Phe 192 848 PRT Chlamydia 192 Met Ala Ser His His HisHis His His Gly Ala Ile Ser Cys Leu Arg 1 5 10 15 Gly Asp Val Val IleSer Gly Asn Lys Gly Arg Val Glu Phe Lys Asp 20 25 30 Asn Ile Ala Thr ArgLeu Tyr Val Glu Glu Thr Val Glu Lys Val Glu 35 40 45 Glu Val Glu Pro AlaPro Glu Gln Lys Asp Asn Asn Glu Leu Ser Phe 50 55 60 Leu Gly Ser Val GluGln Ser Phe Ile Thr Ala Ala Asn Gln Ala Leu 65 70 75 80 Phe Ala Ser GluAsp Gly Asp Leu Ser Pro Glu Ser Ser Ile Ser Ser 85 90 95 Glu Glu Leu AlaLys Arg Arg Glu Cys Ala Gly Gly Ala Ile Phe Ala 100 105 110 Lys Arg ValArg Ile Val Asp Asn Gln Glu Ala Val Val Phe Ser Asn 115 120 125 Asn PheSer Asp Ile Tyr Gly Gly Ala Ile Phe Thr Gly Ser Leu Arg 130 135 140 GluGlu Asp Lys Leu Asp Gly Gln Ile Pro Glu Val Leu Ile Ser Gly 145 150 155160 Asn Ala Gly Asp Val Val Phe Ser Gly Asn Ser Ser Lys Arg Asp Glu 165170 175 His Leu Pro His Thr Gly Gly Gly Ala Ile Cys Thr Gln Asn Leu Thr180 185 190 Ile Ser Gln Asn Thr Gly Asn Val Leu Phe Tyr Asn Asn Val AlaCys 195 200 205 Ser Gly Gly Ala Val Arg Ile Glu Asp His Gly Asn Val LeuLeu Glu 210 215 220 Ala Phe Gly Gly Asp Ile Val Phe Lys Gly Asn Ser SerPhe Arg Ala 225 230 235 240 Gln Gly Ser Asp Ala Ile Tyr Phe Ala Gly LysGlu Ser His Ile Thr 245 250 255 Ala Leu Asn Ala Thr Glu Gly His Ala IleVal Phe His Asp Ala Leu 260 265 270 Val Phe Glu Asn Leu Lys Glu Arg LysSer Ala Glu Val Leu Leu Ile 275 280 285 Asn Ser Arg Glu Asn Pro Gly TyrThr Gly Ser Ile Arg Phe Leu Glu 290 295 300 Ala Glu Ser Lys Val Pro GlnCys Ile His Val Gln Gln Gly Ser Leu 305 310 315 320 Glu Leu Leu Asn GlyAla Thr Leu Cys Ser Tyr Gly Phe Lys Gln Asp 325 330 335 Ala Gly Ala LysLeu Val Leu Ala Ala Gly Ser Lys Leu Lys Ile Leu 340 345 350 Asp Ser GlyThr Pro Val Gln Gly His Ala Ile Ser Lys Pro Glu Ala 355 360 365 Glu IleGlu Ser Ser Ser Glu Pro Glu Gly Ala His Ser Leu Trp Ile 370 375 380 AlaLys Asn Ala Gln Thr Thr Val Pro Met Val Asp Ile His Thr Ile 385 390 395400 Ser Val Asp Leu Ala Ser Phe Ser Ser Ser Gln Gln Glu Gly Thr Val 405410 415 Glu Ala Pro Gln Val Ile Val Pro Gly Gly Ser Tyr Val Arg Ser Gly420 425 430 Glu Leu Asn Leu Glu Leu Val Asn Thr Thr Gly Thr Gly Tyr GluAsn 435 440 445 His Ala Leu Leu Lys Asn Glu Ala Lys Val Pro Leu Met SerPhe Val 450 455 460 Ala Ser Ser Asp Glu Ala Ser Ala Glu Ile Ser Asn LeuSer Val Ser 465 470 475 480 Asp Leu Gln Ile His Val Ala Thr Pro Glu IleGlu Glu Asp Thr Tyr 485 490 495 Gly His Met Gly Asp Trp Ser Glu Ala LysIle Gln Asp Gly Thr Leu 500 505 510 Val Ile Asn Trp Asn Pro Thr Gly TyrArg Leu Asp Pro Gln Lys Ala 515 520 525 Gly Ala Leu Val Phe Asn Ala LeuTrp Glu Glu Gly Ala Val Leu Ser 530 535 540 Ala Leu Lys Asn Ala Arg PheAla His Asn Leu Thr Ala Gln Arg Met 545 550 555 560 Glu Phe Asp Tyr SerThr Asn Val Trp Gly Phe Ala Phe Gly Gly Phe 565 570 575 Arg Thr Leu SerAla Glu Asn Leu Val Ala Ile Asp Gly Tyr Lys Gly 580 585 590 Ala Tyr GlyGly Ala Ser Ala Gly Val Asp Ile Gln Leu Met Glu Asp 595 600 605 Phe ValLeu Gly Val Ser Gly Ala Ala Phe Leu Gly Lys Met Asp Ser 610 615 620 GlnLys Phe Asp Ala Glu Val Ser Arg Lys Gly Val Val Gly Ser Val 625 630 635640 Tyr Thr Gly Phe Leu Ala Gly Ser Trp Phe Phe Lys Gly Gln Tyr Ser 645650 655 Leu Gly Glu Thr Gln Asn Asp Met Lys Thr Arg Tyr Gly Val Leu Gly660 665 670 Glu Ser Ser Ala Ser Trp Thr Ser Arg Gly Val Leu Ala Asp AlaLeu 675 680 685 Val Glu Tyr Arg Ser Leu Val Gly Pro Val Arg Pro Thr PheTyr Ala 690 695 700 Leu His Phe Asn Pro Tyr Val Glu Val Ser Tyr Ala SerMet Lys Phe 705 710 715 720 Pro Gly Phe Thr Glu Gln Gly Arg Glu Ala ArgSer Phe Glu Asp Ala 725 730 735 Ser Leu Thr Asn Ile Thr Ile Pro Leu GlyMet Lys Phe Glu Leu Ala 740 745 750 Phe Ile Lys Gly Gln Phe Ser Glu ValAsn Ser Leu Gly Ile Ser Tyr 755 760 765 Ala Trp Glu Ala Tyr Arg Lys ValGlu Gly Gly Ala Val Gln Leu Leu 770 775 780 Glu Ala Gly Phe Asp Trp GluGly Ala Pro Met Asp Leu Pro Arg Gln 785 790 795 800 Glu Leu Arg Val AlaLeu Glu Asn Asn Thr Glu Trp Ser Ser Tyr Phe 805 810 815 Ser Thr Val LeuGly Leu Thr Ala Phe Cys Gly Gly Phe Thr Ser Thr 820 825 830 Asp Ser LysLeu Gly Tyr Glu Ala Asn Thr Gly Leu Arg Leu Ile Phe 835 840 845 193 778PRT Chlamydia 193 Met His His His His His His Gly Leu Ala Ser Cys ValAsp Leu His 1 5 10 15 Ala Gly Gly Gln Ser Val Asn Glu Leu Val Tyr ValGly Pro Gln Ala 20 25 30 Val Leu Leu Leu Asp Gln Ile Arg Asp Leu Phe ValGly Ser Lys Asp 35 40 45 Ser Gln Ala Glu Gly Gln Tyr Arg Leu Ile Val GlyAsp Pro Ser Ser 50 55 60 Phe Gln Glu Lys Asp Ala Asp Thr Leu Pro Gly LysVal Glu Gln Ser 65 70 75 80 Thr Leu Phe Ser Val Thr Asn Pro Val Val PheGln Gly Val Asp Gln 85 90 95 Gln Asp Gln Val Ser Ser Gln Gly Leu Ile CysSer Phe Thr Ser Ser 100 105 110 Asn Leu Asp Ser Pro Arg Asp Gly Glu SerPhe Leu Gly Ile Ala Phe 115 120 125 Val Gly Asp Ser Ser Lys Ala Gly IleThr Leu Thr Asp Val Lys Ala 130 135 140 Ser Leu Ser Gly Ala Ala Leu TyrSer Thr Glu Asp Leu Ile Phe Glu 145 150 155 160 Lys Ile Lys Gly Gly LeuGlu Phe Ala Ser Cys Ser Ser Leu Glu Gln 165 170 175 Gly Gly Ala Cys AlaAla Gln Ser Ile Leu Ile His Asp Cys Gln Gly 180 185 190 Leu Gln Val LysHis Cys Thr Thr Ala Val Asn Ala Glu Gly Ser Ser 195 200 205 Ala Asn AspHis Leu Gly Phe Gly Gly Gly Ala Phe Phe Val Thr Gly 210 215 220 Ser LeuSer Gly Glu Lys Ser Leu Tyr Met Pro Ala Gly Asp Met Val 225 230 235 240Val Ala Asn Cys Asp Gly Ala Ile Ser Phe Glu Gly Asn Ser Ala Asn 245 250255 Phe Ala Asn Gly Gly Ala Ile Ala Ala Ser Gly Lys Val Leu Phe Val 260265 270 Ala Asn Asp Lys Lys Thr Ser Phe Ile Glu Asn Arg Ala Leu Ser Gly275 280 285 Gly Ala Ile Ala Ala Ser Ser Asp Ile Ala Phe Gln Asn Cys AlaGlu 290 295 300 Leu Val Phe Lys Gly Asn Cys Ala Ile Gly Thr Glu Asp LysGly Ser 305 310 315 320 Leu Gly Gly Gly Ala Ile Ser Ser Leu Gly Thr ValLeu Leu Gln Gly 325 330 335 Asn His Gly Ile Thr Cys Asp Lys Asn Glu SerAla Ser Gln Gly Gly 340 345 350 Ala Ile Phe Gly Lys Asn Cys Gln Ile SerAsp Asn Glu Gly Pro Val 355 360 365 Val Phe Arg Asp Ser Thr Ala Cys LeuGly Gly Gly Ala Ile Ala Ala 370 375 380 Gln Glu Ile Val Ser Ile Gln AsnAsn Gln Ala Gly Ile Ser Phe Glu 385 390 395 400 Gly Gly Lys Ala Ser PheGly Gly Gly Ile Ala Cys Gly Ser Phe Ser 405 410 415 Ser Ala Gly Gly AlaSer Val Leu Gly Thr Ile Asp Ile Ser Lys Asn 420 425 430 Leu Gly Ala IleSer Phe Ser Arg Thr Leu Cys Thr Thr Ser Asp Leu 435 440 445 Gly Gln MetGlu Tyr Gln Gly Gly Gly Ala Leu Phe Gly Glu Asn Ile 450 455 460 Ser LeuSer Glu Asn Ala Gly Val Leu Thr Phe Lys Asp Asn Ile Val 465 470 475 480Lys Thr Phe Ala Ser Asn Gly Lys Ile Leu Gly Gly Gly Ala Ile Leu 485 490495 Ala Thr Gly Lys Val Glu Ile Thr Asn Asn Ser Gly Gly Ile Ser Phe 500505 510 Thr Gly Asn Ala Arg Ala Pro Gln Ala Leu Pro Thr Gln Glu Glu Phe515 520 525 Pro Leu Phe Ser Lys Lys Glu Gly Arg Pro Leu Ser Ser Gly TyrSer 530 535 540 Gly Gly Gly Ala Ile Leu Gly Arg Glu Val Ala Ile Leu HisAsn Ala 545 550 555 560 Ala Val Val Phe Glu Gln Asn Arg Leu Gln Cys SerGlu Glu Glu Ala 565 570 575 Thr Leu Leu Gly Cys Cys Gly Gly Gly Ala ValHis Gly Met Asp Ser 580 585 590 Thr Ser Ile Val Gly Asn Ser Ser Val ArgPhe Gly Asn Asn Tyr Ala 595 600 605 Met Gly Gln Gly Val Ser Gly Gly AlaLeu Leu Ser Lys Thr Val Gln 610 615 620 Leu Ala Gly Asn Gly Ser Val AspPhe Ser Arg Asn Ile Ala Ser Leu 625 630 635 640 Gly Gly Gly Ala Leu GlnAla Ser Glu Gly Asn Cys Glu Leu Val Asp 645 650 655 Asn Gly Tyr Val LeuPhe Arg Asp Asn Arg Gly Arg Val Tyr Gly Gly 660 665 670 Ala Ile Ser CysLeu Arg Gly Asp Val Val Ile Ser Gly Asn Lys Gly 675 680 685 Arg Val GluPhe Lys Asp Asn Ile Ala Thr Arg Leu Tyr Val Glu Glu 690 695 700 Thr ValGlu Lys Val Glu Glu Val Glu Pro Ala Pro Glu Gln Lys Asp 705 710 715 720Asn Asn Glu Leu Ser Phe Leu Gly Ser Val Glu Gln Ser Phe Ile Thr 725 730735 Ala Ala Asn Gln Ala Leu Phe Ala Ser Glu Asp Gly Asp Leu Ser Pro 740745 750 Glu Ser Ser Ile Ser Ser Glu Glu Leu Ala Lys Arg Arg Glu Cys Ala755 760 765 Gly Gly Ala Asp Ser Ser Arg Ser Gly Cys 770 775 194 948 PRTChlamydia 194 Met Ala Ser Met His His His His His His Val Lys Ile GluAsn Phe 1 5 10 15 Ser Gly Gln Gly Ile Phe Ser Gly Asn Lys Ala Ile AspAsn Thr Thr 20 25 30 Glu Gly Ser Ser Ser Lys Ser Asn Val Leu Gly Gly AlaVal Tyr Ala 35 40 45 Lys Thr Leu Phe Asn Leu Asp Ser Gly Ser Ser Arg ArgThr Val Thr 50 55 60 Phe Ser Gly Asn Thr Val Ser Ser Gln Ser Thr Thr GlyGln Val Ala 65 70 75 80 Gly Gly Ala Ile Tyr Ser Pro Thr Val Thr Ile AlaThr Pro Val Val 85 90 95 Phe Ser Lys Asn Ser Ala Thr Asn Asn Ala Asn AsnAla Thr Asp Thr 100 105 110 Gln Arg Lys Asp Thr Phe Gly Gly Ala Ile GlyAla Thr Ser Ala Val 115 120 125 Ser Leu Ser Gly Gly Ala His Phe Leu GluAsn Val Ala Asp Leu Gly 130 135 140 Ser Ala Ile Gly Leu Val Pro Asp ThrGln Asn Thr Glu Thr Val Lys 145 150 155 160 Leu Glu Ser Gly Ser Tyr TyrPhe Glu Lys Asn Lys Ala Leu Lys Arg 165 170 175 Ala Thr Ile Tyr Ala ProVal Val Ser Ile Lys Ala Tyr Thr Ala Thr 180 185 190 Phe Asn Gln Asn ArgSer Leu Glu Glu Gly Ser Ala Ile Tyr Phe Thr 195 200 205 Lys Glu Ala SerIle Glu Ser Leu Gly Ser Val Leu Phe Thr Gly Asn 210 215 220 Leu Val ThrPro Thr Leu Ser Thr Thr Thr Glu Gly Thr Pro Ala Thr 225 230 235 240 ThrSer Gly Asp Val Thr Lys Tyr Gly Ala Ala Ile Phe Gly Gln Ile 245 250 255Ala Ser Ser Asn Gly Ser Gln Thr Asp Asn Leu Pro Leu Lys Leu Ile 260 265270 Ala Ser Gly Gly Asn Ile Cys Phe Arg Asn Asn Glu Tyr Arg Pro Thr 275280 285 Ser Ser Asp Thr Gly Thr Ser Thr Phe Cys Ser Ile Ala Gly Asp Val290 295 300 Lys Leu Thr Met Gln Ala Ala Lys Gly Lys Thr Ile Ser Phe PheAsp 305 310 315 320 Ala Ile Arg Thr Ser Thr Lys Lys Thr Gly Thr Gln AlaThr Ala Tyr 325 330 335 Asp Thr Leu Asp Ile Asn Lys Ser Glu Asp Ser GluThr Val Asn Ser 340 345 350 Ala Phe Thr Gly Thr Ile Leu Phe Ser Ser GluLeu His Glu Asn Lys 355 360 365 Ser Tyr Ile Pro Gln Asn Val Val Leu HisSer Gly Ser Leu Val Leu 370 375 380 Lys Pro Asn Thr Glu Leu His Val IleSer Phe Glu Gln Lys Glu Gly 385 390 395 400 Ser Ser Leu Val Met Thr ProGly Ser Val Leu Ser Asn Gln Thr Val 405 410 415 Ala Asp Gly Ala Leu ValIle Asn Asn Met Thr Ile Asp Leu Ser Ser 420 425 430 Val Glu Lys Asn GlyIle Ala Glu Gly Asn Ile Phe Thr Pro Pro Glu 435 440 445 Leu Arg Ile IleAsp Thr Thr Thr Ser Gly Ser Gly Gly Thr Pro Ser 450 455 460 Thr Asp SerGlu Ser Asn Gln Asn Ser Asp Asp Thr Lys Glu Gln Asn 465 470 475 480 AsnAsn Asp Ala Ser Asn Gln Gly Glu Ser Ala Asn Gly Ser Ser Ser 485 490 495Pro Ala Val Ala Ala Ala His Thr Ser Arg Thr Arg Asn Phe Ala Ala 500 505510 Ala Ala Thr Ala Thr Pro Thr Thr Thr Pro Thr Ala Thr Thr Thr Thr 515520 525 Ser Asn Gln Val Ile Leu Gly Gly Glu Ile Lys Leu Ile Asp Pro Asn530 535 540 Gly Thr Phe Phe Gln Asn Pro Ala Leu Arg Ser Asp Gln Gln IleSer 545 550 555 560 Leu Leu Val Leu Pro Thr Asp Ser Ser Lys Met Gln AlaGln Lys Ile 565 570 575 Val Leu Thr Gly Asp Ile Ala Pro Gln Lys Gly TyrThr Gly Thr Leu 580 585 590 Thr Leu Asp Pro Asp Gln Leu Gln Asn Gly ThrIle Ser Ala Leu Trp 595 600 605 Lys Phe Asp Ser Tyr Arg Gln Trp Ala TyrVal Pro Arg Asp Asn His 610 615 620 Phe Tyr Ala Asn Ser Ile Leu Gly SerGln Met Ser Met Val Thr Val 625 630 635 640 Lys Gln Gly Leu Leu Asn AspLys Met Asn Leu Ala Arg Phe Asp Glu 645 650 655 Val Ser Tyr Asn Asn LeuTrp Ile Ser Gly Leu Gly Thr Met Leu Ser 660 665 670 Gln Val Gly Thr ProThr Ser Glu Glu Phe Thr Tyr Tyr Ser Arg Gly 675 680 685 Ala Ser Val AlaLeu Asp Ala Lys Pro Ala His Asp Val Ile Val Gly 690 695 700 Ala Ala PheSer Lys Met Ile Gly Lys Thr Lys Ser Leu Lys Arg Glu 705 710 715 720 AsnAsn Tyr Thr His Lys Gly Ser Glu Tyr Ser Tyr Gln Ala Ser Val 725 730 735Tyr Gly Gly Lys Pro Phe His Phe Val Ile Asn Lys Lys Thr Glu Lys 740 745750 Ser Leu Pro Leu Leu Leu Gln Gly Val Ile Ser Tyr Gly Tyr Ile Lys 755760 765 His Asp Thr Val Thr His Tyr Pro Thr Ile Arg Glu Arg Asn Gln Gly770 775 780 Glu Trp Glu Asp Leu Gly Trp Leu Thr Ala Leu Arg Val Ser SerVal 785 790 795 800 Leu Arg Thr Pro Ala Gln Gly Asp Thr Lys Arg Ile ThrVal Tyr Gly 805 810 815 Glu Leu Glu Tyr Ser Ser Ile Arg Gln Lys Gln PheThr Glu Thr Glu 820 825 830 Tyr Asp Pro Arg Tyr Phe Asp Asn Cys Thr TyrArg Asn Leu Ala Ile 835 840 845 Pro Met Gly Leu Ala Phe Glu Gly Glu LeuSer Gly Asn Asp Ile Leu 850 855 860 Met Tyr Asn Arg Phe Ser Val Ala TyrMet Pro Ser Ile Tyr Arg Asn 865 870 875 880 Ser Pro Thr Cys Lys Tyr GlnVal Leu Ser Ser Gly Glu Gly Gly Glu 885 890 895 Ile Ile Cys Gly Val ProThr Arg Asn Ser Ala Arg Gly Glu Tyr Ser 900 905 910 Thr Gln Leu Tyr ProGly Pro Leu Trp Thr Leu Tyr Gly Ser Tyr Thr 915 920 925 Ile Glu Ala AspAla His Thr Leu Ala His Met Met Asn Cys Gly Ala 930 935 940 Arg Met ThrPhe 945 195 821 PRT Chlamydia 195 Met His His His His His His Glu AlaSer Ser Ile Gln Asp Gln Ile 1 5 10 15 Lys Asn Thr Asp Cys Asn Val SerLys Val Gly Tyr Ser Thr Ser Gln 20 25 30 Ala Phe Thr Asp Met Met Leu AlaAsp Asn Thr Glu Tyr Arg Ala Ala 35 40 45 Asp Ser Val Ser Phe Tyr Asp PheSer Thr Ser Ser Gly Leu Pro Arg 50 55 60 Lys His Leu Ser Ser Ser Ser GluAla Ser Pro Thr Thr Glu Gly Val 65 70 75 80 Ser Ser Ser Ser Ser Gly GluAsn Thr Glu Asn Ser Gln Asp Ser Ala 85 90 95 Pro Ser Ser Gly Glu Thr AspLys Lys Thr Glu Glu Glu Leu Asp Asn 100 105 110 Gly Gly Ile Ile Tyr AlaArg Glu Lys Leu Thr Ile Ser Glu Ser Gln 115 120 125 Asp Ser Leu Ser AsnPro Ser Ile Glu Leu His Asp Asn Ser Phe Phe 130 135 140 Phe Gly Glu GlyGlu Val Ile Phe Asp His Arg Val Ala Leu Lys Asn 145 150 155 160 Gly GlyAla Ile Tyr Gly Glu Lys Glu Val Val Phe Glu Asn Ile Lys 165 170 175 SerLeu Leu Val Glu Val Asn Ile Ser Val Glu Lys Gly Gly Ser Val 180 185 190Tyr Ala Lys Glu Arg Val Ser Leu Glu Asn Val Thr Glu Ala Thr Phe 195 200205 Ser Ser Asn Gly Gly Glu Gln Gly Gly Gly Gly Ile Tyr Ser Glu Gln 210215 220 Asp Met Leu Ile Ser Asp Cys Asn Asn Val His Phe Gln Gly Asn Ala225 230 235 240 Ala Gly Ala Thr Ala Val Lys Gln Cys Leu Asp Glu Glu MetIle Val 245 250 255 Leu Leu Thr Glu Cys Val Asp Ser Leu Ser Glu Asp ThrLeu Asp Ser 260 265 270 Thr Pro Glu Thr Glu Gln Thr Lys Ser Asn Gly AsnGln Asp Gly Ser 275 280 285 Ser Glu Thr Lys Asp Thr Gln Val Ser Glu SerPro Glu Ser Thr Pro 290 295 300 Ser Pro Asp Asp Val Leu Gly Lys Gly GlyGly Ile Tyr Thr Glu Lys 305 310 315 320 Ser Leu Thr Ile Thr Gly Ile ThrGly Thr Ile Asp Phe Val Ser Asn 325 330 335 Ile Ala Thr Asp Ser Gly AlaGly Val Phe Thr Lys Glu Asn Leu Ser 340 345 350 Cys Thr Asn Thr Asn SerLeu Gln Phe Leu Lys Asn Ser Ala Gly Gln 355 360 365 His Gly Gly Gly AlaTyr Val Thr Gln Thr Met Ser Val Thr Asn Thr 370 375 380 Thr Ser Glu SerIle Thr Thr Pro Pro Leu Val Gly Glu Val Ile Phe 385 390 395 400 Ser GluAsn Thr Ala Lys Gly His Gly Gly Gly Ile Cys Thr Asn Lys 405 410 415 LeuSer Leu Ser Asn Leu Lys Thr Val Thr Leu Thr Lys Asn Ser Ala 420 425 430Lys Glu Ser Gly Gly Ala Ile Phe Thr Asp Leu Ala Ser Ile Pro Thr 435 440445 Thr Asp Thr Pro Glu Ser Ser Thr Pro Ser Ser Ser Ser Pro Ala Ser 450455 460 Thr Pro Glu Val Val Ala Ser Ala Lys Ile Asn Arg Phe Phe Ala Ser465 470 475 480 Thr Ala Glu Pro Ala Ala Pro Ser Leu Thr Glu Ala Glu SerAsp Gln 485 490 495 Thr Asp Gln Thr Glu Thr Ser Asp Thr Asn Ser Asp IleAsp Val Ser 500 505 510 Ile Glu Asn Ile Leu Asn Val Ala Ile Asn Gln AsnThr Ser Ala Lys 515 520 525 Lys Gly Gly Ala Ile Tyr Gly Lys Lys Ala LysLeu Ser Arg Ile Asn 530 535 540 Asn Leu Glu Leu Ser Gly Asn Ser Ser GlnAsp Val Gly Gly Gly Leu 545 550 555 560 Cys Leu Thr Glu Ser Val Glu PheAsp Ala Ile Gly Ser Leu Leu Ser 565 570 575 His Tyr Asn Ser Ala Ala LysGlu Gly Gly Val Ile His Ser Lys Thr 580 585 590 Val Thr Leu Ser Asn LeuLys Ser Thr Phe Thr Phe Ala Asp Asn Thr 595 600 605 Val Lys Ala Ile ValGlu Ser Thr Pro Glu Ala Pro Glu Glu Ile Pro 610 615 620 Pro Val Glu GlyGlu Glu Ser Thr Ala Thr Glu Asn Pro Asn Ser Asn 625 630 635 640 Thr GluGly Ser Ser Ala Asn Thr Asn Leu Glu Gly Ser Gln Gly Asp 645 650 655 ThrAla Asp Thr Gly Thr Gly Val Val Asn Asn Glu Ser Gln Asp Thr 660 665 670Ser Asp Thr Gly Asn Ala Glu Ser Gly Glu Gln Leu Gln Asp Ser Thr 675 680685 Gln Ser Asn Glu Glu Asn Thr Leu Pro Asn Ser Ser Ile Asp Gln Ser 690695 700 Asn Glu Asn Thr Asp Glu Ser Ser Asp Ser His Thr Glu Glu Ile Thr705 710 715 720 Asp Glu Ser Val Ser Ser Ser Ser Lys Ser Gly Ser Ser ThrPro Gln 725 730 735 Asp Gly Gly Ala Ala Ser Ser Gly Ala Pro Ser Gly AspGln Ser Ile 740 745 750 Ser Ala Asn Ala Cys Leu Ala Lys Ser Tyr Ala AlaSer Thr Asp Ser 755 760 765 Ser Pro Val Ser Asn Ser Ser Gly Ser Asp ValThr Ala Ser Ser Asp 770 775 780 Asn Pro Asp Ser Ser Ser Ser Gly Asp SerAla Gly Asp Ser Glu Gly 785 790 795 800 Pro Thr Glu Pro Glu Ala Gly SerThr Thr Glu Thr Pro Thr Leu Ile 805 810 815 Gly Gly Gly Ala Ile 820 196525 PRT Chlamydia 196 Met His His His His His His Thr Ala Ala Ser AspAsn Phe Gln Leu 1 5 10 15 Ser Gln Gly Gly Gln Gly Phe Ala Ile Pro IleGly Gln Ala Met Ala 20 25 30 Ile Ala Gly Gln Ile Lys Leu Pro Thr Val HisIle Gly Pro Thr Ala 35 40 45 Phe Leu Gly Leu Gly Val Val Asp Asn Asn GlyAsn Gly Ala Arg Val 50 55 60 Gln Arg Val Val Gly Ser Ala Pro Ala Ala SerLeu Gly Ile Ser Thr 65 70 75 80 Gly Asp Val Ile Thr Ala Val Asp Gly AlaPro Ile Asn Ser Ala Thr 85 90 95 Ala Met Ala Asp Ala Leu Asn Gly His HisPro Gly Asp Val Ile Ser 100 105 110 Val Thr Trp Gln Thr Lys Ser Gly GlyThr Arg Thr Gly Asn Val Thr 115 120 125 Leu Ala Glu Gly Pro Pro Ala GluPhe Pro Leu Val Pro Arg Gly Ser 130 135 140 Pro Leu Pro Val Gly Asn ProAla Glu Pro Ser Leu Leu Ile Asp Gly 145 150 155 160 Thr Met Trp Glu GlyAla Ser Gly Asp Pro Cys Asp Pro Cys Ala Thr 165 170 175 Trp Cys Asp AlaIle Ser Ile Arg Ala Gly Tyr Tyr Gly Asp Tyr Val 180 185 190 Phe Asp ArgVal Leu Lys Val Asp Val Asn Lys Thr Phe Ser Gly Met 195 200 205 Ala AlaThr Pro Thr Gln Ala Ile Gly Asn Ala Ser Asn Thr Asn Gln 210 215 220 ProGlu Ala Asn Gly Arg Pro Asn Ile Ala Tyr Gly Arg His Met Gln 225 230 235240 Asp Ala Glu Trp Phe Ser Asn Ala Ala Phe Leu Ala Leu Asn Ile Trp 245250 255 Asp Arg Phe Asp Ile Phe Cys Thr Leu Gly Ala Ser Asn Gly Tyr Phe260 265 270 Lys Ala Ser Ser Ala Ala Phe Asn Leu Val Gly Leu Ile Gly PheSer 275 280 285 Ala Ala Ser Ser Ile Ser Thr Asp Leu Pro Met Gln Leu ProAsn Val 290 295 300 Gly Ile Thr Gln Gly Val Val Glu Phe Tyr Thr Asp ThrSer Phe Ser 305 310 315 320 Trp Ser Val Gly Ala Arg Gly Ala Leu Trp GluCys Gly Cys Ala Thr 325 330 335 Leu Gly Ala Glu Phe Gln Tyr Ala Gln SerAsn Pro Lys Ile Glu Met 340 345 350 Leu Asn Val Thr Ser Ser Pro Ala GlnPhe Val Ile His Lys Pro Arg 355 360 365 Gly Tyr Lys Gly Ala Ser Ser AsnPhe Pro Leu Pro Ile Thr Ala Gly 370 375 380 Thr Thr Glu Ala Thr Asp ThrLys Ser Ala Thr Ile Lys Tyr His Glu 385 390 395 400 Trp Gln Val Gly LeuAla Leu Ser Tyr Arg Leu Asn Met Leu Val Pro 405 410 415 Tyr Ile Gly ValAsn Trp Ser Arg Ala Thr Phe Asp Ala Asp Thr Ile 420 425 430 Arg Ile AlaGln Pro Lys Leu Lys Ser Glu Ile Leu Asn Ile Thr Thr 435 440 445 Trp AsnPro Ser Leu Ile Gly Ser Thr Thr Ala Leu Pro Asn Asn Ser 450 455 460 GlyLys Asp Val Leu Ser Asp Val Leu Gln Ile Ala Ser Ile Gln Ile 465 470 475480 Asn Lys Met Lys Ser Arg Lys Ala Cys Gly Val Ala Val Gly Ala Thr 485490 495 Leu Ile Asp Ala Asp Lys Trp Ser Ile Thr Gly Glu Ala Arg Leu Ile500 505 510 Asn Glu Arg Ala Ala His Met Asn Ala Gln Phe Arg Phe 515 520525 197 43 DNA Chlamydia 197 gataggcgcg ccgcaatcat gaaatttatg tcagctactgctg 43 198 34 DNA Chlamydia 198 cagaacgcgt ttagaatgtc atacgagcac cgca 34199 6 DNA Chlamydia 199 gcaatc 6 200 34 DNA Chlamydia 200 tgcaatcatgagttcgcaga aagatataaa aagc 34 201 38 DNA Chlamydia 201 cagagctagcttaaaagatc aatcgcaatc cagtattc 38 202 5 DNA Chlamydia 202 caatc 5 203 31DNA Chlamydia 203 tgcaatcatg aaaaaagcgt ttttcttttt c 31 204 31 DNAChlamydia 204 cagaacgcgt ctagaatcgc agagcaattt c 31 205 30 DNA Chlamydia205 gtgcaatcat gattcctcaa ggaatttacg 30 206 31 DNA Chlamydia 206cagaacgcgt ttagaaccgg actttacttc c 31 207 50 DNA Chlamydia 207cagacatatg catcaccatc accatcacga ggcgagctcg atccaagatc 50 208 40 DNAChlamydia 208 cagaggtacc tcagatagca ctctctccta ttaaagtagg 40 209 55 DNAChlamydia 209 cagagctagc atgcatcacc atcaccatca cgttaagatt gagaacttctctggc 55 210 35 DNA Chlamydia 210 cagaggtacc ttagaatgtc atacgagcac cgcag35 211 36 DNA Chlamydia 211 cagacatatg catcaccatc accatcacgg gttagc 36212 35 DNA Chlamydia 212 cagaggtacc tcagctcctc cagcacactc tcttc 35 21351 DNA Chlamydia 213 cagagctagc catcaccatc accatcacgg tgctatttcttgcttacgtg g 51 214 38 DNA Chlamydia 214 cagaggtact taaaagatcaatcgcaatcc agtattcg 38 215 48 DNA Chlamydia 215 cagaggatcc acatcaccatcaccatcacg gactagctag agaggttc 48 216 31 DNA Chlamydia 216 cagagaattcctagaatcgc agagcaattt c 31 217 7 DNA Chlamydia 217 tgcaatc 7 218 22 PRTChlamydia 218 Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Asp SerSer Leu 1 5 10 15 Val Pro Ser Ser Asp Pro 20 219 51 DNA Chlamydia 219cagaggtacc gcatcaccat caccatcaca tgattcctca aggaatttac g 51 220 33 DNAChlamydia 220 cagagcggcc gcttagaacc ggactttact tcc 33 221 24 PRTChlamydia 221 Met Ala Ser Met Thr Gly Gly Gln Gln Asn Gly Arg Asp SerSer Leu 1 5 10 15 Val Pro His His His His His His 20 222 46 DNAChlamydia 222 cagagctagc catcaccatc accatcacct ctttggccag gatccc 46 22330 DNA Chlamydia 223 cagaactagt ctagaacctg taagtggtcc 30 224 20 PRTArtificial Sequence Made in a lab 224 Met Ser Gln Lys Asn Lys Asn SerAla Phe Met His Pro Val Asn Ile 1 5 10 15 Ser Thr Asp Leu 20 225 20 PRTArtificial Sequence Made in a lab 225 Lys Asn Ser Ala Phe Met His ProVal Asn Ile Ser Thr Asp Leu Ala 1 5 10 15 Val Ile Val Gly 20 226 20 PRTArtificial Sequence Made in a lab 226 His Pro Val Asn Ile Ser Thr AspLeu Ala Val Ile Val Gly Lys Gly 1 5 10 15 Pro Met Pro Arg 20 227 20 PRTArtificial Sequence Made in a lab 227 Ser Thr Asp Leu Ala Val Ile ValGly Lys Gly Pro Met Pro Arg Thr 1 5 10 15 Glu Ile Val Lys 20 228 20 PRTArtificial Sequence Made in a lab 228 Val Ile Val Gly Lys Gly Pro MetPro Arg Thr Glu Ile Val Lys Lys 1 5 10 15 Val Trp Glu Tyr 20 229 20 PRTArtificial Sequence Made in a lab 229 Gly Pro Met Pro Arg Thr Glu IleVal Lys Lys Val Trp Glu Tyr Ile 1 5 10 15 Lys Lys His Asn 20 230 20 PRTArtificial Sequence Made in a lab 230 Ile Lys Lys His Asn Cys Gln AspGln Lys Asn Lys Arg Asn Ile Leu 1 5 10 15 Pro Asp Ala Asn 20 231 20 PRTArtificial Sequence Made in a lab 231 Asn Cys Gln Asp Gln Lys Asn LysArg Asn Ile Leu Pro Asp Ala Asn 1 5 10 15 Leu Ala Lys Val 20 232 20 PRTArtificial Sequence Made in a lab 232 Lys Asn Lys Arg Asn Ile Leu ProAsp Ala Asn Leu Ala Lys Val Phe 1 5 10 15 Gly Ser Ser Asp 20 233 20 PRTArtificial Sequence Made in a lab 233 Ile Leu Pro Asp Ala Asn Leu AlaLys Val Phe Gly Ser Ser Asp Pro 1 5 10 15 Ile Asp Met Phe 20 234 20 PRTArtificial Sequence Made in a lab 234 Asn Leu Ala Lys Val Phe Gly SerSer Asp Pro Ile Asp Met Phe Gln 1 5 10 15 Met Thr Lys Ala 20 235 22 PRTArtificial Sequence Made in a lab 235 Phe Gly Ser Ser Asp Pro Ile AspMet Phe Gln Met Thr Lys Ala Leu 1 5 10 15 Ser Lys His Ile Val Lys 20 23620 PRT Artificial Sequence Made in a lab 236 Val Glu Ile Thr Gln Ala ValPro Lys Tyr Ala Thr Val Gly Ser Pro 1 5 10 15 Tyr Pro Val Glu 20 237 20PRT Artificial Sequence Made in a lab 237 Ala Val Pro Lys Tyr Ala ThrVal Gly Ser Pro Tyr Pro Val Glu Ile 1 5 10 15 Thr Ala Thr Gly 20 238 20PRT Artificial Sequence Made in a lab 238 Ala Thr Val Gly Ser Pro TyrPro Val Glu Ile Thr Ala Thr Gly Lys 1 5 10 15 Arg Asp Cys Val 20 239 20PRT Artificial Sequence Made in a lab 239 Pro Tyr Pro Val Glu Ile ThrAla Thr Gly Lys Arg Asp Cys Val Asp 1 5 10 15 Val Ile Ile Thr 20 240 21PRT Artificial Sequence Made in a lab 240 Ile Thr Ala Thr Gly Lys ArgAsp Cys Val Asp Val Ile Ile Thr Gln 1 5 10 15 Gln Leu Pro Cys Glu 20 24120 PRT Artificial Sequence Made in a lab 241 Lys Arg Asp Cys Val Asp ValIle Ile Thr Gln Gln Leu Pro Cys Glu 1 5 10 15 Ala Glu Phe Val 20 242 20PRT Artificial Sequence Made in a lab 242 Asp Val Ile Ile Thr Gln GlnLeu Pro Cys Glu Ala Glu Phe Val Arg 1 5 10 15 Ser Asp Pro Ala 20 243 20PRT Artificial Sequence Made in a lab 243 Thr Gln Gln Leu Pro Cys GluAla Glu Phe Val Arg Ser Asp Pro Ala 1 5 10 15 Thr Thr Pro Thr 20 244 20PRT Artificial Sequence Made in a lab 244 Cys Glu Ala Glu Phe Val ArgSer Asp Pro Ala Thr Thr Pro Thr Ala 1 5 10 15 Asp Gly Lys Leu 20 245 20PRT Artificial Sequence Made in a lab 245 Val Arg Ser Asp Pro Ala ThrThr Pro Thr Ala Asp Gly Lys Leu Val 1 5 10 15 Trp Lys Ile Asp 20 246 20PRT Artificial Sequence Made in a lab 246 Ala Thr Thr Pro Thr Ala AspGly Lys Leu Val Trp Lys Ile Asp Arg 1 5 10 15 Leu Gly Gln Gly 20 247 20PRT Artificial Sequence Made in a lab 247 Ala Asp Gly Lys Leu Val TrpLys Ile Asp Arg Leu Gly Gln Gly Glu 1 5 10 15 Lys Ser Lys Ile 20 248 20PRT Artificial Sequence Made in a lab 248 Val Trp Lys Ile Asp Arg LeuGly Gln Gly Glu Lys Ser Lys Ile Thr 1 5 10 15 Val Trp Val Lys 20 249 20PRT Artificial Sequence Made in a lab 249 Arg Leu Gly Gln Gly Glu LysSer Lys Ile Thr Val Trp Val Lys Pro 1 5 10 15 Leu Lys Glu Gly 20 250 20PRT Artificial Sequence Made in a lab 250 Gly Glu Lys Ser Lys Ile ThrVal Trp Val Lys Pro Leu Lys Glu Gly 1 5 10 15 Cys Cys Phe Thr 20 251 16PRT Artificial Sequence Made in a lab 251 Gly Glu Lys Ser Lys Ile ThrVal Trp Val Lys Pro Leu Lys Glu Gly 1 5 10 15 252 12 PRT ArtificialSequence Made in a lab 252 Lys Ile Thr Val Trp Val Lys Pro Leu Lys GluGly 1 5 10 253 16 PRT Artificial Sequence Made in a lab 253 Gly Asp LysCys Lys Ile Thr Val Trp Val Lys Pro Leu Lys Glu Gly 1 5 10 15 254 20 PRTArtificial Sequence Made in a lab 254 Thr Glu Tyr Pro Leu Leu Ala AspPro Ser Phe Lys Ile Ser Glu Ala 1 5 10 15 Phe Gly Val Leu 20 255 20 PRTArtificial Sequence Made in a lab 255 Leu Ala Asp Pro Ser Phe Lys IleSer Glu Ala Phe Gly Val Leu Asn 1 5 10 15 Pro Glu Gly Ser 20 256 20 PRTArtificial Sequence Made in a lab 256 Phe Lys Ile Ser Glu Ala Phe GlyVal Leu Asn Pro Glu Gly Ser Leu 1 5 10 15 Ala Leu Arg Ala 20 257 20 PRTArtificial Sequence Made in a lab 257 Ala Phe Gly Val Leu Asn Pro GluGly Ser Leu Ala Leu Arg Ala Thr 1 5 10 15 Phe Leu Ile Asp 20 258 20 PRTArtificial Sequence Made in a lab 258 Asn Pro Glu Gly Ser Leu Ala LeuArg Ala Thr Phe Leu Ile Asp Lys 1 5 10 15 His Gly Val Ile 20 259 20 PRTArtificial Sequence Made in a lab 259 Leu Ala Leu Arg Ala Thr Phe LeuIle Asp Lys His Gly Val Ile Arg 1 5 10 15 His Ala Val Ile 20 260 20 PRTArtificial Sequence Made in a lab 260 Thr Phe Leu Ile Asp Lys His GlyVal Ile Arg His Ala Val Ile Asn 1 5 10 15 Asp Leu Pro Leu 20 261 20 PRTArtificial Sequence Made in a lab 261 Lys His Gly Val Ile Arg His AlaVal Ile Asn Asp Leu Pro Leu Gly 1 5 10 15 Arg Ser Ile Asp 20 262 20 PRTArtificial Sequence Made in a lab 262 Arg His Ala Val Ile Asn Asp LeuPro Leu Gly Arg Ser Ile Asp Glu 1 5 10 15 Glu Leu Arg Ile 20 263 897 DNAChlamydia misc_feature (1)...(897) n = A,T,C or G 263 atggcttctatatgcggacg tttagggtct ggtacaggga atgctctaaa agcttttttt 60 acacagcccaacaataaaat ggcaagggta gtaaataaga cgaagggagt ggataagact 120 attaaggttgccaagtctgc tgccgaattg accgcaaata ttttggaaca agctggaggc 180 gcgggctcttccgcacacat tacagcttcc caagtgtcca aaggattagg ggatgcgaga 240 actgttgtcgctttagggaa tgcctttaac ggagcgttgc caggaacagt tcaaagtgcg 300 caaagcttcttctctcacat gaaagctgct agtcagaaaa cgcaagaagg ggatgagggg 360 ctcacagcagatctttgtgt gtctcataag cgcagagcgg ctgcggctgt ctgtagcatc 420 atcggaggaattacctacct cgcgacattc ggagctatcc gtccgattct gtttgtcaac 480 aaaatgctggcaaaaccgtt tctttcttcc caaactaaag caaatatggg atcttctgtt 540 agctatattatggcggctaa ccatgcagcg tctgtggtgg gtgctggact cgctatcagt 600 gcgnaaagagcagattgcga agcccgctgc gctcgtattg cgagagaaga gtcgttactc 660 gaagtgccgggagaggaaaa tgcttgcgag aagaaagtcg ctggagagaa agccaagacg 720 ttcacgcgcatcaagtatgc actcctcact atgctcgaga agtttttgga atgcgttgcc 780 gacgttttcaaattggtgcc gctgcctatt acaatgggta ttcgtgcgat tgtggctgct 840 ggatgtacgttcacttctgc aattattgga ttgtgcactt tctgcgccag agcataa 897 264 298 PRTChlamydia VARIANT (1)...(298) Xaa = Any Amino Acid 264 Met Ala Ser IleCys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu 1 5 10 15 Lys Ala PhePhe Thr Gln Pro Asn Asn Lys Met Ala Arg Val Val Asn 20 25 30 Lys Thr LysGly Val Asp Lys Thr Ile Lys Val Ala Lys Ser Ala Ala 35 40 45 Glu Leu ThrAla Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly Ser Ser 50 55 60 Ala His IleThr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp Ala Arg 65 70 75 80 Thr ValVal Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu Pro Gly Thr 85 90 95 Val GlnSer Ala Gln Ser Phe Phe Ser His Met Lys Ala Ala Ser Gln 100 105 110 LysThr Gln Glu Gly Asp Glu Gly Leu Thr Ala Asp Leu Cys Val Ser 115 120 125His Lys Arg Arg Ala Ala Ala Ala Val Cys Ser Ile Ile Gly Gly Ile 130 135140 Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg Pro Ile Leu Phe Val Asn 145150 155 160 Lys Met Leu Ala Lys Pro Phe Leu Ser Ser Gln Thr Lys Ala AsnMet 165 170 175 Gly Ser Ser Val Ser Tyr Ile Met Ala Ala Asn His Ala AlaSer Val 180 185 190 Val Gly Ala Gly Leu Ala Ile Ser Ala Xaa Arg Ala AspCys Glu Ala 195 200 205 Arg Cys Ala Arg Ile Ala Arg Glu Glu Ser Leu LeuGlu Val Pro Gly 210 215 220 Glu Glu Asn Ala Cys Glu Lys Lys Val Ala GlyGlu Lys Ala Lys Thr 225 230 235 240 Phe Thr Arg Ile Lys Tyr Ala Leu LeuThr Met Leu Glu Lys Phe Leu 245 250 255 Glu Cys Val Ala Asp Val Phe LysLeu Val Pro Leu Pro Ile Thr Met 260 265 270 Gly Ile Arg Ala Ile Val AlaAla Gly Cys Thr Phe Thr Ser Ala Ile 275 280 285 Ile Gly Leu Cys Thr PheCys Ala Arg Ala 290 295 265 897 DNA Chlamydia misc_feature (1)...(897) n= A,T,C or G 265 atggcttcta tatgcggacg tttagggtct ggtacaggga atgctctaaaagcttttttt 60 acacagccca acaataaaat ggcaagggta gtaaataaga cgaagggaatggataagact 120 attaaggttg ccaagtctgc tgccgaattg accgcaaata ttttggaacaagctggaggc 180 gcgggctctt ccgcacacat tacagcttcc caagtgtcca aaggattaggggatgcgaga 240 actgttgtcg ctttagggaa tgcctttaac ggagcgttgc caggaacagttcaaagtgcg 300 caaagcttct tctctcacat gaaagctgct agtcagaaaa cgcaagaaggggatgagggg 360 ctcacagcag atctttgtgt gtctcataag cgcagagcgg ctgcggctgtctgtagcatc 420 atcggaggaa ttacctacct cgcgacattc ggagctatcc gtccgattctgtttgtcaac 480 aaaatgctgg caaaaccgtt tctttcttcc caaactaaag caaatatgggatcttctgtt 540 agctatatta tggcggctaa ccatgcagcg tctgtggtgg gtgctggactcgctatcagt 600 gcgnaaagag cagattgcga agcccgctgc gctcgtattg cgagagaagagtcgttactc 660 gaagtgccgg gagaggaaaa tgcttgcgag aagaaagtcg ctggagagaaagccaagacg 720 ttcacgcgca tcaagtatgc actcctcact atgctcgaga agtttttggaatgcgttgcc 780 gacgttttca aattggtgcc gctgcctatt acaatgggta ttcgtgcgattgtggctgct 840 ggatgtacgt tcacttctgc aattattgga ttgtgcactt tctgcgccagagcataa 897 266 298 PRT Chlamydia VARIANT (1)...(298) Xaa = Any AminoAcid 266 Met Ala Ser Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly Asn Ala Leu1 5 10 15 Lys Ala Phe Phe Thr Gln Pro Asn Asn Lys Met Ala Arg Val ValAsn 20 25 30 Lys Thr Lys Gly Met Asp Lys Thr Ile Lys Val Ala Lys Ser AlaAla 35 40 45 Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala Gly SerSer 50 55 60 Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly Asp AlaArg 65 70 75 80 Thr Val Val Ala Leu Gly Asn Ala Phe Asn Gly Ala Leu ProGly Thr 85 90 95 Val Gln Ser Ala Gln Ser Phe Phe Ser His Met Lys Ala AlaSer Gln 100 105 110 Lys Thr Gln Glu Gly Asp Glu Gly Leu Thr Ala Asp LeuCys Val Ser 115 120 125 His Lys Arg Arg Ala Ala Ala Ala Val Cys Ser IleIle Gly Gly Ile 130 135 140 Thr Tyr Leu Ala Thr Phe Gly Ala Ile Arg ProIle Leu Phe Val Asn 145 150 155 160 Lys Met Leu Ala Lys Pro Phe Leu SerSer Gln Thr Lys Ala Asn Met 165 170 175 Gly Ser Ser Val Ser Tyr Ile MetAla Ala Asn His Ala Ala Ser Val 180 185 190 Val Gly Ala Gly Leu Ala IleSer Ala Xaa Arg Ala Asp Cys Glu Ala 195 200 205 Arg Cys Ala Arg Ile AlaArg Glu Glu Ser Leu Leu Glu Val Pro Gly 210 215 220 Glu Glu Asn Ala CysGlu Lys Lys Val Ala Gly Glu Lys Ala Lys Thr 225 230 235 240 Phe Thr ArgIle Lys Tyr Ala Leu Leu Thr Met Leu Glu Lys Phe Leu 245 250 255 Glu CysVal Ala Asp Val Phe Lys Leu Val Pro Leu Pro Ile Thr Met 260 265 270 GlyIle Arg Ala Ile Val Ala Ala Gly Cys Thr Phe Thr Ser Ala Ile 275 280 285Ile Gly Leu Cys Thr Phe Cys Ala Arg Ala 290 295 267 680 DNA Chlamydia267 tctatatcca tattgatagg aaaaaacgtc gcagaaagat tttagctatg acgtttatcc 60gagctttagg atattcaaca gatgcagata ttattgaaga gttcttttct gtagaggagc 120gttccttacg ttcagagaag gattttgtcg cgttagttgg taaagtttta gctgataacg 180tagttgatgc ggattcttca ttagtttacg ggaaagctgg agagaagcta agtactgcta 240tgctaaaacg catcttagat acgggagtcc aatctttgaa gattgctgtt ggcgcagatg 300aaaatcaccc aattattaag atgctcgcaa aagatcctac ggattcttac gaagctgctc 360ttaaagattt ttatcgcaga ttacgaccag gagagcctgc aactttagct aatgctcgat 420ccacaattat gcgtttattc ttcgatgcta aacgttataa tttaggccgc gttggacgtt 480ataaattaaa taaaaaatta ggcttcccat tagacgacga aacattatct caagtgactt 540tgagaaaaga agatgttatc ggcgcgttga aatatttgat tcgtttgcga atgggcgatg 600agaagacatc tatcgatgat attgaccatt tggcaaaccg acgagttcgc tctgttggag 660aactaattca gaatcactgt 680 268 359 DNA Chlamydia 268 cttatgttctggagaatgtt gcaacaacat attaatcgaa ccagctcctc ctagtaacat 60 agaaaccaagcccttttgag aaaaaacctg tacttcgcat cctttagcca tttgttgaat 120 agctcctaacaaagagctaa ttttttcctc ttccttgttt ttctgaggcg ctgtggactc 180 taaatatagcaagtgctctt ggaacacctc atcaacaatc gcttgtccta gattaggtat 240 agagactgtctctccatcaa ttaaatggag tttcaaagta atatcccctt ccgtccctcc 300 atcacaagactctatgaaag ctatctgatt ccatcgagca gaaatgtatg gggaaatac 359 269 124 DNAChlamydia 269 gatcgaatca attgagggag ctcattaaca agaatagctg cagtttctttgcgttcttct 60 ggaataacaa gaaataggta atcggtacca ttgatagaac gaacacgacaaatcgcagaa 120 ggtt 124 270 219 DNA Chlamydia 270 gatcctgttg ggcctagtaataatacgttg gatttcccat aactcacttg tttatcctgc 60 ataagagcac ggatacgcttatagtggtta tagacggcaa ccgaaatcgt ttttttcgcg 120 cgctcttgtc caatgacataagagtcgatg tggcgtttga tttctttagg ggttaacact 180 ctcagacttg ttggagagcttgtggaagat gttgcgatc 219 271 511 DNA Chlamydia misc_feature (1)...(511)n = A,T,C or G 271 ggatccgaat tcggcacgag gagaaaatat aggaggttccakcatcggaa gatctaatag 60 acaaagaggt tttggcatag atggctcctc cttgtacgttcaacgatgat tgggagggat 120 tgttatcgat agcttggttc ccagagaact gacaagtcccgctacattga gagaatgtaa 180 cctgttctcc atagatagct cctcctacta cacctgaataagttggtgtt gctggagatg 240 atggtgcggc tgctgcggct gcttgtaggg aagcagcagctgcagcaggt gctgaagctg 300 ttgttgcgac tcctgtggat gaggagtttg ctttgttgttcgagaaagag aagcctgatt 360 tcagattaga aatatttaca gttttagcat gtaagcctccaccttctttc ccaacaaggt 420 tctctgttac agataaggag actagangca tctagttttaaagatttttt acagcagata 480 cctccaccta tctctgtagc ggagttctca g 511 272 598DNA Chlamydia 272 ctcttcctct cctcaatcta gttctggagc aactacagtc tccgactcaggagactctag 60 ctctggctca aactcggata cctcaaaaac agttccagtc acagctaaaggcggtgggct 120 ttatactgat aagaatcttt cgattactaa catcacagga attatcgaaattgcaaataa 180 caaagcgaca gatgttggag gtggtgctta cgtaaaagga acccttacttgtaaaaactc 240 tcaccgtcta caatttttga aaaactcttc cgataaacaa ggtggaggaatctacggaga 300 agacaacatc accctatcta atttgacagg gaagactcta ttccaagagaatactgccaa 360 aaaagagggc ggtggactct tcataaaagg tacagataaa gctcttacaatgacaggact 420 ggatagtttc tgtttaatta ataacacatc agaaaaacat ggtggtgggagcctttgtta 480 ccaaagaaat ctctcagact tacacctctt gatgtggaaa caattccaggaatcacgcct 540 gtacatggtg aaacagtcat tactggcaat aaatctacag gaggtaatggtggagggc 598 273 126 DNA Chlamydia 273 ggatccgaat tcggcacgag atgagccttatagtttaaca aaagcttctc acattccttc 60 gatagctttt tattagccgt ttttagcatcctaatgagat ctcctcgttc gtaacaaata 120 cgagag 126 274 264 DNA Chlamydia274 ggatccgaat tcggcacgag ctcttttaaa tcttaattac aaaaagacaa attaattcaa 60tttttcaaaa aagaatttaa acattaattg ttgtaaaaaa acaatattta ttctaaaata 120ataaccatag ttacggggga atctctttca tggtttattt tagagctcat caacctaggc 180atacgcctaa aacatttcct ttgaaagttc accattcgtt ctccgataag catcctcaaa 240ttgctaaagc tatgtggatt acgg 264 275 359 DNA Chlamydia 275 ggatccgaattcggcacgag ataaaacctg aaccacaaca aagatctaaa acttcttgat 60 tttcagctgcaaattctttt agataaatat caaccatttc ttcagtttca tatcttggaa 120 ttaaaacttgttctcttaaa ttaattctag tatttaagta ttcaacatag cccattatta 180 attgaattggataattttgc cttaataatt cacattcttt ttcagtaatt ttaggttcta 240 aaccgtaccgctttttttct aaaattaatg tttcttcatt attcatttta taagccactt 300 tcctttattttttgattttg ttcttctgtt agtaatgctt caataatagt taataattt 359 276 357 DNAChlamydia 276 aaaacaattg atataatttt ttttttcata acttccagac tcctttctagaaaagtcttt 60 atgggtagta gtgactctaa cgttttttat tattaagacg atccccggagatccttttaa 120 tgatgaaaac ggaaacatcc tttcgccaga aactttagca ctattaaagaatcgttacgg 180 gttagataag cctttattca cccagtatct tatctatttg aaatgtctgctaacactaga 240 tttcggggaa tctcttatct acaaagatcg aaatctcagc attattgctgccgctcttcc 300 atcttccgct attcttggac ttgaaagctt gtgtttactc gtgccgaattcggatcc 357 277 505 DNA Chlamydia 277 ggatccgaat tcggcacgag ctcgtgccgattgcttgctt cagtcacccc atcggtatag 60 agcactaaaa gagactcctc ttcaagaacgagagtgtaag cagggtgagg aggaacttca 120 ggtaaaaatc ctaaggccat accaggatgcgacaggaaag agatatctcc attaggagct 180 cggagacacg ctgggttgtg gccacaagaatagtattcta gttctcgtgt tgcgtaatga 240 taacaataaa tgcatagtgt tacaaacatcccagattcag ctgtctgttg atagaagaga 300 gcagctgttt gttgaacggc ttcttgaatagaggagagct cactcaaaaa ggtatgtaac 360 atgtttttca ggaataagga gtaggcgcacgcattgactc ctttcccgga agcatcagca 420 acgattagaa agagtttagc ttggggaccttcgcctataa caaagatatc aaagaaatct 480 cctcctaccg taactgcagg aatat 505 278407 DNA Chlamydia 278 ggatccgaat tcggcacgag aactactgag caaattgggtatccaacttc ctctttacga 60 aagaaaaaca gaaggcattc tccataccaa gatttgttgcatcgacaata aaactccaat 120 ctttggctct gctaactgga gcggtgctgg tatgattaaaaactttgaag acctattcat 180 ccttcgccca attacagaga cacagcttca ggcctttatggacgtctggt ctcttctaga 240 aacaaatagc tcctatctgt ccccagagag cgtgcttacggcccctactc cttcaagtag 300 acctactcaa caagatacag attctgatga cgaacaaccgagtaccagcc agcaagctat 360 ccgtatgaga aaataggatt agggaaacaa aacgacagcaaaccaca 407 279 351 DNA Chlamydia 279 ctcgtgccgc ttacaggagg cttgtatcctttaaaataga gtttttctta tgaccccatg 60 tggcgatagg ccgggtctag cgccgatagtagaaatatcg gttggttttt gtccttgagg 120 ggatcgtata ctttttcaaa gtatggtccccgtatcgatt atctggaggc tcttatgtct 180 ttttttcata ctagaaaata taagcttatcctcagaggac tcttgtgttt agcaggctgt 240 ttcttaatga acagctgttc ctctagtcgaggaaatcaac ccgctgatga gagcatctat 300 gtcttgtcta tgaatcgcat gatttgtgattctcgtgccg aattcggatc c 351 280 522 DNA Chlamydia 280 ggatccgaattcggcacgag cagaggaaaa aggcgatact cctcttgaag atcgtttcac 60 agaagatctttccgaagtct ctggagaaga ttttcgagga ttgaaaaatt cgttcgatga 120 tgattcttcttctgacgaaa ttctcgatgc gctcacaagt aaattttctg atcccacaat 180 aaaggatctagctcttgatt atctaattca aatagctccc tctgatggga aacttaagtc 240 cgctctcattcaggcaaagc atcaactgat gagccagaat cctcaggcga ttgttggagg 300 acgcaatgttctgttagctt cagaaacctt tgcttccaga gcaaatacat ctccttcatc 360 gcttcgctccttatatttcc aagtaacctc atccccctct aattgcgcta atttacatca 420 aatgcttgcttcttactcgc catcagagaa aaccgctgtt atggagtttc tagtgaatgg 480 catggtagcagatttaaaat cggagggccc ttccattcct cc 522 281 577 DNA Chlamydia 281ggatccgaat tcggcacgag atgcttctat tacaattggt ttggatgcgg aaaaagctta 60ccagcttatt ctagaaaagt tgggagatca aattcttggt ggaattgctg atactattgt 120tgatagtaca gtccaagata ttttagacaa aatcacaaca gacccttctc taggtttgtt 180gaaagctttt aacaactttc caatcactaa taaaattcaa tgcaacgggt tattcactcc 240caggaacatt gaaactttat taggaggaac tgaaatagga aaattcacag tcacacccaa 300aagctctggg agcatgttct tagtctcagc agatattatt gcatcaagaa tggaaggcgg 360cgttgttcta gctttggtac gagaaggtga ttctaagccc tacgcgatta gttatggata 420ctcatcaggc gttcctaatt tatgtagtct aagaaccaga attattaata caggattgac 480tccgacaacg tattcattac gtgtaggcgg tttagaaagc ggtgtggtat gggttaatgc 540cctttctaat ggcaatgata ttttaggaat aacaaat 577 282 607 DNA Chlamydia 282actmatcttc cccgggctcg agtgcggccg caagcttgtc gacggagctc gatacaaaaa 60tgtgtgcgtg tgaaccgctt cttcaaaagc ttgtcttaaa agatattgtc tcgcttccgg 120attagttaca tgtttaaaaa ttgctagaac aatattattc ccaaccaagc tctctgcggt 180gctgaaaaaa cctaaattca aaagaatgac tcgccgctca tcttcagaaa gacgatccga 240cttccataat tcgatgtctt tccccatggg gatctctgta gggagccagt tatttgcgca 300gccattcaaa taatgttccc aagcccattt gtacttaata ggaacaagtt ggttgacatc 360gacctggttg cagttcacta gacgcttgct atttagatta acgcgtttct gttttccatc 420taaaatatct gcttgcataa gaaccgttaa ttttattgtt aatttatatg attaattact 480gacatgcttc acacccttct tccaaagaac agacaggtgc tttcttcgct ctttcaacaa 540taattcctgc cgaagcagac ttattcttca tccaacgagg ctgaattcct ctcttattaa 600tatctac 607 283 1077 DNA Chlamydia 283 ggatccgaat tcggcacgag aagttaacgatgacgatttg ttcctttggt agagaaggag 60 caatcgaaac taaatgtgcg agagcatgtgaagactccaa tgcaggaata atcccctcat 120 ttctagtaag caggaaaaaa gctcgtaacgcctcttcatc ggtggctaat gtataaaagg 180 ctcgtcctga ctcatgcatt tcggcatgatctggcccaac tgaaggataa tctaatccag 240 cggaaatgga gtgagtttgt aatacttgtccatcgtcatc ttgaagaaga tacgaataaa 300 atccgtggaa tactccaggt cgccctgttgcaaaacgtgc tgcatgtttt cctgaagaaa 360 tgcccagtcc tcccccttcc actccaattaattggacttt tggattcggg ataaaatgat 420 ggaaaaatcc aatagcgttg gagccacctccgatacatgc aatcagaata tcaggatctc 480 ttcctgcaac tgcatggatt tgctctttcacttcagcgct tataacagac tgaaaaaatc 540 gaacgatatc gggataaggt aaaggtcctaaggccgatcc taagcaatag tgagtaaatg 600 agtgtgttgt tgcccaatct tgtagagcttgattaactgc atctttgagt ccacaagatc 660 cttttgttac agaaacgact tcagcacctaaaaagcgcat tttctctaca tttggtttct 720 gtcgttccac atcttttgct cccatgtatactacacaatc taatcctaga taagcacacg 780 ctgttgctgt tgctactcca tgttgtcccgcacctgtttc agctacaaca cgtgttttcc 840 caagatattt agcaagcaaa cactgaccaagagcattatt cagtttatgt gctcctgtat 900 gcaaaagatc ttcgcgttta agaaatactctagggccatc aatagctcga gcaaaattct 960 taacttcagt cagaggagtt tgtctccccgcatagttttt caaaatacaa tctagttcag 1020 ataaaaaact ttgctgagtt ttgagaatctcccattccgc ttttagattc tgtatag 1077 284 407 DNA Chlamydia 284 ggatccgaattcggcacgag aactactgag caaattgggt atccaacttc ctctttacga 60 aagaaaaacagaaggcattc tccataccaa gatttgttgc atcgacaata aaactccaat 120 ctttggctctgctaactgga gcggtgctgg tatgattaaa aactttgaag acctattcat 180 ccttcgcccaattacagaga cacagcttca ggcctttatg gacgtctggt ctcttctaga 240 aacaaatagctcctatctgt ccccagagag cgtgcttacg gcccctactc cttcaagtag 300 acctactcaacaagatacag attctgatga cgaacaaccg agtaccagcc agcaagctat 360 ccgtatgagaaaataggatt agggaaacaa aacgacagca aaccaca 407 285 802 DNA Chlamydia 285ggatccgaat tcggcacgag ttagcttaat gtctttgtca tctctaccta catttgcagc 60taattctaca ggcacaattg gaatcgttaa tttacgtcgc tgcctagaag agtctgctct 120tgggaaaaaa gaatctgctg aattcgaaaa gatgaaaaac caattctcta acagcatggg 180gaagatggag gaagaactgt cttctatcta ttccaagctc caagacgacg attacatgga 240aggtctatcc gagaccgcag ctgccgaatt aagaaaaaaa ttcgaagatc tatctgcaga 300atacaacaca gctcaagggc agtattacca aatattaaac caaagtaatc tcaagcgcat 360gcaaaagatt atggaagaag tgaaaaaagc ttctgaaact gtgcgtattc aagaaggctt 420gtcagtcctt cttaacgaag atattgtctt atctatcgat agttcggcag ataaaaccga 480tgctgttatt aaagttcttg atgattcttt tcaaaataat taacatgcga agctagccga 540ggagtgccgt atgtctcaat ccacttattc tcttgaacaa ttagctgatt ttttgaaagt 600cgagtttcaa ggaaatggag ctactcttct ttccggagtt gaagagatcg aggaagcaaa 660aacggcacac atcacattct tagataatga aaaatatgct aaacatttaa aatcatcgga 720agctggcgct atcatcatat ctcgaacaca gtttcaaaaa tatcgagact tgaataaaaa 780ctttcttatc acttctgagt ct 802 286 588 DNA Chlamydia 286 ggatccgaattcggcacgag gcaatattta ctcccaacat tacggttcca aataagcgat 60 aaggtcttctaataaggaag ttaatgtaag aggctttttt attgcttttc gtaaggtagt 120 attgcaaccgcacgcgattg aatgatacgc aagccatttc catcatggaa aagaaccctt 180 ggacaaaaatacaaaggagg ttcactccta accagaaaaa gggagagtta gtttccatgg 240 gttttccttatatacacccg tttcacacaa ttaggagccg cgtctagtat ttggaataca 300 aattgtccccaagcgaattt tgttcctgtt tcagggattt ctcctaattg ttctgtcagc 360 catccgcctatggtaacgca attagctgta gtaggaagat caactccaaa caggtcatag 420 aaatcagaaagctcataggt gcctgcagca ataacaacat tcttgtctga gtgagcgaat 480 tgtttaaaagatgggcgatt atgagctacc tcatcagaga ctattttaaa tagatcattt 540 tgggtaatcaatccttctat agacccatat tcatcaatga taatctcg 588 287 489 DNA Chlamydiamisc_feature (1)...(489) n = A,T,C or G 287 agtgcctatt gttttgcaggctttgtctga tgatagcgat accgtacgtg agattgctgt 60 acaagtagct gttatgtatggttctagttg cttactgcgc gccgtgggcg atttagcgaa 120 aaatgattct tctattcaagtacgcatcac tgcttatcgt gctgcagccg tgttggagat 180 acaagatctt gtgcctcatttacgagttgt agtccaaaat acacaattag atggaacgga 240 aagaagagaa gcttggagatctttatgtgt tcttactcgg cctcatagtg gtgtattaac 300 tggcatagat caagctttaatgacctgtga gatgttaaag gaatatcctg aaaagtgtac 360 ggaagaacag attcgtacattattggctgc agatcatcca gaagtgcagg tagctacttt 420 acagatcatt ctgagaggaggtagagtatt ccggtcatct tctataatgg aatcggttct 480 cgtgccgnt 489 288 191DNA Chlamydia 288 ggatccgaat tcaggatatg ctgttgggtt atcaataaaa agggttttgccattttttaa 60 gacgactttg tagataacgc taggagctgt agcaataata tcgagatcaaattctctaga 120 gattctctca aagatgattt ctaagtgcag cagtcctaaa aatccacagcggaacccaaa 180 tccgagagag t 191 289 515 DNA Chlamydia 289 ggatccgaattcggcacgag gagcgacgtg aaatagtgga atcttcccgt attcttatta 60 cttctgcgttgccttacgca aatggtcctt tgcattttgg acatattacc ggtgcttatt 120 tgcctgcagatgtttatgcg cgttttcaga gactacaagg caaagaggtt ttgtatattt 180 gtggttctgatgaatacgga atcgcaatta cccttaatgc agagttggca ggcatggggt 240 atcaagaatatgtcgacatg tatcataagc ttcataaaga taccttcaag aaattgggaa 300 tttctgtagatttcttttcc agaactacga acgcttatca tcctgctatt gtgcaagatt 360 tctatcgaaacttgcaggaa cgcggactgg tagagaatca ggtgaccgaa cagctgtatt 420 ctgaggaagaagggaagttt ttagcggacc gttatgttgt aggtacttgt cccaagtgtg 480 ggtttgatcgagctcgagga gatgagtgtc agcag 515 290 522 DNA Chlamydia 290 ggatccgaattcggcacgag ggaggaatgg aagggccctc cgattktama tctgctacca 60 tgccattcactagaaactcc ataacagcgg ttttctctga tggcgagtaa gaagcaagca 120 tttgatgtaaattagcgcaa ttagaggggg atgaggttac ttggaaatat aaggagcgaa 180 gcgatgaaggagatgtattt gctctggaag caaaggtttc tgaagctaac agaacattgc 240 gtcctccaacaatcgcctga ggattctggc tcatcagttg atgctttgcc tgaatgagag 300 cggacttaagtttcccatca gagggagcta tttgaattag ataatcaaga gctagatcct 360 ttattgtgggatcagaaaat ttacttgtga gcgcatcgag aatttcgtca gaagaagaat 420 catcatcgaacgaatttttc aatcctcgaa aatcttctcc agagacttcg gaaagatctt 480 ctgtgaaacgatcttcaaga ggagtatcgc ctttttccyc tg 522 291 1002 DNA Chlamydia 291atggcgacta acgcaattag atcggcagga agtgcagcaa gtaagatgct gctgccagtt 60gccaaagaac cagcggctgt cagctccttt gctcagaaag ggatttattg tattcaacaa 120ttttttacaa accctgggaa taagttagca aagtttgtag gggcaacaaa aagtttagat 180aaatgcttta agctaagtaa ggcggtttct gactgtgtcg taggatcgct ggaagaggcg 240ggatgcacag gggacgcatt gacctccgcg agaaacgccc agggtatgtt aaaaacaact 300cgagaagttg ttgccttagc taatgtgctc aatggagctg ttccatctat cgttaactcg 360actcagaggt gttaccaata cacacgtcaa gccttcgagt taggaagcaa gacaaaagaa 420agaaaaacgc ctggggagta tagtaaaatg ctattaactc gaggtgatta cctattggca 480gcttccaggg aagcttgtac ggcagtcggt gcaacgactt actcagcgac attcggtgtt 540ttacgtccgt taatgttaat caataaactc acagcaaaac cattcttaga caaagcgact 600gtaggcaatt ttggcacggc tgttgctgga attatgacca ttaatcatat ggcaggagtt 660gctggtgctg ttggcggaat cgcattagaa caaaagctgt tcaaacgtgc gaaggaatcc 720ctatacaatg agagatgtgc cttagaaaac caacaatctc agttgagtgg ggacgtgatt 780ctaagcgcgg aaagggcatt acgtaaagaa cacgttgcta ctctaaaaag aaatgtttta 840actcttcttg aaaaagcttt agagttggta gtggatggag tcaaactcat tcctttaccg 900attacagtgg cttgctccgc tgcaatttct ggagccttga cggcagcatc cgcaggaatt 960ggcttatata gcatatggca gaaaacaaag tctggcaaat aa 1002 292 333 PRTChlamydia 292 Met Ala Thr Asn Ala Ile Arg Ser Ala Gly Ser Ala Ala SerLys Met 1 5 10 15 Leu Leu Pro Val Ala Lys Glu Pro Ala Ala Val Ser SerPhe Ala Gln 20 25 30 Lys Gly Ile Tyr Cys Ile Gln Gln Phe Phe Thr Asn ProGly Asn Lys 35 40 45 Leu Ala Lys Phe Val Gly Ala Thr Lys Ser Leu Asp LysCys Phe Lys 50 55 60 Leu Ser Lys Ala Val Ser Asp Cys Val Val Gly Ser LeuGlu Glu Ala 65 70 75 80 Gly Cys Thr Gly Asp Ala Leu Thr Ser Ala Arg AsnAla Gln Gly Met 85 90 95 Leu Lys Thr Thr Arg Glu Val Val Ala Leu Ala AsnVal Leu Asn Gly 100 105 110 Ala Val Pro Ser Ile Val Asn Ser Thr Gln ArgCys Tyr Gln Tyr Thr 115 120 125 Arg Gln Ala Phe Glu Leu Gly Ser Lys ThrLys Glu Arg Lys Thr Pro 130 135 140 Gly Glu Tyr Ser Lys Met Leu Leu ThrArg Gly Asp Tyr Leu Leu Ala 145 150 155 160 Ala Ser Arg Glu Ala Cys ThrAla Val Gly Ala Thr Thr Tyr Ser Ala 165 170 175 Thr Phe Gly Val Leu ArgPro Leu Met Leu Ile Asn Lys Leu Thr Ala 180 185 190 Lys Pro Phe Leu AspLys Ala Thr Val Gly Asn Phe Gly Thr Ala Val 195 200 205 Ala Gly Ile MetThr Ile Asn His Met Ala Gly Val Ala Gly Ala Val 210 215 220 Gly Gly IleAla Leu Glu Gln Lys Leu Phe Lys Arg Ala Lys Glu Ser 225 230 235 240 LeuTyr Asn Glu Arg Cys Ala Leu Glu Asn Gln Gln Ser Gln Leu Ser 245 250 255Gly Asp Val Ile Leu Ser Ala Glu Arg Ala Leu Arg Lys Glu His Val 260 265270 Ala Thr Leu Lys Arg Asn Val Leu Thr Leu Leu Glu Lys Ala Leu Glu 275280 285 Leu Val Val Asp Gly Val Lys Leu Ile Pro Leu Pro Ile Thr Val Ala290 295 300 Cys Ser Ala Ala Ile Ser Gly Ala Leu Thr Ala Ala Ser Ala GlyIle 305 310 315 320 Gly Leu Tyr Ser Ile Trp Gln Lys Thr Lys Ser Gly Lys325 330 293 7 DNA Chlamydia 293 tgcaatc 7 294 196 PRT Chlamydia 294 ThrMet Gly Ser Leu Val Gly Arg Gln Ala Pro Asp Phe Ser Gly Lys 5 10 15 AlaVal Val Cys Gly Glu Glu Lys Glu Ile Ser Leu Ala Asp Phe Arg 20 25 30 GlyLys Tyr Val Val Leu Phe Phe Tyr Pro Lys Asp Phe Thr Tyr Val 35 40 45 CysPro Thr Glu Leu His Ala Phe Gln Asp Arg Leu Val Asp Phe Glu 50 55 60 GluHis Gly Ala Val Val Leu Gly Cys Ser Val Asp Asp Ile Glu Thr 65 70 75 80His Ser Arg Trp Leu Thr Val Ala Arg Asp Ala Gly Gly Ile Glu Gly 85 90 95Thr Glu Tyr Pro Leu Leu Ala Asp Pro Ser Phe Lys Ile Ser Glu Ala 100 105110 Phe Gly Val Leu Asn Pro Glu Gly Ser Leu Ala Leu Arg Ala Thr Phe 115120 125 Leu Ile Asp Lys His Gly Val Ile Arg His Ala Val Ile Asn Asp Leu130 135 140 Pro Leu Gly Arg Ser Ile Asp Glu Glu Leu Arg Ile Leu Asp SerLeu 145 150 155 160 Ile Phe Phe Glu Asn His Gly Met Val Cys Pro Ala AsnTrp Arg Ser 165 170 175 Gly Glu Arg Gly Met Val Pro Ser Glu Glu Gly LeuLys Glu Tyr Phe 180 185 190 Gln Thr Met Asp 195 295 181 PRT Chlamydia295 Lys Gly Gly Lys Met Ser Thr Thr Ile Ser Gly Asp Ala Ser Ser Leu 5 1015 Pro Leu Pro Thr Ala Ser Cys Val Glu Thr Lys Ser Thr Ser Ser Ser 20 2530 Thr Lys Gly Asn Thr Cys Ser Lys Ile Leu Asp Ile Ala Leu Ala Ile 35 4045 Val Gly Ala Leu Val Val Val Ala Gly Val Leu Ala Leu Val Leu Cys 50 5560 Ala Ser Asn Val Ile Phe Thr Val Ile Gly Ile Pro Ala Leu Ile Ile 65 7075 80 Gly Ser Ala Cys Val Gly Ala Gly Ile Ser Arg Leu Met Tyr Arg Ser 8590 95 Ser Tyr Ala Ser Leu Glu Ala Lys Asn Val Leu Ala Glu Gln Arg Leu100 105 110 Arg Asn Leu Ser Glu Glu Lys Asp Ala Leu Ala Ser Val Ser PheIle 115 120 125 Asn Lys Met Phe Leu Arg Gly Leu Thr Asp Asp Leu Gln AlaLeu Glu 130 135 140 Ala Lys Val Met Glu Phe Glu Ile Asp Cys Leu Asp ArgLeu Glu Lys 145 150 155 160 Asn Glu Gln Ala Leu Leu Ser Asp Val Arg LeuVal Leu Ser Ser Tyr 165 170 175 Thr Arg Trp Leu Asp 180 296 124 PRTChlamydia 296 Ile Tyr Glu Val Met Asn Met Asp Leu Glu Thr Arg Arg SerPhe Ala 5 10 15 Val Gln Gln Gly His Tyr Gln Asp Pro Arg Ala Ser Asp TyrAsp Leu 20 25 30 Pro Arg Ala Ser Asp Tyr Asp Leu Pro Arg Ser Pro Tyr ProThr Pro 35 40 45 Pro Leu Pro Ser Arg Tyr Gln Leu Gln Asn Met Asp Val GluAla Gly 50 55 60 Phe Arg Glu Ala Val Tyr Ala Ser Phe Val Ala Gly Met TyrAsn Tyr 65 70 75 80 Val Val Thr Gln Pro Gln Glu Arg Ile Pro Asn Ser GlnGln Val Glu 85 90 95 Gly Ile Leu Arg Asp Met Leu Thr Asn Gly Ser Gln ThrPhe Ser Asn 100 105 110 Leu Met Gln Arg Trp Asp Arg Glu Val Asp Arg Glu115 120 297 488 PRT Chlamydia 297 Lys Gly Ser Leu Pro Ile Leu Gly ProPhe Leu Asn Gly Lys Met Gly 5 10 15 Phe Trp Arg Thr Ser Ile Met Lys MetAsn Arg Ile Trp Leu Leu Leu 20 25 30 Leu Thr Phe Ser Ser Ala Ile His SerPro Val Arg Gly Glu Ser Leu 35 40 45 Val Cys Lys Asn Ala Leu Gln Asp LeuSer Phe Leu Glu His Leu Leu 50 55 60 Gln Val Lys Tyr Ala Pro Lys Thr TrpLys Glu Gln Tyr Leu Gly Trp 65 70 75 80 Asp Leu Val Gln Ser Ser Val SerAla Gln Gln Lys Leu Arg Thr Gln 85 90 95 Glu Asn Pro Ser Thr Ser Phe CysGln Gln Val Leu Ala Asp Phe Ile 100 105 110 Gly Gly Leu Asn Asp Phe HisAla Gly Val Thr Phe Phe Ala Ile Glu 115 120 125 Ser Ala Tyr Leu Pro TyrThr Val Gln Lys Ser Ser Asp Gly Arg Phe 130 135 140 Tyr Phe Val Asp IleMet Thr Phe Ser Ser Glu Ile Arg Val Gly Asp 145 150 155 160 Glu Leu LeuGlu Val Asp Gly Ala Pro Val Gln Asp Val Leu Ala Thr 165 170 175 Leu TyrGly Ser Asn His Lys Gly Thr Ala Ala Glu Glu Ser Ala Ala 180 185 190 LeuArg Thr Leu Phe Ser Arg Met Ala Ser Leu Gly His Lys Val Pro 195 200 205Ser Gly Arg Thr Thr Leu Lys Ile Arg Arg Pro Phe Gly Thr Thr Arg 210 215220 Glu Val Arg Val Lys Trp Arg Tyr Val Pro Glu Gly Val Gly Asp Leu 225230 235 240 Ala Thr Ile Ala Pro Ser Ile Arg Ala Pro Gln Leu Gln Lys SerMet 245 250 255 Arg Ser Phe Phe Pro Lys Lys Asp Asp Ala Phe His Arg SerSer Ser 260 265 270 Leu Phe Tyr Ser Pro Met Val Pro His Phe Trp Ala GluLeu Arg Asn 275 280 285 His Tyr Ala Thr Ser Gly Leu Lys Ser Gly Tyr AsnIle Gly Ser Thr 290 295 300 Asp Gly Phe Leu Pro Val Ile Gly Pro Val IleTrp Glu Ser Glu Gly 305 310 315 320 Leu Phe Arg Ala Tyr Ile Ser Ser ValThr Asp Gly Asp Gly Lys Ser 325 330 335 His Lys Val Gly Phe Leu Arg IlePro Thr Tyr Ser Trp Gln Asp Met 340 345 350 Glu Asp Phe Asp Pro Ser GlyPro Pro Pro Trp Glu Glu Phe Ala Lys 355 360 365 Ile Ile Gln Val Phe SerSer Asn Thr Glu Ala Leu Ile Ile Asp Gln 370 375 380 Thr Asn Asn Pro GlyGly Ser Val Leu Tyr Leu Tyr Ala Leu Leu Ser 385 390 395 400 Met Leu ThrAsp Arg Pro Leu Glu Leu Pro Lys His Arg Met Ile Leu 405 410 415 Thr GlnAsp Glu Val Val Asp Ala Leu Asp Trp Leu Thr Leu Leu Glu 420 425 430 AsnVal Asp Thr Asn Val Glu Ser Arg Leu Ala Leu Gly Asp Asn Met 435 440 445Glu Gly Tyr Thr Val Asp Leu Gln Val Ala Glu Tyr Leu Lys Ser Phe 450 455460 Gly Arg Gln Val Leu Asn Cys Trp Ser Lys Gly Asp Ile Glu Leu Ser 465470 475 480 Thr Pro Ile Pro Leu Phe Gly Phe 485 298 140 PRT Chlamydia298 Arg Ile Asp Ile Ser Ser Val Thr Phe Phe Ile Gly Ile Leu Leu Ala 5 1015 Val Asn Ala Leu Thr Tyr Ser His Val Leu Arg Asp Leu Ser Val Ser 20 2530 Met Asp Ala Leu Phe Ser Arg Asn Thr Leu Ala Val Leu Leu Gly Leu 35 4045 Val Ser Ser Val Leu Asp Asn Val Pro Leu Val Ala Ala Thr Ile Gly 50 5560 Met Tyr Asp Leu Pro Met Asn Asp Pro Leu Trp Lys Leu Ile Ala Tyr 65 7075 80 Thr Ala Gly Thr Gly Gly Ser Ile Leu Ile Ile Gly Ser Ala Ala Gly 8590 95 Val Ala Tyr Met Gly Met Glu Lys Val Ser Phe Gly Trp Tyr Val Lys100 105 110 His Ala Ser Trp Ile Ala Leu Ala Ser Tyr Phe Gly Gly Leu AlaVal 115 120 125 Tyr Phe Leu Met Glu Asn Cys Val Asn Leu Phe Val 130 135140 299 361 PRT Chlamydia 299 His Gln Glu Ile Ala Asp Ser Pro Leu ValLys Lys Ala Glu Glu Gln 5 10 15 Ile Asn Gln Ala Gln Gln Asp Ile Gln ThrIle Thr Pro Ser Gly Leu 20 25 30 Asp Ile Pro Ile Val Gly Pro Ser Gly SerAla Ala Ser Ala Gly Ser 35 40 45 Ala Ala Gly Ala Leu Lys Ser Ser Asn AsnSer Gly Arg Ile Ser Leu 50 55 60 Leu Leu Asp Asp Val Asp Asn Glu Met AlaAla Ile Ala Met Gln Gly 65 70 75 80 Phe Arg Ser Met Ile Glu Gln Phe AsnVal Asn Asn Pro Ala Thr Ala 85 90 95 Lys Glu Leu Gln Ala Met Glu Ala GlnLeu Thr Ala Met Ser Asp Gln 100 105 110 Leu Val Gly Ala Asp Gly Glu LeuPro Ala Glu Ile Gln Ala Ile Lys 115 120 125 Asp Ala Leu Ala Gln Ala LeuLys Gln Pro Ser Ala Asp Gly Leu Ala 130 135 140 Thr Ala Met Gly Gln ValAla Phe Ala Ala Ala Lys Val Gly Gly Gly 145 150 155 160 Ser Ala Gly ThrAla Gly Thr Val Gln Met Asn Val Lys Gln Leu Tyr 165 170 175 Lys Thr AlaPhe Ser Ser Thr Ser Ser Ser Ser Tyr Ala Ala Ala Leu 180 185 190 Ser AspGly Tyr Ser Ala Tyr Lys Thr Leu Asn Ser Leu Tyr Ser Glu 195 200 205 SerArg Ser Gly Val Gln Ser Ala Ile Ser Gln Thr Ala Asn Pro Ala 210 215 220Leu Ser Arg Ser Val Ser Arg Ser Gly Ile Glu Ser Gln Gly Arg Ser 225 230235 240 Ala Asp Ala Ser Gln Arg Ala Ala Glu Thr Ile Val Arg Asp Ser Gln245 250 255 Thr Leu Gly Asp Val Tyr Ser Arg Leu Gln Val Leu Asp Ser LeuMet 260 265 270 Ser Thr Ile Val Ser Asn Pro Gln Ala Asn Gln Glu Glu IleMet Gln 275 280 285 Lys Leu Thr Ala Ser Ile Ser Lys Ala Pro Gln Phe GlyTyr Pro Ala 290 295 300 Val Gln Asn Ser Val Asp Ser Leu Gln Lys Phe AlaAla Gln Leu Glu 305 310 315 320 Arg Glu Phe Val Asp Gly Glu Arg Ser LeuAla Glu Ser Gln Glu Asn 325 330 335 Ala Phe Arg Lys Gln Pro Ala Phe IleGln Gln Val Leu Val Asn Ile 340 345 350 Ala Ser Leu Phe Ser Gly Tyr LeuSer 355 360 300 207 PRT Chlamydia 300 Ser Ser Lys Ile Val Ser Leu CysGlu Gly Ala Val Ala Asp Ala Arg 5 10 15 Met Cys Lys Ala Glu Leu Ile LysLys Glu Ala Asp Ala Tyr Leu Phe 20 25 30 Cys Glu Lys Ser Gly Ile Tyr LeuThr Lys Lys Glu Gly Ile Leu Ile 35 40 45 Pro Ser Ala Gly Ile Asp Glu SerAsn Thr Asp Gln Pro Phe Val Leu 50 55 60 Tyr Pro Lys Asp Ile Leu Gly SerCys Asn Arg Ile Gly Glu Trp Leu 65 70 75 80 Arg Asn Tyr Phe Arg Val LysGlu Leu Gly Val Ile Ile Thr Asp Ser 85 90 95 His Thr Thr Pro Met Arg ArgGly Val Leu Gly Ile Gly Leu Cys Trp 100 105 110 Tyr Gly Phe Ser Pro LeuHis Asn Tyr Ile Gly Ser Leu Asp Cys Phe 115 120 125 Gly Arg Pro Leu GlnMet Thr Gln Ser Asn Leu Val Asp Ala Leu Ala 130 135 140 Val Ala Ala ValVal Cys Met Gly Glu Gly Asn Glu Gln Thr Pro Leu 145 150 155 160 Ala ValIle Glu Gln Ala Pro Asn Met Val Tyr His Ser Tyr Pro Thr 165 170 175 SerArg Glu Glu Tyr Cys Ser Leu Arg Ile Asp Glu Thr Glu Asp Leu 180 185 190Tyr Gly Pro Phe Leu Gln Ala Val Thr Trp Ser Gln Glu Lys Lys 195 200 205301 183 PRT Chlamydia 301 Ile Pro Pro Ala Pro Arg Gly His Pro Gln IleGlu Val Thr Phe Asp 5 10 15 Ile Asp Ala Asn Gly Ile Leu His Val Ser AlaLys Asp Ala Ala Ser 20 25 30 Gly Arg Glu Gln Lys Ile Arg Ile Glu Ala SerSer Gly Leu Lys Glu 35 40 45 Asp Glu Ile Gln Gln Met Ile Arg Asp Ala GluLeu His Lys Glu Glu 50 55 60 Asp Lys Gln Arg Lys Glu Ala Ser Asp Val LysAsn Glu Ala Asp Gly 65 70 75 80 Met Ile Phe Arg Ala Glu Lys Ala Val LysAsp Tyr His Asp Lys Ile 85 90 95 Pro Ala Glu Leu Val Lys Glu Ile Glu GluHis Ile Glu Lys Val Arg 100 105 110 Gln Ala Ile Lys Glu Asp Ala Ser ThrThr Ala Ile Lys Ala Ala Ser 115 120 125 Asp Glu Leu Ser Thr Arg Met GlnLys Ile Gly Glu Ala Met Gln Ala 130 135 140 Gln Ser Ala Ser Ala Ala AlaSer Ser Ala Ala Asn Ala Gln Gly Gly 145 150 155 160 Pro Asn Ile Asn SerGlu Asp Leu Lys Lys His Ser Phe Ser Thr Arg 165 170 175 Pro Pro Ala GlyGly Ser Ala 180 302 232 PRT Chlamydia 302 Met Thr Lys His Gly Lys ArgIle Arg Gly Ile Gln Glu Thr Tyr Asp 5 10 15 Leu Ala Lys Ser Tyr Ser LeuGly Glu Ala Ile Asp Ile Leu Lys Gln 20 25 30 Cys Pro Thr Val Arg Phe AspGln Thr Val Asp Val Ser Val Lys Leu 35 40 45 Gly Ile Asp Pro Arg Lys SerAsp Gln Gln Ile Arg Gly Ser Val Ser 50 55 60 Leu Pro His Gly Thr Gly LysVal Leu Arg Ile Leu Val Phe Ala Ala 65 70 75 80 Gly Asp Lys Ala Ala GluAla Ile Glu Ala Gly Ala Asp Phe Val Gly 85 90 95 Ser Asp Asp Leu Val GluLys Ile Lys Gly Gly Trp Val Asp Phe Asp 100 105 110 Val Ala Val Ala ThrPro Asp Met Met Arg Glu Val Gly Lys Leu Gly 115 120 125 Lys Val Leu GlyPro Arg Asn Leu Met Pro Thr Pro Lys Ala Gly Thr 130 135 140 Val Thr ThrAsp Val Val Lys Thr Ile Ala Glu Leu Arg Lys Gly Lys 145 150 155 160 IleGlu Phe Lys Ala Asp Arg Ala Gly Val Cys Asn Val Gly Val Ala 165 170 175Lys Leu Ser Phe Asp Ser Ala Gln Ile Lys Glu Asn Val Glu Ala Leu 180 185190 Cys Ala Ala Leu Val Lys Ala Lys Pro Ala Thr Ala Lys Gly Gln Tyr 195200 205 Leu Val Asn Phe Thr Ile Ser Ser Thr Met Gly Pro Gly Val Thr Val210 215 220 Asp Thr Arg Glu Leu Ile Ala Leu 225 230 303 238 PRTchlamydia 303 Ile Asn Ser Lys Leu Glu Thr Lys Asn Leu Ile Tyr Leu LysLeu Lys 5 10 15 Ile Lys Lys Ser Phe Lys Met Gly Asn Ser Gly Phe Tyr LeuTyr Asn 20 25 30 Thr Gln Asn Cys Val Phe Ala Asp Asn Ile Lys Val Gly GlnMet Thr 35 40 45 Glu Pro Leu Lys Asp Gln Gln Ile Ile Leu Gly Thr Thr SerThr Pro 50 55 60 Val Ala Ala Lys Met Thr Ala Ser Asp Gly Ile Ser Leu ThrVal Ser 65 70 75 80 Asn Asn Pro Ser Thr Asn Ala Ser Ile Thr Ile Gly LeuAsp Ala Glu 85 90 95 Lys Ala Tyr Gln Leu Ile Leu Glu Lys Leu Gly Asp GlnIle Leu Gly 100 105 110 Gly Ile Ala Asp Thr Ile Val Asp Ser Thr Val GlnAsp Ile Leu Asp 115 120 125 Lys Ile Thr Thr Asp Pro Ser Leu Gly Leu LeuLys Ala Phe Asn Asn 130 135 140 Phe Pro Ile Thr Asn Lys Ile Gln Cys AsnGly Leu Phe Thr Pro Arg 145 150 155 160 Asn Ile Glu Thr Leu Leu Gly GlyThr Glu Ile Gly Lys Phe Thr Val 165 170 175 Thr Pro Lys Ser Ser Gly SerMet Phe Leu Val Ser Ala Asp Ile Ile 180 185 190 Ala Ser Arg Met Glu GlyGly Val Val Leu Ala Leu Val Arg Glu Gly 195 200 205 Asp Ser Lys Pro TyrAla Ile Ser Tyr Gly Tyr Ser Ser Gly Val Pro 210 215 220 Asn Leu Cys SerLeu Arg Thr Arg Ile Ile Asn Thr Gly Leu 225 230 235 304 133 PRTChlamydia 304 His Met His His His His His His Met Ala Ser Ile Cys GlyArg Leu 5 10 15 Gly Ser Gly Thr Gly Asn Ala Leu Lys Ala Phe Phe Thr GlnPro Ser 20 25 30 Asn Lys Met Ala Arg Val Val Asn Lys Thr Lys Gly Met AspLys Thr 35 40 45 Val Lys Val Ala Lys Ser Ala Ala Glu Leu Thr Ala Asn IleLeu Glu 50 55 60 Gln Ala Gly Gly Ala Gly Ser Ser Ala His Ile Thr Ala SerGln Val 65 70 75 80 Ser Lys Gly Leu Gly Asp Thr Arg Thr Val Val Ala LeuGly Asn Ala 85 90 95 Phe Asn Gly Ala Leu Pro Gly Thr Val Gln Ser Ala GlnSer Phe Phe 100 105 110 Ser His Met Lys Ala Ala Ser Gln Lys Thr Gln GluGly Asp Glu Gly 115 120 125 Leu Thr Ala Asp Leu 130 305 125 PRTChlamydia 305 Met Ala Ser Ile Cys Gly Arg Leu Gly Ser Gly Thr Gly AsnAla Leu 5 10 15 Lys Ala Phe Phe Thr Gln Pro Ser Asn Lys Met Ala Arg ValVal Asn 20 25 30 Lys Thr Lys Gly Met Asp Lys Thr Val Lys Val Ala Lys SerAla Ala 35 40 45 Glu Leu Thr Ala Asn Ile Leu Glu Gln Ala Gly Gly Ala GlySer Ser 50 55 60 Ala His Ile Thr Ala Ser Gln Val Ser Lys Gly Leu Gly AspThr Arg 65 70 75 80 Thr Val Val Ala Leu Gly Asn Ala Phe Asn Gly Ala LeuPro Gly Thr 85 90 95 Val Gln Ser Ala Gln Ser Phe Phe Ser His Met Lys AlaAla Ser Gln 100 105 110 Lys Thr Gln Glu Gly Asp Glu Gly Leu Thr Ala AspLeu 115 120 125 306 38 DNA Chlamydia trachomatis 306 gagagcggccgctcatgttt ataacaaagg aacttatg 38 307 39 DNA Chlamydia trachomatis 307gagagcggcc gcttacttag gtgagaagaa gggagtttc 39 308 1860 DNA Chlamydiatrachomatis 308 atgcatcacc atcaccatca cacggccgcg tccgataact tccagctgtcccagggtggg 60 cagggattcg ccattccgat cgggcaggcg atggcgatcg cgggccagatcaagcttccc 120 accgttcata tcgggcctac cgccttcctc ggcttgggtg ttgtcgacaacaacggcaac 180 ggcgcacgag tccaacgcgt ggtcgggagc gctccggcgg caagtctcggcatctccacc 240 ggcgacgtga tcaccgcggt cgacggcgct ccgatcaact cggccaccgcgatggcggac 300 gcgcttaacg ggcatcatcc cggtgacgtc atctcggtga cctggcaaaccaagtcgggc 360 ggcacgcgta cagggaacgt gacattggcc gagggacccc cggccgaattctgcagatat 420 ccatcacact ggcggccgct catgtttata acaaaggaac ttatgaatcgagttatagaa 480 atccatgctc actacgatca aagacaactt tctcaatctc caaatacaaacttcttagta 540 catcatcctt atcttactct tattcccaag tttctactag gagctctaatcgtctatgct 600 ccttattcgt ttgcagaaat ggaattagct atttctggac ataaacaaggtaaagatcga 660 gataccttta ccatgatctc ttcctgtcct gaaggcacta attacatcatcaatcgcaaa 720 ctcatactca gtgatttctc gttactaaat aaagtttcat cagggggagcctttcggaat 780 ctagcaggga aaatttcctt cttaggaaaa aattcttctg cgtccattcattttaaacac 840 attaatatca atggttttgg agccggagtc ttttctgaat cctctattgaatttactgat 900 ttacgaaaac ttgttgcttt tggatctgaa agcacaggag gaatttttactgcgaaagag 960 gacatctctt ttaaaaacaa ccaccacatt gccttccgca ataatatcaccaaagggaat 1020 ggtggcgtta tccagctcca aggagatatg aaaggaagcg tatcctttgtagatcaacgt 1080 ggagctatca tctttaccaa taaccaagct gtaacttctt catcaatgaaacatagtggt 1140 cgtggaggag caattagcgg tgacttcgca ggatccagaa ttctttttcttaataaccaa 1200 caaattactt tcgaaggcaa tagcgctgtg catggaggtg ctatctacaataagaatggc 1260 cttgtcgagt tcttaggaaa tgcaggacct cttgccttta aagagaacacaacaatagct 1320 aacgggggag ctatatacac aagtaatttc aaagcgaatc aacaaacatcccccattcta 1380 ttctctcaaa atcatgcgaa taagaaaggc ggagcgattt acgcgcaatatgtgaactta 1440 gaacagaatc aagatactat tcgctttgaa aaaaataccg ctaaagaaggcggtggagcc 1500 atcacctctt ctcaatgctc aattactgct cataatacca tcactttttccgataatgct 1560 gccggagatc ttggaggagg agcaattctt ctagaaggga aaaaaccttctctaaccttg 1620 attgctcata gtggtaatat tgcatttagc ggcaatacca tgcttcatatcaccaaaaaa 1680 gcttccctag atcgacacaa ttctatctta atcaaagaag ctccctataaaatccaactt 1740 gcagcgaaca aaaaccattc tattcatttc tttgatcctg tcatggcattgtcagcatca 1800 tcttccccta tacaaatcaa tgctcctgag tatgaaactc ccttcttctcacctaagtaa 1860 309 619 PRT Chlamydia trachomatis 309 Met His His HisHis His His Thr Ala Ala Ser Asp Asn Phe Gln Leu 1 5 10 15 Ser Gln GlyGly Gln Gly Phe Ala Ile Pro Ile Gly Gln Ala Met Ala 20 25 30 Ile Ala GlyGln Ile Lys Leu Pro Thr Val His Ile Gly Pro Thr Ala 35 40 45 Phe Leu GlyLeu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val 50 55 60 Gln Arg ValVal Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr 65 70 75 80 Gly AspVal Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr 85 90 95 Ala MetAla Asp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser 100 105 110 ValThr Trp Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr 115 120 125Leu Ala Glu Gly Pro Pro Ala Glu Phe Cys Arg Tyr Pro Ser His Trp 130 135140 Arg Pro Leu Met Phe Ile Thr Lys Glu Leu Met Asn Arg Val Ile Glu 145150 155 160 Ile His Ala His Tyr Asp Gln Arg Gln Leu Ser Gln Ser Pro AsnThr 165 170 175 Asn Phe Leu Val His His Pro Tyr Leu Thr Leu Ile Pro LysPhe Leu 180 185 190 Leu Gly Ala Leu Ile Val Tyr Ala Pro Tyr Ser Phe AlaGlu Met Glu 195 200 205 Leu Ala Ile Ser Gly His Lys Gln Gly Lys Asp ArgAsp Thr Phe Thr 210 215 220 Met Ile Ser Ser Cys Pro Glu Gly Thr Asn TyrIle Ile Asn Arg Lys 225 230 235 240 Leu Ile Leu Ser Asp Phe Ser Leu LeuAsn Lys Val Ser Ser Gly Gly 245 250 255 Ala Phe Arg Asn Leu Ala Gly LysIle Ser Phe Leu Gly Lys Asn Ser 260 265 270 Ser Ala Ser Ile His Phe LysHis Ile Asn Ile Asn Gly Phe Gly Ala 275 280 285 Gly Val Phe Ser Glu SerSer Ile Glu Phe Thr Asp Leu Arg Lys Leu 290 295 300 Val Ala Phe Gly SerGlu Ser Thr Gly Gly Ile Phe Thr Ala Lys Glu 305 310 315 320 Asp Ile SerPhe Lys Asn Asn His His Ile Ala Phe Arg Asn Asn Ile 325 330 335 Thr LysGly Asn Gly Gly Val Ile Gln Leu Gln Gly Asp Met Lys Gly 340 345 350 SerVal Ser Phe Val Asp Gln Arg Gly Ala Ile Ile Phe Thr Asn Asn 355 360 365Gln Ala Val Thr Ser Ser Ser Met Lys His Ser Gly Arg Gly Gly Ala 370 375380 Ile Ser Gly Asp Phe Ala Gly Ser Arg Ile Leu Phe Leu Asn Asn Gln 385390 395 400 Gln Ile Thr Phe Glu Gly Asn Ser Ala Val His Gly Gly Ala IleTyr 405 410 415 Asn Lys Asn Gly Leu Val Glu Phe Leu Gly Asn Ala Gly ProLeu Ala 420 425 430 Phe Lys Glu Asn Thr Thr Ile Ala Asn Gly Gly Ala IleTyr Thr Ser 435 440 445 Asn Phe Lys Ala Asn Gln Gln Thr Ser Pro Ile LeuPhe Ser Gln Asn 450 455 460 His Ala Asn Lys Lys Gly Gly Ala Ile Tyr AlaGln Tyr Val Asn Leu 465 470 475 480 Glu Gln Asn Gln Asp Thr Ile Arg PheGlu Lys Asn Thr Ala Lys Glu 485 490 495 Gly Gly Gly Ala Ile Thr Ser SerGln Cys Ser Ile Thr Ala His Asn 500 505 510 Thr Ile Thr Phe Ser Asp AsnAla Ala Gly Asp Leu Gly Gly Gly Ala 515 520 525 Ile Leu Leu Glu Gly LysLys Pro Ser Leu Thr Leu Ile Ala His Ser 530 535 540 Gly Asn Ile Ala PheSer Gly Asn Thr Met Leu His Ile Thr Lys Lys 545 550 555 560 Ala Ser LeuAsp Arg His Asn Ser Ile Leu Ile Lys Glu Ala Pro Tyr 565 570 575 Lys IleGln Leu Ala Ala Asn Lys Asn His Ser Ile His Phe Phe Asp 580 585 590 ProVal Met Ala Leu Ser Ala Ser Ser Ser Pro Ile Gln Ile Asn Ala 595 600 605Pro Glu Tyr Glu Thr Pro Phe Phe Ser Pro Lys 610 615 310 39 DNA Chlamydiatrachomatis 310 gagagcggcc gctccattct attcatttct ttgatcctg 39 311 33 DNAChlamydia trachomatis 311 gagagcggcc gcttagaagc caacatagcc tcc 33 3122076 DNA Chlamydia trachomatis 312 atgcatcacc atcaccatca cacggccgcgtccgataact tccagctgtc ccagggtggg 60 cagggattcg ccattccgat cgggcaggcgatggcgatcg cgggccagat caagcttccc 120 accgttcata tcgggcctac cgccttcctcggcttgggtg ttgtcgacaa caacggcaac 180 ggcgcacgag tccaacgcgt ggtcgggagcgctccggcgg caagtctcgg catctccacc 240 ggcgacgtga tcaccgcggt cgacggcgctccgatcaact cggccaccgc gatggcggac 300 gcgcttaacg ggcatcatcc cggtgacgtcatctcggtga cctggcaaac caagtcgggc 360 ggcacgcgta cagggaacgt gacattggccgagggacccc cggccgaatt ctgcagatat 420 ccatcacact ggcggccgct ccattctattcatttctttg atcctgtcat ggcattgtca 480 gcatcatctt cccctataca aatcaatgctcctgagtatg aaactccctt cttctcacct 540 aagggtatga tcgttttctc gggtgcgaatcttttagatg atgctaggga agatgttgca 600 aatagaacat cgatttttaa ccaacccgttcatctatata atggcaccct atctatcgaa 660 aatggagccc atctgattgt ccaaagcttcaaacagaccg gaggacgtat cagtttatct 720 ccaggatcct ccttggctct atacacgatgaactcgttct tccatggcaa catatccagc 780 aaagaacccc tagaaattaa tggtttaagctttggagtag atatctctcc ttctaatctt 840 caagcagaga tccgtgccgg caacgctcctttacgattat ccggatcccc atctatccat 900 gatcctgaag gattattcta cgaaaatcgcgatactgcag catcaccata ccaaatggaa 960 atcttgctca cctctgataa aactgtagatatctccaaat ttactactga ttctctagtt 1020 acgaacaaac aatcaggatt ccaaggagcctggcatttta gctggcagcc aaatactata 1080 aacaatacta aacaaaaaat attaagagcttcttggctcc caacaggaga atatgtcctt 1140 gaatccaatc gagtggggcg tgccgttcctaattccttat ggagcacatt tttactttta 1200 cagacagcct ctcataactt aggcgatcatctatgtaata atcgatctct tattcctact 1260 tcatacttcg gagttttaat tggaggaactggagcagaaa tgtctaccca ctcctcagaa 1320 gaagaaagct ttatatctcg tttaggagctacaggaacct ctatcatacg cttaactccc 1380 tccctgacac tctctggagg aggctcacatatgttcggag attcgttcgt tgcagactta 1440 ccagaacaca tcacttcaga aggaattgttcagaatgtcg gtttaaccca tgtctgggga 1500 ccccttactg tcaattctac attatgtgcagccttagatc acaacgcgat ggtccgcata 1560 tgctccaaaa aagatcacac ctatgggaaatgggatacat tcggtatgcg aggaacatta 1620 ggagcctctt atacattcct agaatatgatcaaactatgc gcgtattctc attcgccaac 1680 atcgaagcca caaatatctt gcaaagagcttttactgaaa caggctataa cccaagaagt 1740 ttttccaaga caaaacttct aaacatcgccatccccatag ggattggtta tgaattctgc 1800 ttagggaata gctcttttgc tctactaggtaagggatcca tcggttactc tcgagatatt 1860 aaacgagaaa acccatccac tcttgctcacctggctatga atgattttgc ttggactacc 1920 aatggctgtt cagttccaac ctccgcacacacattggcaa atcaattgat tcttcgctat 1980 aaagcatgtt ccttatacat cacggcatatactatcaacc gtgaagggaa gaacctctcc 2040 aatagcttat cctgcggagg ctatgttggcttctaa 2076 313 691 PRT Chlamydia trachomatis 313 Met His His His HisHis His Thr Ala Ala Ser Asp Asn Phe Gln Leu 1 5 10 15 Ser Gln Gly GlyGln Gly Phe Ala Ile Pro Ile Gly Gln Ala Met Ala 20 25 30 Ile Ala Gly GlnIle Lys Leu Pro Thr Val His Ile Gly Pro Thr Ala 35 40 45 Phe Leu Gly LeuGly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val 50 55 60 Gln Arg Val ValGly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr 65 70 75 80 Gly Asp ValIle Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr 85 90 95 Ala Met AlaAsp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser 100 105 110 Val ThrTrp Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr 115 120 125 LeuAla Glu Gly Pro Pro Ala Glu Phe Cys Arg Tyr Pro Ser His Trp 130 135 140Arg Pro Leu His Ser Ile His Phe Phe Asp Pro Val Met Ala Leu Ser 145 150155 160 Ala Ser Ser Ser Pro Ile Gln Ile Asn Ala Pro Glu Tyr Glu Thr Pro165 170 175 Phe Phe Ser Pro Lys Gly Met Ile Val Phe Ser Gly Ala Asn LeuLeu 180 185 190 Asp Asp Ala Arg Glu Asp Val Ala Asn Arg Thr Ser Ile PheAsn Gln 195 200 205 Pro Val His Leu Tyr Asn Gly Thr Leu Ser Ile Glu AsnGly Ala His 210 215 220 Leu Ile Val Gln Ser Phe Lys Gln Thr Gly Gly ArgIle Ser Leu Ser 225 230 235 240 Pro Gly Ser Ser Leu Ala Leu Tyr Thr MetAsn Ser Phe Phe His Gly 245 250 255 Asn Ile Ser Ser Lys Glu Pro Leu GluIle Asn Gly Leu Ser Phe Gly 260 265 270 Val Asp Ile Ser Pro Ser Asn LeuGln Ala Glu Ile Arg Ala Gly Asn 275 280 285 Ala Pro Leu Arg Leu Ser GlySer Pro Ser Ile His Asp Pro Glu Gly 290 295 300 Leu Phe Tyr Glu Asn ArgAsp Thr Ala Ala Ser Pro Tyr Gln Met Glu 305 310 315 320 Ile Leu Leu ThrSer Asp Lys Thr Val Asp Ile Ser Lys Phe Thr Thr 325 330 335 Asp Ser LeuVal Thr Asn Lys Gln Ser Gly Phe Gln Gly Ala Trp His 340 345 350 Phe SerTrp Gln Pro Asn Thr Ile Asn Asn Thr Lys Gln Lys Ile Leu 355 360 365 ArgAla Ser Trp Leu Pro Thr Gly Glu Tyr Val Leu Glu Ser Asn Arg 370 375 380Val Gly Arg Ala Val Pro Asn Ser Leu Trp Ser Thr Phe Leu Leu Leu 385 390395 400 Gln Thr Ala Ser His Asn Leu Gly Asp His Leu Cys Asn Asn Arg Ser405 410 415 Leu Ile Pro Thr Ser Tyr Phe Gly Val Leu Ile Gly Gly Thr GlyAla 420 425 430 Glu Met Ser Thr His Ser Ser Glu Glu Glu Ser Phe Ile SerArg Leu 435 440 445 Gly Ala Thr Gly Thr Ser Ile Ile Arg Leu Thr Pro SerLeu Thr Leu 450 455 460 Ser Gly Gly Gly Ser His Met Phe Gly Asp Ser PheVal Ala Asp Leu 465 470 475 480 Pro Glu His Ile Thr Ser Glu Gly Ile ValGln Asn Val Gly Leu Thr 485 490 495 His Val Trp Gly Pro Leu Thr Val AsnSer Thr Leu Cys Ala Ala Leu 500 505 510 Asp His Asn Ala Met Val Arg IleCys Ser Lys Lys Asp His Thr Tyr 515 520 525 Gly Lys Trp Asp Thr Phe GlyMet Arg Gly Thr Leu Gly Ala Ser Tyr 530 535 540 Thr Phe Leu Glu Tyr AspGln Thr Met Arg Val Phe Ser Phe Ala Asn 545 550 555 560 Ile Glu Ala ThrAsn Ile Leu Gln Arg Ala Phe Thr Glu Thr Gly Tyr 565 570 575 Asn Pro ArgSer Phe Ser Lys Thr Lys Leu Leu Asn Ile Ala Ile Pro 580 585 590 Ile GlyIle Gly Tyr Glu Phe Cys Leu Gly Asn Ser Ser Phe Ala Leu 595 600 605 LeuGly Lys Gly Ser Ile Gly Tyr Ser Arg Asp Ile Lys Arg Glu Asn 610 615 620Pro Ser Thr Leu Ala His Leu Ala Met Asn Asp Phe Ala Trp Thr Thr 625 630635 640 Asn Gly Cys Ser Val Pro Thr Ser Ala His Thr Leu Ala Asn Gln Leu645 650 655 Ile Leu Arg Tyr Lys Ala Cys Ser Leu Tyr Ile Thr Ala Tyr ThrIle 660 665 670 Asn Arg Glu Gly Lys Asn Leu Ser Asn Ser Leu Ser Cys GlyGly Tyr 675 680 685 Val Gly Phe 690 314 38 DNA Chlamydia trachomatis 314gagagcggcc gctcatgatt aaaagaactt ctctatcc 38 315 36 DNA Chlamydiatrachomatis 315 agcggccgct tataattctg catcatcttc tatggc 36 316 1941 DNAChlamydia trachomatis 316 atgcatcacc atcaccatca cacggccgcg tccgataacttccagctgtc ccagggtggg 60 cagggattcg ccattccgat cgggcaggcg atggcgatcgcgggccagat caagcttccc 120 accgttcata tcgggcctac cgccttcctc ggcttgggtgttgtcgacaa caacggcaac 180 ggcgcacgag tccaacgcgt ggtcgggagc gctccggcggcaagtctcgg catctccacc 240 ggcgacgtga tcaccgcggt cgacggcgct ccgatcaactcggccaccgc gatggcggac 300 gcgcttaacg ggcatcatcc cggtgacgtc atctcggtgacctggcaaac caagtcgggc 360 ggcacgcgta cagggaacgt gacattggcc gagggacccccggccgaatt ctgcagatat 420 ccatcacact ggcggccgct catgattaaa agaacttctctatcctttgc ttgcctcagt 480 tttttttatc tttcaactat atccattttg caagctaatgaaacggatac gctacagttc 540 cggcgattta ctttttcgga tagagagatt cagttcgtcctagatcccgc ctctttaatt 600 accgcccaaa acatcgtttt atctaattta cagtcaaacggaaccggagc ctgtaccatt 660 tcaggcaata cgcaaactca aatcttttct aattccgttaacaccaccgc agattctggt 720 ggagcctttg atatggttac tacctcattc acggcctctgataatgctaa tctactcttc 780 tgcaacaact actgcacaca taataaaggc ggaggagctattcgttccgg aggacctatt 840 cgattcttaa ataatcaaga cgtgcttttt tataataacatatcggcagg ggctaaatat 900 gttggaacag gagatcacaa cgaaaaaaat aggggcggtgcgctttatgc aactactatc 960 actttgacag ggaatcgaac tcttgccttt attaacaatatgtctggaga ctgcggtgga 1020 gccatctctg ctgacactca aatatcaata actgataccgttaaaggaat tttatttgaa 1080 aacaatcaca cgctcaatca tataccgtac acgcaagctgaaaatatggc acgaggagga 1140 gcaatctgta gtagaagaga cttgtgctca atcagcaataattctggtcc catagttttt 1200 aactataacc aaggcgggaa aggtggagct attagcgctacccgatgtgt tattgacaat 1260 aacaaagaaa gaatcatctt ttcaaacaat agttccctgggatggagcca atcttcttct 1320 gcaagtaacg gaggagccat tcaaacgaca caaggatttactttacgaaa taataaaggc 1380 tctatctact tcgacagcaa cactgctaca cacgccgggggagccattaa ctgtggttac 1440 attgacatcc gagataacgg acccgtctat tttctaaataactctgctgc ctggggagcg 1500 gcctttaatt tatcgaaacc acgttcagcg acaaattatatccatacagg gacaggcgat 1560 attgttttta ataataacgt tgtctttact cttgacggtaatttattagg gaaacggaaa 1620 ctttttcata ttaataataa tgagataaca ccatatacattgtctctcgg cgctaaaaaa 1680 gatactcgta tctattttta tgatcttttc caatgggagcgtgttaaaga aaatactagc 1740 aataacccac catctcctac cagtagaaac accattaccgttaacccgga aacagagttt 1800 tctggagctg ttgtgttctc ctacaatcaa atgtctagtgacatacgaac tctgatgggt 1860 aaagaacaca attacattaa agaagcccca actactttaaaattcggaac gctagccata 1920 gaagatgatg cagaattata a 1941 317 646 PRTChlamydia trachomatis 317 Met His His His His His His Thr Ala Ala SerAsp Asn Phe Gln Leu 1 5 10 15 Ser Gln Gly Gly Gln Gly Phe Ala Ile ProIle Gly Gln Ala Met Ala 20 25 30 Ile Ala Gly Gln Ile Lys Leu Pro Thr ValHis Ile Gly Pro Thr Ala 35 40 45 Phe Leu Gly Leu Gly Val Val Asp Asn AsnGly Asn Gly Ala Arg Val 50 55 60 Gln Arg Val Val Gly Ser Ala Pro Ala AlaSer Leu Gly Ile Ser Thr 65 70 75 80 Gly Asp Val Ile Thr Ala Val Asp GlyAla Pro Ile Asn Ser Ala Thr 85 90 95 Ala Met Ala Asp Ala Leu Asn Gly HisHis Pro Gly Asp Val Ile Ser 100 105 110 Val Thr Trp Gln Thr Lys Ser GlyGly Thr Arg Thr Gly Asn Val Thr 115 120 125 Leu Ala Glu Gly Pro Pro AlaGlu Phe Cys Arg Tyr Pro Ser His Trp 130 135 140 Arg Pro Leu Met Ile LysArg Thr Ser Leu Ser Phe Ala Cys Leu Ser 145 150 155 160 Phe Phe Tyr LeuSer Thr Ile Ser Ile Leu Gln Ala Asn Glu Thr Asp 165 170 175 Thr Leu GlnPhe Arg Arg Phe Thr Phe Ser Asp Arg Glu Ile Gln Phe 180 185 190 Val LeuAsp Pro Ala Ser Leu Ile Thr Ala Gln Asn Ile Val Leu Ser 195 200 205 AsnLeu Gln Ser Asn Gly Thr Gly Ala Cys Thr Ile Ser Gly Asn Thr 210 215 220Gln Thr Gln Ile Phe Ser Asn Ser Val Asn Thr Thr Ala Asp Ser Gly 225 230235 240 Gly Ala Phe Asp Met Val Thr Thr Ser Phe Thr Ala Ser Asp Asn Ala245 250 255 Asn Leu Leu Phe Cys Asn Asn Tyr Cys Thr His Asn Lys Gly GlyGly 260 265 270 Ala Ile Arg Ser Gly Gly Pro Ile Arg Phe Leu Asn Asn GlnAsp Val 275 280 285 Leu Phe Tyr Asn Asn Ile Ser Ala Gly Ala Lys Tyr ValGly Thr Gly 290 295 300 Asp His Asn Glu Lys Asn Arg Gly Gly Ala Leu TyrAla Thr Thr Ile 305 310 315 320 Thr Leu Thr Gly Asn Arg Thr Leu Ala PheIle Asn Asn Met Ser Gly 325 330 335 Asp Cys Gly Gly Ala Ile Ser Ala AspThr Gln Ile Ser Ile Thr Asp 340 345 350 Thr Val Lys Gly Ile Leu Phe GluAsn Asn His Thr Leu Asn His Ile 355 360 365 Pro Tyr Thr Gln Ala Glu AsnMet Ala Arg Gly Gly Ala Ile Cys Ser 370 375 380 Arg Arg Asp Leu Cys SerIle Ser Asn Asn Ser Gly Pro Ile Val Phe 385 390 395 400 Asn Tyr Asn GlnGly Gly Lys Gly Gly Ala Ile Ser Ala Thr Arg Cys 405 410 415 Val Ile AspAsn Asn Lys Glu Arg Ile Ile Phe Ser Asn Asn Ser Ser 420 425 430 Leu GlyTrp Ser Gln Ser Ser Ser Ala Ser Asn Gly Gly Ala Ile Gln 435 440 445 ThrThr Gln Gly Phe Thr Leu Arg Asn Asn Lys Gly Ser Ile Tyr Phe 450 455 460Asp Ser Asn Thr Ala Thr His Ala Gly Gly Ala Ile Asn Cys Gly Tyr 465 470475 480 Ile Asp Ile Arg Asp Asn Gly Pro Val Tyr Phe Leu Asn Asn Ser Ala485 490 495 Ala Trp Gly Ala Ala Phe Asn Leu Ser Lys Pro Arg Ser Ala ThrAsn 500 505 510 Tyr Ile His Thr Gly Thr Gly Asp Ile Val Phe Asn Asn AsnVal Val 515 520 525 Phe Thr Leu Asp Gly Asn Leu Leu Gly Lys Arg Lys LeuPhe His Ile 530 535 540 Asn Asn Asn Glu Ile Thr Pro Tyr Thr Leu Ser LeuGly Ala Lys Lys 545 550 555 560 Asp Thr Arg Ile Tyr Phe Tyr Asp Leu PheGln Trp Glu Arg Val Lys 565 570 575 Glu Asn Thr Ser Asn Asn Pro Pro SerPro Thr Ser Arg Asn Thr Ile 580 585 590 Thr Val Asn Pro Glu Thr Glu PheSer Gly Ala Val Val Phe Ser Tyr 595 600 605 Asn Gln Met Ser Ser Asp IleArg Thr Leu Met Gly Lys Glu His Asn 610 615 620 Tyr Ile Lys Glu Ala ProThr Thr Leu Lys Phe Gly Thr Leu Ala Ile 625 630 635 640 Glu Asp Asp AlaGlu Leu 645 318 34 DNA Chlamydia trachomatis 318 gagagcggcc gctcgacatacgaactctga tggg 34 319 33 DNA Chlamydia trachomatis 319 gagagcggccgcttaaaaga ccagagctcc tcc 33 320 2148 DNA Chlamydia trachomatis 320atgcatcacc atcaccatca cacggccgcg tccgataact tccagctgtc ccagggtggg 60cagggattcg ccattccgat cgggcaggcg atggcgatcg cgggccagat caagcttccc 120accgttcata tcgggcctac cgccttcctc ggcttgggtg ttgtcgacaa caacggcaac 180ggcgcacgag tccaacgcgt ggtcgggagc gctccggcgg caagtctcgg catctccacc 240ggcgacgtga tcaccgcggt cgacggcgct ccgatcaact cggccaccgc gatggcggac 300gcgcttaacg ggcatcatcc cggtgacgtc atctcggtga cctggcaaac caagtcgggc 360ggcacgcgta cagggaacgt gacattggcc gagggacccc cggccgaatt ctgcagatat 420ccatcacact ggcggccgct cgacatacga actctgatgg gtaaagaaca caattacatt 480aaagaagccc caactacttt aaaattcgga acgctagcca tagaagatga tgcagaatta 540gaaatcttca atatcccgtt tacccaaaat ccgactagcc ttcttgcttt aggaagcggc 600gctacgctga ctgttggaaa gcacggtaag ctcaatatta caaatcttgg tgttatttta 660cccattattc tcaaagaggg gaagagtccg ccttgtattc gcgtcaaccc acaagatatg 720acccaaaata ctggtaccgg ccaaactcca tcaagcacaa gtagtataag cactccaatg 780attatcttta atgggcgcct ctcaattgta gacgaaaatt atgaatcagt ctacgacagt 840atggacctct ccagagggaa agcagaacaa ctaattctat ccatagaaac cactaatgat 900gggcaattag actccaattg gcaaagttct ctgaatactt ctctactctc tcctccacac 960tatggctatc aaggtctatg gactcctaat tggataacaa caacctatac catcacgctt 1020aataataatt cttcagctcc aacatctgct acctccatcg ctgagcagaa aaaaactagt 1080gaaactttta ctcctagtaa cacaactaca gctagtatcc ctaatattaa agcttccgca 1140ggatcaggct ctggatcggc ttccaattca ggagaagtta cgattaccaa acataccctt 1200gttgtaaact gggcaccagt cggctacata gtagatccta ttcgtagagg agatctgata 1260gccaatagct tagtacattc aggaagaaac atgaccatgg gcttacgatc attactcccg 1320gataactctt ggtttgcttt gcaaggagct gcaacaacat tatttacaaa acaacaaaaa 1380cgtttgagtt atcatggcta ctcttctgca tcaaaggggt ataccgtctc ttctcaagca 1440tcaggagctc atggtcataa gtttcttctt tccttctccc agtcatctga taagatgaaa 1500gaaaaagaaa caaataaccg cctttcttct cgttactatc tttctgcttt atgtttcgaa 1560catcctatgt ttgatcgcat tgctcttatc ggagcagcag cttgcaatta tggaacacat 1620aacatgcgga gtttctatgg aactaaaaaa tcttctaaag ggaaatttca ctctacaacc 1680ttaggagctt ctcttcgctg tgaactacgc gatagtatgc ctttacgatc aataatgctc 1740accccatttg ctcaggcttt attctctcga acagaaccag cttctatccg agaaagcggt 1800gatctagcta gattatttac attagagcaa gcccatactg ccgttgtctc tccaatagga 1860atcaaaggag cttattcttc tgatacatgg ccaacactct cttgggaaat ggaactagct 1920taccaaccca ccctctactg gaaacgtcct ctactcaaca cactattaat ccaaaataac 1980ggttcttggg tcaccacaaa taccccatta gctaaacatt ccttttatgg gagaggttct 2040cactccctca aattttctca tctgaaacta tttgctaact atcaagcaga agtggctact 2100tccactgtct cacactacat caatgcagga ggagctctgg tcttttaa 2148 321 715 PRTChlamydia trachomatis 321 Met His His His His His His Thr Ala Ala SerAsp Asn Phe Gln Leu 1 5 10 15 Ser Gln Gly Gly Gln Gly Phe Ala Ile ProIle Gly Gln Ala Met Ala 20 25 30 Ile Ala Gly Gln Ile Lys Leu Pro Thr ValHis Ile Gly Pro Thr Ala 35 40 45 Phe Leu Gly Leu Gly Val Val Asp Asn AsnGly Asn Gly Ala Arg Val 50 55 60 Gln Arg Val Val Gly Ser Ala Pro Ala AlaSer Leu Gly Ile Ser Thr 65 70 75 80 Gly Asp Val Ile Thr Ala Val Asp GlyAla Pro Ile Asn Ser Ala Thr 85 90 95 Ala Met Ala Asp Ala Leu Asn Gly HisHis Pro Gly Asp Val Ile Ser 100 105 110 Val Thr Trp Gln Thr Lys Ser GlyGly Thr Arg Thr Gly Asn Val Thr 115 120 125 Leu Ala Glu Gly Pro Pro AlaGlu Phe Cys Arg Tyr Pro Ser His Trp 130 135 140 Arg Pro Leu Asp Ile ArgThr Leu Met Gly Lys Glu His Asn Tyr Ile 145 150 155 160 Lys Glu Ala ProThr Thr Leu Lys Phe Gly Thr Leu Ala Ile Glu Asp 165 170 175 Asp Ala GluLeu Glu Ile Phe Asn Ile Pro Phe Thr Gln Asn Pro Thr 180 185 190 Ser LeuLeu Ala Leu Gly Ser Gly Ala Thr Leu Thr Val Gly Lys His 195 200 205 GlyLys Leu Asn Ile Thr Asn Leu Gly Val Ile Leu Pro Ile Ile Leu 210 215 220Lys Glu Gly Lys Ser Pro Pro Cys Ile Arg Val Asn Pro Gln Asp Met 225 230235 240 Thr Gln Asn Thr Gly Thr Gly Gln Thr Pro Ser Ser Thr Ser Ser Ile245 250 255 Ser Thr Pro Met Ile Ile Phe Asn Gly Arg Leu Ser Ile Val AspGlu 260 265 270 Asn Tyr Glu Ser Val Tyr Asp Ser Met Asp Leu Ser Arg GlyLys Ala 275 280 285 Glu Gln Leu Ile Leu Ser Ile Glu Thr Thr Asn Asp GlyGln Leu Asp 290 295 300 Ser Asn Trp Gln Ser Ser Leu Asn Thr Ser Leu LeuSer Pro Pro His 305 310 315 320 Tyr Gly Tyr Gln Gly Leu Trp Thr Pro AsnTrp Ile Thr Thr Thr Tyr 325 330 335 Thr Ile Thr Leu Asn Asn Asn Ser SerAla Pro Thr Ser Ala Thr Ser 340 345 350 Ile Ala Glu Gln Lys Lys Thr SerGlu Thr Phe Thr Pro Ser Asn Thr 355 360 365 Thr Thr Ala Ser Ile Pro AsnIle Lys Ala Ser Ala Gly Ser Gly Ser 370 375 380 Gly Ser Ala Ser Asn SerGly Glu Val Thr Ile Thr Lys His Thr Leu 385 390 395 400 Val Val Asn TrpAla Pro Val Gly Tyr Ile Val Asp Pro Ile Arg Arg 405 410 415 Gly Asp LeuIle Ala Asn Ser Leu Val His Ser Gly Arg Asn Met Thr 420 425 430 Met GlyLeu Arg Ser Leu Leu Pro Asp Asn Ser Trp Phe Ala Leu Gln 435 440 445 GlyAla Ala Thr Thr Leu Phe Thr Lys Gln Gln Lys Arg Leu Ser Tyr 450 455 460His Gly Tyr Ser Ser Ala Ser Lys Gly Tyr Thr Val Ser Ser Gln Ala 465 470475 480 Ser Gly Ala His Gly His Lys Phe Leu Leu Ser Phe Ser Gln Ser Ser485 490 495 Asp Lys Met Lys Glu Lys Glu Thr Asn Asn Arg Leu Ser Ser ArgTyr 500 505 510 Tyr Leu Ser Ala Leu Cys Phe Glu His Pro Met Phe Asp ArgIle Ala 515 520 525 Leu Ile Gly Ala Ala Ala Cys Asn Tyr Gly Thr His AsnMet Arg Ser 530 535 540 Phe Tyr Gly Thr Lys Lys Ser Ser Lys Gly Lys PheHis Ser Thr Thr 545 550 555 560 Leu Gly Ala Ser Leu Arg Cys Glu Leu ArgAsp Ser Met Pro Leu Arg 565 570 575 Ser Ile Met Leu Thr Pro Phe Ala GlnAla Leu Phe Ser Arg Thr Glu 580 585 590 Pro Ala Ser Ile Arg Glu Ser GlyAsp Leu Ala Arg Leu Phe Thr Leu 595 600 605 Glu Gln Ala His Thr Ala ValVal Ser Pro Ile Gly Ile Lys Gly Ala 610 615 620 Tyr Ser Ser Asp Thr TrpPro Thr Leu Ser Trp Glu Met Glu Leu Ala 625 630 635 640 Tyr Gln Pro ThrLeu Tyr Trp Lys Arg Pro Leu Leu Asn Thr Leu Leu 645 650 655 Ile Gln AsnAsn Gly Ser Trp Val Thr Thr Asn Thr Pro Leu Ala Lys 660 665 670 His SerPhe Tyr Gly Arg Gly Ser His Ser Leu Lys Phe Ser His Leu 675 680 685 LysLeu Phe Ala Asn Tyr Gln Ala Glu Val Ala Thr Ser Thr Val Ser 690 695 700His Tyr Ile Asn Ala Gly Gly Ala Leu Val Phe 705 710 715 322 37 DNAChlamydia trachomatis 322 gagagcggcc gctcatgcct ttttctttga gatctac 37323 36 DNA Chlamydia trachomatis 323 gagagcggcc gcttacacag atccattaccggactg 36 324 1896 DNA Chlamydia trachomatis 324 atgcatcacc atcaccatcacacggccgcg tccgataact tccagctgtc ccagggtggg 60 cagggattcg ccattccgatcgggcaggcg atggcgatcg cgggccagat caagcttccc 120 accgttcata tcgggcctaccgccttcctc ggcttgggtg ttgtcgacaa caacggcaac 180 ggcgcacgag tccaacgcgtggtcgggagc gctccggcgg caagtctcgg catctccacc 240 ggcgacgtga tcaccgcggtcgacggcgct ccgatcaact cggccaccgc gatggcggac 300 gcgcttaacg ggcatcatcccggtgacgtc atctcggtga cctggcaaac caagtcgggc 360 ggcacgcgta cagggaacgtgacattggcc gagggacccc cggccgaatt ctgcagatat 420 ccatcacact ggcggccgctcatgcctttt tctttgagat ctacatcatt ttgtttttta 480 gcttgtttgt gttcctattcgtatggattc gcgagctctc ctcaagtgtt aacacctaat 540 gtaaccactc cttttaagggggacgatgtt tacttgaatg gagactgcgc ttttgtcaat 600 gtctatgcag gggcagagaacggctcaatt atctcagcta atggcgacaa tttaacgatt 660 accggacaaa accatacattatcatttaca gattctcaag ggccagttct tcaaaattat 720 gccttcattt cagcaggagagacacttact ctgaaagatt tttcgagttt gatgttctcg 780 aaaaatgttt cttgcggagaaaagggaatg atctcaggga aaaccgtgag tatttccgga 840 gcaggcgaag tgattttttgggataactct gtggggtatt ctcctttgtc tattgtgcca 900 gcatcgactc caactcctccagcaccagca ccagctcctg ctgcttcaag ctctttatct 960 ccaacagtta gtgatgctcggaaagggtct attttttctg tagagactag tttggagatc 1020 tcaggcgtca aaaaaggggtcatgttcgat aataatgccg ggaattttgg aacagttttt 1080 cgaggtaata gtaataataatgctggtagt gggggtagtg ggtctgctac aacaccaagt 1140 tttacagtta aaaactgtaaagggaaagtt tctttcacag ataacgtagc ctcctgtgga 1200 ggcggagtag tctacaaaggaactgtgctt ttcaaagaca atgaaggagg catattcttc 1260 cgagggaaca cagcatacgatgatttaggg attcttgctg ctactagtcg ggatcagaat 1320 acggagacag gaggcggtggaggagttatt tgctctccag atgattctgt aaagtttgaa 1380 ggcaataaag gttctattgtttttgattac aactttgcaa aaggcagagg cggaagcatc 1440 ctaacgaaag aattctctcttgtagcagat gattcggttg tctttagtaa caatacagca 1500 gaaaaaggcg gtggagctatttatgctcct actatcgata taagcacgaa tggaggatcg 1560 attctgtttg aaagaaaccgagctgcagaa ggaggcgcca tctgcgtgag tgaagcaagc 1620 tctggttcaa ctggaaatcttactttaagc gcttctgatg gggatattgt tttttctggg 1680 aatatgacga gtgatcgtcctggagagcgc agcgcagcaa gaatcttaag tgatggaacg 1740 actgtttctt taaatgcttccggactatcg aagctgatct tttatgatcc tgtagtacaa 1800 aataattcag cagcgggtgcatcgacacca tcaccatctt cttcttctat gcctggtgct 1860 gtcacgatta atcagtccggtaatggatct gtgtaa 1896 325 631 PRT Chlamydia trachomatis 325 Met His HisHis His His His Thr Ala Ala Ser Asp Asn Phe Gln Leu 1 5 10 15 Ser GlnGly Gly Gln Gly Phe Ala Ile Pro Ile Gly Gln Ala Met Ala 20 25 30 Ile AlaGly Gln Ile Lys Leu Pro Thr Val His Ile Gly Pro Thr Ala 35 40 45 Phe LeuGly Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val 50 55 60 Gln ArgVal Val Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr 65 70 75 80 GlyAsp Val Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr 85 90 95 AlaMet Ala Asp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser 100 105 110Val Thr Trp Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr 115 120125 Leu Ala Glu Gly Pro Pro Ala Glu Phe Cys Arg Tyr Pro Ser His Trp 130135 140 Arg Pro Leu Met Pro Phe Ser Leu Arg Ser Thr Ser Phe Cys Phe Leu145 150 155 160 Ala Cys Leu Cys Ser Tyr Ser Tyr Gly Phe Ala Ser Ser ProGln Val 165 170 175 Leu Thr Pro Asn Val Thr Thr Pro Phe Lys Gly Asp AspVal Tyr Leu 180 185 190 Asn Gly Asp Cys Ala Phe Val Asn Val Tyr Ala GlyAla Glu Asn Gly 195 200 205 Ser Ile Ile Ser Ala Asn Gly Asp Asn Leu ThrIle Thr Gly Gln Asn 210 215 220 His Thr Leu Ser Phe Thr Asp Ser Gln GlyPro Val Leu Gln Asn Tyr 225 230 235 240 Ala Phe Ile Ser Ala Gly Glu ThrLeu Thr Leu Lys Asp Phe Ser Ser 245 250 255 Leu Met Phe Ser Lys Asn ValSer Cys Gly Glu Lys Gly Met Ile Ser 260 265 270 Gly Lys Thr Val Ser IleSer Gly Ala Gly Glu Val Ile Phe Trp Asp 275 280 285 Asn Ser Val Gly TyrSer Pro Leu Ser Ile Val Pro Ala Ser Thr Pro 290 295 300 Thr Pro Pro AlaPro Ala Pro Ala Pro Ala Ala Ser Ser Ser Leu Ser 305 310 315 320 Pro ThrVal Ser Asp Ala Arg Lys Gly Ser Ile Phe Ser Val Glu Thr 325 330 335 SerLeu Glu Ile Ser Gly Val Lys Lys Gly Val Met Phe Asp Asn Asn 340 345 350Ala Gly Asn Phe Gly Thr Val Phe Arg Gly Asn Ser Asn Asn Asn Ala 355 360365 Gly Ser Gly Gly Ser Gly Ser Ala Thr Thr Pro Ser Phe Thr Val Lys 370375 380 Asn Cys Lys Gly Lys Val Ser Phe Thr Asp Asn Val Ala Ser Cys Gly385 390 395 400 Gly Gly Val Val Tyr Lys Gly Thr Val Leu Phe Lys Asp AsnGlu Gly 405 410 415 Gly Ile Phe Phe Arg Gly Asn Thr Ala Tyr Asp Asp LeuGly Ile Leu 420 425 430 Ala Ala Thr Ser Arg Asp Gln Asn Thr Glu Thr GlyGly Gly Gly Gly 435 440 445 Val Ile Cys Ser Pro Asp Asp Ser Val Lys PheGlu Gly Asn Lys Gly 450 455 460 Ser Ile Val Phe Asp Tyr Asn Phe Ala LysGly Arg Gly Gly Ser Ile 465 470 475 480 Leu Thr Lys Glu Phe Ser Leu ValAla Asp Asp Ser Val Val Phe Ser 485 490 495 Asn Asn Thr Ala Glu Lys GlyGly Gly Ala Ile Tyr Ala Pro Thr Ile 500 505 510 Asp Ile Ser Thr Asn GlyGly Ser Ile Leu Phe Glu Arg Asn Arg Ala 515 520 525 Ala Glu Gly Gly AlaIle Cys Val Ser Glu Ala Ser Ser Gly Ser Thr 530 535 540 Gly Asn Leu ThrLeu Ser Ala Ser Asp Gly Asp Ile Val Phe Ser Gly 545 550 555 560 Asn MetThr Ser Asp Arg Pro Gly Glu Arg Ser Ala Ala Arg Ile Leu 565 570 575 SerAsp Gly Thr Thr Val Ser Leu Asn Ala Ser Gly Leu Ser Lys Leu 580 585 590Ile Phe Tyr Asp Pro Val Val Gln Asn Asn Ser Ala Ala Gly Ala Ser 595 600605 Thr Pro Ser Pro Ser Ser Ser Ser Met Pro Gly Ala Val Thr Ile Asn 610615 620 Gln Ser Gly Asn Gly Ser Val 625 630 326 40 DNA Chlamydiatrachomatis 326 gagagcggcc gctcgatcct gtagtacaaa ataattcagc 40 327 33DNA Chlamydia trachomatis 327 gagagcggcc gcttaaaaga ttctattcaa gcc 33328 2148 DNA Chlymadia trachomatis 328 atgcatcacc atcaccatca cacggccgcgtccgataact tccagctgtc ccagggtggg 60 cagggattcg ccattccgat cgggcaggcgatggcgatcg cgggccagat caagcttccc 120 accgttcata tcgggcctac cgccttcctcggcttgggtg ttgtcgacaa caacggcaac 180 ggcgcacgag tccaacgcgt ggtcgggagcgctccggcgg caagtctcgg catctccacc 240 ggcgacgtga tcaccgcggt cgacggcgctccgatcaact cggccaccgc gatggcggac 300 gcgcttaacg ggcatcatcc cggtgacgtcatctcggtga cctggcaaac caagtcgggc 360 ggcacgcgta cagggaacgt gacattggccgagggacccc cggccgaatt ctgcagatat 420 ccatcacact ggcggccgct cgatcctgtagtacaaaata attcagcagc gggtgcatcg 480 acaccatcac catcttcttc ttctatgcctggtgctgtca cgattaatca gtccggtaat 540 ggatctgtga tttttaccgc cgagtcattgactccttcag aaaaacttca agttcttaac 600 tctacttcta acttcccagg agctctgactgtgtcaggag gggagttggt tgtgacggaa 660 ggagctacct taactactgg gaccattacagccacctctg gacgagtgac tttaggatcc 720 ggagcttcgt tgtctgccgt tgcaggtgctgcaaataata attatacttg tacagtatct 780 aagttgggga ttgatttaga atcctttttaactcctaact ataagacggc catactgggt 840 gcggatggaa cagttactgt taacagcggctctactttag acctagtgat ggagaatgag 900 gcagaggtct atgataatcc gctttttgtgggatcgctga caattccttt tgttactcta 960 tcttctagta gtgctagtaa cggagttacaaaaaattctg tcactattaa tgatgcagac 1020 gctgcgcact atgggtatca aggctcttggtctgcagatt ggacgaaacc gcctctggct 1080 cctgatgcta aggggatggt acctcctaataccaataaca ctctgtatct gacatggaga 1140 cctgcttcga attacggtga atatcgactggatcctcaga gaaagggaga actagtaccc 1200 aactctcttt gggtagcggg atctgcattaagaaccttta ctaatggttt gaaagaacac 1260 tatgtttcta gagatgttgg atttgtagcatctctgcatg ctctcgggga ttatattctg 1320 aattatacgc aagatgatcg ggatggctttttagctagat atgggggatt ccaggcgacc 1380 gcagcctccc attatgaaaa tgggtcaatatttggagtgg cttttggaca actctatggt 1440 cagacaaaga gcagaatgta ttactctaaagatgctggga acatgacgat gttgtcctgt 1500 ttcggaagaa gttacgtaga tattaaaggaacagaaactg ttatgtattg ggagacggct 1560 tatggctatt ctgtgcacag aatgcatacgcagtatttta atgacaaaac gcagaagttc 1620 gatcattcga aatgtcattg gcacaacaataactattatg cgtttgtagg tgccgagcat 1680 aatttcttag agtactgcat tcctactcgtcagttagcta gagattatga gcttacaggg 1740 tttatgcgtt ttgaaatggc cggaggatggtccagttcta cacgagaaac tggctcccta 1800 actagatatt tcgctcgcgg gtcagggcataatatgtcgc ttccaatagg aattgtagct 1860 catgcagttt ctcatgtgcg aagatctcctccttctaaac tgacactaaa tatgggatat 1920 agaccagaca tttggcgtgt cactccacattgcaatatgg aaattattgc taacggagtg 1980 aagacaccta tacaaggatc cccgctggcacggcatgcct tcttcttaga agtgcatgat 2040 actttgtata ttcatcattt tggaagagcctatatgaact attcattaga tgctcgtcgt 2100 cgacaaaccg cacattttgt atctatgggcttgaatagaa tcttttaa 2148 329 715 PRT Chlamydia trachomatis 329 Met HisHis His His His His Thr Ala Ala Ser Asp Asn Phe Gln Leu 1 5 10 15 SerGln Gly Gly Gln Gly Phe Ala Ile Pro Ile Gly Gln Ala Met Ala 20 25 30 IleAla Gly Gln Ile Lys Leu Pro Thr Val His Ile Gly Pro Thr Ala 35 40 45 PheLeu Gly Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val 50 55 60 GlnArg Val Val Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr 65 70 75 80Gly Asp Val Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr 85 90 95Ala Met Ala Asp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser 100 105110 Val Thr Trp Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr 115120 125 Leu Ala Glu Gly Pro Pro Ala Glu Phe Cys Arg Tyr Pro Ser His Trp130 135 140 Arg Pro Leu Asp Pro Val Val Gln Asn Asn Ser Ala Ala Gly AlaSer 145 150 155 160 Thr Pro Ser Pro Ser Ser Ser Ser Met Pro Gly Ala ValThr Ile Asn 165 170 175 Gln Ser Gly Asn Gly Ser Val Ile Phe Thr Ala GluSer Leu Thr Pro 180 185 190 Ser Glu Lys Leu Gln Val Leu Asn Ser Thr SerAsn Phe Pro Gly Ala 195 200 205 Leu Thr Val Ser Gly Gly Glu Leu Val ValThr Glu Gly Ala Thr Leu 210 215 220 Thr Thr Gly Thr Ile Thr Ala Thr SerGly Arg Val Thr Leu Gly Ser 225 230 235 240 Gly Ala Ser Leu Ser Ala ValAla Gly Ala Ala Asn Asn Asn Tyr Thr 245 250 255 Cys Thr Val Ser Lys LeuGly Ile Asp Leu Glu Ser Phe Leu Thr Pro 260 265 270 Asn Tyr Lys Thr AlaIle Leu Gly Ala Asp Gly Thr Val Thr Val Asn 275 280 285 Ser Gly Ser ThrLeu Asp Leu Val Met Glu Asn Glu Ala Glu Val Tyr 290 295 300 Asp Asn ProLeu Phe Val Gly Ser Leu Thr Ile Pro Phe Val Thr Leu 305 310 315 320 SerSer Ser Ser Ala Ser Asn Gly Val Thr Lys Asn Ser Val Thr Ile 325 330 335Asn Asp Ala Asp Ala Ala His Tyr Gly Tyr Gln Gly Ser Trp Ser Ala 340 345350 Asp Trp Thr Lys Pro Pro Leu Ala Pro Asp Ala Lys Gly Met Val Pro 355360 365 Pro Asn Thr Asn Asn Thr Leu Tyr Leu Thr Trp Arg Pro Ala Ser Asn370 375 380 Tyr Gly Glu Tyr Arg Leu Asp Pro Gln Arg Lys Gly Glu Leu ValPro 385 390 395 400 Asn Ser Leu Trp Val Ala Gly Ser Ala Leu Arg Thr PheThr Asn Gly 405 410 415 Leu Lys Glu His Tyr Val Ser Arg Asp Val Gly PheVal Ala Ser Leu 420 425 430 His Ala Leu Gly Asp Tyr Ile Leu Asn Tyr ThrGln Asp Asp Arg Asp 435 440 445 Gly Phe Leu Ala Arg Tyr Gly Gly Phe GlnAla Thr Ala Ala Ser His 450 455 460 Tyr Glu Asn Gly Ser Ile Phe Gly ValAla Phe Gly Gln Leu Tyr Gly 465 470 475 480 Gln Thr Lys Ser Arg Met TyrTyr Ser Lys Asp Ala Gly Asn Met Thr 485 490 495 Met Leu Ser Cys Phe GlyArg Ser Tyr Val Asp Ile Lys Gly Thr Glu 500 505 510 Thr Val Met Tyr TrpGlu Thr Ala Tyr Gly Tyr Ser Val His Arg Met 515 520 525 His Thr Gln TyrPhe Asn Asp Lys Thr Gln Lys Phe Asp His Ser Lys 530 535 540 Cys His TrpHis Asn Asn Asn Tyr Tyr Ala Phe Val Gly Ala Glu His 545 550 555 560 AsnPhe Leu Glu Tyr Cys Ile Pro Thr Arg Gln Leu Ala Arg Asp Tyr 565 570 575Glu Leu Thr Gly Phe Met Arg Phe Glu Met Ala Gly Gly Trp Ser Ser 580 585590 Ser Thr Arg Glu Thr Gly Ser Leu Thr Arg Tyr Phe Ala Arg Gly Ser 595600 605 Gly His Asn Met Ser Leu Pro Ile Gly Ile Val Ala His Ala Val Ser610 615 620 His Val Arg Arg Ser Pro Pro Ser Lys Leu Thr Leu Asn Met GlyTyr 625 630 635 640 Arg Pro Asp Ile Trp Arg Val Thr Pro His Cys Asn MetGlu Ile Ile 645 650 655 Ala Asn Gly Val Lys Thr Pro Ile Gln Gly Ser ProLeu Ala Arg His 660 665 670 Ala Phe Phe Leu Glu Val His Asp Thr Leu TyrIle His His Phe Gly 675 680 685 Arg Ala Tyr Met Asn Tyr Ser Leu Asp AlaArg Arg Arg Gln Thr Ala 690 695 700 His Phe Val Ser Met Gly Leu Asn ArgIle Phe 705 710 715 330 38 DNA Chlymadia trachomatis 330 gagagcggccgctcatgaaa tggctgtcag ctactgcg 38 331 34 DNA Chlymadia trachomatis 331gagcggccgc ttacttaatg cgaatttctt caag 34 332 1557 DNA Chlymadiatrachomatis 332 atgcatcacc atcaccatca cacggccgcg tccgataact tccagctgtcccagggtggg 60 cagggattcg ccattccgat cgggcaggcg atggcgatcg cgggccagatcaagcttccc 120 accgttcata tcgggcctac cgccttcctc ggcttgggtg ttgtcgacaacaacggcaac 180 ggcgcacgag tccaacgcgt ggtcgggagc gctccggcgg caagtctcggcatctccacc 240 ggcgacgtga tcaccgcggt cgacggcgct ccgatcaact cggccaccgcgatggcggac 300 gcgcttaacg ggcatcatcc cggtgacgtc atctcggtga cctggcaaaccaagtcgggc 360 ggcacgcgta cagggaacgt gacattggcc gagggacccc cggccgaattctgcagatat 420 ccatcacact ggcggccgct catgaaatgg ctgtcagcta ctgcggtgtttgctgctgtt 480 ctcccctcag tttcagggtt ttgcttccca gaacctaaag aattaaatttctctcgcgta 540 gaaacttctt cctctaccac ttttactgaa acaattggag aagctggggcagaatatatc 600 gtctctggta acgcatcttt cacaaaattt accaacattc ctactaccgatacaacaact 660 cccacgaact caaactcctc tagctctagc ggagaaactg cttccgtttctgaggatagt 720 gactctacaa caacgactcc tgatcctaaa ggtggcggcg ccttttataacgcgcactcc 780 ggagttttgt cctttatgac acgatcagga acagaaggtt ccttaactctgtctgagata 840 aaaatgactg gtgaaggcgg tgctatcttc tctcaaggag agctgctatttacagatctg 900 acaagtctaa ccatccaaaa taacttatcc cagctatccg gaggagcgatttttggagga 960 tctacaatct ccctatcagg gattactaaa gcgactttct cctgcaactctgcagaagtt 1020 cctgctcctg ttaagaaacc tacagaacct aaagctcaaa cagcaagcgaaacgtcgggt 1080 tctagtagtt ctagcggaaa tgattcggtg tcttccccca gttccagtagagctgaaccc 1140 gcagcagcta atcttcaaag tcactttatt tgtgctacag ctactcctgctgctcaaacc 1200 gatacagaaa catcaactcc ctctcataag ccaggatctg ggggagctatctatgctaaa 1260 ggcgacctta ctatcgcaga ctctcaagag gtactattct caataaataaagctactaaa 1320 gatggaggag cgatctttgc tgagaaagat gtttctttcg agaatattacatcattaaaa 1380 gtacaaacta acggtgctga agaaaaggga ggagctatct atgctaaaggtgacctctca 1440 attcaatctt ctaaacagag tctttttaat tctaactaca gtaaacaaggtgggggggct 1500 ctatatgttg aaggaggtat aaacttccaa gatcttgaag aaattcgcattaagtaa 1557 333 518 PRT Chlymadia trachomatis 333 Met His His His HisHis His Thr Ala Ala Ser Asp Asn Phe Gln Leu 1 5 10 15 Ser Gln Gly GlyGln Gly Phe Ala Ile Pro Ile Gly Gln Ala Met Ala 20 25 30 Ile Ala Gly GlnIle Lys Leu Pro Thr Val His Ile Gly Pro Thr Ala 35 40 45 Phe Leu Gly LeuGly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val 50 55 60 Gln Arg Val ValGly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr 65 70 75 80 Gly Asp ValIle Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr 85 90 95 Ala Met AlaAsp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser 100 105 110 Val ThrTrp Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr 115 120 125 LeuAla Glu Gly Pro Pro Ala Glu Phe Cys Arg Tyr Pro Ser His Trp 130 135 140Arg Pro Leu Met Lys Trp Leu Ser Ala Thr Ala Val Phe Ala Ala Val 145 150155 160 Leu Pro Ser Val Ser Gly Phe Cys Phe Pro Glu Pro Lys Glu Leu Asn165 170 175 Phe Ser Arg Val Glu Thr Ser Ser Ser Thr Thr Phe Thr Glu ThrIle 180 185 190 Gly Glu Ala Gly Ala Glu Tyr Ile Val Ser Gly Asn Ala SerPhe Thr 195 200 205 Lys Phe Thr Asn Ile Pro Thr Thr Asp Thr Thr Thr ProThr Asn Ser 210 215 220 Asn Ser Ser Ser Ser Ser Gly Glu Thr Ala Ser ValSer Glu Asp Ser 225 230 235 240 Asp Ser Thr Thr Thr Thr Pro Asp Pro LysGly Gly Gly Ala Phe Tyr 245 250 255 Asn Ala His Ser Gly Val Leu Ser PheMet Thr Arg Ser Gly Thr Glu 260 265 270 Gly Ser Leu Thr Leu Ser Glu IleLys Met Thr Gly Glu Gly Gly Ala 275 280 285 Ile Phe Ser Gln Gly Glu LeuLeu Phe Thr Asp Leu Thr Ser Leu Thr 290 295 300 Ile Gln Asn Asn Leu SerGln Leu Ser Gly Gly Ala Ile Phe Gly Gly 305 310 315 320 Ser Thr Ile SerLeu Ser Gly Ile Thr Lys Ala Thr Phe Ser Cys Asn 325 330 335 Ser Ala GluVal Pro Ala Pro Val Lys Lys Pro Thr Glu Pro Lys Ala 340 345 350 Gln ThrAla Ser Glu Thr Ser Gly Ser Ser Ser Ser Ser Gly Asn Asp 355 360 365 SerVal Ser Ser Pro Ser Ser Ser Arg Ala Glu Pro Ala Ala Ala Asn 370 375 380Leu Gln Ser His Phe Ile Cys Ala Thr Ala Thr Pro Ala Ala Gln Thr 385 390395 400 Asp Thr Glu Thr Ser Thr Pro Ser His Lys Pro Gly Ser Gly Gly Ala405 410 415 Ile Tyr Ala Lys Gly Asp Leu Thr Ile Ala Asp Ser Gln Glu ValLeu 420 425 430 Phe Ser Ile Asn Lys Ala Thr Lys Asp Gly Gly Ala Ile PheAla Glu 435 440 445 Lys Asp Val Ser Phe Glu Asn Ile Thr Ser Leu Lys ValGln Thr Asn 450 455 460 Gly Ala Glu Glu Lys Gly Gly Ala Ile Tyr Ala LysGly Asp Leu Ser 465 470 475 480 Ile Gln Ser Ser Lys Gln Ser Leu Phe AsnSer Asn Tyr Ser Lys Gln 485 490 495 Gly Gly Gly Ala Leu Tyr Val Glu GlyGly Ile Asn Phe Gln Asp Leu 500 505 510 Glu Glu Ile Arg Ile Lys 515 33437 DNA Chlymadia trachomatis 334 gagagcggcc gctcggtgac ctctcaattcaatcttc 37 335 39 DNA Chlamydia trachomatis 335 gagagcggcc gcttagttctctgttacaga taaggagac 39 336 1758 DNA Chlymadia trachomatis 336atgcatcacc atcaccatca cacggccgcg tccgataact tccagctgtc ccagggtggg 60cagggattcg ccattccgat cgggcaggcg atggcgatcg cgggccagat caagcttccc 120accgttcata tcgggcctac cgccttcctc ggcttgggtg ttgtcgacaa caacggcaac 180ggcgcacgag tccaacgcgt ggtcgggagc gctccggcgg caagtctcgg catctccacc 240ggcgacgtga tcaccgcggt cgacggcgct ccgatcaact cggccaccgc gatggcggac 300gcgcttaacg ggcatcatcc cggtgacgtc atctcggtga cctggcaaac caagtcgggc 360ggcacgcgta cagggaacgt gacattggcc gagggacccc cggccgaatt ctgcagatat 420ccatcacact ggcggccgct cggtgacctc tcaattcaat cttctaaaca gagtcttttt 480aattctaact acagtaaaca aggtgggggg gctctatatg ttgaaggagg tataaacttc 540caagatcttg aagaaattcg cattaagtac aataaagctg gaacgttcga aacaaaaaaa 600atcactttac cttctttaaa agctcaagca tctgcaggaa atgcagatgc ttgggcctct 660tcctctcctc aatctggttc tggagcaact acagtctccg actcaggaga ctctagctct 720ggctcagact cggatacctc agaaacagtt ccagtcacag ctaaaggcgg tgggctttat 780actgataaga atctttcgat tactaacatc acaggaatta tcgaaattgc aaataacaaa 840gcgacagatg ttggaggtgg tgcttacgta aaaggaaccc ttacttgtga aaactctcac 900cgtctacaat ttttgaaaaa ctcttccgat aaacaaggtg gaggaatcta cggagaagac 960aacatcaccc tatctaattt gacagggaag actctattcc aagagaatac tgccaaagaa 1020gagggcggtg gactcttcat aaaaggtaca gataaagctc ttacaatgac aggactggat 1080agtttctgtt taattaataa cacatcagaa aaacatggtg gtggagcctt tgttaccaaa 1140gaaatctctc agacttacac ctctgatgtg gaaacaattc caggaatcac gcctgtacat 1200ggtgaaacag tcattactgg caataaatct acaggaggta atggtggagg cgtgtgtaca 1260aaacgtcttg ccttatctaa ccttcaaagc atttctatat ccgggaattc tgcagcagaa 1320aatggtggtg gagcccacac atgcccagat agcttcccaa cggcggatac tgcagaacag 1380cccgcagcag cttctgccgc gacgtctact cccaaatctg ccccggtctc aactgctcta 1440agcacacctt catcttctac cgtctcttca ttaaccttac tagcagcctc ttcacaagcc 1500tctcctgcaa cctctaataa ggaaactcaa gatcctaatg ctgatacaga cttattgatc 1560gattatgtag ttgatacgac tatcagcaaa aacactgcta agaaaggcgg tggaatctat 1620gctaaaaaag ccaagatgtc ccgcatagac caactgaata tctctgagaa ctccgctaca 1680gagataggtg gaggtatctg ctgtaaagaa tctttagaac tagatgctct agtctcctta 1740tctgtaacag agaactaa 1758 337 585 PRT Chlamydia trachomatis 337 Met HisHis His His His His Thr Ala Ala Ser Asp Asn Phe Gln Leu 1 5 10 15 SerGln Gly Gly Gln Gly Phe Ala Ile Pro Ile Gly Gln Ala Met Ala 20 25 30 IleAla Gly Gln Ile Lys Leu Pro Thr Val His Ile Gly Pro Thr Ala 35 40 45 PheLeu Gly Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val 50 55 60 GlnArg Val Val Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr 65 70 75 80Gly Asp Val Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr 85 90 95Ala Met Ala Asp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser 100 105110 Val Thr Trp Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr 115120 125 Leu Ala Glu Gly Pro Pro Ala Glu Phe Cys Arg Tyr Pro Ser His Trp130 135 140 Arg Pro Leu Gly Asp Leu Ser Ile Gln Ser Ser Lys Gln Ser LeuPhe 145 150 155 160 Asn Ser Asn Tyr Ser Lys Gln Gly Gly Gly Ala Leu TyrVal Glu Gly 165 170 175 Gly Ile Asn Phe Gln Asp Leu Glu Glu Ile Arg IleLys Tyr Asn Lys 180 185 190 Ala Gly Thr Phe Glu Thr Lys Lys Ile Thr LeuPro Ser Leu Lys Ala 195 200 205 Gln Ala Ser Ala Gly Asn Ala Asp Ala TrpAla Ser Ser Ser Pro Gln 210 215 220 Ser Gly Ser Gly Ala Thr Thr Val SerAsp Ser Gly Asp Ser Ser Ser 225 230 235 240 Gly Ser Asp Ser Asp Thr SerGlu Thr Val Pro Val Thr Ala Lys Gly 245 250 255 Gly Gly Leu Tyr Thr AspLys Asn Leu Ser Ile Thr Asn Ile Thr Gly 260 265 270 Ile Ile Glu Ile AlaAsn Asn Lys Ala Thr Asp Val Gly Gly Gly Ala 275 280 285 Tyr Val Lys GlyThr Leu Thr Cys Glu Asn Ser His Arg Leu Gln Phe 290 295 300 Leu Lys AsnSer Ser Asp Lys Gln Gly Gly Gly Ile Tyr Gly Glu Asp 305 310 315 320 AsnIle Thr Leu Ser Asn Leu Thr Gly Lys Thr Leu Phe Gln Glu Asn 325 330 335Thr Ala Lys Glu Glu Gly Gly Gly Leu Phe Ile Lys Gly Thr Asp Lys 340 345350 Ala Leu Thr Met Thr Gly Leu Asp Ser Phe Cys Leu Ile Asn Asn Thr 355360 365 Ser Glu Lys His Gly Gly Gly Ala Phe Val Thr Lys Glu Ile Ser Gln370 375 380 Thr Tyr Thr Ser Asp Val Glu Thr Ile Pro Gly Ile Thr Pro ValHis 385 390 395 400 Gly Glu Thr Val Ile Thr Gly Asn Lys Ser Thr Gly GlyAsn Gly Gly 405 410 415 Gly Val Cys Thr Lys Arg Leu Ala Leu Ser Asn LeuGln Ser Ile Ser 420 425 430 Ile Ser Gly Asn Ser Ala Ala Glu Asn Gly GlyGly Ala His Thr Cys 435 440 445 Pro Asp Ser Phe Pro Thr Ala Asp Thr AlaGlu Gln Pro Ala Ala Ala 450 455 460 Ser Ala Ala Thr Ser Thr Pro Lys SerAla Pro Val Ser Thr Ala Leu 465 470 475 480 Ser Thr Pro Ser Ser Ser ThrVal Ser Ser Leu Thr Leu Leu Ala Ala 485 490 495 Ser Ser Gln Ala Ser ProAla Thr Ser Asn Lys Glu Thr Gln Asp Pro 500 505 510 Asn Ala Asp Thr AspLeu Leu Ile Asp Tyr Val Val Asp Thr Thr Ile 515 520 525 Ser Lys Asn ThrAla Lys Lys Gly Gly Gly Ile Tyr Ala Lys Lys Ala 530 535 540 Lys Met SerArg Ile Asp Gln Leu Asn Ile Ser Glu Asn Ser Ala Thr 545 550 555 560 GluIle Gly Gly Gly Ile Cys Cys Lys Glu Ser Leu Glu Leu Asp Ala 565 570 575Leu Val Ser Leu Ser Val Thr Glu Asn 580 585 338 38 DNA Chlamydaitrachomatis 338 gagagcggcc gctcgaccaa ctgaatatct ctgagaac 38 339 35 DNAChlamydia trachomatis 339 gagagcggcc gcttaagaga ctacgtggag ttctg 35 3401965 DNA Chlamydia trachomatis 340 atgcatcacc atcaccatca cacggccgcgtccgataact tccagctgtc ccagggtggg 60 cagggattcg ccattccgat cgggcaggcgatggcgatcg cgggccagat caagcttccc 120 accgttcata tcgggcctac cgccttcctcggcttgggtg ttgtcgacaa caacggcaac 180 ggcgcacgag tccaacgcgt ggtcgggagcgctccggcgg caagtctcgg catctccacc 240 ggcgacgtga tcaccgcggt cgacggcgctccgatcaact cggccaccgc gatggcggac 300 gcgcttaacg ggcatcatcc cggtgacgtcatctcggtga cctggcaaac caagtcgggc 360 ggcacgcgta cagggaacgt gacattggccgagggacccc cggccgaatt ctgcagatat 420 ccatcacact ggcggccgct cgaccaactgaatatctctg agaactccgc tacagagata 480 ggtggaggta tctgctgtaa agaatctttagaactagatg ctctagtctc cttatctgta 540 acagagaacc ttgttgggaa agaaggtggaggcttacatg ctaaaactgt aaatatttct 600 aatctgaaat caggcttctc tttctcgaacaacaaagcaa actcctcatc cacaggagtc 660 gcaacaacag cttcagcacc tgctgcagctgctgcttccc tacaagcagc cgcagcagcc 720 gcaccatcat ctccagcaac accaacttattcaggtgtag taggaggagc tatctatgga 780 gaaaaggtta cattctctca atgtagcgggacttgtcagt tctctgggaa ccaagctatc 840 gataacaatc cctcccaatc atcgttgaacgtacaaggag gagccatcta tgccaaaacc 900 tctttgtcta ttggatcttc cgatgctggaacctcctata ttttctcggg gaacagtgtc 960 tccactggga aatctcaaac aacagggcaaatagcgggag gagcgatcta ctcccctact 1020 gttacattga attgtcctgc gacattctctaacaatacag cctctatagc tacaccgaag 1080 acttcttctg aagatggatc ctcaggaaattctattaaag ataccattgg aggagccatt 1140 gcagggacag ccattaccct atctggagtctctcgatttt cagggaatac ggctgattta 1200 ggagctgcaa taggaactct agctaatgcaaatacaccca gtgcaactag cggatctcaa 1260 aatagcatta cagaaaaaat tactttagaaaacggttctt ttatttttga aagaaaccaa 1320 gctaataaac gtggagcgat ttactctcctagcgtttcca ttaaagggaa taatattacc 1380 ttcaatcaaa atacatccac tcatgatggaagcgctatct actttacaaa agatgctacg 1440 attgagtctt taggatctgt tctttttacaggaaataacg ttacagctac acaagctagt 1500 tctgcaacat ctggacaaaa tacaaatactgccaactatg gggcagccat ctttggagat 1560 ccaggaacca ctcaatcgtc tcaaacagatgccattttaa cccttcttgc ttcttctgga 1620 aacattactt ttagcaacaa cagtttacagaataaccaag gtgatactcc cgctagcaag 1680 ttttgtagta ttgcaggata cgtcaaactctctctacaag ccgctaaagg gaagactatt 1740 agctttttcg attgtgtgca cacctctaccaaaaaaacag gttcaacaca aaacgtttat 1800 gaaactttag atattaataa agaagagaacagtaatccat atacaggaac tattgtgttc 1860 tcttctgaat tacatgaaaa caaatcttacatcccacaga atgcaatcct tcacaacgga 1920 actttagttc ttaaagagaa aacagaactccacgtagtct cttaa 1965 341 654 PRT Chlamydia trachomatis 341 Met His HisHis His His His Thr Ala Ala Ser Asp Asn Phe Gln Leu 1 5 10 15 Ser GlnGly Gly Gln Gly Phe Ala Ile Pro Ile Gly Gln Ala Met Ala 20 25 30 Ile AlaGly Gln Ile Lys Leu Pro Thr Val His Ile Gly Pro Thr Ala 35 40 45 Phe LeuGly Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val 50 55 60 Gln ArgVal Val Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr 65 70 75 80 GlyAsp Val Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr 85 90 95 AlaMet Ala Asp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser 100 105 110Val Thr Trp Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr 115 120125 Leu Ala Glu Gly Pro Pro Ala Glu Phe Cys Arg Tyr Pro Ser His Trp 130135 140 Arg Pro Leu Asp Gln Leu Asn Ile Ser Glu Asn Ser Ala Thr Glu Ile145 150 155 160 Gly Gly Gly Ile Cys Cys Lys Glu Ser Leu Glu Leu Asp AlaLeu Val 165 170 175 Ser Leu Ser Val Thr Glu Asn Leu Val Gly Lys Glu GlyGly Gly Leu 180 185 190 His Ala Lys Thr Val Asn Ile Ser Asn Leu Lys SerGly Phe Ser Phe 195 200 205 Ser Asn Asn Lys Ala Asn Ser Ser Ser Thr GlyVal Ala Thr Thr Ala 210 215 220 Ser Ala Pro Ala Ala Ala Ala Ala Ser LeuGln Ala Ala Ala Ala Ala 225 230 235 240 Ala Pro Ser Ser Pro Ala Thr ProThr Tyr Ser Gly Val Val Gly Gly 245 250 255 Ala Ile Tyr Gly Glu Lys ValThr Phe Ser Gln Cys Ser Gly Thr Cys 260 265 270 Gln Phe Ser Gly Asn GlnAla Ile Asp Asn Asn Pro Ser Gln Ser Ser 275 280 285 Leu Asn Val Gln GlyGly Ala Ile Tyr Ala Lys Thr Ser Leu Ser Ile 290 295 300 Gly Ser Ser AspAla Gly Thr Ser Tyr Ile Phe Ser Gly Asn Ser Val 305 310 315 320 Ser ThrGly Lys Ser Gln Thr Thr Gly Gln Ile Ala Gly Gly Ala Ile 325 330 335 TyrSer Pro Thr Val Thr Leu Asn Cys Pro Ala Thr Phe Ser Asn Asn 340 345 350Thr Ala Ser Ile Ala Thr Pro Lys Thr Ser Ser Glu Asp Gly Ser Ser 355 360365 Gly Asn Ser Ile Lys Asp Thr Ile Gly Gly Ala Ile Ala Gly Thr Ala 370375 380 Ile Thr Leu Ser Gly Val Ser Arg Phe Ser Gly Asn Thr Ala Asp Leu385 390 395 400 Gly Ala Ala Ile Gly Thr Leu Ala Asn Ala Asn Thr Pro SerAla Thr 405 410 415 Ser Gly Ser Gln Asn Ser Ile Thr Glu Lys Ile Thr LeuGlu Asn Gly 420 425 430 Ser Phe Ile Phe Glu Arg Asn Gln Ala Asn Lys ArgGly Ala Ile Tyr 435 440 445 Ser Pro Ser Val Ser Ile Lys Gly Asn Asn IleThr Phe Asn Gln Asn 450 455 460 Thr Ser Thr His Asp Gly Ser Ala Ile TyrPhe Thr Lys Asp Ala Thr 465 470 475 480 Ile Glu Ser Leu Gly Ser Val LeuPhe Thr Gly Asn Asn Val Thr Ala 485 490 495 Thr Gln Ala Ser Ser Ala ThrSer Gly Gln Asn Thr Asn Thr Ala Asn 500 505 510 Tyr Gly Ala Ala Ile PheGly Asp Pro Gly Thr Thr Gln Ser Ser Gln 515 520 525 Thr Asp Ala Ile LeuThr Leu Leu Ala Ser Ser Gly Asn Ile Thr Phe 530 535 540 Ser Asn Asn SerLeu Gln Asn Asn Gln Gly Asp Thr Pro Ala Ser Lys 545 550 555 560 Phe CysSer Ile Ala Gly Tyr Val Lys Leu Ser Leu Gln Ala Ala Lys 565 570 575 GlyLys Thr Ile Ser Phe Phe Asp Cys Val His Thr Ser Thr Lys Lys 580 585 590Thr Gly Ser Thr Gln Asn Val Tyr Glu Thr Leu Asp Ile Asn Lys Glu 595 600605 Glu Asn Ser Asn Pro Tyr Thr Gly Thr Ile Val Phe Ser Ser Glu Leu 610615 620 His Glu Asn Lys Ser Tyr Ile Pro Gln Asn Ala Ile Leu His Asn Gly625 630 635 640 Thr Leu Val Leu Lys Glu Lys Thr Glu Leu His Val Val Ser645 650 342 36 DNA Chlamydia trachomatis 342 gagagcggcc gctcggaactattgtgttct cttctg 36 343 35 DNA Chlamydia trachomatis 343 gagagcggccgcttagaaga tcatgcgagc accgc 35 344 2103 DNA Chlamydia trachomatis 344atgcatcacc atcaccatca cacggccgcg tccgataact tccagctgtc ccagggtggg 60cagggattcg ccattccgat cgggcaggcg atggcgatcg cgggccagat caagcttccc 120accgttcata tcgggcctac cgccttcctc ggcttgggtg ttgtcgacaa caacggcaac 180ggcgcacgag tccaacgcgt ggtcgggagc gctccggcgg caagtctcgg catctccacc 240ggcgacgtga tcaccgcggt cgacggcgct ccgatcaact cggccaccgc gatggcggac 300gcgcttaacg ggcatcatcc cggtgacgtc atctcggtga cctggcaaac caagtcgggc 360ggcacgcgta cagggaacgt gacattggcc gagggacccc cggccgaatt ctgcagatat 420ccatcacact ggcggccgct cggaactatt gtgttctctt ctgaattaca tgaaaacaaa 480tcttacatcc cacagaatgc aatccttcac aacggaactt tagttcttaa agagaaaaca 540gaactccacg tagtctcttt tgagcagaaa gaagggtcta aattaattat ggaacccgga 600gctgtgttat ctaaccaaaa catagctaac ggagctctag ctatcaatgg gttaacgatt 660gatctttcca gtatggggac tcctcaagca ggggaaatct tctctcctcc agaattacgt 720atcgttgcca cgacctctag tgcatccgga ggaagcgggg tcagcagtag tataccaaca 780aatcctaaaa ggatttctgc agcagtgcct tcaggttctg ccgcaactac tccaactatg 840agcgagaaca aagttttcct aacaggagac cttactttaa tagatcctaa tggaaacttt 900taccaaaacc ctatgttagg aagcgatcta gatgtaccac taattaagct tccgactaac 960acaagtgacg tccaagtcta tgatttaact ttatctgggg atcttttccc tcagaaaggg 1020tacatgggaa cctggacatt agattctaat ccacaaacag ggaaacttca agccagatgg 1080acattcgata cctatcgtcg ctgggtatac atacctaggg ataatcattt ttatgcgaac 1140tctatcttag gctcccaaaa ctcaatgatt gttgtgaagc aagggcttat caacaacatg 1200ttgaataatg cccgcttcga tgatatcgct tacaataact tctgggtttc aggagtagga 1260actttcttag ctcaacaagg aactcctctt tccgaagaat tcagttacta cagccgcgga 1320acttcagttg ccatcgatgc caaacctaga caagatttta tcctaggagc tgcatttagt 1380aagatagtgg ggaaaaccaa agccatcaaa aaaatgcata attacttcca taagggctct 1440gagtactctt accaagcttc tgtctatgga ggtaaattcc tgtatttctt gctcaataag 1500caacatggtt gggcacttcc tttcctaata caaggagtcg tgtcctatgg acatattaaa 1560catgatacaa caacacttta cccttctatc catgaaagaa ataaaggaga ttgggaagat 1620ttaggatggt tagcggatct tcgtatctct atggatctta aagaaccttc taaagattct 1680tctaaacgga tcactgtcta tggggaactc gagtattcca gcattcgcca gaaacagttc 1740acagaaatcg attacgatcc aagacacttc gatgattgtg cttacagaaa tctgtcgctt 1800cctgtgggat gcgctgtcga aggagctatc atgaactgta atattcttat gtataataag 1860cttgcattag cctacatgcc ttctatctac agaaataatc ctgtctgtaa atatcgggta 1920ttgtcttcga atgaagctgg tcaagttatc tgcggagtgc caactagaac ctctgctaga 1980gcagaataca gtactcaact atatcttggt cccttctgga ctctctacgg aaactatact 2040atcgatgtag gcatgtatac gctatcgcaa atgactagct gcggtgctcg catgatcttc 2100taa 2103 345 700 PRT Chlamydia trachomatis 345 Met His His His His HisHis Thr Ala Ala Ser Asp Asn Phe Gln Leu 1 5 10 15 Ser Gln Gly Gly GlnGly Phe Ala Ile Pro Ile Gly Gln Ala Met Ala 20 25 30 Ile Ala Gly Gln IleLys Leu Pro Thr Val His Ile Gly Pro Thr Ala 35 40 45 Phe Leu Gly Leu GlyVal Val Asp Asn Asn Gly Asn Gly Ala Arg Val 50 55 60 Gln Arg Val Val GlySer Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr 65 70 75 80 Gly Asp Val IleThr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr 85 90 95 Ala Met Ala AspAla Leu Asn Gly His His Pro Gly Asp Val Ile Ser 100 105 110 Val Thr TrpGln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr 115 120 125 Leu AlaGlu Gly Pro Pro Ala Glu Phe Cys Arg Tyr Pro Ser His Trp 130 135 140 ArgPro Leu Gly Thr Ile Val Phe Ser Ser Glu Leu His Glu Asn Lys 145 150 155160 Ser Tyr Ile Pro Gln Asn Ala Ile Leu His Asn Gly Thr Leu Val Leu 165170 175 Lys Glu Lys Thr Glu Leu His Val Val Ser Phe Glu Gln Lys Glu Gly180 185 190 Ser Lys Leu Ile Met Glu Pro Gly Ala Val Leu Ser Asn Gln AsnIle 195 200 205 Ala Asn Gly Ala Leu Ala Ile Asn Gly Leu Thr Ile Asp LeuSer Ser 210 215 220 Met Gly Thr Pro Gln Ala Gly Glu Ile Phe Ser Pro ProGlu Leu Arg 225 230 235 240 Ile Val Ala Thr Thr Ser Ser Ala Ser Gly GlySer Gly Val Ser Ser 245 250 255 Ser Ile Pro Thr Asn Pro Lys Arg Ile SerAla Ala Val Pro Ser Gly 260 265 270 Ser Ala Ala Thr Thr Pro Thr Met SerGlu Asn Lys Val Phe Leu Thr 275 280 285 Gly Asp Leu Thr Leu Ile Asp ProAsn Gly Asn Phe Tyr Gln Asn Pro 290 295 300 Met Leu Gly Ser Asp Leu AspVal Pro Leu Ile Lys Leu Pro Thr Asn 305 310 315 320 Thr Ser Asp Val GlnVal Tyr Asp Leu Thr Leu Ser Gly Asp Leu Phe 325 330 335 Pro Gln Lys GlyTyr Met Gly Thr Trp Thr Leu Asp Ser Asn Pro Gln 340 345 350 Thr Gly LysLeu Gln Ala Arg Trp Thr Phe Asp Thr Tyr Arg Arg Trp 355 360 365 Val TyrIle Pro Arg Asp Asn His Phe Tyr Ala Asn Ser Ile Leu Gly 370 375 380 SerGln Asn Ser Met Ile Val Val Lys Gln Gly Leu Ile Asn Asn Met 385 390 395400 Leu Asn Asn Ala Arg Phe Asp Asp Ile Ala Tyr Asn Asn Phe Trp Val 405410 415 Ser Gly Val Gly Thr Phe Leu Ala Gln Gln Gly Thr Pro Leu Ser Glu420 425 430 Glu Phe Ser Tyr Tyr Ser Arg Gly Thr Ser Val Ala Ile Asp AlaLys 435 440 445 Pro Arg Gln Asp Phe Ile Leu Gly Ala Ala Phe Ser Lys IleVal Gly 450 455 460 Lys Thr Lys Ala Ile Lys Lys Met His Asn Tyr Phe HisLys Gly Ser 465 470 475 480 Glu Tyr Ser Tyr Gln Ala Ser Val Tyr Gly GlyLys Phe Leu Tyr Phe 485 490 495 Leu Leu Asn Lys Gln His Gly Trp Ala LeuPro Phe Leu Ile Gln Gly 500 505 510 Val Val Ser Tyr Gly His Ile Lys HisAsp Thr Thr Thr Leu Tyr Pro 515 520 525 Ser Ile His Glu Arg Asn Lys GlyAsp Trp Glu Asp Leu Gly Trp Leu 530 535 540 Ala Asp Leu Arg Ile Ser MetAsp Leu Lys Glu Pro Ser Lys Asp Ser 545 550 555 560 Ser Lys Arg Ile ThrVal Tyr Gly Glu Leu Glu Tyr Ser Ser Ile Arg 565 570 575 Gln Lys Gln PheThr Glu Ile Asp Tyr Asp Pro Arg His Phe Asp Asp 580 585 590 Cys Ala TyrArg Asn Leu Ser Leu Pro Val Gly Cys Ala Val Glu Gly 595 600 605 Ala IleMet Asn Cys Asn Ile Leu Met Tyr Asn Lys Leu Ala Leu Ala 610 615 620 TyrMet Pro Ser Ile Tyr Arg Asn Asn Pro Val Cys Lys Tyr Arg Val 625 630 635640 Leu Ser Ser Asn Glu Ala Gly Gln Val Ile Cys Gly Val Pro Thr Arg 645650 655 Thr Ser Ala Arg Ala Glu Tyr Ser Thr Gln Leu Tyr Leu Gly Pro Phe660 665 670 Trp Thr Leu Tyr Gly Asn Tyr Thr Ile Asp Val Gly Met Tyr ThrLeu 675 680 685 Ser Gln Met Thr Ser Cys Gly Ala Arg Met Ile Phe 690 695700 346 37 DNA Chlamydia trachomatis 346 gagagcggcc gctcatgaaatttatgtcag ctactgc 37 347 37 DNA Chlamydia trachomatis 347 gagagcggccgcttaccctg taattccagt gatggtc 37 348 1464 DNA Chlamydia trachomatis 348atgcatcacc atcaccatca cacggccgcg tccgataact tccagctgtc ccagggtggg 60cagggattcg ccattccgat cgggcaggcg atggcgatcg cgggccagat caagcttccc 120accgttcata tcgggcctac cgccttcctc ggcttgggtg ttgtcgacaa caacggcaac 180ggcgcacgag tccaacgcgt ggtcgggagc gctccggcgg caagtctcgg catctccacc 240ggcgacgtga tcaccgcggt cgacggcgct ccgatcaact cggccaccgc gatggcggac 300gcgcttaacg ggcatcatcc cggtgacgtc atctcggtga cctggcaaac caagtcgggc 360ggcacgcgta cagggaacgt gacattggcc gagggacccc cggccgaatt ctgcagatat 420ccatcacact ggcggccgct catgaaattt atgtcagcta ctgctgtatt tgctgcagta 480ctctcctccg ttactgaggc gagctcgatc caagatcaaa taaagaatac cgactgcaat 540gttagcaaag taggatattc aacttctcaa gcatttactg atatgatgct agcagacaac 600acagagtatc gagctgctga tagtgtttca ttctatgact tttcgacatc ttccggatta 660cctagaaaac atcttagtag tagtagtgaa gcttctccaa cgacagaagg agtgtcttca 720tcttcatctg gagaaaatac tgagaattca caagattcag ctccctcttc tggagaaact 780gataagaaaa cagaagaaga actagacaat ggcggaatca tttatgctag agagaaacta 840actatctcag aatctcagga ctctctctct aatccaagca tagaactcca tgacaatagt 900tttttcttcg gagaaggtga agttatcttt gatcacagag ttgccctcaa aaacggagga 960gctatttatg gagagaaaga ggtagtcttt gaaaacataa aatctctact agtagaagta 1020aatatctcgg tcgagaaagg gggtagcgtc tatgcaaaag aacgagtatc tttagaaaat 1080gttaccgaag caaccttctc ctccaatggt ggggaacaag gtggtggtgg aatctattca 1140gaacaagata tgttaatcag tgattgcaac aatgtacatt tccaagggaa tgctgcagga 1200gcaacagcag taaaacaatg tctggatgaa gaaatgatcg tattgctcac agaatgcgtt 1260gatagcttat ccgaagatac actggatagc actccagaaa cggaacagac taagtcaaat 1320ggaaatcaag atggttcgtc tgaaacaaaa gatacacaag tatcagaatc accagaatca 1380actcctagcc ccgacgatgt tttaggtaaa ggtggtggta tctatacaga aaaatctttg 1440accatcactg gaattacagg gtaa 1464 349 487 PRT Chlamydia trachomatis 349Met His His His His His His Thr Ala Ala Ser Asp Asn Phe Gln Leu 1 5 1015 Ser Gln Gly Gly Gln Gly Phe Ala Ile Pro Ile Gly Gln Ala Met Ala 20 2530 Ile Ala Gly Gln Ile Lys Leu Pro Thr Val His Ile Gly Pro Thr Ala 35 4045 Phe Leu Gly Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val 50 5560 Gln Arg Val Val Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr 65 7075 80 Gly Asp Val Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr 8590 95 Ala Met Ala Asp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser100 105 110 Val Thr Trp Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn ValThr 115 120 125 Leu Ala Glu Gly Pro Pro Ala Glu Phe Cys Arg Tyr Pro SerHis Trp 130 135 140 Arg Pro Leu Met Lys Phe Met Ser Ala Thr Ala Val PheAla Ala Val 145 150 155 160 Leu Ser Ser Val Thr Glu Ala Ser Ser Ile GlnAsp Gln Ile Lys Asn 165 170 175 Thr Asp Cys Asn Val Ser Lys Val Gly TyrSer Thr Ser Gln Ala Phe 180 185 190 Thr Asp Met Met Leu Ala Asp Asn ThrGlu Tyr Arg Ala Ala Asp Ser 195 200 205 Val Ser Phe Tyr Asp Phe Ser ThrSer Ser Gly Leu Pro Arg Lys His 210 215 220 Leu Ser Ser Ser Ser Glu AlaSer Pro Thr Thr Glu Gly Val Ser Ser 225 230 235 240 Ser Ser Ser Gly GluAsn Thr Glu Asn Ser Gln Asp Ser Ala Pro Ser 245 250 255 Ser Gly Glu ThrAsp Lys Lys Thr Glu Glu Glu Leu Asp Asn Gly Gly 260 265 270 Ile Ile TyrAla Arg Glu Lys Leu Thr Ile Ser Glu Ser Gln Asp Ser 275 280 285 Leu SerAsn Pro Ser Ile Glu Leu His Asp Asn Ser Phe Phe Phe Gly 290 295 300 GluGly Glu Val Ile Phe Asp His Arg Val Ala Leu Lys Asn Gly Gly 305 310 315320 Ala Ile Tyr Gly Glu Lys Glu Val Val Phe Glu Asn Ile Lys Ser Leu 325330 335 Leu Val Glu Val Asn Ile Ser Val Glu Lys Gly Gly Ser Val Tyr Ala340 345 350 Lys Glu Arg Val Ser Leu Glu Asn Val Thr Glu Ala Thr Phe SerSer 355 360 365 Asn Gly Gly Glu Gln Gly Gly Gly Gly Ile Tyr Ser Glu GlnAsp Met 370 375 380 Leu Ile Ser Asp Cys Asn Asn Val His Phe Gln Gly AsnAla Ala Gly 385 390 395 400 Ala Thr Ala Val Lys Gln Cys Leu Asp Glu GluMet Ile Val Leu Leu 405 410 415 Thr Glu Cys Val Asp Ser Leu Ser Glu AspThr Leu Asp Ser Thr Pro 420 425 430 Glu Thr Glu Gln Thr Lys Ser Asn GlyAsn Gln Asp Gly Ser Ser Glu 435 440 445 Thr Lys Asp Thr Gln Val Ser GluSer Pro Glu Ser Thr Pro Ser Pro 450 455 460 Asp Asp Val Leu Gly Lys GlyGly Gly Ile Tyr Thr Glu Lys Ser Leu 465 470 475 480 Thr Ile Thr Gly IleThr Gly 485 350 37 DNA Chlamydia trachomatis 350 gagagcggcc gctcgatacacaagtatcag aatcacc 37 351 37 DNA Chlamydia trachomatis 351 gagagcggccgcttaagagg acgatgagac actctcg 37 352 1752 DNA Chlamydia trachomatis 352atgcatcacc atcaccatca cacggccgcg tccgataact tccagctgtc ccagggtggg 60cagggattcg ccattccgat cgggcaggcg atggcgatcg cgggccagat caagcttccc 120accgttcata tcgggcctac cgccttcctc ggcttgggtg ttgtcgacaa caacggcaac 180ggcgcacgag tccaacgcgt ggtcgggagc gctccggcgg caagtctcgg catctccacc 240ggcgacgtga tcaccgcggt cgacggcgct ccgatcaact cggccaccgc gatggcggac 300gcgcttaacg ggcatcatcc cggtgacgtc atctcggtga cctggcaaac caagtcgggc 360ggcacgcgta cagggaacgt gacattggcc gagggacccc cggccgaatt ctgcagatat 420ccatcacact ggcggccgct cgatacacaa gtatcagaat caccagaatc aactcctagc 480cccgacgatg ttttaggtaa aggtggtggt atctatacag aaaaatcttt gaccatcact 540ggaattacag ggactataga ttttgtcagt aacatagcta ccgattctgg agcaggtgta 600ttcactaaag aaaacttgtc ttgcaccaac acgaatagcc tacagttttt gaaaaactcg 660gcaggtcaac atggaggagg agcctacgtt actcaaacca tgtctgttac taatacaact 720agtgaaagta taactactcc ccctctcgta ggagaagtga ttttctctga aaatacagct 780aaagggcacg gtggtggtat ctgcactaac aaactttctt tatctaattt aaaaacggtg 840actctcacta aaaactctgc aaaggagtct ggaggagcta tttttacaga tctagcgtct 900ataccaacaa cagatacccc agagtcttct accccctctt cctcctcgcc tgcaagcact 960cccgaagtag ttgcttctgc taaaataaat cgattctttg cctctacggc agaaccggca 1020gccccttctc taacagaggc tgagtctgat caaacggatc aaacagaaac ttctgatact 1080aatagcgata tagacgtgtc gattgagaac attttgaatg tcgctatcaa tcaaaacact 1140tctgcgaaaa aaggaggggc tatttacggg aaaaaagcta aactttcccg tattaacaat 1200cttgaacttt cagggaattc atcccaggat gtaggaggag gtctctgttt aactgaaagc 1260gtagaatttg atgcaattgg atcgctctta tcccactata actctgctgc taaagaaggt 1320ggggttattc attctaaaac ggttactcta tctaacctca agtctacctt cacttttgca 1380gataacactg ttaaagcaat agtagaaagc actcctgaag ctccagaaga gattcctcca 1440gtagaaggag aagagtctac agcaacagaa aatccgaatt ctaatacaga aggaagttcg 1500gctaacacta accttgaagg atctcaaggg gatactgctg atacagggac tggtgttgtt 1560aacaatgagt ctcaagacac atcagatact ggaaacgctg aatctggaga acaactacaa 1620gattctacac aatctaatga agaaaatacc cttcccaata gtagtattga tcaatctaac 1680gaaaacacag acgaatcatc tgatagccac actgaggaaa taactgacga gagtgtctca 1740tcgtcctctt aa 1752 353 583 PRT Chlamydia trachomatis 353 Met His His HisHis His His Thr Ala Ala Ser Asp Asn Phe Gln Leu 1 5 10 15 Ser Gln GlyGly Gln Gly Phe Ala Ile Pro Ile Gly Gln Ala Met Ala 20 25 30 Ile Ala GlyGln Ile Lys Leu Pro Thr Val His Ile Gly Pro Thr Ala 35 40 45 Phe Leu GlyLeu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val 50 55 60 Gln Arg ValVal Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr 65 70 75 80 Gly AspVal Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr 85 90 95 Ala MetAla Asp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser 100 105 110 ValThr Trp Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr 115 120 125Leu Ala Glu Gly Pro Pro Ala Glu Phe Cys Arg Tyr Pro Ser His Trp 130 135140 Arg Pro Leu Asp Thr Gln Val Ser Glu Ser Pro Glu Ser Thr Pro Ser 145150 155 160 Pro Asp Asp Val Leu Gly Lys Gly Gly Gly Ile Tyr Thr Glu LysSer 165 170 175 Leu Thr Ile Thr Gly Ile Thr Gly Thr Ile Asp Phe Val SerAsn Ile 180 185 190 Ala Thr Asp Ser Gly Ala Gly Val Phe Thr Lys Glu AsnLeu Ser Cys 195 200 205 Thr Asn Thr Asn Ser Leu Gln Phe Leu Lys Asn SerAla Gly Gln His 210 215 220 Gly Gly Gly Ala Tyr Val Thr Gln Thr Met SerVal Thr Asn Thr Thr 225 230 235 240 Ser Glu Ser Ile Thr Thr Pro Pro LeuVal Gly Glu Val Ile Phe Ser 245 250 255 Glu Asn Thr Ala Lys Gly His GlyGly Gly Ile Cys Thr Asn Lys Leu 260 265 270 Ser Leu Ser Asn Leu Lys ThrVal Thr Leu Thr Lys Asn Ser Ala Lys 275 280 285 Glu Ser Gly Gly Ala IlePhe Thr Asp Leu Ala Ser Ile Pro Thr Thr 290 295 300 Asp Thr Pro Glu SerSer Thr Pro Ser Ser Ser Ser Pro Ala Ser Thr 305 310 315 320 Pro Glu ValVal Ala Ser Ala Lys Ile Asn Arg Phe Phe Ala Ser Thr 325 330 335 Ala GluPro Ala Ala Pro Ser Leu Thr Glu Ala Glu Ser Asp Gln Thr 340 345 350 AspGln Thr Glu Thr Ser Asp Thr Asn Ser Asp Ile Asp Val Ser Ile 355 360 365Glu Asn Ile Leu Asn Val Ala Ile Asn Gln Asn Thr Ser Ala Lys Lys 370 375380 Gly Gly Ala Ile Tyr Gly Lys Lys Ala Lys Leu Ser Arg Ile Asn Asn 385390 395 400 Leu Glu Leu Ser Gly Asn Ser Ser Gln Asp Val Gly Gly Gly LeuCys 405 410 415 Leu Thr Glu Ser Val Glu Phe Asp Ala Ile Gly Ser Leu LeuSer His 420 425 430 Tyr Asn Ser Ala Ala Lys Glu Gly Gly Val Ile His SerLys Thr Val 435 440 445 Thr Leu Ser Asn Leu Lys Ser Thr Phe Thr Phe AlaAsp Asn Thr Val 450 455 460 Lys Ala Ile Val Glu Ser Thr Pro Glu Ala ProGlu Glu Ile Pro Pro 465 470 475 480 Val Glu Gly Glu Glu Ser Thr Ala ThrGlu Asn Pro Asn Ser Asn Thr 485 490 495 Glu Gly Ser Ser Ala Asn Thr AsnLeu Glu Gly Ser Gln Gly Asp Thr 500 505 510 Ala Asp Thr Gly Thr Gly ValVal Asn Asn Glu Ser Gln Asp Thr Ser 515 520 525 Asp Thr Gly Asn Ala GluSer Gly Glu Gln Leu Gln Asp Ser Thr Gln 530 535 540 Ser Asn Glu Glu AsnThr Leu Pro Asn Ser Ser Ile Asp Gln Ser Asn 545 550 555 560 Glu Asn ThrAsp Glu Ser Ser Asp Ser His Thr Glu Glu Ile Thr Asp 565 570 575 Glu SerVal Ser Ser Ser Ser 580 354 39 DNA Chlamydia trachomatis 354 gagagcggccgctcgatcaa tctaacgaaa acacagacg 39 355 36 DNA Chlamydia trachomatis 355gagagcggcc gcttagacca aagctccatc agcaac 36 356 2052 DNA Chlamydiatrachomatis 356 atgcatcacc atcaccatca cacggccgcg tccgataact tccagctgtcccagggtggg 60 cagggattcg ccattccgat cgggcaggcg atggcgatcg cgggccagatcaagcttccc 120 accgttcata tcgggcctac cgccttcctc ggcttgggtg ttgtcgacaacaacggcaac 180 ggcgcacgag tccaacgcgt ggtcgggagc gctccggcgg caagtctcggcatctccacc 240 ggcgacgtga tcaccgcggt cgacggcgct ccgatcaact cggccaccgcgatggcggac 300 gcgcttaacg ggcatcatcc cggtgacgtc atctcggtga cctggcaaaccaagtcgggc 360 ggcacgcgta cagggaacgt gacattggcc gagggacccc cggccgaattctgcagatat 420 ccatcacact ggcggccgct cgatcaatct aacgaaaaca cagacgaatcatctgatagc 480 cacactgagg aaataactga cgagagtgtc tcatcgtcct ctaaaagtggatcatctact 540 cctcaagatg gaggagcagc ttcttcaggg gctccctcag gagatcaatctatctctgca 600 aacgcttgtt tagctaaaag ctatgctgcg agtactgata gctcccctgtatctaattct 660 tcaggttcag acgttactgc atcttctgat aatccagact cttcctcatctggagatagc 720 gctggagact ctgaaggacc gactgagcca gaagctggtt ctacaacagaaactcctact 780 ttaataggag gaggwgctat ctatggagaa actgttaaga ttgagaacttctctggccaa 840 ggaatatttt ctggaaacaa agctatcgat aacaccacag aaggctcctcttccaaatct 900 aacgtcctcg gaggtgcggt ctatgctaaa acattgttta atctcgatagcgggagctct 960 agacgaactg tcaccttctc cgggaatact gtctcttctc aatctacaacaggtcaggtt 1020 gctggaggag ctatctactc tcctactgta accattgcta ctcctgtagtattttctaaa 1080 aactctgcaa caaacaatgc taataacgct acagatactc agagaaaagacacctttgga 1140 ggagctatcg gagctacttc tgctgtttct ctatcaggag gggctcatttcttagaaaac 1200 gttgctgacc tcggatctgc tattgggttg gtgccagaca cacaaaatacagaaacagtg 1260 aaattagagt ctggctccta ctactttgaa aaaaataaag ctttaaaacgagctactatt 1320 tacgcacctg tcgtttccat taaagcctat actgcgacat ttaaccaaaacagatctcta 1380 gaagaaggaa gcgcgattta ctttacaaaa gaagcatcta ttgagtctttaggctctgtt 1440 ctcttcacag gaaacttagt aaccccaacg ctaagcacaa ctacagaaggcacaccagcc 1500 acaacctcag gagatgtaac aaaatatggt gctgctatct ttggacaaatagcaagctca 1560 aacggatctc agacggataa ccttcccctg aaactcattg cttcaggaggaaatatttgt 1620 ttccgaaaca atgaataccg tcctacttct tctgataccg gaacctctactttctgtagt 1680 attgcgggag atgttaaatt aaccatgcaa gctgcaaaag ggaaaacgatcagtttcttt 1740 gatgcaatcc ggacctctac taagaaaaca ggtacacagg caactgcctacgatactctc 1800 gatattaata aatctgagga ttcagaaact gtaaactctg cgtttacaggaacgattctg 1860 ttctcctctg aattacatga aaataaatcc tatattccac aaaacgtagttctacacagt 1920 ggatctcttg tattgaagcc aaataccgag cttcatgtca tttcttttgagcagaaagaa 1980 ggctcttctc tcgttatgac acctggatct gttctttcga accagactgttgctgatgga 2040 gctttggtct aa 2052 357 683 PRT Chlamydia trachomatis 357Met His His His His His His Thr Ala Ala Ser Asp Asn Phe Gln Leu 1 5 1015 Ser Gln Gly Gly Gln Gly Phe Ala Ile Pro Ile Gly Gln Ala Met Ala 20 2530 Ile Ala Gly Gln Ile Lys Leu Pro Thr Val His Ile Gly Pro Thr Ala 35 4045 Phe Leu Gly Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val 50 5560 Gln Arg Val Val Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr 65 7075 80 Gly Asp Val Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr 8590 95 Ala Met Ala Asp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser100 105 110 Val Thr Trp Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn ValThr 115 120 125 Leu Ala Glu Gly Pro Pro Ala Glu Phe Cys Arg Tyr Pro SerHis Trp 130 135 140 Arg Pro Leu Asp Gln Ser Asn Glu Asn Thr Asp Glu SerSer Asp Ser 145 150 155 160 His Thr Glu Glu Ile Thr Asp Glu Ser Val SerSer Ser Ser Lys Ser 165 170 175 Gly Ser Ser Thr Pro Gln Asp Gly Gly AlaAla Ser Ser Gly Ala Pro 180 185 190 Ser Gly Asp Gln Ser Ile Ser Ala AsnAla Cys Leu Ala Lys Ser Tyr 195 200 205 Ala Ala Ser Thr Asp Ser Ser ProVal Ser Asn Ser Ser Gly Ser Asp 210 215 220 Val Thr Ala Ser Ser Asp AsnPro Asp Ser Ser Ser Ser Gly Asp Ser 225 230 235 240 Ala Gly Asp Ser GluGly Pro Thr Glu Pro Glu Ala Gly Ser Thr Thr 245 250 255 Glu Thr Pro ThrLeu Ile Gly Gly Gly Ala Ile Tyr Gly Glu Thr Val 260 265 270 Lys Ile GluAsn Phe Ser Gly Gln Gly Ile Phe Ser Gly Asn Lys Ala 275 280 285 Ile AspAsn Thr Thr Glu Gly Ser Ser Ser Lys Ser Asn Val Leu Gly 290 295 300 GlyAla Val Tyr Ala Lys Thr Leu Phe Asn Leu Asp Ser Gly Ser Ser 305 310 315320 Arg Arg Thr Val Thr Phe Ser Gly Asn Thr Val Ser Ser Gln Ser Thr 325330 335 Thr Gly Gln Val Ala Gly Gly Ala Ile Tyr Ser Pro Thr Val Thr Ile340 345 350 Ala Thr Pro Val Val Phe Ser Lys Asn Ser Ala Thr Asn Asn AlaAsn 355 360 365 Asn Ala Thr Asp Thr Gln Arg Lys Asp Thr Phe Gly Gly AlaIle Gly 370 375 380 Ala Thr Ser Ala Val Ser Leu Ser Gly Gly Ala His PheLeu Glu Asn 385 390 395 400 Val Ala Asp Leu Gly Ser Ala Ile Gly Leu ValPro Asp Thr Gln Asn 405 410 415 Thr Glu Thr Val Lys Leu Glu Ser Gly SerTyr Tyr Phe Glu Lys Asn 420 425 430 Lys Ala Leu Lys Arg Ala Thr Ile TyrAla Pro Val Val Ser Ile Lys 435 440 445 Ala Tyr Thr Ala Thr Phe Asn GlnAsn Arg Ser Leu Glu Glu Gly Ser 450 455 460 Ala Ile Tyr Phe Thr Lys GluAla Ser Ile Glu Ser Leu Gly Ser Val 465 470 475 480 Leu Phe Thr Gly AsnLeu Val Thr Pro Thr Leu Ser Thr Thr Thr Glu 485 490 495 Gly Thr Pro AlaThr Thr Ser Gly Asp Val Thr Lys Tyr Gly Ala Ala 500 505 510 Ile Phe GlyGln Ile Ala Ser Ser Asn Gly Ser Gln Thr Asp Asn Leu 515 520 525 Pro LeuLys Leu Ile Ala Ser Gly Gly Asn Ile Cys Phe Arg Asn Asn 530 535 540 GluTyr Arg Pro Thr Ser Ser Asp Thr Gly Thr Ser Thr Phe Cys Ser 545 550 555560 Ile Ala Gly Asp Val Lys Leu Thr Met Gln Ala Ala Lys Gly Lys Thr 565570 575 Ile Ser Phe Phe Asp Ala Ile Arg Thr Ser Thr Lys Lys Thr Gly Thr580 585 590 Gln Ala Thr Ala Tyr Asp Thr Leu Asp Ile Asn Lys Ser Glu AspSer 595 600 605 Glu Thr Val Asn Ser Ala Phe Thr Gly Thr Ile Leu Phe SerSer Glu 610 615 620 Leu His Glu Asn Lys Ser Tyr Ile Pro Gln Asn Val ValLeu His Ser 625 630 635 640 Gly Ser Leu Val Leu Lys Pro Asn Thr Glu LeuHis Val Ile Ser Phe 645 650 655 Glu Gln Lys Glu Gly Ser Ser Leu Val MetThr Pro Gly Ser Val Leu 660 665 670 Ser Asn Gln Thr Val Ala Asp Gly AlaLeu Val 675 680

What is claimed is:
 1. A method of stimulating an immune response, saidmethod comprising administering a composition comprising an isolatedpolypeptide comprising an immunogenic portion of a polypeptide sequenceselected from the group consisting of (a) the polypeptide of SEQ IDNO:178; and (b) a sequence 95% identical to the polypeptide of SEQ IDNO:178, and thereby stimulating an immune response to a Chlamydia pmpDprotein.
 2. The method of claim 1 wherein the polypeptide of (b)stimulates T cells, wherein said polypeptide of (b) is an immunogenicportion of SEQ ID NO:178.
 3. The method of claim 1, wherein thecomposition further comprises a physiologically acceptable carrier. 4.The method of claim 1, wherein the composition further comprises anadjuvant.